Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	O
network	O
in	O
chronic	O
lymphocytic	O
leukemia	O
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	O
/	O
deleted	O
clones	O
.	O

Chronic	O
Lymphocytic	O
Leukemia	O
(	O
CLL	O
)	O
is	O
a	O
lymphoproliferative	O
disorder	O
with	O
either	O
indolent	O
or	O
aggressive	O
clinical	O
course	O
.	O

Current	O
treatment	B-P
regiments	I-P
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	O
or	O
deletions	O
of	O
the	O
short	O
arm	O
of	O
chromosome	O
17	O
(	O
del17p	O
)	O
-	O
remain	O
highly	O
challenging	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
identified	O
USP7	O
,	O
a	O
known	O
de-ubiquitinase	O
with	O
multiple	O
roles	O
in	O
cellular	O
homeostasis	O
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
CLL	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
CLL	O
samples	O
and	O
in	O
CLL	O
cell	O
lines	O
USP7	O
is	O
:	O
i	O
)	O
over-expressed	O
through	O
a	O
mechanism	O
involving	O
miR-338-3p	O
and	O
miR-181b	O
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	O
2	O
(	O
CK2	O
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
CLL	O
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

Treatment	B-P
of	O
primary	O
CLL	O
samples	O
and	O
cell	O
lines	O
with	O
P5091	O
induces	O
cell	O
growth	O
arrest	O
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	O
and	O
-	O
null	O
environment	O
.	O

Importantly	O
,	O
PTEN	O
acts	O
as	O
the	O
main	O
tumor	O
suppressive	O
mediator	O
along	O
the	O
USP7	O
-	O
PTEN	O
axis	O
in	O
a	O
p53	O
dispensable	O
manner	O
.	O

In	O
conclusion	O
,	O
we	O
propose	O
USP7	O
as	O
a	O
new	O
druggable	O
target	O
in	O
CLL	O
.	O

Adjunctive	B-P
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double-blind	O
,	O
randomised	O
,	O
placebo-controlled	O
trial	O
.	O

Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side-effect	O
of	O
treatment	B-P
with	O
antipsychotics	O
.	O

This	O
double-blind	O
,	O
placebo-controlled	O
study	O
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	B-P
treatment	I-P
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	B-P
levels	I-P
and	O
sexual	O
side-effects	O
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

Thirty	O
patients	O
taking	O
risperidone	O
were	O
enrolled	O
into	O
the	O
trial	O
(	O
CTRI/2012/11/003114	O
)	O
.	O

Aripiprazole	O
was	O
administered	O
at	O
a	O
fixed	O
daily	O
dose	O
of	O
10	O
mg/day	O
for	O
8	O
weeks	O
.	O

Serum	B-P
prolactin	I-P
was	O
measured	O
at	O
baseline	O
and	O
at	O
8	O
weeks	O
.	O

Hyperprolactinaemia	O
-related	O
problems	O
,	O
psychopathology	O
and	O
side-effects	O
were	O
evaluated	O
every	O
2	O
weeks	O
.	O

Prolactin	O
levels	O
decreased	O
by	O
58	O
%	O
in	O
the	O
aripiprazole	O
group	O
compared	O
with	O
an	O
increase	O
by	O
22	O
%	O
in	O
the	O
placebo	O
group	O
.	O

Prolactin	O
levels	O
normalised	O
in	O
46	O
%	O
of	O
patients	O
in	O
the	O
aripiprazole	O
group	O
(	O
number	O
needed	O
to	O
treat	O
,	O
NNT=2	O
)	O
.	O

Aripiprazole	O
improved	O
erectile	O
dysfunction	O
in	O
five	O
out	O
of	O
six	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
change	O
in	O
psychopathology	O
or	O
side-effects	O
between	O
groups	O
.	O

Adjunctive	B-P
aripiprazole	O
reduced	O
prolactin	B-P
levels	I-P
in	O
those	O
treated	B-P
with	I-P
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	O
symptoms	O
.	O

This	O
is	O
a	O
potential	O
treatment	B-P
for	O
hyperprolactinaemia	O
observed	O
during	O
treatment	B-P
with	O
second-generation	O
antipsychotics	O
.	O

None	O
.	O

©	O
The	O
Royal	O
College	O
of	O
Psychiatrists	O
2015	O
.	O

This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Non-Commercial	O
,	O
No	O
Derivatives	O
(	O
CC	O
BY-NC-ND	O
)	O
licence	O
.	O

Effects	O
of	O
antrosterol	O
from	O
Antrodia	O
camphorata	O
submerged	O
whole	O
broth	O
on	O
lipid	O
homeostasis	O
,	O
antioxidation	O
,	O
alcohol	O
clearance	O
,	O
and	O
anti-inflammation	O
in	O
livers	O
of	O
chronic	O
-	O
alcohol	O
fed	O
mice	O
.	O

Antrodia	O
camphorata	O
is	O
a	O
functional	O
fungus	O
in	O
Taiwan	O
and	O
owns	O
several	O
pharmacological	O
functions	O
.	O

Antrosterol	O
,	O
a	O
bioactive	O
constitute	O
of	O
sterols	O
in	O
edible	O
Antrodia	O
camphorata	O
submerged	O
whole	O
broth	O
,	O
can	O
protect	O
liver	O
from	O
CCl4	O
damage	O
via	O
enhancing	O
antioxidant	O
and	O
anti-inflammatory	O
capacities	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
hepatoprotection	O
of	O
antrosterol	O
(	O
named	O
as	O
EK100	O
)	O
against	O
alcohol	O
consumption	O
.	O

A	O
Lieber-DeCarli	O
regular	O
EtOH	O
diet	O
(	O
EtOH	O
liquid	B-P
diet	I-P
,	O
5	O
%	O
(	O
v/v	O
)	O
alcohol	O
)	O
was	O
applied	O
to	O
induce	O
alcoholic	O
liver	O
damage	O
.	O

Mice	O
were	O
randomly	O
divided	O
into	O
5	O
groups	O
:	O
(	O
1	O
)	O
Control	O
:	O
control	B-P
liquid	I-P
diet	I-P
;	O
(	O
2	O
)	O
EtOH	O
:	O
EtOH	O
liquid	B-P
diet	I-P
;	O
(	O
3	O
)	O
EK100_1X	O
:	O
EtOH	O
liquid	B-P
diet	I-P
and	O
1mg	O
EK100	O
(	O
Antrosterol	O
)	O
/Kg	O
body	O
weight	O
(	O
bw	O
)	O
;	O
(	O
4	O
)	O
EK100_5X	O
:	O
EtOH	O
liquid	B-P
diet	I-P
and	O
5mg	O
EK100	O
/Kg	O
bw	O
;	O
(	O
5	O
)	O
EK100_10X	O
:	O
EtOH	O
liquid	B-P
diet	I-P
and	O
10mg	O
EK100	O
/Kg	O
bw	O
.	O

At	O
the	O
end	O
of	O
experiment	O
,	O
the	O
livers	O
were	O
collected	O
for	O
histo-pathological	O
analyses	O
,	O
RNA	B-P
and	O
protein	O
extraction	B-P
,	O
and	O
enzymatic	O
activities	O
.	O

Antrosterol	O
reduced	O
serum	O
/	O
liver	O
lipids	O
of	O
alcohol	O
-	O
diet	B-P
fed	O
mice	O
which	O
highly	O
related	O
to	O
upregulated	O
fatty	O
acid	O
β-oxidation	O
and	O
downregulated	O
lipogenesis	O
,	O
and	O
increased	O
fecal	O
lipid	O
/	O
bile-acid	O
outputs	O
.	O

Antrosterol	O
enhanced	O
hepatic	O
antioxidant	O
capabilities	O
in	O
alcohol	O
-	O
diet	B-P
fed	O
mice	O
while	O
it	O
also	O
lowered	O
serum	O
alcohol	O
level	O
,	O
as	O
well	O
as	O
increased	O
alcohol	O
dehydrogenase	O
(	O
ADH	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
and	O
decreased	O
CYP2E1	O
protein	O
expression	O
in	O
livers	O
of	O
alcohol	O
-	O
diet	B-P
fed	O
mice	O
.	O

Besides	O
,	O
antrosterol	O
lowered	O
hepatic	O
inflammation	O
and	O
fibrosis	O
related	O
gene	O
expressions	O
,	O
as	O
well	O
as	O
serum	B-P
AST	I-P
/	O
ALT	B-P
values	O
and	O
TNF-α	O
/	O
IL-1β	O
contents	O
in	O
alcohol	O
-	O
diet	B-P
fed	O
mice	O
.	O

Based	O
on	O
the	O
results	O
,	O
hepatoprotection	O
of	O
antrosterol	O
is	O
mostly	O
attributed	O
to	O
its	O
regulations	O
of	O
lipid	O
homeostasis	O
,	O
antioxidant	O
capability	O
,	O
alcohol	O
metabolism	O
,	O
and	O
anti-inflammation	O
.	O

Physicochemical	O
characterization	O
of	O
chitosan	O
-	O
hyaluronan	O
-coated	O
solid	O
lipid	O
nanoparticles	O
for	O
the	O
targeted	O
delivery	B-P
of	O
paclitaxel	O
:	O
a	O
proof-of-concept	O
study	O
in	O
breast	O
cancer	O
cells	O
.	O

To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	O
(	O
PAX	O
)	O
.	O

SLN	O
loaded	O
with	O
PAX	O
were	O
prepared	O
via	O
modified	O
high-pressure	B-P
hot	I-P
homogenization	I-P
.	O

Formulation	O
parameters	O
were	O
optimized	O
to	O
obtain	O
a	O
high-quality	O
delivery	O
system	O
.	O

SLN	O
cores	O
were	O
coated	O
,	O
layer-by-layer	O
,	O
with	O
a	O
chitosan	O
and	O
hyaluronan	O
(	O
HA	O
)	O
shell	O
.	O

Selectivity	O
toward	O
HA	O
receptors	O
was	O
tested	O
in	O
a	O
breast	O
cancer	O
cell	O
line	O
,	O
MCF-7	O
.	O

Stable	O
and	O
reproducible	O
nano-sized	O
and	O
negatively	O
charged	O
nanoparticles	O
resulted	O
.	O

Findings	O
reveal	O
that	O
chitosan	O
-	O
HA	O
-coated	O
SLN	O
facilitated	O
the	O
targeting	O
,	O
cellular	O
uptake	O
and	O
the	O
time-/dose-controlled	O
delivery	O
and	O
release	O
of	O
PAX	O
,	O
enhancing	O
intrinsic	B-P
chemotherapeutic	I-P
activities	I-P
.	O

SLN	O
are	O
suitable	O
carrier	O
candidates	O
for	O
nano-oncology	O
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	O
potential	O
overcoming	O
multidrug-resistant	O
cancer	O
cells	O
.	O

Interoception	O
and	O
Positive	O
Symptoms	O
in	O
Schizophrenia	O
.	O

The	O
present	O
study	O
focuses	O
on	O
the	O
multifaceted	O
concept	O
of	O
self-disturbance	O
in	O
schizophrenia	O
,	O
adding	O
knowledge	O
about	O
a	O
not	O
yet	O
investigated	O
aspect	O
,	O
which	O
is	O
the	O
interoceptive	O
accuracy	O
.	O

Starting	O
from	O
the	O
assumption	O
that	O
interoceptive	O
accuracy	O
requires	O
an	O
intact	O
sense	O
of	O
self	O
,	O
which	O
otherwise	O
was	O
proved	O
to	O
be	O
altered	O
in	O
schizophrenia	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
explore	O
interoceptive	O
accuracy	O
in	O
a	O
group	O
of	O
schizophrenia	O
patients	O
,	O
compared	O
to	O
healthy	O
controls	O
.	O

Furthermore	O
,	O
the	O
possible	O
association	O
between	O
interoceptive	O
accuracy	O
and	O
patients	O
'	O
positive	O
and	O
negative	O
symptomatology	O
was	O
assessed	O
.	O

To	O
pursue	O
these	O
goals	O
,	O
a	O
group	O
of	O
23	O
schizophrenia	O
patients	O
and	O
a	O
group	O
of	O
23	O
healthy	O
controls	O
performed	O
a	O
heartbeat	O
perception	O
task	O
.	O

Patients	O
'	O
symptomatology	O
was	O
assessed	O
by	O
means	O
of	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
.	O

Results	O
demonstrated	O
significantly	O
lower	O
interoceptive	O
accuracy	O
in	O
schizophrenia	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

This	O
difference	O
was	O
not	O
accounted	O
for	O
participants	O
'	O
age	O
,	O
BMI	O
,	O
anxiety	O
levels	O
,	O
and	O
heart	O
rate	O
.	O

Furthermore	O
,	O
patients	O
'	O
illness	O
severity	O
,	O
attention	O
and	O
pharmacological	B-P
treatment	I-P
did	O
not	O
influence	O
their	O
interoceptive	O
accuracy	O
levels	O
.	O

Interestingly	O
,	O
a	O
strong	O
positive	O
relation	O
between	O
interoceptive	O
accuracy	O
and	O
positive	O
symptoms	O
severity	O
,	O
especially	O
Grandiosity	O
,	O
was	O
found	O
.	O

The	O
present	O
results	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
interoceptive	O
accuracy	O
is	O
altered	O
in	O
schizophrenia	O
.	O

Furthermore	O
,	O
they	O
prove	O
a	O
specific	O
association	O
between	O
interoceptive	O
accuracy	O
and	O
positive	O
symptomatology	O
,	O
suggesting	O
that	O
the	O
symptom	O
Grandiosity	O
might	O
be	O
protective	O
against	O
an	O
altered	O
basic	O
sense	O
of	O
self	O
in	O
patients	O
characterized	O
by	O
higher	O
sensibility	O
to	O
their	O
inner	O
bodily	O
sensations	O
.	O

Association	O
between	O
Leukoaraiosis	O
and	O
Poor	O
Outcome	O
is	O
not	O
due	O
to	O
Reperfusion	O
Inefficiency	O
after	O
Intravenous	B-P
Thrombolysis	I-P
.	O

Leukoaraiosis	O
(	O
LA	O
)	O
is	O
associated	O
with	O
structural	O
and	O
functional	O
cerebrovascular	O
impairment	O
,	O
which	O
may	O
compromise	O
the	O
capacity	O
of	O
ischemic	O
tissue	O
to	O
maximize	O
reperfusion	O
after	O
intravenous	B-P
thrombolysis	I-P
(	O
IVT	B-P
)	O
.	O

We	O
aimed	O
to	O
determine	O
whether	O
severe	O
LA	O
is	O
correlated	O
with	O
reperfusion	O
inefficiency	O
,	O
which	O
contributes	O
to	O
infarct	O
growth	O
and	O
poor	O
functional	O
outcome	O
.	O

We	O
analyzed	O
data	O
from	O
our	O
consecutive	O
acute	O
ischemic	O
stroke	O
(	O
AIS	O
)	O
patients	O
who	O
had	O
acquired	O
baseline	O
and	O
24-h	O
follow-up	O
diffusion-	B-P
and	O
perfusion-weighted	B-P
imaging	I-P
.	O

Reperfusion	O
was	O
defined	O
as	O
reduction	B-P
of	O
≥70	O
%	O
of	O
hypoperfusion	O
lesion	O
at	O
24	O
h	O
from	O
baseline	O
.	O

Severe	O
LA	O
was	O
defined	O
as	O
Fazekas	O
score	O
2	O
or	O
3	O
on	O
FLAIR	B-P
images	I-P
.	O

We	O
investigated	O
the	O
relationship	O
between	O
severity	O
of	O
LA	O
and	O
reperfusion	O
status	O
.	O

Multivariate	O
statistical	O
analysis	O
was	O
carried	O
out	O
for	O
modeling	O
the	O
independent	O
predictors	O
of	O
reperfusion	O
,	O
infarct	O
growth	O
,	O
and	O
functional	O
outcome	O
.	O

Finally	O
,	O
79	O
patients	O
were	O
included	O
,	O
among	O
them	O
30	O
(	O
37.97	O
%	O
)	O
had	O
severe	O
LA	O
.	O

Reperfusion	O
was	O
observed	O
in	O
41	O
(	O
51.89	O
%	O
)	O
patients	O
,	O
the	O
proportion	O
of	O
reperfusion	O
was	O
very	O
similar	O
in	O
patients	O
with	O
and	O
without	O
severe	O
LA	O
(	O
53.33	O
vs	O
51.02	O
%	O
,	O
p	O
=	O
1.000	O
)	O
.	O

Large	O
artery	O
occlusion	O
was	O
the	O
only	O
independent	O
unfavorable	O
predictor	O
for	O
reperfusion	O
(	O
OR	O
=	O
0.202	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
0.060-0.673	O
;	O
p	O
=	O
0.014	O
)	O
.	O

Multiple	O
linear	O
regression	O
analysis	O
revealed	O
that	O
severe	O
LA	O
was	O
independently	O
associated	O
with	O
infarct	O
growth	O
(	O
standardized	O
coefficients	O
=	O
0.191	O
,	O
p	O
=	O
0.040	O
)	O
.	O

Severe	O
LA	O
was	O
also	O
an	O
independent	O
predictor	O
of	O
poor	O
outcome	O
(	O
mRS	O
≥	O
3	O
)	O
(	O
OR	O
=	O
4.004	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
1.267-12.656	O
,	O
p	O
=	O
0.018	O
)	O
after	O
adjusting	O
for	O
reperfusion	O
and	O
baseline	O
severity	O
of	O
stroke	O
.	O

Severe	O
LA	O
was	O
associated	O
with	O
infarct	O
growth	O
and	O
poor	O
outcome	O
independent	O
of	O
reperfusion	O
status	O
,	O
which	O
may	O
expand	O
the	O
notion	O
that	O
LA	O
contributes	O
the	O
intrinsic	O
vulnerability	O
of	O
brain	O
tissue	O
to	O
acute	O
ischemic	O
insults	O
.	O

The	O
burden	O
of	O
LA	O
may	O
not	O
serve	O
as	O
an	O
imaging	O
indicator	O
of	O
reperfusion	O
inefficiency	O
after	O
IVT	B-P
for	O
AIS	O
patients	O
.	O

One	O
Stage	O
Aesthetic	O
and	O
Functional	O
Reconstruction	B-P
of	O
Major	O
Lower	O
Lip	O
Defects	O
.	O

Multiple	O
techniques	O
have	O
been	O
used	O
for	O
reconstruction	B-P
of	O
large	O
defects	O
of	O
the	O
lower	O
lip	O
.	O

However	O
,	O
some	O
complications	O
,	O
such	O
as	O
microstomia	O
,	O
distortion	O
of	O
oral	O
commissure	O
,	O
lip	O
functional	O
problems	O
,	O
and	O
sensory	O
loss	O
might	O
occur	O
with	O
these	O
techniques	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
a	O
new	O
method	O
of	O
reconstruction	B-P
of	O
large	O
lower	O
lip	O
defects	O
after	O
excision	B-P
of	O
squamous	O
cell	O
carcinoma	O
.	O

Eighteen	O
patients	O
with	O
lower	O
lip	O
squamous	O
cell	O
carcinomas	O
were	O
managed	O
with	O
this	O
new	O
technique	O
of	O
reconstruction	B-P
using	O
dermal	B-P
fat	I-P
flap	I-P
,	O
mucobuccal	O
flap	O
,	O
and	O
muscle	B-P
transfer	I-P
after	O
excision	B-P
of	O
the	O
tumor	O
with	O
1-cm	O
safety	O
margin	O
on	O
both	O
sides	O
.	O

The	O
functional	O
and	O
aesthetic	O
assessments	O
were	O
performed	O
at	O
least	O
6	O
months	O
after	O
surgery	B-P
,	O
and	O
the	O
results	O
were	O
compared	O
statistically	O
with	O
a	O
control	O
group	O
.	O

Of	O
the	O
18	O
patients	O
,	O
sensibility	O
was	O
normal	O
in	O
16	O
(	O
89	O
%	O
)	O
and	O
complete	O
competence	O
was	O
determined	O
in	O
all	O
cases	O
(	O
100	O
%	O
)	O
.	O

In	O
17	O
patients	O
(	O
94	O
%	O
)	O
,	O
complete	O
and	O
symmetric	O
pouting	O
and	O
mouth-opening	O
movements	O
were	O
ensured	O
.	O

Interlabial	O
measurements	O
would	O
be	O
better	O
in	O
all	O
patients	O
.	O

Nasolabial	O
asymmetry	O
was	O
detected	O
in	O
1	O
patient	O
(	O
6	O
%	O
)	O
and	O
apparent	O
mentolabial	O
scar	O
tissue	O
was	O
detected	O
in	O
2	O
patients	O
(	O
11	O
%	O
)	O
.	O

The	O
new	O
vermilion	O
was	O
of	O
equal	O
width	O
to	O
the	O
upper	O
lip	O
vermilion	O
in	O
15	O
patients	O
(	O
83	O
%	O
)	O
.	O

Based	O
on	O
our	O
results	O
,	O
this	O
technique	O
could	O
be	O
considered	O
a	O
good	O
choice	O
for	O
repair	B-P
of	O
major	O
lip	O
defects	O
.	O

In	O
addition	O
,	O
using	O
this	O
technique	O
will	O
give	O
good	O
aesthetic	O
and	O
functional	O
results	O
.	O

Genetically	O
encoded	O
calcium	O
indicators	O
for	O
studying	O
long-term	O
calcium	O
dynamics	O
during	O
apoptosis	O
.	O

Intracellular	O
calcium	O
release	O
is	O
essential	O
for	O
regulating	O
almost	O
all	O
cellular	O
functions	O
.	O

Specific	O
spatio-temporal	O
patterns	O
of	O
cytosolic	O
calcium	O
elevations	O
are	O
critical	O
determinants	O
of	O
cell	O
fate	O
in	O
response	O
to	O
pro-apoptotic	O
cellular	O
stressors	O
.	O

As	O
the	O
apoptotic	O
program	O
can	O
take	O
hours	O
or	O
days	O
,	O
measurement	O
of	O
long-term	O
calcium	O
dynamics	O
are	O
essential	O
for	O
understanding	O
the	O
mechanistic	O
role	O
of	O
calcium	O
in	O
apoptotic	O
cell	O
death	O
.	O

Due	O
to	O
the	O
technical	O
limitations	O
of	O
using	O
calcium	O
-	O
sensitive	O
dyes	O
to	O
measure	O
cytosolic	O
calcium	O
little	O
is	O
known	O
about	O
long-term	O
calcium	O
dynamics	O
in	O
living	O
cells	O
after	O
treatment	B-P
with	O
apoptosis	O
-	O
inducing	O
drugs	O
.	O

Genetically	O
encoded	O
calcium	O
indicators	O
could	O
potentially	O
overcome	O
some	O
of	O
the	O
limitations	O
of	O
calcium	O
-	O
sensitive	O
dyes	O
.	O

Here	O
,	O
we	O
compared	O
the	O
performance	O
of	O
the	O
genetically	O
encoded	O
calcium	O
indicators	O
GCaMP6s	O
and	O
GCaMP6f	O
with	O
the	O
ratiometric	O
dye	O
Fura-2	O
.	O

GCaMP6s	O
performed	O
as	O
well	O
or	O
better	O
than	O
Fura-2	O
in	O
detecting	O
agonist	O
-	O
induced	O
calcium	O
transients	O
.	O

We	O
then	O
examined	O
the	O
utility	O
of	O
GCaMP6s	O
for	O
continuously	O
measuring	O
apoptotic	O
calcium	B-P
release	I-P
over	O
the	O
course	O
of	O
ten	O
hours	O
after	O
treatment	B-P
with	O
staurosporine	O
.	O

We	O
found	O
that	O
GCaMP6s	O
was	O
suitable	O
for	O
measuring	O
apoptotic	O
calcium	B-P
release	I-P
over	O
long	O
time	O
courses	O
and	O
revealed	O
significant	O
heterogeneity	O
in	O
calcium	B-P
release	I-P
dynamics	O
in	O
individual	O
cells	O
challenged	O
with	O
staurosporine	O
.	O

Our	O
results	O
suggest	O
GCaMP6s	O
is	O
an	O
excellent	O
indicator	O
for	O
monitoring	O
long-term	O
changes	O
cytosolic	O
calcium	O
during	O
apoptosis	O
.	O

AAV9	O
-	O
NPC1	O
significantly	O
ameliorates	O
Purkinje	O
cell	O
death	O
and	O
behavioral	O
abnormalities	O
in	O
mouse	O
NPC	O
disease	O
.	O

Niemann-Pick	O
type	O
C	O
(	O
NPC	O
)	O
disease	O
is	O
a	O
fatal	O
inherited	O
neurodegenerative	O
disorder	O
caused	O
by	O
loss-of-function	O
mutations	O
in	O
the	O
NPC1	O
or	O
NPC2	O
gene	O
.	O

There	O
is	O
no	O
effective	O
way	O
to	O
treat	O
NPC	O
disease	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
adeno-associated	O
virus	O
(	O
AAV	O
)	O
serotype	O
9	O
(	O
AAV9	O
)	O
to	O
deliver	O
a	O
functional	O
NPC1	O
gene	O
systemically	O
into	O
NPC1	O
(	O
-/-	O
)	O
mice	O
at	O
postnatal	B-P
day	I-P
4	I-P
.	O

One	O
single	O
AAV9-NPC1	B-P
injection	I-P
resulted	O
in	O
robust	O
NPC1	O
expression	O
in	O
various	O
tissues	O
,	O
including	O
brain	O
,	O
heart	O
,	O
and	O
lung	O
.	O

Strikingly	O
,	O
AAV9-mediated	O
NPC1	O
delivery	O
significantly	O
promoted	O
Purkinje	O
cell	O
survival	O
,	O
restored	O
locomotor	O
activity	O
and	O
coordination	O
,	O
and	O
increased	O
the	O
lifespan	O
of	O
NPC1	O
(	O
-/-	O
)	O
mice	O
.	O

Our	O
work	O
suggests	O
that	O
AAV-based	B-P
gene	I-P
therapy	I-P
is	O
a	O
promising	O
means	O
to	O
treat	O
NPC	O
disease	O
.	O

The	O
Pretreatment	O
Neutrophil-to-Lymphocyte	O
Ratio	O
is	O
a	O
Prognostic	O
Determinant	O
of	O
T3	O
-	O
4	O
Hypopharyngeal	O
Squamous	O
Cell	O
Carcinoma	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
clinicopathological	O
factors	O
that	O
influence	O
recurrence	O
and	O
survival	O
in	O
patients	O
who	O
undergo	O
operations	B-P
for	O
T3	O
-	O
4	O
hypopharyngeal	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
.	O

One	O
hundred	O
and	O
five	O
patients	O
who	O
underwent	O
surgery	B-P
between	O
2001	O
and	O
2008	O
for	O
advanced	O
hypopharyngeal	O
SCCs	O
were	O
consecutively	O
enrolled	O
and	O
reviewed	O
.	O

The	O
pretreatment	O
neutrophil-to-lymphocyte	O
ratio	O
(	O
NLR	O
;	O
median	O
3.22	O
,	O
range	O
0.62-46.50	O
)	O
was	O
associated	O
with	O
disease	O
recurrence	O
and	O
patient	O
survival	O
.	O

A	O
difference	O
in	O
the	O
5-year	O
cumulative	O
disease	O
recurrence	O
rate	O
between	O
patients	O
with	O
high	O
(	O
≥3.22	O
)	O
and	O
low	O
(	O
<	O
3.22	O
)	O
NLRs	O
was	O
significant	O
(	O
60.4	O
and	O
36.5	O
%	O
,	O
respectively	O
;	O
p	O
=	O
0.004	O
)	O
.	O

A	O
multivariate	O
analysis	O
confirmed	O
that	O
an	O
NLR	O
≥3.22	O
was	O
an	O
independent	O
indicator	O
of	O
a	O
poor	O
prognosis	O
for	O
advanced	O
hypopharyngeal	O
SCC	O
,	O
as	O
per	O
the	O
following	O
parameters	O
:	O
overall	O
survival	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
2.53	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.48-4.30	O
,	O
p	O
=	O
0.001	O
)	O
,	O
disease-specific	O
survival	O
(	O
HR	O
2.45	O
,	O
95	O
%	O
CI	O
1.38-4.34	O
,	O
p	O
=	O
0.002	O
)	O
,	O
and	O
disease-free	O
survival	O
(	O
HR	O
2.18	O
,	O
95	O
%	O
CI	O
1.24-3.83	O
,	O
p	O
=	O
0.007	O
)	O
.	O

Additional	O
prognostic	O
factors	O
per	O
the	O
survival	O
analyses	O
included	O
lymph	O
node	O
density	O
,	O
surgical	O
margin	O
,	O
lymphovascular	O
invasion	O
,	O
and	O
perineural	O
invasion	O
.	O

An	O
NLR	O
≥3.22	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
disease	O
recurrence	O
and	O
poor	O
survival	O
in	O
patients	O
with	O
T3	O
-	O
4	O
hypopharyngeal	O
SCCs	O
.	O

We	O
propose	O
the	O
use	O
of	O
the	O
NLR	O
to	O
broaden	O
the	O
current	O
TNM	O
staging	O
system	O
;	O
the	O
development	O
of	O
a	O
more	O
effective	O
treatment	B-P
protocol	I-P
for	O
patients	O
with	O
high	O
NLRs	O
will	O
be	O
essential	O
.	O

Involvement	O
of	O
apoptotic	O
pathways	O
in	O
docosahexaenoic	O
acid	O
-induced	O
benefit	O
in	O
prostate	O
cancer	O
:	O
Pathway-focused	O
gene	O
expression	O
analysis	O
using	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	O
pathways	O
that	O
involved	O
in	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
-induced	O
apoptosis	O
of	O
prostate	O
cancer	O
cells	O
.	O

Human	O
prostate	O
cancer	O
DU145	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	O
oil	O
,	O
omega-3	O
PUFA	O
(	O
DHA	O
,	O
and	O
Eicosapentaenoic	O
acid	O
,	O
EPA	O
)	O
,	O
or	O
omega-6	O
PUFA	O
(	O
Arachidonic	O
acid	O
,	O
AA	O
)	O
.	O

Cell	O
viability	O
and	O
apoptosis	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
Hoechst	B-P
staining	I-P
.	O

Pathway-focused	O
gene	O
expression	O
profiling	O
of	O
DU145	O
cells	O
was	O
analyzed	O
with	O
the	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

The	O
results	O
were	O
verified	O
by	O
real	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT-qPCR	O
)	O
.	O

AA	O
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	O
of	O
DU145	O
cells	O
.	O

However	O
,	O
exposure	O
with	O
fish	O
oil	O
,	O
EPA	O
,	O
or	O
DHA	O
for	O
24	O
h	O
significantly	O
affected	O
cell	O
viability	O
.	O

The	O
growth	O
inhibition	O
of	O
DHA	O
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	O
and	O
showed	O
a	O
time-dependent	O
increase	O
.	O

DHA	O
exposure	O
caused	O
typical	O
apoptotic	O
characteristics	O
.	O

Ten	O
genes	O
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	O
were	O
less	O
expressed	O
following	O
DHA	O
exposure	O
.	O

RT-qPCR	O
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	O
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	O
.	O

KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	O
may	O
induce	O
the	O
apoptosis	O
of	O
cancer	O
cells	O
preferentially	O
through	O
mediating	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K/AKT	O
,	O
and	O
NF-κB	O
signaling	O
pathways	O
.	O

Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	O
on	O
human	O
prostate	O
carcinoma	O
cell	O
line	O
DU145	O
.	O

The	O
pro-apoptotic	O
effect	O
of	O
DHA	O
on	O
DU145	O
cells	O
may	O
involve	O
mediation	O
various	O
pathways	O
,	O
especially	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K/AKT	O
,	O
and	O
NF-κB	O
signaling	O
pathways	O
.	O

Molecular	O
mechanisms	O
of	O
DHA	O
on	O
apoptosis	O
of	O
cancer	O
cells	O
still	O
need	O
to	O
be	O
further	O
clarified	O
.	O

The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
natural	O
rewards	O
following	O
long-term	O
withdrawal	B-P
from	O
morphine	O
:	O
no	O
anhedonia	O
but	O
persistent	O
maladaptive	O
behaviors	O
for	O
high-value	O
rewards	O
.	O

The	O
negative	O
affective	O
state	O
,	O
e.g.	O
,	O
anhedonia	O
,	O
emerges	O
after	O
abstinence	B-P
from	O
abused	O
drugs	O
may	O
be	O
linked	O
to	O
the	O
motivational	O
processes	O
of	O
drug	O
craving	O
and	O
relapse	O
.	O

Although	O
anhedonia	O
diminishes	O
over	O
time	O
with	O
drug	O
abstinence	O
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	O
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	B-P
.	O

The	O
behavioral	O
responses	O
to	O
natural	O
rewards	O
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	O
withdrawal	B-P
from	O
morphine	O
.	O

Male	O
rats	O
were	O
pretreated	O
with	O
either	O
a	O
binge-like	O
morphine	O
paradigm	O
or	O
daily	O
saline	B-P
injection	I-P
for	O
5	O
days	O
.	O

The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
three	O
natural	O
rewards	O
(	O
sucrose	O
solutions	O
4	O
,	O
15	O
,	O
and	O
60	O
%	O
,	O
social	O
stimulus	O
:	O
male	O
rat	O
,	O
and	O
sexual	O
stimulus	O
:	O
estrous	O
female	O
rat	O
)	O
were	O
examined	O
under	O
varied	O
testing	O
conditions	O
.	O

The	O
morphine	O
-	O
withdrawn	B-P
rats	O
significantly	O
increased	O
their	O
intake	O
of	O
15	O
%	O
sucrose	O
solution	O
during	O
the	O
1-h	O
consumption	B-P
test	I-P
and	O
their	O
operant	O
responding	O
for	O
15	O
%	O
sucrose	O
solution	O
under	O
a	O
progressive	O
ratio	O
(	O
PR	O
)	O
schedule	O
of	O
reinforcement	O
.	O

When	O
obtaining	O
a	O
reinforcer	O
was	O
associated	O
with	O
a	O
0.5	O
mA	O
foot	O
shock	B-P
under	O
a	O
PR-punishment	O
schedule	O
,	O
the	O
morphine	O
-	O
withdrawn	B-P
rats	O
showed	O
a	O
higher	O
performance	O
for	O
60	O
%	O
sucrose	O
solution	O
.	O

Meanwhile	O
,	O
the	O
morphine	O
-	O
withdrawn	B-P
rats	O
displayed	O
a	O
higher	O
motivation	O
to	O
sexual	O
stimulus	O
during	O
the	O
free-approach	B-P
test	I-P
and	O
more	O
approaching	O
behaviors	O
towards	O
sexual	O
stimulus	O
in	O
a	O
conflict-based	B-P
approach	I-P
test	I-P
(	O
concurrent	O
presence	O
of	O
reward	O
and	O
aversive	O
stimulus	O
)	O
.	O

No	O
anhedonia	O
-like	O
behavior	O
but	O
sensitized	O
behaviors	O
for	O
natural	O
rewards	O
were	O
found	O
after	O
long-term	O
morphine	O
withdrawal	B-P
.	O

Notably	O
,	O
the	O
morphine	O
-	O
withdrawn	B-P
rats	O
displayed	O
persistent	O
motivated	O
behaviors	O
for	O
high-value	O
rewards	O
(	O
60	O
%	O
sucrose	O
and	O
sexual	O
stimulus	O
)	O
in	O
the	O
conflict	B-P
tests	I-P
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	O
-	O
treated	O
rats	O
.	O

Aquaporin-2	O
excretion	O
in	O
hospitalized	O
patients	O
with	O
cirrhosis	O
:	O
Relation	O
to	O
development	O
of	O
renal	O
insufficiency	O
and	O
mortality	O
.	O

Urinary	O
aquaporin-2	O
(	O
AQP2	O
)	O
is	O
a	O
parameter	O
of	O
water	O
transport	O
in	O
the	O
principal	O
cells	O
in	O
the	O
distal	O
part	O
of	O
the	O
nephron	O
and	O
involved	O
in	O
water	O
retention	O
in	O
cirrhosis	O
and	O
may	O
be	O
a	O
marker	O
of	O
renal	O
function	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
AQP2	O
as	O
a	O
predictor	O
of	O
renal	O
insufficiency	O
and	O
death	O
in	O
patients	O
with	O
cirrhosis	O
.	O

Urine	O
samples	O
from	O
199	O
patients	O
(	O
90	O
patients	O
without	O
organ	O
failure	O
[	O
Group	O
1	O
]	O
,	O
58	O
patients	O
with	O
organ	O
failure	O
excluding	O
renal	O
failure	O
[	O
Group	O
2	O
]	O
,	O
and	O
51	O
patients	O
with	O
organ	O
failure	O
including	O
renal	O
failure	O
[	O
Group	O
3	O
]	O
)	O
from	O
the	O
CANONIC	O
study	O
were	O
analyzed	O
for	O
urine	O
AQP2	O
and	O
urine	O
osmolality	O
.	O

There	O
was	O
no	O
difference	O
in	O
AQP2	O
between	O
the	O
three	O
groups	O
.	O

Urine	O
osmolality	O
was	O
significantly	O
lower	O
in	O
patients	O
in	O
Group	O
3	O
versus	O
Group	O
1	O
and	O
Group	O
2	O
(	O
P	O
=	O
0.0004	O
)	O
.	O

No	O
relation	O
was	O
found	O
between	O
AQP2	O
and	O
glomerular	B-P
filtration	I-P
rate	I-P
or	O
creatinine	O
;	O
however	O
,	O
AQP2	O
was	O
a	O
significant	O
predictor	O
of	O
the	O
development	O
of	O
renal	O
insufficiency	O
(	O
P	O
=	O
0.0485	O
)	O
.	O

In	O
a	O
univariate	O
analysis	O
,	O
AQP2	O
was	O
a	O
significant	O
predictor	O
of	O
14	O
and	O
28-day	O
survival	O
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate	O
analysis	O
.	O

Aquaporin-2	O
was	O
not	O
associated	O
with	O
disease	O
severity	O
or	O
markers	O
of	O
renal	O
function	O
but	O
was	O
a	O
predictor	O
for	O
the	O
development	O
of	O
renal	O
insufficiency	O
and	O
death	O
.	O

Therefore	O
,	O
its	O
future	O
use	O
as	O
marker	O
of	O
renal	O
insufficiency	O
could	O
be	O
promising	O
,	O
but	O
further	O
research	O
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	O
useful	O
tool	O
.	O

Quantitating	O
the	O
lateral	O
skin	O
stiffness	O
by	O
a	O
new	O
and	O
versatile	O
electro-mechanical	O
instrument	O
.	O

Preliminary	O
studies	O
.	O

A	O
new	O
electro-mechanical	O
device	O
for	O
measuring	O
the	O
lateral	O
stiffness	O
of	O
the	O
skin	O
is	O
now	O
available	O
.	O

It	O
basically	O
allows	O
to	O
recording	O
the	O
forces	O
that	O
the	O
skin	O
opposes	O
to	O
a	O
lateral	O
displacement	O
(	O
1-2	O
mm	O
)	O
of	O
a	O
pinching	O
type	O
movement	O
.	O

Preliminary	O
assays	O
of	O
this	O
device	O
to	O
various	O
skin	O
sites	O
and	O
an	O
artificial	O
substrate	O
aimed	O
at	O
defining	O
its	O
major	O
characteristics	O
(	O
sensitivity	O
,	O
reproducibility	O
,	O
variations	O
according	O
to	O
skin	O
site	O
)	O
.	O

The	O
calibration	O
of	O
the	O
device	O
(	O
Khelometer	O
(	O
®	O
)	O
)	O
and	O
assessment	O
of	O
its	O
reproducibility	O
were	O
carried	O
out	O
through	O
the	O
use	O
of	O
elastometer	O
substrates	O
of	O
various	O
stiffness	O
's	O
.	O

The	O
device	O
was	O
then	O
used	O
,	O
in	O
vivo	O
,	O
at	O
different	O
skin	O
sites	O
(	O
scalp	O
,	O
inner	O
and	O
outer	O
forearms	O
,	O
cheeks	O
)	O
of	O
213	O
healthy	O
Japanese	O
women	O
of	O
various	O
ages	O
.	O

The	O
short-time	O
effect	O
of	O
a	O
hydrating	O
regimen	O
(	O
7	O
%	O
glycerol	O
)	O
was	O
recorded	O
on	O
the	O
outer	O
forearm	O
.	O

This	O
new	O
device	O
offers	O
an	O
appreciable	O
reproducibility	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
coefficient	O
of	O
variation	O
of	O
2-4	O
%	O
and	O
5-14	O
%	O
,	O
respectively	O
)	O
.	O

Unlike	O
other	O
biophysical	O
methods	O
,	O
the	O
Khelometer	O
(	O
®	O
)	O
can	O
be	O
easily	O
applied	O
onto	O
the	O
human	O
scalp	O
that	O
shows	O
a	O
higher	O
stiffness	O
than	O
the	O
two	O
other	O
skin	O
sites	O
,	O
increasing	O
with	O
age	O
and	O
presence	O
of	O
alopecia	O
.	O

In	O
all	O
the	O
three	O
studied	O
skin	O
sites	O
,	O
the	O
impact	O
of	O
age	O
leads	O
to	O
significantly	O
higher	O
lateral	O
skin	O
stiffness	O
(	O
LSS	O
,	O
expressed	O
as	O
N/mm	O
)	O
values	O
.	O

The	O
latter	O
were	O
found	O
significantly	O
different	O
between	O
the	O
two	O
sides	O
of	O
the	O
forearms	O
where	O
the	O
outer	O
(	O
sun-exposed	O
)	O
side	O
showed	O
statistically	O
slightly	O
higher	O
LSS	O
,	O
than	O
the	O
unexposed	O
inner	O
side	O
.	O

LSS	O
values	O
found	O
on	O
cheeks	O
(	O
≈0.5	O
N/mm	O
)	O
were	O
about	O
four	O
times	O
lower	O
than	O
those	O
of	O
the	O
scalp	O
(	O
≈2	O
N/mm	O
)	O
and	O
about	O
half	O
those	O
of	O
forearms	O
(	O
≈1	O
N/mm	O
)	O
.	O

The	O
effect	O
of	O
a	O
7	O
%	O
glycerol	O
based	O
formula	O
was	O
recorded	O
20	O
min	O
post	O
application	B-P
onto	O
the	O
forearm	O
,	O
leading	O
to	O
a	O
slight	O
drop	O
in	O
LSS	O
(	O
approx	O
.	O

15	O
%	O
)	O
as	O
compared	O
to	O
a	O
vehicle-applied	O
skin	O
site	O
.	O

These	O
preliminary	O
studies	O
clearly	O
indicate	O
that	O
this	O
new	O
device	O
,	O
applicable	O
to	O
any	O
skin	O
site	O
,	O
offers	O
appreciable	O
assets	O
such	O
as	O
sensitivity	O
and	O
reproducibility	O
.	O

Accordingly	O
,	O
it	O
appears	O
as	O
a	O
new	O
approach	O
in	O
the	O
non-invasive	O
biophysical	O
measurements	O
of	O
the	O
skin	O
surface	O
,	O
in	O
both	O
advanced	O
and	O
applied	O
research	O
investigations	O
.	O

Use	O
of	O
the	O
levonorgestrel	O
52-mg	O
intrauterine	O
system	O
in	O
adolescent	O
and	O
young	O
adult	O
solid	B-P
organ	I-P
transplant	I-P
recipients	O
:	O
a	O
case	O
series	O
.	O

This	O
case	O
series	O
reports	O
on	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
levonorgestrel	O
52-mg	O
intrauterine	O
system	O
in	O
adolescent	O
and	O
young	O
adult	O
solid	B-P
organ	I-P
transplant	I-P
recipients	O
.	O

All	O
patients	O
used	O
the	O
device	O
for	O
contraception	B-P
,	O
with	O
no	O
documented	O
cases	O
of	O
disseminated	O
pelvic	O
infection	O
or	O
unplanned	O
pregnancy	O
.	O

Highly	O
fluorescent	O
gold	O
nanoclusters	O
stabilized	O
by	O
food	O
proteins	O
:	O
From	O
preparation	O
to	O
application	O
in	O
detection	B-P
of	O
food	O
contaminants	O
and	O
bioactive	O
nutrients	O
.	O

Applications	O
of	O
nanotechnology	O
in	O
food	O
have	O
rapidly	O
increased	O
in	O
the	O
past	O
decades	O
.	O

Ultra-small	O
gold	O
nanoclusters	O
(	O
Au	O
NCs	O
)	O
,	O
composed	O
of	O
several	O
to	O
roughly	O
a	O
hundred	O
atoms	O
,	O
represent	O
a	O
kind	O
of	O
novel	O
nanomaterials	O
.	O

The	O
Au	O
NCs	O
directed	O
by	O
food	O
proteins	O
have	O
drawn	O
considerable	O
research	O
attention	O
due	O
to	O
their	O
environmentally	O
friendly	O
preparation	O
,	O
strong	O
fluorescence	O
,	O
excellent	O
photo-stability	O
and	O
favorable	O
biocompatibility	O
.	O

These	O
interesting	O
protein-Au	O
hybrids	O
have	O
opened	O
up	O
a	O
new	O
area	O
at	O
the	O
nano-bio-food	O
interface	O
,	O
not	O
only	O
did	O
they	O
provide	O
the	O
missing	O
link	O
between	O
single	O
metal	O
atoms	O
and	O
plasmonic	O
metal	O
nanoparticles	O
,	O
but	O
also	O
developed	O
the	O
hybrid	O
system	O
between	O
biomacromolecule	O
and	O
inorganic	O
ions	O
.	O

In	O
this	O
review	O
,	O
we	O
highlighted	O
the	O
synthesis	O
strategies	O
and	O
optical	O
properties	O
of	O
the	O
Au	O
NCs	O
stabilized	O
by	O
typical	O
food	O
proteins	O
as	O
well	O
as	O
their	O
applications	O
in	O
detection	B-P
of	O
food	O
contaminants	O
or	O
bioactive	O
nutrients	O
.	O

In	O
addition	O
,	O
we	O
discussed	O
current	O
challenges	O
and	O
future	O
development	O
in	O
food	O
proteins	O
directed	O
gold	O
nanoclusters	O
for	O
size-controlled	O
synthesis	O
and	O
multifunctional	O
applications	O
.	O

Correlation	O
of	O
the	O
Lipid	O
Profile	B-P
,	O
BMI	O
and	O
Bone	O
Mineral	O
Density	O
in	O
Postmenopausal	O
Women	O
.	O

To	O
the	O
reduction	O
of	O
bone	O
density	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
contribute	O
elevated	O
lipid	O
parameters	O
and	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
.	O

The	O
goal	O
of	O
our	O
study	O
was	O
to	O
determine	O
the	O
correlation	O
between	O
lipid	O
parameters	O
,	O
BMI	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

The	O
study	O
was	O
carried	O
out	O
by	O
matched	O
type	O
between	O
experimental	O
group	O
and	O
controls	O
.	O

The	O
experimental	O
group	O
consisted	O
of	O
100	O
females	O
at	O
postmenopausal	O
age	O
,	O
in	O
which	O
by	O
the	O
DEXA	B-P
method	I-P
was	O
diagnosed	O
osteoporosis	O
at	O
the	O
Department	O
of	O
Endocrinology	O
,	O
Diabetes	O
and	O
Metabolic	O
Diseases	O
,	O
University	O
Medical	O
Center	O
of	O
RS	O
during	O
2015-2016	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
100	O
females	O
in	O
a	O
postmenopausal	O
age	O
but	O
without	O
diagnosed	O
osteoporosis	O
.	O

The	O
groups	O
were	O
matched	O
by	O
age	O
(	O
±	O
2	O
years	O
)	O
.	O

To	O
all	O
participants	O
of	O
the	O
study	O
were	O
carried	O
out	O
biochemical	B-P
analysis	I-P
of	I-P
blood	I-P
,	O
or	O
the	O
analysis	O
of	O
the	O
lipid	O
profile	B-P
that	O
included	O
total	O
cholesterol	O
,	O
LDL	O
cholesterol	O
,	O
triglycerides	O
(	O
TG	O
)	O
and	O
HDL	O
cholesterol	O
,	O
and	O
was	O
determined	O
the	O
values	O
of	O
BMI	O
and	O
waist	O
circumference	O
(	O
WC	O
)	O
.	O

Analysis	O
of	O
the	O
data	O
of	O
our	O
research	O
shows	O
that	O
by	O
the	O
univariate	O
logistic	O
regression	O
the	O
values	O
of	O
lipid	O
parameters	O
total	O
cholesterol	O
(	O
p=0.000	O
)	O
,	O
LDL	O
(	O
p=0.005	O
)	O
and	O
TG	O
(	O
p=0.033	O
)	O
were	O
significantly	O
associated	O
with	O
osteoporosis	O
,	O
while	O
in	O
multivariate	O
logistic	O
model	O
only	O
total	O
cholesterol	O
(	O
p=	O
0.018	O
)	O
was	O
found	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

BMI	O
values	O
were	O
not	O
statistically	O
significantly	O
associated	O
with	O
osteoporosis	O
(	O
p=0.727	O
)	O
.	O

On	O
the	O
decrease	O
in	O
bone	O
mineral	O
density	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
influence	O
many	O
risk	O
factors	O
whose	O
identification	O
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	O
prevention	O
of	O
this	O
disease	O
in	O
the	O
elderly	O
.	O

Vaginal	O
Infections	O
of	O
Albanian	O
women	O
Infected	O
with	O
HPV	O
and	O
their	O
impact	O
in	O
intraepithelial	O
cervical	O
lesions	O
evidenced	O
by	O
Pap	B-P
test	I-P
.	O

Cervical	B-P
cytology	I-P
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-P
of	O
the	O
population	O
in	O
identifying	O
precancerous	O
lesions	O
of	O
the	O
uterine	O
cervix	O
.	O

To	O
estimate	O
the	O
frequency	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
positivity	O
in	O
a	O
group	O
of	O
Albanian	O
women	O
,	O
the	O
prevalence	O
of	O
vaginal	O
coinfections	O
,	O
and	O
the	O
relationship	O
of	O
coinfections	O
with	O
HPV	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	O
or	O
cervical	O
intraepithelial	O
lesions	O
(	O
CIN	O
)	O
.	O

In	O
this	O
retrospective	O
study	O
,	O
2075	O
vaginal	B-P
smears	I-P
were	O
examined	O
.	O

The	O
Papanicolaou	B-P
stain	I-P
was	O
used	O
for	O
all	O
slides	O
.	O

The	O
New	B-P
Bethesda	I-P
System	I-P
2001	O
was	O
used	O
for	O
the	O
interpretations	B-P
of	I-P
the	I-P
smears	I-P
.	O

Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
version	O
19.0	O
.	O

Prevalence	O
of	O
HPV	O
positivity	O
was	O
43.9	O
%	O
with	O
an	O
average	O
age	O
of	O
35.48	O
±	O
9.27	O
years	O
.	O

Candida	O
coinfection	O
resulted	O
in	O
57.8	O
%	O
of	O
HPV	O
positive	O
women	O
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O

Gardnerella	O
coinfection	O
resulted	O
in	O
36	O
(	O
23	O
%	O
)	O
,	O
mixed	O
flora	O
in	O
34	O
(	O
8	O
%	O
)	O
,	O
and	O
Trichomonas	O
vaginalis	O
in	O
50	O
%	O
of	O
HPV	O
positive	O
woman	O
.	O

Among	O
the	O
women	O
with	O
positive	O
HPV	O
,	O
19	O
%	O
had	O
CIN	O
,	O
8	O
%	O
had	O
metaplasia	O
,	O
and	O
1	O
%	O
had	O
metaplasia	O
and	O
CIN	O
;	O
9	O
%	O
of	O
the	O
women	O
with	O
HPV	O
had	O
CIN1	O
and	O
one	O
of	O
the	O
coinfections	O
.	O

There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	O
and	O
HPV	O
positivity	O
as	O
well	O
as	O
between	O
CIN1	O
and	O
coinfections	O
.	O

HPV	O
infection	O
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	O
,	O
and	O
bacterial	O
coinfections	O
in	O
HPV	O
positive	O
women	O
have	O
a	O
statistically	O
significant	O
impact	O
in	O
the	O
development	O
of	O
metaplasia	O
.	O

Changes	O
in	O
the	O
Dermal	O
Structure	O
during	O
Cultured	O
Epidermal	O
Autograft	O
Engraftment	B-P
Process	I-P
.	O

The	O
use	O
of	O
cultured	O
epithelial	O
autografts	O
for	O
the	O
treatment	B-P
of	O
extensive	O
burn	O
wounds	O
has	O
become	O
popular	O
in	O
recent	O
years	O
.	O

We	O
examined	O
extensive	O
burn	O
wounds	O
in	O
14	O
patients	O
by	O
using	O
a	O
combination	O
of	O
autograft	O
and	O
cultured	O
epithelial	O
autografts	O
developed	O
in	O
Japan	O
(	O
JACE	O
)	O
.	O

We	O
undertook	O
a	O
skin	B-P
biopsy	I-P
at	O
2	O
,	O
4	O
,	O
and	O
6	O
weeks	O
after	O
transplantation	B-P
with	O
JACE	O
.	O

By	O
using	O
electron	B-P
microscopy	I-P
we	O
observed	O
the	O
engraftment	B-P
process	I-P
.	O

In	O
transmission	O
electron	O
microscope	O
findings	O
,	O
we	O
recognized	O
the	O
engraftment	B-P
process	I-P
of	O
JACE	O
.	O

Keratinocytes	O
matured	O
gradually	O
.	O

Collagen	O
fibers	O
formed	O
thick	O
bundles	O
in	O
the	O
dermis	O
layer	O
.	O

In	O
scanning	O
electron	O
microscope	O
findings	O
,	O
we	O
observed	O
papillary	O
dermis	O
development	O
on	O
the	O
artificial	O
dermis	O
.	O

After	O
managing	O
wound	O
bed	O
preparation	O
by	O
using	O
artificial	O
dermis	O
,	O
we	O
were	O
able	O
to	O
recognize	O
the	O
good	O
result	O
of	O
grafting	B-P
JACE	O
on	O
meshed	O
6:1	O
split	O
thickness	O
autografts	O
.	O

This	O
is	O
because	O
the	O
auto	O
dermis	O
from	O
autograft	O
extended	O
under	O
the	O
JACE	O
,	O
binding	O
between	O
JACE	O
,	O
and	O
the	O
dermis	O
became	O
strong	O
.	O

Personalized	B-P
Medicine	I-P
applied	O
to	O
Forensic	O
Sciences	O
:	O
new	O
advances	O
and	O
perspectives	O
for	O
a	O
tailored	O
forensic	O
approach	O
.	O

Personalized	B-P
medicine	I-P
(	O
PM	B-P
)	O
,	O
included	O
in	O
P5	O
medicine	O
(	O
Personalized	O
,	O
Predictive	O
,	O
Preventive	O
,	O
Participative	O
and	O
Precision	O
medicine	O
)	O
is	O
an	O
innovative	B-P
approach	I-P
to	O
the	O
patient	O
,	O
emerging	O
from	O
the	O
need	O
to	O
tailor	O
and	O
to	O
fit	O
the	O
profile	O
of	O
each	O
individual	O
.	O

PM	B-P
promises	O
to	O
dramatically	O
impact	O
also	O
on	O
forensic	O
sciences	O
and	O
justice	O
system	O
in	O
ways	O
we	O
are	O
only	O
beginning	O
to	O
understand	O
.	O

The	O
application	O
of	O
omics	O
(	O
genomic	O
,	O
transcriptomics	O
,	O
epigenetics/imprintomics	O
,	O
proteomic	O
and	O
metabolomics	O
)	O
is	O
ever	O
more	O
fundamental	O
in	O
the	O
so	O
called	O
``	O
molecular	B-P
autopsy	I-P
``	O
.	O

Emerging	O
fields	O
of	O
interest	O
in	O
forensic	O
pathology	O
are	O
represented	O
by	O
diagnosis	O
and	O
detection	B-P
of	O
predisposing	O
conditions	O
to	O
fatal	O
thromboembolic	O
and	O
hypertensive	O
events	O
,	O
determination	O
of	O
genetic	O
variants	O
related	O
to	O
sudden	O
death	O
,	O
such	O
as	O
congenital	O
long	O
QT	O
syndromes	O
,	O
demonstration	O
of	O
lesions	O
vitality	O
,	O
identification	O
of	O
biological	O
matrices	O
and	O
species	O
diagnosis	O
of	O
a	O
forensic	O
trace	O
on	O
crime	O
scenes	O
without	O
destruction	O
of	O
the	O
DNA	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
describe	O
the	O
state-of-art	O
in	O
the	O
application	O
of	O
personalized	B-P
medicine	I-P
in	O
forensic	O
sciences	O
,	O
to	O
understand	O
the	O
possibilities	O
of	O
integration	O
in	O
routine	O
investigation	O
of	O
these	O
procedures	O
with	O
classical	O
post-mortem	B-P
studies	I-P
and	O
to	O
underline	O
the	O
importance	O
of	O
these	O
new	O
updates	O
in	O
medical	O
examiners	O
'	O
armamentarium	O
in	O
determining	O
cause	O
of	O
death	O
or	O
contributing	O
factors	O
to	O
death	O
.	O

Midodrine	O
and	O
tolvaptan	O
in	O
patients	O
with	O
cirrhosis	O
and	O
refractory	O
or	O
recurrent	O
ascites	O
:	O
a	O
randomised	O
pilot	O
study	O
.	O

Splanchnic	O
arterial	O
vasodilatation	O
and	O
subsequent	O
sodium	O
and	O
water	O
retention	O
play	O
an	O
important	O
role	O
in	O
cirrhotic	O
ascites	O
.	O

Midodrine	O
and	O
tolvaptan	O
have	O
been	O
used	O
separately	O
in	O
these	O
patients	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
use	O
of	O
combination	B-P
of	O
midodrine	O
and	O
tolvaptan	O
in	O
the	O
control	O
of	O
ascites	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
midodrine	O
,	O
tolvaptan	O
and	O
their	O
combination	B-P
in	O
control	O
of	O
refractory	O
or	O
recurrent	O
ascites	O
in	O
cirrhotics	O
.	O

Fifty	O
cirrhotic	O
patients	O
with	O
refractory	O
or	O
recurrent	O
ascites	O
were	O
randomised	O
to	O
receive	O
midodrine	O
(	O
n=13	O
)	O
,	O
tolvaptan	O
(	O
n=12	O
)	O
or	O
both	O
(	O
n=13	O
)	O
plus	O
standard	O
medical	B-P
therapy	I-P
(	O
SMT	B-P
)	O
or	O
SMT	B-P
alone	O
(	O
n=12	O
)	O
.	O

A	O
significant	O
increase	O
in	O
urinary	O
volume	O
and	O
urinary	O
sodium	O
at	O
1	O
and	O
3	O
months	O
(	O
P	O
<	O
.05	O
)	O
was	O
observed	O
in	O
all	O
groups	O
except	O
SMT	B-P
.	O

There	O
was	O
no	O
worsening	O
of	O
renal	O
or	O
hepatic	O
function	O
in	O
any	O
group	O
.	O

There	O
was	O
deterioration	O
of	O
model	O
for	O
end-stage	O
liver	O
disease	O
(	O
MELD	O
)	O
in	O
SMT	O
.	O

Midodrine	O
as	O
well	O
as	O
combination	B-P
of	O
midodrine	O
and	O
tolvaptan	O
but	O
not	O
tolvaptan	O
alone	O
was	O
superior	O
to	O
SMT	B-P
in	O
control	O
of	O
ascites	O
at	O
3	O
months	O
(	O
P	O
<	O
.05	O
)	O
.	O

The	O
combination	B-P
therapy	I-P
was	O
also	O
superior	O
to	O
midodrine	O
in	O
the	O
control	O
of	O
ascites	O
at	O
1	O
month	O
.	O

The	O
morbidity	O
and	O
mortality	O
were	O
similar	O
in	O
all	O
the	O
groups	O
except	O
SMT	B-P
.	O

The	O
results	O
of	O
this	O
pilot	O
study	O
suggest	O
that	O
midodrine	O
and	O
combination	B-P
with	O
tolvaptan	O
better	O
controls	O
ascites	O
without	O
any	O
renal	O
or	O
hepatic	O
dysfunction	O
.	O

The	O
combination	B-P
therapy	I-P
rapidly	O
controls	O
ascites	O
as	O
compared	O
to	O
midodrine	O
or	O
tolvaptan	O
alone	O
.	O

Anti-Alzheimer	O
's	O
disease	O
activity	O
of	O
compounds	O
from	O
the	O
root	O
bark	O
of	O
Morus	O
alba	O
L.	O
The	O
inhibition	O
of	O
acetylcholinesterase	O
(	O
AChE	O
)	O
,	O
butyrylcholinesterase	O
(	O
BChE	O
)	O
,	O
and	O
β-site	O
amyloid	O
precursor	O
protein	O
cleaving	O
enzyme	O
1	O
(	O
BACE1	O
)	O
plays	O
important	O
roles	O
in	O
prevention	O
and	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Among	O
the	O
individual	O
parts	O
of	O
Morus	O
alba	O
L.	O
including	O
root	O
bark	O
,	O
branches	O
,	O
leaves	O
,	O
and	O
fruits	O
,	O
the	O
root	O
bark	O
showed	O
the	O
most	O
potent	O
enzyme	O
inhibitory	O
activities	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
anti-AD	O
activity	O
of	O
the	O
M.	O
alba	O
root	O
bark	O
and	O
its	O
isolate	O
compounds	O
,	O
including	O
mulberrofuran	O
G	O
(	O
1	O
)	O
,	O
albanol	O
B	O
(	O
2	O
)	O
,	O
and	O
kuwanon	O
G	O
(	O
3	O
)	O
via	O
inhibition	O
of	O
AChE	O
,	O
BChE	O
,	O
and	O
BACE1	O
.	O

Compounds	O
1	O
and	O
2	O
showed	O
strong	O
AChE-	O
and	O
BChE-inhibitory	O
activities	O
;	O
1-3	O
showed	O
significant	O
BACE1	O
inhibitory	O
activity	O
.	O

Based	O
on	O
the	O
kinetic	O
study	O
with	O
AChE	O
and	O
BChE	O
,	O
2	O
and	O
3	O
showed	O
noncompetitive-type	O
inhibition	O
;	O
1	O
showed	O
mixed-type	O
inhibition	O
.	O

Moreover	O
,	O
1-3	O
showed	O
mixed-type	O
inhibition	O
against	O
BACE1	O
.	O

The	O
molecular	O
docking	O
simulations	O
of	O
1-3	O
demonstrated	O
negative	O
binding	O
energies	O
,	O
indicating	O
a	O
high	O
affinity	O
to	O
AChE	O
and	O
BACE1	O
.	O

The	O
hydroxyl	O
group	O
of	O
1-3	O
formed	O
hydrogen	O
bond	O
with	O
the	O
amino	O
acid	O
residues	O
located	O
at	O
AChE	O
and	O
BACE1	O
.	O

Consequently	O
,	O
these	O
results	O
indicate	O
that	O
the	O
root	O
bark	O
of	O
M.	O
alba	O
and	O
its	O
active	O
compounds	O
might	O
be	O
promising	O
candidates	O
for	O
preventive	B-P
and	O
therapeutic	O
agents	O
for	O
AD	O
.	O

The	O
SmartOR	O
:	O
a	O
distributed	O
sensor	O
network	O
to	O
improve	O
operating	O
room	O
efficiency	O
.	O

Despite	O
the	O
significant	O
expense	O
of	O
OR	O
time	O
,	O
best	O
practice	O
achieves	O
only	O
70	O
%	O
efficiency	O
.	O

Compounding	O
this	O
problem	O
is	O
a	O
lack	O
of	O
real-time	O
data	O
.	O

Most	O
current	O
OR	O
utilization	O
programs	O
require	O
manual	O
data	O
entry	O
.	O

Automated	O
systems	O
require	O
installation	O
and	O
maintenance	O
of	O
expensive	O
tracking	O
hardware	O
throughout	O
the	O
institution	O
.	O

This	O
study	O
developed	O
an	O
inexpensive	O
,	O
automated	O
OR	O
utilization	O
system	O
and	O
analyzed	O
data	O
from	O
multiple	O
operating	O
rooms	O
.	O

OR	O
activity	O
was	O
deconstructed	O
into	O
four	O
room	O
states	O
.	O

A	O
sensor	O
network	O
was	O
then	O
developed	O
to	O
automatically	O
capture	O
these	O
states	O
using	O
only	O
three	O
sensors	O
,	O
a	O
local	O
wireless	O
network	O
,	O
and	O
a	O
data	O
capture	O
computer	O
.	O

Two	O
systems	O
were	O
then	O
installed	O
into	O
two	O
ORs	O
,	O
recordings	O
captured	O
24/7	O
.	O

The	O
SmartOR	O
recorded	O
the	O
following	O
events	O
:	O
any	O
room	O
activity	O
,	O
patient	O
entry/exit	O
time	O
,	O
anesthesia	O
time	O
,	O
laparoscopy	B-P
time	O
,	O
room	O
turnover	O
time	O
,	O
and	O
time	O
of	O
preoperative	O
patient	O
identification	O
by	O
the	O
surgeon	O
.	O

From	O
November	O
2014	O
to	O
December	O
2015	O
,	O
data	O
on	O
1003	O
cases	O
were	O
collected	O
.	O

The	O
mean	O
turnover	O
time	O
was	O
36	O
min	O
,	O
and	O
38	O
%	O
of	O
cases	O
met	O
the	O
institutional	O
goal	O
of	O
≤30	O
min	O
.	O

Data	O
analysis	O
also	O
identified	O
outlier	O
cases	O
(	O
>	O
1	O
SD	O
from	O
mean	O
)	O
in	O
the	O
domains	O
of	O
time	O
from	O
patient	O
entry	O
into	O
the	O
OR	O
to	O
intubation	B-P
(	O
11	O
%	O
of	O
cases	O
)	O
and	O
time	O
from	O
extubation	B-P
to	O
patient	O
exiting	O
the	O
OR	O
(	O
11	O
%	O
of	O
cases	O
)	O
.	O

Time	O
from	O
surgeon	O
identification	O
of	O
patient	O
to	O
scheduled	O
procedure	O
start	O
time	O
was	O
11	O
min	O
(	O
institution	O
bylaws	O
require	O
20	O
min	O
before	O
scheduled	O
start	O
time	O
)	O
,	O
yet	O
OR	O
teams	O
required	O
22	O
min	O
on	O
average	O
to	O
bring	O
a	O
patient	O
into	O
the	O
room	O
after	O
surgeon	O
identification	O
.	O

The	O
SmartOR	O
automatically	O
and	O
reliably	O
captures	O
data	O
on	O
OR	O
room	O
state	O
and	O
,	O
in	O
real	O
time	O
,	O
identifies	O
outlier	O
cases	O
that	O
may	O
be	O
examined	O
closer	O
to	O
improve	O
efficiency	O
.	O

As	O
no	O
manual	O
entry	O
is	O
required	O
,	O
the	O
data	O
are	O
indisputable	O
and	O
allow	O
OR	O
teams	O
to	O
maintain	O
a	O
patient	O
-centric	O
focus	O
.	O

Role	O
of	O
breast	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
in	O
predicting	O
residual	O
lobular	O
carcinoma	O
in	O
situ	O
after	O
initial	O
excision	B-P
.	O

Breast	B-P
magnetic	I-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
is	O
a	O
useful	O
screening	B-P
modality	O
in	O
detecting	B-P
suspicious	O
lesions	O
in	O
patients	O
with	O
a	O
history	O
of	O
lobular	O
carcinoma	O
in	O
situ	O
(	O
LCIS	O
)	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
breast	B-P
MR	I-P
imaging	I-P
in	O
detecting	B-P
remnant	O
LCIS	O
lesions	O
after	O
initial	O
excision	B-P
.	O

Between	O
2011	O
and	O
2015	O
,	O
29	O
patients	O
with	O
LCIS	O
who	O
underwent	O
initial	O
excision	B-P
were	O
enrolled	O
.	O

Breast	B-P
ultrasonography	I-P
and	O
breast	B-P
MR	I-P
imaging	I-P
was	O
conducted	O
after	O
initial	O
excision	B-P
.	O

Imaging	O
findings	O
were	O
compared	O
with	O
pathologic	O
results	O
.	O

There	O
were	O
nine	O
(	O
31.0	O
%	O
)	O
cases	O
with	O
positive	O
margins	O
after	O
initial	O
excision	B-P
;	O
they	O
were	O
LCIS	O
(	O
n=8	O
)	O
and	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
)	O
.	O

Residual	O
lesions	O
were	O
identified	O
in	O
12	O
cases	O
;	O
they	O
were	O
invasive	O
lobular	O
carcinoma	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
LCIS	O
(	O
n=9	O
;	O
31.0	O
%	O
)	O
,	O
atypical	O
lobular	O
hyperplasia	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
,	O
and	O
papillary	O
carcinoma	O
in	O
situ	O
(	O
n=1	O
;	O
3.4	O
%	O
)	O
.	O

Prior	O
to	O
the	O
second	O
operation	B-P
,	O
these	O
lesions	O
could	O
be	O
detected	O
in	O
seven	O
cases	O
using	O
ultrasonography	B-P
(	O
sensitivity	O
,	O
53.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
and	O
in	O
10	O
cases	O
using	O
breast	B-P
MR	I-P
imaging	I-P
(	O
sensitivity	O
,	O
83.3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
.	O

Breast	B-P
MR	I-P
imaging	I-P
showed	O
higher	O
sensitivity	O
than	O
breast	B-P
ultrasonography	I-P
in	O
detecting	B-P
remnant	O
LCIS	O
lesions	O
.	O

If	O
a	O
suspicious	O
lesion	O
was	O
found	O
using	O
breast	B-P
MR	I-P
imaging	I-P
,	O
a	O
second	O
operation	B-P
should	O
be	O
considered	O
because	O
of	O
the	O
possibility	O
of	O
multifocality	O
,	O
even	O
if	O
LCIS	O
was	O
confirmed	O
at	O
the	O
initial	O
operation	B-P
.	O

Tissue-engineered	B-P
cardiac	O
patch	O
seeded	B-P
with	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
promoted	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
in	O
a	O
rat	O
model	O
.	O

Thousands	O
of	O
babies	O
are	O
born	O
with	O
congenital	O
heart	O
defects	O
that	O
require	O
surgical	B-P
repair	I-P
involving	O
a	O
prosthetic	O
implant	O
.	O

Lack	O
of	O
growth	O
in	O
prosthetic	O
grafts	O
is	O
especially	O
detrimental	O
in	O
pediatric	B-P
surgery	I-P
.	O

Cell	O
seeded	B-P
biodegradable	O
tissue	O
engineered	O
grafts	O
are	O
a	O
novel	O
solution	O
to	O
this	O
problem	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
of	O
seeding	B-P
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
(	O
hiPS-CMs	O
)	O
onto	O
a	O
biodegradable	O
cardiac	O
patch	O
.	O

The	O
hiPS-CMs	O
were	O
cultured	B-P
on	O
a	O
biodegradable	O
patch	O
composed	O
of	O
a	O
polyglycolic	O
acid	O
(	O
PGA	O
)	O
and	O
a	O
50:50	O
poly	O
(	O
l-lactic-co-ε-caprolactone	O
)	O
copolymer	O
(	O
PLCL	O
)	O
for	O
1	O
week	O
.	O

Male	O
athymic	O
rats	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
of	O
10	O
animals	O
each	O
:	O
1.	O
hiPS-CM	O
seeded	B-P
group	O
,	O
and	O
2	O
.	O

Unseeded	O
group	O
.	O

After	O
culture	B-P
,	O
the	O
cardiac	O
patch	O
was	O
implanted	B-P
to	O
repair	B-P
a	O
defect	O
with	O
a	O
diameter	O
of	O
2	O
mm	O
created	O
in	O
the	O
right	O
ventricular	O
outflow	O
tract	O
(	O
RVOT	O
)	O
wall	O
.	O

Hearts	O
were	O
explanted	B-P
at	O
4	O
(	O
n	O
=	O
2	O
)	O
,	O
8	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
16	O
(	O
n	O
=	O
6	O
)	O
weeks	O
after	O
patch	O
implantation	B-P
.	O

Explanted	B-P
patches	O
were	O
assessed	O
immunohistochemically	B-P
.	O

Seeded	B-P
patch	O
explants	B-P
did	O
not	O
stain	O
positive	O
for	O
α-actinin	O
(	O
marker	O
of	O
cardiomyocytes	O
)	O
at	O
the	O
4	O
week	O
time	O
point	O
,	O
suggesting	O
that	O
the	O
cultured	B-P
hiPS-CMs	O
evacuated	O
the	O
patch	O
in	O
the	O
early	O
phase	O
of	O
tissue	O
remodeling	O
.	O

However	O
,	O
after	O
16	O
weeks	O
implantation	B-P
,	O
the	O
area	O
fraction	O
of	O
positively	O
stained	O
α-actinin	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
seeded	B-P
group	O
than	O
in	O
the	O
unseeded	O
group	O
(	O
Seeded	B-P
group	O
:	O
6.1	O
±	O
2.8	O
%	O
vs.	O
Unseeded	O
group	O
:	O
0.95	O
±	O
0.50	O
%	O
,	O
p	O
=	O
0.004	O
)	O
,	O
suggesting	O
cell	O
seeding	B-P
promoted	O
regenerative	O
proliferation	O
of	O
host	O
cardiomyocytes	O
.	O

Seeded	B-P
hiPS-CMs	O
were	O
not	O
present	O
in	O
the	O
patch	O
after	O
4	O
weeks	O
.	O

However	O
,	O
we	O
surmise	O
that	O
they	O
influenced	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
via	O
a	O
paracrine	O
mechanism	O
.	O

Tissue-engineered	B-P
hiPS-CMs	O
seeded	B-P
cardiac	O
patches	O
warrant	O
further	O
investigation	O
for	O
use	O
in	O
the	O
repair	B-P
of	O
congenital	O
heart	O
diseases	O
.	O

Direct	O
Repair	O
of	O
Lumbar	O
Pars	O
Interarticularis	O
Defects	O
by	O
Utilizing	O
Intraoperative	O
O-Arm-Based	O
Navigation	O
and	O
Microendoscopic	B-P
Techniques	I-P
.	O

A	O
retrospective	O
analysis	O
of	O
the	O
clinical	O
outcomes	O
of	O
eight	O
patients	O
with	O
the	O
lumbar	O
pars	O
interarticulars	O
defects	O
treated	O
by	O
direct	O
repair	O
with	O
the	O
aid	O
of	O
intraoperative	O
O-arm	O
based	O
navigation	O
and	O
microendoscopic	B-P
techniques	I-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
direct	O
screw	O
repair	O
by	O
using	O
minimally	B-P
invasive	I-P
surgery	I-P
for	O
the	O
lumbar	O
pars	O
interarticulars	O
defects	O
in	O
a	O
pilot	O
study	O
.	O

Direct	O
repair	O
of	O
pars	O
interarticulars	O
defects	O
has	O
been	O
used	O
to	O
treat	B-P
young	O
adult	O
patients	O
.	O

Reports	O
concerning	O
direct	O
repair	O
by	O
minimally	B-P
invasive	I-P
techniques	I-P
for	O
pars	O
interarticulars	O
defects	O
are	O
quite	O
rare	O
.	O

Review	O
of	O
medical	O
records	O
identified	O
eight	O
consecutive	O
patients	O
treated	O
with	O
intraoperative	O
O-arm	O
based	O
navigation	O
and	O
microendoscopic	B-P
techniques	I-P
.	O

Debridement	B-P
and	O
autograft	B-P
of	O
pars	O
interarticularis	O
defects	O
was	O
performed	O
under	O
microendoscopic	B-P
procedure	I-P
.	O

Then	O
,	O
percutaneous	O
bilateral	O
intralaminar	O
screws	O
were	O
inserted	O
by	O
utilizing	O
intraoperative	O
navigation	O
.	O

The	O
clinical	O
and	O
radiological	O
data	O
were	O
collected	O
and	O
analyzed	O
retrospectively	O
.	O

Eight	O
patients	O
had	O
a	O
mean	O
age	O
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	O
at	O
the	O
time	O
of	O
treatment	B-P
.	O

Symptoms	O
included	O
axial	O
back	O
pain	O
in	O
100	O
%	O
of	O
patients	O
without	O
concomitant	O
radiculopathy	O
.	O

Autograft	B-P
was	O
used	O
in	O
all	O
cases	O
.	O

The	O
average	O
follow-up	O
duration	O
was	O
27.4	O
months	O
with	O
a	O
range	O
of	O
20	O
to	O
33	O
months	O
.	O

Symptoms	O
resolved	O
completely	O
or	O
partially	O
in	O
all	O
patients	O
.	O

Low	O
back	O
pain	O
visual	O
analog	O
scores	O
decrease	O
from	O
preoperative	O
6.8	O
to	O
postoperative	O
1.4	O
of	O
eight	O
cases	O
.	O

Of	O
16	O
pars	O
defects	O
,	O
healing	O
was	O
observed	O
in	O
13	O
(	O
81.3	O
%	O
)	O
at	O
last	O
radiological	O
follow-up	O
.	O

One	O
patient	O
with	O
bilateral	O
fusion	O
failure	O
refused	O
revision	B-P
surgery	I-P
because	O
of	O
mild	O
complaint	O
.	O

No	O
complications	O
such	O
as	O
dural	O
tear	O
,	O
nerve	O
root	O
injury	O
,	O
and	O
infection	O
occurred	O
.	O

Minimally	B-P
invasive	I-P
direct	O
repair	O
of	O
the	O
pars	O
interarticularis	O
defects	O
with	O
intralaminar	O
screws	O
by	O
using	O
microendoscopic	B-P
system	I-P
and	O
navigation	O
procedure	O
can	O
provide	O
safe	O
and	O
effective	O
treatment	B-P
of	O
spondylolysis	O
with	O
satisfactory	O
clinical	O
and	O
radiological	O
outcomes	O
,	O
which	O
need	O
some	O
special	O
tools	O
with	O
steep	O
learning	O
curve	O
.	O

4	O
.	O

Three-dimensional	O
carbon	O
nanotube	O
scaffolds	O
for	O
long-term	O
maintenance	O
and	O
expansion	O
of	O
human	O
mesenchymal	O
stem	O
cells	O
.	O

Expansion	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
and	O
maintenance	O
of	O
their	O
self-renewal	O
capacity	O
in	O
vitro	O
requires	O
specialized	O
robust	O
cell	O
culture	O
systems	O
.	O

Conventional	O
approaches	O
using	O
animal-derived	O
or	O
artificial	O
matrices	O
and	O
a	O
cocktail	O
of	O
growth	O
factors	O
have	O
limitations	O
such	O
as	O
consistency	O
,	O
scalability	O
,	O
pathogenicity	O
,	O
and	O
loss	O
of	O
MSC	O
phenotype	O
.	O

Herein	O
,	O
we	O
report	O
the	O
use	O
of	O
all-carbon	O
3-D	O
single	O
-	O
and	O
multiwalled	O
carbon	O
nanotube	O
scaffolds	O
(	O
SWCNTs	O
and	O
MWCNTs	O
)	O
as	O
artificial	O
matrices	O
for	O
long-term	O
maintenance	O
and	O
expansion	O
of	O
human	O
MSCs	O
.	O

Three-dimensional	O
SWCNT	O
and	O
MWCNT	O
scaffolds	O
were	O
fabricated	O
using	O
a	O
novel	O
radical	O
initiated	O
thermal	O
cross-linking	O
method	O
that	O
covalently	O
cross-links	O
CNTs	O
to	O
form	O
3-D	O
macroporous	O
all-carbon	O
architectures	O
.	O

Adipose-derived	O
human	O
MSCs	O
showed	O
good	O
cell	O
viability	O
,	O
attachment	O
,	O
proliferation	O
,	O
and	O
infiltration	O
in	O
MWCNT	O
and	O
SWCNT	O
scaffolds	O
comparable	O
to	O
poly	O
(	O
lactic-co-glycolic	O
)	O
acid	O
(	O
PLGA	O
)	O
scaffolds	O
(	O
baseline	O
control	O
)	O
.	O

ADSCs	O
retained	O
stem	O
cell	O
phenotype	O
after	O
30	O
days	O
and	O
satisfied	O
the	O
International	O
Society	O
for	O
Cellular	O
Therapy	O
's	O
(	O
ISCT	O
)	O
minimal	O
criteria	O
for	O
MSCs	O
.	O

Post	O
expansion	O
,	O
(	O
1	O
)	O
ADSCs	O
showed	O
in	O
vitro	O
adherence	O
to	O
tissue	O
culture	O
polystyrene	O
(	O
TCPS	O
)	O
;	O
(	O
2	O
)	O
MSC	O
surface	O
antigen	O
expression	O
[	O
CD14	O
(	O
-	O
)	O
,	O
CD19	O
(	O
-	O
)	O
,	O
CD34	O
(	O
-	O
)	O
,	O
CD45	O
(	O
-	O
)	O
,	O
CD73	O
(	O
+	O
)	O
,	O
CD90	O
(	O
+	O
)	O
,	O
CD105	O
(	O
+	O
)	O
]	O
;	O
and	O
(	O
3	O
)	O
trilineage	O
differentiation	O
into	O
osteoblasts	O
,	O
adipocytes	O
,	O
and	O
chondrocytes	O
.	O

Results	O
show	O
that	O
cross-linked	O
3-D	O
MWCNTs	O
and	O
SWCNTs	O
scaffolds	O
are	O
suitable	O
for	O
ex	O
vivo	O
expansion	O
and	O
maintenance	O
of	O
MSCs	O
for	O
therapeutic	B-P
applications	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
A	O
,	O
2017	O
.	O

Central	O
nervous	O
system	O
tumours	O
profile	B-P
at	O
a	O
referral	O
center	O
in	O
the	O
Brazilian	O
Amazon	O
region	O
,	O
1997-2014	O
.	O

Tumours	O
of	O
the	O
Central	O
Nervous	O
System	O
(	O
CNS	O
)	O
are	O
an	O
important	O
cause	O
of	O
mortality	O
from	O
cancer	O
.	O

Epidemiological	O
data	O
on	O
neoplams	O
affecting	O
the	O
CNS	O
are	O
scarce	O
in	O
Brazil	O
,	O
especially	O
in	O
the	O
Amazon	O
region	O
.	O

The	O
study	O
aims	O
at	O
describing	O
the	O
histopathological	O
profile	B-P
of	O
CNS	O
tumours	O
cases	O
at	O
a	O
high-complexity	O
referral	O
cancer	O
center	O
.	O

This	O
study	O
has	O
described	O
a	O
17-year-series	O
profile	B-P
of	O
CNS	O
tumours	O
,	O
registered	O
at	O
a	O
high-complexity	O
referral	O
cancer	O
center	O
in	O
Pará	O
state	O
,	O
from	O
January	O
1997	O
until	O
July	O
2014	O
in	O
the	O
Brazilian	O
Amazon	O
Region	O
.	O

Data	O
was	O
gathered	O
from	O
histopathology	O
reports	O
kept	O
in	O
the	O
hospital	O
's	O
cancer	O
registry	O
and	O
949	O
cases	O
of	O
CNS	O
tumours	O
were	O
analyzed	O
.	O

The	O
most	O
common	O
histopathology	O
were	O
neuroepithelial	O
tumours	O
(	O
approx	O
.	O

40	O
%	O
)	O
and	O
meningioma	O
was	O
the	O
most	O
frequent	O
especific	O
tumor	O
histologic	O
subtype	O
(	O
22.2	O
%	O
)	O
.	O

Neuroepithelial	O
tumours	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
ages	O
ranging	O
from	O
less	O
than	O
a	O
year	O
to	O
19	O
years	O
,	O
whereas	O
metastatic	O
tumours	O
were	O
prevalent	O
in	O
patients	O
over	O
40	O
years	O
of	O
age	O
.	O

It	O
was	O
not	O
found	O
temporal	O
trends	O
during	O
the	O
studied	O
period	O
.	O

The	O
knowledge	O
of	O
these	O
tumours	O
profile	B-P
is	O
valuable	O
for	O
the	O
understanding	O
of	O
cancer	O
epidemiology	O
in	O
the	O
region	O
,	O
since	O
its	O
prevalence	O
is	O
currently	O
underreported	O
and	O
more	O
awareness	O
on	O
the	O
disease	O
is	O
needed	O
.	O

Regulatory	O
role	O
of	O
cytosolic	O
phospholipase	O
A2	O
alpha	O
in	O
the	O
induction	O
of	O
CD40	O
in	O
microglia	O
.	O

The	O
aberrant	O
expression	O
of	O
CD40	O
,	O
a	O
co-stimulatory	O
receptor	O
found	O
on	O
the	O
antigen-presenting	O
cells	O
,	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
various	O
degenerative	O
diseases	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
the	O
reduction	O
of	O
cytosolic	O
phospholipase	O
A2	O
alpha	O
(	O
cPLA2α	O
)	O
protein	O
overexpression	O
and	O
activation	O
in	O
the	O
spinal	O
cord	O
of	O
a	O
mouse	O
model	O
of	O
ALS	O
,	O
hmSOD1	O
G93A	O
,	O
inhibited	O
CD40	O
upregulation	O
in	O
microglia	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
cPLA2α	O
has	O
a	O
direct	O
,	O
participatory	O
role	O
in	O
the	O
molecular	O
events	O
leading	O
to	O
CD40	O
induction	O
.	O

Cultures	B-P
of	O
primary	O
mouse	O
microglia	O
or	O
BV-2	O
microglia	O
cell	O
line	O
exposed	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
interferon	O
gamma	O
(	O
IFNγ	O
)	O
for	O
different	O
periods	O
of	O
time	O
,	O
in	O
order	O
to	O
study	O
the	O
role	O
of	O
cPLA2α	O
in	O
the	O
events	O
leading	O
to	O
CD40	O
protein	O
induction	O
.	O

Addition	O
of	O
LPS	O
or	O
IFNγ	O
caused	O
a	O
significant	O
upregulation	O
of	O
cPLA2α	O
and	O
of	O
CD40	O
,	O
while	O
prevention	O
of	O
cPLA2α	O
upregulation	O
by	O
a	O
specific	O
oligonucleotide	O
antisense	O
(	O
AS	O
)	O
prevented	O
the	O
induction	O
of	O
CD40	O
,	O
suggesting	O
a	O
role	O
of	O
cPLA2α	O
in	O
the	O
induction	O
of	O
CD40	O
.	O

Addition	O
of	O
LPS	O
to	O
microglia	O
caused	O
an	O
immediate	O
activation	O
of	O
cPLA2α	O
detected	O
by	O
its	O
phosphorylated	O
form	O
,	O
while	O
addition	O
of	O
IFNγ	O
induced	O
cPLA2α	O
activation	O
at	O
a	O
later	O
time	O
scale	O
(	O
4	O
h	O
)	O
.	O

The	O
activation	O
of	O
cPLA2α	O
is	O
mediated	O
by	O
ERK	O
activity	O
.	O

Suppression	O
of	O
cPLA2α	O
activity	O
inhibited	O
superoxide	O
production	O
by	O
NOX2-NADPH	O
oxidase	O
and	O
activation	O
of	O
NF-κB	O
detected	O
by	O
the	O
phosphorylation	O
of	O
p65	O
on	O
serine	O
536	O
at	O
15	O
min	O
by	O
LPS	O
and	O
at	O
4	O
h	O
by	O
IFNγ	O
.	O

Inhibition	O
of	O
NOX2	O
prevented	O
NF-κB	O
activation	O
and	O
CD40	O
induction	O
but	O
did	O
not	O
affect	O
cPLA2α	O
activation	O
,	O
suggesting	O
cPLA2α	O
is	O
located	O
upstream	O
to	O
NOX2	O
and	O
NF-κB	O
.	O

The	O
activation	O
of	O
cPLA2	O
by	O
LPS	O
was	O
mediated	O
by	O
both	O
adaptor	O
proteins	O
downstream	O
to	O
LPS	O
receptor	O
;	O
TRIF	O
and	O
MyD88	O
,	O
while	O
the	O
activation	O
of	O
cPLA2α	O
by	O
IFNγ	O
was	O
mediated	O
by	O
the	O
secreted	O
TNF-α	O
at	O
4	O
h.	O
The	O
early	O
activation	O
of	O
STAT1α	O
(	O
detected	O
by	O
phospho-serine727	O
and	O
phoshpo-tyrosine701	O
)	O
by	O
IFNγ	O
and	O
the	O
late	O
activation	O
of	O
STAT1α	O
by	O
LPS	O
were	O
not	O
affected	O
in	O
the	O
presence	O
of	O
cPLA2α	O
inhibitors	O
,	O
indicating	O
that	O
STAT1α	O
is	O
not	O
under	O
cPLA2α	O
regulation	O
.	O

Our	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
cPLA2	O
upregulates	O
CD40	O
protein	O
expression	O
induced	O
by	O
either	O
LPS	O
or	O
IFNγ	O
,	O
and	O
this	O
regulatory	O
effect	O
is	O
mediated	O
via	O
the	O
activation	O
of	O
NOX2-NADPH	O
oxidase	O
and	O
NF-κB	O
.	O

Cumulatively	O
,	O
our	O
results	O
indicate	O
that	O
cPLA2α	O
may	O
serve	O
as	O
a	O
pivotal	O
amplifier	O
of	O
the	O
inflammatory	O
response	O
in	O
the	O
CNS	O
.	O

Incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	O
cataract	O
in	O
Children	O
of	O
Lahore	O
.	O

To	O
check	O
the	O
incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	O
cataract	O
in	O
infants	O
.	O

The	O
descriptive	O
study	O
was	O
conducted	O
at	O
Layton	O
Rahmatullah	O
Benevolent	O
Trust	O
,	O
Lahore	O
,	O
Pakistan	O
,	O
from	O
October	O
2013	O
to	O
April	O
2014	O
,	O
and	O
comprised	O
children	O
under	O
15	O
years	O
of	O
age	O
who	O
had	O
rubella	O
syndrome	O
,	O
herpes	O
simplex	O
,	O
birth	O
trauma	O
,	O
trisomy	O
21	O
,	O
Nance-Horan	O
syndrome	O
or	O
Lowe	O
's	O
syndrome	O
.	O

Of	O
the	O
38,000	O
cases	O
examined	O
,	O
120	O
(	O
0.3	O
%	O
)	O
patients	O
were	O
diagnosed	O
with	O
congenital	O
cataract	O
.	O

Of	O
them	O
,	O
52	O
(	O
43.33	O
%	O
)	O
were	O
aged	O
between	O
2	O
and	O
5	O
years	O
,22	O
(	O
18.33	O
%	O
)	O
<	O
11	O
years	O
and	O
10	O
(	O
8.33	O
%	O
)	O
?	O
15	O
years	O
.	O

Bilateral	O
congenital	O
cataract	O
was	O
observed	O
in	O
91	O
(	O
75.83	O
%	O
)	O
patients	O
and	O
unilateral	O
congenital	O
cataract	O
in	O
29	O
(	O
24.17	O
%	O
)	O
.	O

Environmental	O
factors	O
caused	O
72	O
(	O
62.07	O
%	O
)	O
cases	O
and	O
genetic	O
factors	O
caused	O
44	O
(	O
37.93	O
%	O
)	O
..	O
Congenital	O
cataract	O
predominated	O
in	O
boys	O
compared	O
to	O
girls	O
.	O

Early	O
diagnosis	O
and	O
adequate	O
therapy	B-P
requires	O
specific	O
technology	O
,	O
as	O
well	O
as	O
long-term	O
and	O
permanent	O
care	O
..	O

Glycated	O
Hemoglobin	O
(	O
HbA1c	O
)	O
Correlation	O
with	O
Severity	O
of	O
Coronary	O
Artery	O
Disease	O
in	O
Non-diabetic	O
Patients	O
-	O
A	O
Hospital	O
based	O
Study	O
from	O
North-Eastern	O
India	O
.	O

Glycated	O
Hemoglobin	O
(	O
HbA1c	O
)	O
levels	O
are	O
predictive	O
of	O
cardiovascular	O
disease	O
and	O
mortality	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
however	O
,	O
association	O
of	O
HbA1c	O
with	O
Coronary	O
Artery	O
Disease	O
(	O
CAD	O
)	O
in	O
non-diabetics	O
is	O
inconsistent	O
.	O

To	O
evaluate	O
the	O
correlation	O
between	O
HbA1c	O
level	O
and	O
severity	O
of	O
CAD	O
in	O
non-diabetic	O
patients	O
using	O
SYNTAX	O
score	O
in	O
a	O
cohort	O
of	O
proven	O
CAD	O
on	O
angiography	B-P
at	O
Gauhati	O
Medical	O
College	O
,	O
Guwahati	O
,	O
Assam	O
,	O
India	O
,	O
which	O
is	O
a	O
major	O
tertiary	O
care	O
hospital	O
of	O
North-Eastern	O
India	O
.	O

We	O
prospectively	O
collected	O
data	O
of	O
non-diabetic	O
patients	O
with	O
proven	O
CAD	O
on	O
angiography	B-P
from	O
June	O
2014	O
to	O
June	O
2015	O
.	O

Patients	O
were	O
divided	O
into	O
four	O
groups	O
(	O
interquartiles	O
)	O
according	O
to	O
HbA1c	O
levels	O
,	O
less	O
than	O
4.8	O
%	O
,	O
4.8	O
%	O
to	O
5.1	O
%	O
,	O
5.1	O
%	O
to	O
5.6	O
%	O
,	O
and	O
5.6	O
%	O
to	O
6.5	O
%	O
.	O

Severity	O
of	O
CAD	O
was	O
assessed	O
using	O
SYNTAX	O
score	O
and	O
the	O
number	O
of	O
coronary	O
vessels	O
diseased	O
.	O

We	O
compared	O
different	O
quartiles	O
of	O
HbA1c	O
with	O
regard	O
to	O
SYNTAX	O
score	O
and	O
number	O
of	O
diseased	O
vessels	O
.	O

A	O
total	O
of	O
346	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

Mean	O
age	O
was	O
58.1±10.4	O
years	O
.	O

Of	O
the	O
total	O
91.9	O
%	O
(	O
318	O
)	O
were	O
males	O
,	O
44.8	O
%	O
(	O
155	O
)	O
were	O
hypertensives	O
,	O
29.2	O
%	O
(	O
101	O
)	O
were	O
smokers	O
and	O
34.7	O
%	O
(	O
120	O
)	O
were	O
dyslipidemic	O
.	O

We	O
found	O
that	O
CAD	O
severity	O
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	O
involved	O
was	O
significantly	O
different	O
among	O
quartiles	O
(	O
p-values	O
<	O
0.001	O
and	O
<	O
0.001	O
respectively	O
)	O
.	O

Increase	O
in	O
HbA1c	O
level	O
was	O
strongly	O
correlated	O
with	O
disease	O
severity	O
and	O
higher	O
SYNTAX	O
score	O
.	O

A	O
significant	O
increase	O
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased	O
vessels	O
(	O
p-value	O
<	O
0.001	O
)	O
as	O
HbA1c	O
level	O
increases	O
.	O

Age	O
,	O
gender	O
,	O
hypertension	O
and	O
dyslipidemia	O
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	O
however	O
smoking	O
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
severity	O
of	O
CAD	O
by	O
SYNTAX	O
score	O
(	O
p	O
<	O
0.05	O
)	O
.	O

From	O
this	O
clinical	O
study	O
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	O
exists	O
between	O
HbA1c	O
and	O
severity	O
of	O
CAD	O
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	O
involved	O
in	O
non-	O
diabetes	O
.	O

Us3	O
and	O
Us9	O
proteins	O
contribute	O
to	O
the	O
stromal	O
invasion	O
of	O
bovine	O
herpesvirus	O
1	O
in	O
the	O
respiratory	O
mucosa	O
.	O

Bovine	O
herpesvirus	O
1	O
(	O
BHV-1	O
)	O
infection	O
may	O
lead	O
to	O
conjunctivitis	O
,	O
upper	O
respiratory	O
tract	O
problems	O
,	O
pneumonia	O
,	O
genital	O
disorders	O
and	O
abortion	O
.	O

BHV-1	O
is	O
able	O
to	O
spread	O
quickly	O
in	O
a	O
plaque	O
-wise	O
manner	O
and	O
invade	O
by	O
breaching	O
the	O
basement	O
membrane	O
(	O
BM	O
)	O
barrier	O
in	O
the	O
respiratory	O
mucosa	O
.	O

BHV-1	O
Us3	O
,	O
a	O
serine/threonine	O
kinase	O
,	O
induces	O
a	O
dramatic	O
cytoskeletal	O
reorganization	O
and	O
BHV-1	O
Us9	O
,	O
a	O
tail-anchored	O
membrane	O
protein	O
,	O
is	O
required	O
for	O
axonal	O
transport	O
of	O
viruses	O
in	O
neurons	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
Us3	O
and	O
Us9	O
during	O
BHV-1	O
infection	O
in	O
the	O
respiratory	O
mucosa	O
.	O

First	O
,	O
we	O
constructed	O
and	O
characterized	O
BHV-1	O
Us3	O
null	O
,	O
Us9	O
null	O
and	O
revertant	O
viruses	O
.	O

Then	O
,	O
we	O
analysed	O
the	O
viral	O
replication	O
and	O
plaque	O
size	O
(	O
latitude	O
)	O
in	O
Madin-Darby	O
bovine	O
kidney	O
(	O
MDBK	O
)	O
cells	O
and	O
the	O
respiratory	O
mucosa	O
as	O
well	O
as	O
viral	O
penetration	O
depth	O
underneath	O
the	O
BM	O
of	O
the	O
respiratory	O
mucosa	O
when	O
inoculated	B-P
with	O
these	O
recombinant	O
viruses	O
.	O

Knockout	O
of	O
Us3	O
resulted	O
in	O
a	O
1	O
log10	O
reduction	O
in	O
viral	O
titre	O
and	O
plaque	O
size	O
(	O
latitude	O
)	O
in	O
MDBK	O
cells	O
and	O
the	O
trachea	O
mucosa	O
.	O

There	O
were	O
no	O
defects	O
in	O
the	O
cell-to-cell	O
spread	O
observed	O
for	O
BHV-1	O
Us9	O
null	O
virus	O
.	O

Both	O
BHV-1	O
Us3	O
null	O
and	O
Us9	O
null	O
viruses	O
showed	O
a	O
significant	O
reduction	O
of	O
plaque	O
penetration	O
underneath	O
the	O
BM	O
;	O
however	O
,	O
penetration	O
was	O
not	O
completely	O
inhibited	O
.	O

In	O
conclusion	O
,	O
the	O
current	O
findings	O
demonstrated	O
that	O
Us3	O
and	O
Us9	O
play	O
an	O
important	O
role	O
in	O
the	O
invasion	O
of	O
BHV-1	O
through	O
the	O
BM	O
of	O
the	O
respiratory	O
mucosa	O
,	O
which	O
shows	O
the	O
way	O
forward	O
for	O
research	O
-based	O
attenuation	O
of	O
viruses	O
in	O
order	O
to	O
make	O
safer	O
and	O
better	O
-	O
performing	O
vaccines	O
.	O

Altered	O
expression	O
of	O
the	O
Olr59	O
,	O
Ethe1	O
,	O
and	O
Slc10a2	O
genes	O
in	O
the	O
liver	O
of	O
F344	O
rats	O
by	O
neonatal	O
thyroid	O
hormone	O
disruption	O
.	O

Many	O
concerns	O
have	O
been	O
expressed	O
regarding	O
the	O
possible	O
adverse	O
effects	O
of	O
thyroid	O
hormone-disrupting	O
chemicals	O
in	O
the	O
environment	O
.	O

The	O
disruption	O
of	O
thyroid	O
hormones	O
in	O
the	O
neonatal	O
period	O
may	O
lead	O
to	O
permanent	O
effects	O
on	O
thyroid	O
hormone	O
homeostasis	O
as	O
well	O
as	O
related	O
developmental	O
disorders	O
,	O
as	O
thyroid	O
hormones	O
are	O
essential	O
for	O
regulating	O
the	O
growth	O
and	O
differentiation	O
of	O
many	O
tissues	O
.	O

To	O
understand	O
the	O
long-term	O
alteration	O
in	O
gene	O
expressions	O
by	O
neonatal	O
administration	B-P
of	I-P
thyroid	I-P
hormone	I-P
-like	O
chemicals	O
in	O
general	O
,	O
we	O
identified	O
genes	O
whose	O
expression	O
was	O
altered	O
in	O
the	O
liver	O
,	O
an	O
important	O
component	O
of	O
the	O
thyroid	O
hormone	O
axis	O
,	O
by	O
neonatal	O
exposure	O
to	O
triiodothyronine	O
(	O
T3	O
)	O
.	O

T3	O
was	O
administered	B-P
to	O
male	O
F344	O
rats	O
on	O
postnatal	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
(	O
week	O
0	O
)	O
.	O

At	O
8	O
weeks	O
of	O
age	O
,	O
cDNA	O
microarray	O
analysis	O
was	O
used	O
to	O
identify	O
hepatic	O
genes	O
whose	O
expression	O
was	O
altered	O
by	O
neonatal	O
exposure	O
to	O
T3	O
.	O

Among	O
the	O
up-regulated	O
genes	O
that	O
were	O
identified	O
,	O
the	O
expression	O
of	O
Olr59	O
,	O
Ethe1	O
,	O
and	O
Slc10a2	O
increased	O
specifically	O
in	O
rats	O
neonatally	O
exposed	O
to	O
T3	O
.	O

Interestingly	O
,	O
altered	O
hepatic	O
expression	O
of	O
these	O
genes	O
indeed	O
increased	O
when	O
a	O
hydroxylated	O
polybrominated	O
diphenyl	O
ether	O
(	O
PBDE	O
)	O
,	O
OH-BDE42	O
,	O
which	O
is	O
capable	O
of	O
binding	O
to	O
the	O
TR	O
,	O
was	O
given	O
neonatally	O
.	O

Our	O
data	O
demonstrated	O
that	O
neonatal	O
exposure	O
to	O
thyroid	O
hormones	O
could	O
affect	O
the	O
long-term	O
expression	O
of	O
the	O
genes	O
,	O
which	O
could	O
be	O
useful	O
markers	O
for	O
neonatal	O
effects	O
by	O
thyroid	O
hormone	O
-	O
disrupting	O
chemicals	O
.	O

Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O
Proliferation	O
,	O
Invasion	O
and	O
Drug	O
-	O
Induced	O
Apoptosis	O
in	O
Lymphoblastic	O
Leukemia	O
.	O

Some	O
studies	O
have	O
shown	O
that	O
extracellular	O
pH	O
in	O
tumors	O
,	O
which	O
results	O
in	O
tumor	O
progression	O
,	O
is	O
less	O
than	O
that	O
in	O
normal	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
extracellular	O
acidic	O
pH	O
on	O
proliferation	O
,	O
invasion	O
,	O
and	O
drug	O
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
cells	O
.	O

The	O
cells	O
were	O
cultured	O
in	O
different	O
pH	O
(	O
pH	O
6.6	O
and	O
pH	O
7.4	O
)	O
for	O
12	O
days	O
.	O

Cell	O
proliferation	O
was	O
assessed	O
by	O
MTT	O
assay	O
and	O
cell	O
invasion	O
was	O
assayed	O
by	O
invasion	B-P
assay	I-P
and	O
gene	O
expression	O
analysis	O
of	O
MMP-9	O
.	O

Drug	O
-	O
induced	O
apoptosis	O
was	O
evaluated	O
after	O
exposure	O
to	O
doxorubicin	O
for	O
24	O
hours	O
by	O
annexin	O
V	O
/	O
PI	O
staining	B-P
and	O
gene	O
expression	O
analysis	O
of	O
BAX	O
pro-apoptotic	O
protein	O
.	O

The	O
results	O
indicated	O
the	O
enhanced	O
growth	O
and	O
invasion	O
of	O
leukemic	O
cells	O
at	O
pH	O
6.6	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

Furthermore	O
,	O
the	O
cells	O
at	O
pH	O
6.6	O
were	O
resistant	O
to	O
apoptosis	O
by	O
doxorubicin	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

It	O
can	O
be	O
concluded	O
that	O
acidic	O
pH	O
increases	O
the	O
proliferation	O
,	O
invasion	O
and	O
reduces	O
the	O
drug	O
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Extracellular	O
acidity	O
can	O
influence	O
the	O
behavior	O
of	O
leukemic	O
cells	O
and	O
therefore	O
,	O
the	O
manipulation	O
of	O
extracellular	O
liquid	O
can	O
be	O
selected	O
as	O
a	O
therapeutic	B-P
strategy	I-P
for	O
leukemia	O
,	O
especially	O
for	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Outcomes	O
With	O
Cerclage	B-P
Alone	O
Compared	O
With	O
Cerclage	B-P
Plus	O
17α-Hydroxyprogesterone	O
Caproate	O
.	O

To	O
examine	O
the	O
differences	O
in	O
perinatal	O
outcomes	O
among	O
women	O
with	O
a	O
prior	O
preterm	O
birth	O
who	O
received	O
cerclage	B-P
compared	O
with	O
cerclage	B-P
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

Women	O
with	O
transvaginal	B-P
cerclage	I-P
placement	O
and	O
a	O
prior	O
delivery	O
between	O
16	O
and	O
36	O
weeks	O
of	O
gestation	O
were	O
identified	O
over	O
a	O
10-	O
year	O
period	O
(	O
July	O
2002	O
to	O
May	O
2012	O
)	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

Exclusion	O
criteria	O
were	O
delivery	O
at	O
another	O
institution	O
,	O
abdominal	B-P
cerclage	I-P
,	O
multiple	O
gestations	O
,	O
and	O
major	O
fetal	O
anomalies	O
.	O

Maternal	O
demographics	O
,	O
gestational	O
age	O
at	O
cerclage	B-P
,	O
gestational	O
age	O
at	O
delivery	O
,	O
preterm	O
prelabor	O
rupture	O
of	O
membranes	O
(	O
PROM	O
)	O
,	O
and	O
birth	O
weight	O
were	O
compared	O
between	O
women	O
with	O
a	O
cerclage	B-P
and	O
cerclage	B-P
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

The	O
primary	O
outcome	O
was	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
.	O

Of	O
the	O
411	O
women	O
who	O
had	O
a	O
cerclage	B-P
,	O
260	O
met	O
inclusion	O
criteria	O
.	O

Of	O
these	O
,	O
171	O
received	O
a	O
cerclage	B-P
alone	O
and	O
89	O
received	O
cerclage	B-P
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

The	O
two	O
groups	O
were	O
not	O
different	O
with	O
respect	O
to	O
maternal	O
demographics	O
and	O
gestational	O
age	O
at	O
cerclage	B-P
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
those	O
who	O
received	O
indomethacin	O
at	O
the	O
time	O
of	O
cerclage	B-P
,	O
betamethasone	O
administration	B-P
,	O
and	O
history	O
of	O
a	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
and	O
cerclage	B-P
.	O

Delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
occurred	O
in	O
6	O
%	O
of	O
women	O
receiving	O
both	O
17α-hydroxyprogesterone	O
caproate	O
and	O
cerclage	B-P
compared	O
with	O
16	O
%	O
in	O
the	O
cerclage	B-P
only	O
group	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.31	O
,	O
95	O
%	O
confidence	O
interval	O
0.10-0.78	O
,	O
P=.01	O
)	O
.	O

In	O
the	O
multivariate	O
analysis	O
controlling	O
for	O
indomethacin	O
use	O
,	O
prior	O
cerclage	B-P
,	O
and	O
loop	B-P
electrosurgical	I-P
excision	I-P
procedure	I-P
-	O
cold	B-P
knife	I-P
cone	I-P
there	O
was	O
a	O
73	O
%	O
reduction	O
in	O
delivery	O
in	O
the	O
combined	O
treatment	O
group	O
compared	O
with	O
cerclage	B-P
alone	O
(	O
adjusted	O
OR	O
0.26	O
,	O
P=.02	O
)	O
.	O

A	O
multivariant	O
analysis	O
was	O
conducted	O
with	O
correction	O
for	O
indomethacin	O
at	O
the	O
time	O
of	O
cerclage	B-P
,	O
prior	O
cerclage	B-P
,	O
and	O
loop	B-P
electrosurgical	I-P
excision	I-P
procedure	I-P
-	O
cold	B-P
knife	I-P
cone	I-P
and	O
cerclage	B-P
surgery	B-P
.	O

Even	O
after	O
controlling	O
for	O
significant	O
variables	O
,	O
there	O
remained	O
a	O
73	O
%	O
reduction	O
in	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
in	O
the	O
cerclage	B-P
plus	O
17α-hydroxyprogesterone	O
caproate	O
cohort	O
(	O
adjusted	O
OR	O
0.26	O
,	O
P=.02	O
)	O
.	O

Women	O
receiving	O
transvaginal	B-P
cerclage	I-P
plus	O
17α-hydroxyprogesterone	O
caproate	O
had	O
a	O
69	O
%	O
relative	O
reduction	O
in	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
when	O
compared	O
with	O
women	O
receiving	O
cerclage	B-P
alone	O
.	O

We	O
found	O
no	O
difference	O
in	O
overall	O
preterm	O
delivery	O
or	O
preterm	O
PROM	O
.	O

In	O
this	O
cohort	O
,	O
compared	O
with	O
cerclage	B-P
alone	O
,	O
the	O
likelihood	O
of	O
a	O
viable	O
neonate	O
improves	O
with	O
both	O
treatments	B-P
.	O

Night-waking	O
trajectories	O
and	O
associated	O
factors	O
in	O
French	O
preschoolers	O
from	O
the	O
EDEN	O
birth-cohort	O
.	O

Night	O
waking	O
in	O
preschoolers	O
has	O
been	O
associated	O
with	O
adverse	O
health	O
outcomes	O
in	O
cross-sectional	O
studies	O
,	O
but	O
has	O
rarely	O
been	O
analyzed	O
in	O
a	O
longitudinal	O
setting	O
.	O

Therefore	O
,	O
little	O
is	O
known	O
about	O
the	O
evolution	O
of	O
night	O
waking	O
in	O
early	O
childhood	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
:	O
to	O
identify	O
night-waking	O
trajectories	O
in	O
preschoolers	O
,	O
and	O
to	O
examine	O
the	O
risk	O
factors	O
associated	O
with	O
those	O
trajectories	O
.	O

Analyses	O
were	O
based	O
on	O
the	O
French	O
birth-cohort	O
study	O
EDEN	O
,	O
which	O
recruited	O
2002	O
pregnant	O
women	O
between	O
2003	O
and	O
2006	O
.	O

Data	O
on	O
a	O
child	O
's	O
night	O
waking	O
at	O
the	O
ages	O
of	O
two	O
,	O
three	O
,	O
and	O
five	O
,	O
six	O
years	O
,	O
and	O
potential	O
confounders	O
,	O
were	O
collected	O
through	O
parental	O
self-reported	O
questionnaires	O
.	O

Night-waking	O
trajectories	O
were	O
computerized	O
using	O
group-based	O
trajectory	O
modeling	O
on	O
1346	O
children	O
.	O

Two	O
distinct	O
developmental	O
patterns	O
were	O
identified	O
:	O
the	O
``	O
2-5	O
rare	O
night-waking	O
``	O
(	O
77	O
%	O
of	O
the	O
children	O
)	O
and	O
the	O
``	O
2-5	O
common	O
night-waking	O
``	O
pattern	O
.	O

Logistic	O
regressions	O
were	O
performed	O
to	O
identify	O
the	O
factors	O
associated	O
with	O
the	O
trajectories	O
.	O

Risk	O
factors	O
for	O
belonging	O
to	O
the	O
``	O
2-5	O
common	O
night-waking	O
``	O
trajectory	O
were	O
:	O
exposure	O
to	O
passive	O
smoking	O
at	O
home	O
,	O
daycare	O
in	O
a	O
collective	O
setting	O
,	O
watching	O
television	O
for	O
extended	O
periods	O
,	O
bottle	B-P
feeding	I-P
at	O
night	O
,	O
high	O
emotionality	O
,	O
and	O
low	O
shyness	O
.	O

This	O
approach	O
allowed	O
identification	O
of	O
risk	O
factors	O
associated	O
with	O
night	O
waking	O
during	O
a	O
critical	O
age	O
window	O
,	O
and	O
laid	O
the	O
groundwork	O
for	O
identifying	O
children	O
at	O
higher	O
risk	O
of	O
deleterious	O
sleep	O
patterns	O
.	O

Those	O
risk	O
factors	O
were	O
mainly	O
living	O
habits	O
,	O
which	O
indicated	O
that	O
prevention	O
and	O
intervention	B-P
programs	I-P
could	O
be	O
highly	O
beneficial	O
in	O
this	O
population	O
.	O

Does	O
obtaining	O
an	O
initial	O
magnetic	B-P
resonance	I-P
imaging	I-P
decrease	O
the	O
reamputation	B-P
rates	O
in	O
the	O
diabetic	O
foot	O
?	O
.	O

Diabetes	O
mellitus	O
(	O
DM	O
)	O
through	O
its	O
over	O
glycosylation	O
of	O
neurovascular	O
structures	O
and	O
resultant	O
peripheral	O
neuropathy	O
continues	O
to	O
be	O
the	O
major	O
risk	O
factor	O
for	O
pedal	B-P
amputation	I-P
.	O

Repetitive	O
trauma	O
to	O
the	O
insensate	O
foot	O
results	O
in	O
diabetic	O
foot	O
ulcers	O
,	O
which	O
are	O
at	O
high	O
risk	O
to	O
develop	O
osteomyelitis	O
.	O

Many	O
patients	O
who	O
present	O
with	O
diabetic	O
foot	O
complications	O
will	O
undergo	O
one	O
or	O
more	O
pedal	B-P
amputations	I-P
during	O
the	O
course	O
of	O
their	O
disease	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
obtaining	O
an	O
initial	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
prior	O
to	O
the	O
first	O
amputation	B-P
,	O
is	O
associated	O
with	O
a	O
decreased	O
rate	O
of	O
reamputation	B-P
in	O
the	O
diabetic	O
foot	O
.	O

Our	O
hypothesis	O
was	O
that	O
the	O
rate	O
of	O
reamputation	B-P
may	O
be	O
associated	O
with	O
underutilization	O
of	O
obtaining	O
an	O
initial	O
MRI	B-P
,	O
useful	O
in	O
presurgical	B-P
planning	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
there	O
was	O
an	O
association	O
between	O
the	O
reamputation	B-P
rate	O
in	O
diabetic	O
patients	O
and	O
utilization	O
of	O
MRI	B-P
in	O
the	O
presurgical	B-P
planning	O
and	O
prior	O
to	O
initial	O
forefoot	B-P
amputations	I-P
.	O

Following	O
approval	O
by	O
our	O
institutional	O
review	O
board	O
,	O
our	O
study	O
design	O
consisted	O
of	O
a	O
retrospective	O
cohort	O
analysis	O
of	O
413	O
patients	O
at	O
Staten	O
Island	O
University	O
Hospital	O
,	O
a	O
700-bed	O
tertiary	O
referral	O
center	O
between	O
2008	O
and	O
2013	O
who	O
underwent	O
an	O
initial	O
great	B-P
toe	I-P
(	I-P
hallux	I-P
)	I-P
amputation	I-P
.	O

Of	O
the	O
413	O
patients	O
with	O
a	O
hallux	B-P
amputation	I-P
,	O
there	O
were	O
368	O
eligible	O
patients	O
who	O
had	O
a	O
history	O
of	O
DM	O
with	O
documented	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
within	O
3	O
months	O
of	O
the	O
initial	O
first	O
ray	O
(	O
hallux	O
and	O
first	O
metatarsal	O
)	O
amputation	B-P
and	O
available	O
radiographic	O
data	O
.	O

Statistical	O
analysis	O
compared	O
the	O
incidence	O
rates	O
of	O
reamputation	B-P
between	O
patients	O
who	O
underwent	O
initial	O
MRI	B-P
and	O
those	O
who	O
did	O
not	O
obtain	O
an	O
initial	O
MRI	B-P
prior	O
to	O
their	O
first	O
amputation	B-P
.	O

The	O
reamputation	B-P
rate	O
was	O
compared	O
after	O
adjustment	O
for	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
HbA1c	O
,	O
cardiovascular	O
disease	O
,	O
hypoalbuminemia	O
,	O
smoking	O
,	O
body	O
mass	O
index	O
,	O
and	O
prior	O
antibiotic	B-P
treatment	I-P
.	O

The	O
results	O
of	O
our	O
statistical	O
analysis	O
failed	O
to	O
reveal	O
a	O
significant	O
association	O
between	O
obtaining	O
an	O
initial	O
MRI	B-P
and	O
the	O
reamputation	B-P
rate	O
.	O

We	O
did	O
,	O
however	O
,	O
find	O
a	O
statistical	O
association	O
between	O
obtaining	O
an	O
early	O
MRI	B-P
and	O
decreased	O
mortality	O
rates	O
.	O

Obtaining	O
an	O
early	O
MRI	B-P
was	O
not	O
associated	O
with	O
the	O
reamputation	B-P
rate	O
incidence	O
in	O
the	O
treatment	B-P
of	O
the	O
diabetic	O
foot	O
.	O

It	O
did	O
,	O
however	O
,	O
have	O
a	O
statistically	O
significant	O
association	O
with	O
the	O
mortality	O
rate	O
as	O
demonstrated	O
by	O
the	O
increased	O
survival	O
rate	O
in	O
patients	O
undergoing	O
MRI	B-P
prior	O
to	O
initial	O
amputation	B-P
.	O

Application	O
of	O
an	O
Analytical	O
Solution	O
as	O
a	O
Screening	O
Tool	O
for	O
Sea	O
Water	O
Intrusion	O
.	O

Sea	O
water	O
intrusion	O
into	O
aquifers	O
is	O
problematic	O
in	O
many	O
coastal	O
areas	O
.	O

The	O
physics	O
and	O
chemistry	O
of	O
this	O
issue	O
are	O
complex	O
,	O
and	O
sea	O
water	O
intrusion	O
remains	O
challenging	O
to	O
quantify	O
.	O

Simple	O
assessment	O
tools	O
like	O
analytical	O
models	O
offer	O
advantages	O
of	O
rapid	O
application	O
,	O
but	O
their	O
applicability	O
to	O
field	O
situations	O
is	O
unclear	O
.	O

This	O
study	O
examines	O
the	O
reliability	O
of	O
a	O
popular	O
sharp-interface	O
analytical	O
approach	O
for	O
estimating	O
the	O
extent	O
of	O
sea	O
water	O
in	O
a	O
homogeneous	O
coastal	O
aquifer	O
subjected	O
to	O
pumping	O
and	O
regional	O
flow	O
effects	O
and	O
under	O
steady-state	O
conditions	O
.	O

The	O
analytical	O
model	O
is	O
tested	O
against	O
observations	O
from	O
Canada	O
,	O
the	O
United	O
States	O
,	O
and	O
Australia	O
to	O
assess	O
its	O
utility	O
as	O
an	O
initial	O
approximation	B-P
of	O
sea	O
water	O
extent	O
for	O
the	O
purposes	O
of	O
rapid	O
groundwater	O
management	O
decision	O
making	O
.	O

The	O
occurrence	O
of	O
sea	O
water	O
intrusion	O
resulting	O
in	O
increased	O
salinity	O
at	O
pumping	O
wells	O
was	O
correctly	O
predicted	O
in	O
approximately	O
60	O
%	O
of	O
cases	O
.	O

Application	O
of	O
a	O
correction	O
to	O
account	O
for	O
dispersion	O
did	O
not	O
markedly	O
improve	O
the	O
results	O
.	O

Failure	O
of	O
the	O
analytical	O
model	O
to	O
provide	O
correct	O
predictions	O
can	O
be	O
attributed	O
to	O
mismatches	O
between	O
its	O
simplifying	O
assumptions	O
and	O
more	O
complex	O
field	O
settings	O
.	O

The	O
best	O
results	O
occurred	O
where	O
the	O
toe	O
of	O
the	O
salt	O
water	O
wedge	O
is	O
expected	O
to	O
be	O
the	O
closest	O
to	O
the	O
coast	O
under	O
predevelopment	O
conditions	O
.	O

Predictions	O
were	O
the	O
poorest	O
for	O
aquifers	O
where	O
the	O
salt	O
water	O
wedge	O
was	O
expected	O
to	O
extend	O
further	O
inland	O
under	O
predevelopment	O
conditions	O
and	O
was	O
therefore	O
more	O
dispersive	O
prior	O
to	O
pumping	O
.	O

Sharp-interface	O
solutions	O
remain	O
useful	O
tools	O
to	O
screen	O
for	O
the	O
vulnerability	O
of	O
coastal	O
aquifers	O
to	O
sea	O
water	O
intrusion	O
,	O
although	O
the	O
significant	O
sources	O
of	O
uncertainty	O
identified	O
in	O
this	O
study	O
require	O
careful	O
consideration	O
to	O
avoid	O
misinterpreting	O
sharp-interface	O
results	O
.	O

Inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
channels	O
are	O
major	O
contributors	O
to	O
flow	O
-	O
induced	O
vasodilatation	O
in	O
resistance	O
arteries	O
.	O

Endothelial	O
inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
(	O
Kir2.1	O
)	O
channels	O
regulate	O
flow	O
-	O
induced	O
vasodilatation	O
via	O
nitric	O
oxide	O
(	O
NO	O
)	O
in	O
mouse	O
mesenteric	O
resistance	O
arteries	O
.	O

Deficiency	O
of	O
Kir2.1	O
channels	O
results	O
in	O
elevated	O
blood	O
pressure	O
and	O
increased	O
vascular	O
resistance	O
.	O

Flow	O
-	O
induced	O
vasodilatation	O
in	O
human	O
resistance	O
arteries	O
is	O
also	O
regulated	O
by	O
inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
channels	O
.	O

This	O
study	O
presents	O
the	O
first	O
direct	O
evidence	O
that	O
Kir	O
channels	O
play	O
a	O
critical	O
role	O
in	O
physiological	O
endothelial	O
responses	O
to	O
flow	O
.	O

Inwardly	O
rectifying	O
K	O
(	O
+	O
)	O
(	O
Kir	O
)	O
channels	O
are	O
known	O
to	O
be	O
sensitive	O
to	O
flow	O
,	O
but	O
their	O
role	O
in	O
flow	O
-	O
induced	O
endothelial	O
responses	O
is	O
not	O
known	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
establish	O
the	O
role	O
of	O
Kir	O
channels	O
in	O
flow	O
-	O
induced	O
vasodilatation	O
and	O
to	O
provide	O
first	O
insights	O
into	O
the	O
mechanisms	O
responsible	O
for	O
Kir	O
signalling	O
in	O
this	O
process	O
.	O

First	O
,	O
we	O
establish	O
that	O
primary	O
endothelial	O
cells	O
isolated	O
from	O
murine	O
mesenteric	O
arteries	O
express	O
functional	O
Kir2.1	O
channels	O
sensitive	O
to	O
shear	O
stress	O
.	O

Then	O
,	O
using	O
the	O
Kir2.1	O
(	O
+/-	O
)	O
heterozygous	O
mouse	O
model	O
,	O
we	O
establish	O
that	O
downregulation	O
of	O
Kir2.1	O
results	O
in	O
significant	O
decrease	O
in	O
shear	O
-	O
activated	O
Kir	O
currents	O
and	O
inhibition	O
of	O
endothelium	O
-dependent	O
flow	O
-	O
induced	O
vasodilatation	O
(	O
FIV	O
)	O
assayed	O
in	O
pressurized	O
mesenteric	O
arteries	O
pre-constricted	O
with	O
endothelin-1	O
.	O

Deficiency	O
in	O
Kir2.1	O
also	O
results	O
in	O
the	O
loss	O
of	O
flow	O
-	O
induced	O
phosphorylation	O
of	O
eNOS	O
and	O
Akt	O
,	O
as	O
well	O
as	O
inhibition	O
of	O
NO	O
generation	O
.	O

All	O
the	O
effects	O
are	O
fully	O
rescued	O
by	O
endothelial	O
cell	O
(	O
EC	O
)	O
-specific	O
overexpression	O
of	O
Kir2.1	O
.	O

A	O
component	O
of	O
FIV	O
that	O
is	O
Kir	O
independent	O
is	O
abrogated	O
by	O
blocking	O
Ca	O
(	O
2+	O
)	O
-sensitive	O
K	O
(	O
+	O
)	O
channels	O
.	O

Kir2.1	O
has	O
no	O
effect	O
on	O
endothelium	O
-independent	O
and	O
K	O
(	O
+	O
)	O
-	O
induced	O
vasodilatation	O
in	O
denuded	O
arteries	O
.	O

Kir2.1	O
(	O
+/-	O
)	O
mice	O
also	O
show	O
increased	O
mean	O
blood	O
pressure	O
measured	O
by	O
carotid	O
artery	O
cannulation	B-P
and	O
increased	O
microvascular	O
resistance	O
measured	O
using	O
a	O
tail-cuff	B-P
.	O

Importantly	O
,	O
blocking	O
Kir	O
channels	O
also	O
inhibits	O
flow	O
-	O
induced	O
vasodilatation	O
in	O
human	O
subcutaneous	O
adipose	O
microvessels	O
.	O

Endothelial	O
Kir	O
channels	O
contribute	O
to	O
FIV	O
of	O
mouse	O
mesenteric	O
arteries	O
via	O
an	O
NO	O
-dependent	O
mechanism	O
,	O
whereas	O
Ca	O
(	O
2+	O
)	O
-sensitive	O
K	O
(	O
+	O
)	O
channels	O
mediate	O
FIV	O
via	O
an	O
NO	O
-independent	O
pathway	O
.	O

Kir2	O
channels	O
also	O
regulate	O
vascular	O
resistance	O
and	O
blood	O
pressure	O
.	O

Finally	O
,	O
Kir	O
channels	O
also	O
contribute	O
to	O
FIV	O
in	O
human	O
subcutaneous	O
microvessels	O
.	O

Tooth	O
replacements	O
in	O
young	O
adults	O
with	O
severe	O
hypodontia	O
:	O
Orthodontic	B-P
space	I-P
closure	I-P
,	O
dental	O
implants	O
,	O
and	O
tooth	O
-supported	O
fixed	O
dental	O
prostheses	O
.	O

A	O
follow-up	O
study	O
.	O

Children	O
with	O
severe	O
hypodontia	O
have	O
a	O
substantial	O
impairment	O
of	O
their	O
dental	O
health	O
starting	O
early	O
in	O
life	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
types	O
and	O
locations	O
of	O
substitutes	O
for	O
missing	O
teeth	O
in	O
patients	O
with	O
severe	O
hypodontia	O
and	O
to	O
compare	O
the	O
crown	O
and	O
soft	O
tissue	O
morphologies	O
of	O
orthodontic	B-P
space	I-P
closure	I-P
,	O
dental	O
implants	O
,	O
and	O
tooth	O
-supported	O
fixed	O
dental	O
prostheses	O
for	O
replacing	O
teeth	O
in	O
the	O
anterior	O
region	O
.	O

Fifty	O
patients	O
missing	O
6	O
or	O
more	O
teeth	O
and	O
aged	O
18	O
years	O
or	O
older	O
(	O
mean	O
age	O
,	O
25.6	O
years	O
)	O
took	O
part	O
in	O
a	O
follow-up	O
study	O
.	O

The	O
patients	O
were	O
examined	O
clinically	O
with	O
panoramic	B-P
radiographs	I-P
and	O
clinical	B-P
photographs	I-P
.	O

Crown	O
and	O
soft	O
tissue	O
variables	O
(	O
mucosal	O
discoloration	O
,	O
crown	O
morphology	O
,	O
color	O
,	O
and	O
papilla	O
index	O
)	O
were	O
compared	O
for	O
orthodontic	B-P
space	I-P
closure	I-P
,	O
dental	O
implant	O
fixtures	O
,	O
and	O
fixed	O
dental	O
prostheses	O
.	O

Dental	O
implants	O
,	O
orthodontic	B-P
space	I-P
closure	I-P
,	O
and	O
retaining	O
deciduous	O
teeth	O
were	O
the	O
most	O
commonly	O
prescribed	O
treatments	B-P
.	O

Persisting	O
deciduous	O
teeth	O
showed	O
a	O
good	O
survival	O
rate	O
at	O
the	O
follow-up	O
examination	O
.	O

Mucosal	O
discoloration	O
was	O
seen	O
only	O
for	O
implant	O
fixtures	O
and	O
was	O
evident	O
for	O
almost	O
all	O
fixtures	O
in	O
the	O
anterior	O
mandible	O
and	O
two	O
thirds	O
of	O
those	O
in	O
the	O
anterior	O
maxilla	O
.	O

The	O
papilla	O
index	O
scored	O
poorer	O
for	O
both	O
implant	O
fixtures	O
and	O
fixed	O
dental	O
prostheses	O
compared	O
with	O
orthodontic	B-P
space	I-P
closure	I-P
.	O

Dental	O
implants	O
in	O
the	O
anterior	O
region	O
proved	O
to	O
be	O
an	O
inadequate	O
treatment	O
modality	O
in	O
patients	O
with	O
severe	O
hypodontia	O
because	O
of	O
pronounced	O
mucosal	O
discoloration	O
.	O

Methods	O
to	O
Study	O
Autophagy	O
in	O
Zebrafish	O
.	O

Autophagy	O
(	O
cellular	O
self-eating	O
)	O
is	O
a	O
highly	O
regulated	O
degradation	O
process	O
of	O
the	O
eukaryotic	O
cell	O
during	O
which	O
parts	O
of	O
the	O
cytoplasm	O
are	O
delivered	O
into	O
,	O
and	O
broken	O
down	O
within	O
,	O
the	O
lysosomal	O
compartment	O
.	O

The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	O
of	O
superfluous	O
and	O
damaged	O
cellular	O
constituents	O
,	O
thereby	O
mediating	O
macromolecular	O
and	O
organellar	O
turnover	O
.	O

In	O
addition	O
to	O
maintaining	O
cellular	O
homeostasis	O
,	O
autophagy	O
is	O
involved	O
in	O
various	O
other	O
cellular	O
and	O
developmental	O
processes	O
by	O
degrading	O
specific	O
regulatory	O
proteins	O
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	O
pathogens	O
.	O

The	O
physiological	O
roles	O
and	O
pathological	O
involvement	O
of	O
autophagy	O
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	O
model	O
systems	O
ranging	O
from	O
yeast	O
to	O
mice	O
.	O

Such	O
a	O
tractable	O
animal	O
model	O
applied	O
only	O
recently	O
for	O
autophagy	O
researchis	O
the	O
zebrafish	O
Danio	O
rerio	O
,	O
which	O
also	O
facilitates	O
the	O
analysis	O
of	O
more	O
specific	O
biological	O
processes	O
such	O
as	O
tissue	O
regeneration	O
.	O

In	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	O
and	O
tools	O
that	O
are	O
used	O
to	O
monitor	O
autophagic	O
structures	O
and	O
to	O
assay	B-P
autophagic	O
responses	O
in	O
this	O
vertebrate	O
organism	O
.	O

We	O
place	O
emphasis	O
on	O
genetic	O
(	O
functional	O
)	O
approaches	O
applied	O
for	O
exploring	O
novel	O
cellular	O
and	O
developmental	O
roles	O
of	O
the	O
autophagic	O
process	O
.	O

Engineering	O
and	O
In	O
Vivo	O
Applications	O
of	O
Riboswitches	O
.	O

Riboswitches	O
are	O
common	O
gene	O
regulatory	O
units	O
mostly	O
found	O
in	O
bacteria	O
that	O
are	O
capable	O
of	O
altering	O
gene	O
expression	O
in	O
response	O
to	O
a	O
small	O
molecule	O
.	O

These	O
structured	O
RNA	O
elements	O
consist	O
of	O
two	O
modular	O
subunits	O
:	O
an	O
aptamer	O
domain	O
that	O
binds	O
with	O
high	O
specificity	O
and	O
affinity	O
to	O
a	O
target	O
ligand	O
and	O
an	O
expression	O
platform	O
that	O
transduces	O
ligand	O
binding	O
to	O
a	O
gene	O
expression	O
output	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
engineering	O
novel	O
aptamer	O
domains	O
for	O
new	O
small	O
molecule	O
inducers	O
of	O
gene	O
expression	O
.	O

Modified	O
expression	O
platforms	O
have	O
also	O
been	O
optimized	O
to	O
function	O
when	O
fused	O
with	O
both	O
natural	O
and	O
synthetic	O
aptamer	O
domains	O
.	O

As	O
this	O
field	O
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	O
scaffolds	O
has	O
permitted	O
the	O
development	O
of	O
tools	O
such	O
as	O
RNA	O
-based	O
fluorescent	O
biosensors	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
methods	O
that	O
have	O
been	O
developed	O
to	O
engineer	O
new	O
riboswitches	O
and	O
highlight	O
applications	O
of	O
natural	O
and	O
synthetic	O
riboswitches	O
in	O
enzyme	O
and	O
strain	O
engineering	O
,	O
in	O
controlling	O
gene	O
expression	O
and	O
cellular	O
physiology	O
,	O
and	O
in	O
real-time	B-P
imaging	I-P
of	O
cellular	O
metabolites	O
and	O
signals	O
.	O

Expected	O
final	O
online	O
publication	O
date	O
for	O
the	O
Annual	O
Review	O
of	O
Biochemistry	O
Volume	O
86	O
is	O
June	O
20	O
,	O
2017	O
.	O

Please	O
see	O
http	O
:	O
//www.annualreviews.org/page/journal/pubdates	O
for	O
revised	O
estimates	O
.	O

A	O
novel	O
functional	O
full-fat	O
hard	O
cheese	O
containing	O
liposomal	O
nanoencapsulated	O
green	O
tea	O
catechins	O
:	O
manufacture	O
and	O
recovery	O
following	O
simulated	O
digestion	O
.	O

(	O
+	O
)	O
-Catechin	O
or	O
green	O
tea	O
extract	O
were	O
encapsulated	O
in	O
soy	O
lecithin	O
nanoliposomes	O
and	O
incorporated	O
into	O
a	O
full-fat	O
cheese	O
,	O
then	O
ripened	O
at	O
8	O
°C	O
for	O
90	O
days	O
.	O

Cheese	O
samples	O
were	O
subjected	O
to	O
simulated	O
gastrointestinal	O
digestion	O
to	O
measure	O
total	O
phenolic	O
conten	O
t	O
(	O
TPC	O
)	O
and	O
antioxidant	O
activity	O
of	O
the	O
cheese	O
digesta	O
,	O
and	O
to	O
determine	O
the	O
catechin	O
recovery	O
after	O
digestion	O
by	O
high	B-P
performance	I-P
liquid	I-P
chromatography	I-P
(	O
HPLC	B-P
)	O
.	O

Addition	O
of	O
catechin	O
or	O
green	O
tea	O
extract	O
significantly	O
(	O
P	O
≤	O
0.05	O
)	O
increased	O
TPC	O
and	O
antioxidant	O
activity	O
(	O
measured	O
by	O
ferric	B-P
reducing	I-P
antioxidant	I-P
power	I-P
and	O
oxygen	B-P
radical	I-P
absorbance	I-P
capacity	I-P
)	O
of	O
the	O
full-fat	O
cheese	O
without	O
affecting	O
pH	O
or	O
proximate	O
composition	O
.	O

HPLC	B-P
analysis	I-P
confirmed	O
retention	O
of	O
encapsulated	O
catechins	O
in	O
the	O
cheese	O
curd	O
;	O
however	O
,	O
individual	O
catechins	O
were	O
recovered	O
in	O
differing	O
amounts	O
(	O
15-52	O
%	O
)	O
from	O
cheese	O
digesta	O
after	O
6	O
h	O
of	O
digestion	O
.	O

Transmission	B-P
electron	I-P
microscopy	I-P
and	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
provided	O
evidence	O
for	O
association	O
of	O
nanoliposomes	O
with	O
the	O
surface	O
of	O
milk	O
fat	O
globules	O
inside	O
the	O
cheese	O
matrix	O
.	O

The	O
study	O
shows	O
the	O
potential	O
for	O
using	O
cheese	O
as	O
a	O
delivery	O
vehicle	O
for	O
green	O
tea	O
antioxidants	O
.	O

Midterm	O
Results	O
of	O
Consecutive	O
Periprosthetic	O
Femoral	O
Fractures	O
Vancouver	O
Type	O
A	O
and	O
B.	O
Surgical	O
treatment	O
of	O
periprosthetic	O
femoral	O
fractures	O
has	O
a	O
high	O
complication	O
and	O
mortality	O
rate	O
of	O
more	O
than	O
10	O
%	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
report	O
the	O
outcome	O
of	O
a	O
consecutive	O
single	O
center	O
patient	O
group	O
.	O

Thirty-four	O
consecutive	O
patients	O
(	O
mean	O
age	O
81.2+/-8.5	O
years	O
,	O
14	O
male	O
,	O
20	O
female	O
)	O
with	O
a	O
periprosthetic	O
femoral	O
fracture	O
Vancouver	O
type	O
A	O
(	O
n=5	O
)	O
or	O
type	O
B	O
(	O
n=29	O
)	O
were	O
followed-up	O
after	O
43.2	O
months	O
,	O
none	O
of	O
the	O
patients	O
were	O
lost	O
to	O
follow-up	O
.	O

Nineteen	O
of	O
the	O
patients	O
were	O
treated	O
through	O
change	O
of	O
the	O
stem	O
and	O
cerclage	O
fixation	O
,	O
five	O
by	O
plates	O
and	O
ten	O
by	O
cerclage	O
cables	O
.	O

One	O
successfully	O
treated	O
infection	O
was	O
observed	O
.	O

No	O
further	O
complications	O
have	O
been	O
reported	O
peri-	O
or	O
postoperatively	O
,	O
therefore	O
resulting	O
in	O
2.9	O
%	O
overall	O
complication	O
rate	O
.	O

These	O
results	O
demonstrate	O
that	O
precisely	O
selected	O
revision	B-P
surgery	O
protocol	O
following	O
periprosthetic	O
femoral	O
fractures	O
within	O
elderly	O
multimorbid	O
patients	O
may	O
lead	O
to	O
beneficial	O
outcomes	O
at	O
a	O
low	O
risk	O
of	O
complications	O
.	O

In	O
vitro	O
screening	B-P
and	O
in	O
silico	O
validation	O
revealed	O
key	O
microbes	O
for	O
higher	O
production	O
of	O
significant	O
therapeutic	O
enzyme	O
l-asparaginase	O
.	O

l-asparaginase	O
is	O
an	O
enzyme	O
of	O
medical	O
prominence	O
and	O
reputable	O
as	O
a	O
chemotherapeutic	O
agent	O
.	O

It	O
also	O
has	O
immense	O
potential	O
to	O
cure	O
autoimmune	O
and	O
infectious	O
diseases	O
.	O

The	O
vast	O
application	O
of	O
this	O
enzyme	O
in	O
healthcare	O
sector	O
increases	O
its	O
market	O
demand	O
.	O

However	O
,	O
presently	O
the	O
huge	O
market	O
demand	O
is	O
not	O
achieved	O
completely	O
.	O

This	O
serves	O
the	O
basis	O
to	O
explore	O
better	O
producer	O
microbial	O
strains	O
to	O
bridge	O
the	O
gap	O
between	O
huge	O
demand	O
and	O
supply	O
of	O
this	O
therapeutic	O
enzyme	O
.	O

The	O
present	O
study	O
deals	O
with	O
the	O
successful	O
screening	B-P
of	O
potent	O
microorganisms	O
producing	O
l-asparaginase	O
.	O

47	O
microorganisms	O
were	O
screened	B-P
including	O
bacteria	O
,	O
fungi	O
,	O
and	O
yeasts	O
.	O

Among	O
all	O
,	O
Penicillium	O
lilacinum	O
showed	O
the	O
highest	O
enzyme	O
activity	O
i.e.	O
,	O
39.67	O
IU/ml	O
.	O

Shigella	O
flexneri	O
has	O
23.21	O
IU/ml	O
of	O
enzyme	O
activity	O
(	O
highest	O
among	O
all	O
the	O
bacterial	O
strain	O
tested	O
)	O
.	O

Further	O
,	O
the	O
3-D	O
structure	O
of	O
l-asparaginase	O
from	O
higher	O
producer	O
strains	O
was	O
developed	O
and	O
validated	O
in	O
silico	O
for	O
its	O
activity	O
.	O

l-asparagine	O
(	O
substrate	O
for	O
l-asparaginase	O
)	O
was	O
docked	O
inside	O
the	O
binding	O
pocket	O
of	O
P.	O
lilacinum	O
and	O
S.	O
flexneri	O
.	O

Docking	O
score	O
for	O
the	O
most	O
common	O
substrate	O
l-asparagine	O
is	O
-6.188	O
(	O
P.	O
lilacinum	O
)	O
,	O
-5.576	O
(	O
S.	O
flexneri	O
)	O
which	O
is	O
quite	O
good	O
.	O

Moreover	O
,	O
the	O
chemical	O
property	O
of	O
the	O
binding	O
pocket	O
revealed	O
that	O
amino	O
acid	O
residues	O
Phe	O
243	O
,	O
Gln	O
260	O
,	O
Gly	O
365	O
,	O
Asp	O
386	O
in	O
P.	O
lilacinum	O
and	O
residues	O
Asp	O
181	O
,	O
Thr	O
318	O
,	O
Asn	O
320	O
in	O
S.	O
flexneri	O
have	O
an	O
important	O
role	O
in	O
H-bonding	O
.	O

The	O
in	O
silico	O
results	O
supports	O
and	O
strengthen	O
the	O
wet	O
lab	O
results	O
.	O

The	O
outcome	O
obtained	O
motivates	O
to	O
take	O
the	O
present	O
study	O
result	O
from	O
lab	O
to	O
industry	O
for	O
the	O
economic	O
/	O
massive	O
production	O
of	O
this	O
enzyme	O
for	O
the	O
diverse	O
therapeutic	O
application	O
.	O

Effect	O
of	O
emodin	O
on	O
mobility	O
signal	O
transduction	O
system	O
of	O
gallbladder	O
smooth	O
muscle	O
in	O
Guinea	O
pig	O
with	O
cholelithiasis	O
.	O

To	O
study	O
the	O
effect	O
of	O
emodin	O
on	O
protein	O
and	O
gene	O
expressions	O
of	O
the	O
massagers	O
in	O
mobility	O
signal	O
transduction	O
system	O
of	O
cholecyst	O
smooth	O
muscle	O
cells	O
in	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
.	O

The	O
guinea	O
pigs	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
,	O
such	O
as	O
control	O
group	O
,	O
gall-stone	O
(	O
GS	O
)	O
group	O
,	O
emodin	O
group	O
and	O
ursodeoxycholic	O
acid	O
(	O
UA	O
)	O
group	O
.	O

Cholesterol	O
calculus	O
models	O
were	O
induced	O
in	O
guinea	O
pigs	O
of	O
GS	O
,	O
emodin	O
and	O
UA	O
groups	O
by	O
lithogenic	O
diet	O
,	O
while	O
emodin	O
or	O
UA	O
were	O
given	O
to	O
the	O
corresponding	O
group	O
for	O
7	O
weeks	O
.	O

The	O
histomorphological	O
and	O
ultrastructure	O
change	O
of	O
gallbladder	O
were	O
detected	O
by	O
microscope	O
and	O
electron	O
microscope	O
,	O
the	O
content	O
of	O
plasma	O
cholecystokinin	O
(	O
CCK	O
)	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
were	O
analyzed	O
successively	O
by	O
radioimmunoassay	B-P
and	O
flow	B-P
cytometry	I-P
.	O

The	O
protein	O
and	O
mRNA	O
of	O
Gsα	O
,	O
Giα	O
and	O
Cap	O
in	O
cholecyst	O
cells	O
were	O
determined	O
by	O
western	O
blotting	O
and	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

Emodin	O
or	O
UA	O
can	O
relieve	O
pathogenic	O
changes	O
in	O
epithelial	O
cells	O
and	O
muscle	O
cells	O
in	O
gallbladder	O
of	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
by	O
microscope	O
and	O
transmission	O
electron	O
microscope	O
.	O

In	O
the	O
cholecyst	O
cells	O
of	O
GS	O
group	O
,	O
CCK	O
levels	O
in	O
plasma	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
decreased	O
,	O
the	O
protein	O
and	O
mRNA	O
of	O
GS	O
were	O
down-regulated	O
,	O
the	O
protein	O
and	O
mRNA	O
of	O
Gi	O
and	O
Cap	O
were	O
up-regulated	O
.	O

Emodin	O
significantly	O
decreased	O
the	O
formative	O
rate	O
of	O
gallstone	O
,	O
improved	O
the	O
pathogenic	O
change	O
in	O
epithelial	O
cells	O
and	O
muscle	O
cells	O
,	O
increased	O
CCK	O
levels	O
in	O
plasma	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
cholecyst	O
cells	O
,	O
enhanced	O
the	O
protein	O
and	O
mRNA	O
of	O
Gs	O
in	O
cholecyst	O
cells	O
,	O
reduced	O
the	O
protein	O
and	O
mRNA	O
of	O
Gi	O
and	O
Cap	O
in	O
cholecyst	O
cells	O
in	O
guinea	O
pig	O
with	O
cholesterol	O
calculus	O
.	O

The	O
dysfunction	O
of	O
gallbladder	O
contraction	O
gives	O
rise	O
to	O
the	O
disorders	O
of	O
mobility	O
signal	O
transduction	O
system	O
in	O
cholecyst	O
smooth	O
muscle	O
cells	O
,	O
including	O
low	O
content	O
of	O
plasma	O
CCK	O
and	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
cholecyst	O
cells	O
,	O
abnormal	O
protein	O
and	O
mRNA	O
of	O
Gs	O
,	O
Gi	O
and	O
Cap	O
.	O

Emodin	O
can	O
enhance	O
the	O
contractibility	O
of	O
gallbladder	O
and	O
alleviate	O
cholestasis	O
by	O
regulating	O
plasma	O
CCK	O
levels	O
,	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
cholecyst	O
cells	O
and	O
the	O
protein	O
and	O
mRNA	O
of	O
Gs	O
,	O
Gi	O
and	O
Cap	O
.	O

Single-Nucleotide	O
Polymorphism	O
rs17611	O
of	O
Complement	O
Component	O
5	O
Shows	O
Association	O
with	O
Ischemic	O
Stroke	O
in	O
Northeast	O
Chinese	O
Population	O
.	O

Complement	O
component	O
5	O
(	O
C5	O
)	O
has	O
been	O
described	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
atherosclerosis	O
and	O
cardiovascular	O
disease	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
whether	O
genetic	O
variation	O
of	O
C5	O
was	O
associated	O
with	O
ischemic	O
stroke	O
(	O
IS	O
)	O
in	O
northeast	O
Chinese	O
population	O
.	O

We	O
used	O
a	O
case-control	O
study	O
involving	O
386	O
IS	O
patients	O
and	O
386	O
non-IS	O
controls	O
from	O
a	O
rural	O
population	O
and	O
determined	O
the	O
genotypes	O
of	O
five	O
polymorphisms	O
(	O
rs12237774	O
,	O
rs17611	O
,	O
rs4837805	O
,	O
rs7026551	O
,	O
and	O
rs1017119	O
)	O
of	O
C5	O
gene	O
by	O
Snapshot	O
single-nucleotide	B-P
polymorphism	I-P
genotyping	I-P
assays	I-P
to	O
assess	O
any	O
links	O
with	O
IS	O
.	O

In	O
univariate	O
analysis	O
,	O
rs17611	O
was	O
significantly	O
associated	O
with	O
IS	O
in	O
the	O
additive	O
model	O
,	O
the	O
dominant	O
model	O
,	O
and	O
recessive	O
model	O
(	O
additive	O
p	O
0.031	O
,	O
dominant	O
p	O
0.034	O
,	O
and	O
recessive	O
p	O
0.027	O
)	O
.	O

After	O
adjustment	O
for	O
Binary	O
Logistic	O
Regression	O
,	O
rs17611	O
polymorphism	O
was	O
still	O
significant	O
in	O
three	O
models	O
(	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.306	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.069-1.595	O
,	O
p-value	O
=	O
0.009	O
in	O
an	O
additive	O
model	O
;	O
OR	O
=	O
1.378	O
,	O
95	O
%	O
CI	O
=	O
1.024-1.856	O
,	O
p-value	O
=	O
0.035	O
in	O
a	O
dominant	O
model	O
;	O
and	O
OR	O
=	O
1.511	O
,	O
95	O
%	O
CI	O
=	O
1.048-2.18	O
,	O
p-value	O
=	O
0.027	O
in	O
a	O
recessive	O
model	O
)	O
.	O

In	O
this	O
sample	O
of	O
patients	O
,	O
genetic	O
variation	O
of	O
rs17611	O
in	O
C5	O
is	O
associated	O
with	O
higher	O
prevalence	O
of	O
IS	O
.	O

Size	O
-selective	O
separation	O
and	O
overall	O
-	O
amplification	O
of	O
cell-free	B-P
fetal	I-P
DNA	I-P
fragments	O
using	O
PCR	B-P
-based	I-P
enrichment	I-P
.	O

This	O
study	O
aimed	O
to	O
establish	O
a	O
method	O
for	O
the	O
selective	O
amplification	O
of	O
cell-free	B-P
fetal	I-P
DNA	I-P
(	O
cffDNA	B-P
)	O
in	O
maternal	O
plasma	O
and	O
preserve	O
the	O
integrity	O
of	O
DNA	O
fragments	O
during	O
amplification	O
,	O
thereby	O
providing	O
a	O
sufficient	O
amount	O
of	O
cffDNA	B-P
to	O
meet	O
the	O
requirement	O
of	O
routine	O
non-invasive	O
prenatal	O
testing	O
.	O

We	O
amplified	O
DNA	O
molecules	O
in	O
a	O
one-reaction	O
system	O
without	O
considering	O
their	O
particular	O
sequences	O
and	O
lengths	O
(	O
overall	O
amplification	O
)	O
by	O
using	O
PCR	B-P
-based	I-P
enrichment	I-P
.	O

We	O
then	O
modified	O
PCR	O
conditions	O
to	O
verify	O
the	O
effect	O
of	O
denaturation	O
temperature	O
on	O
DNA	O
amplification	O
on	O
various	O
lengths	O
of	O
DNA	O
(	O
selective	O
overall	O
amplification	O
)	O
.	O

Finally	O
,	O
we	O
used	O
an	O
optimum	O
temperature	O
range	O
to	O
amplify	O
cffDNA	B-P
selectively	O
.	O

Amplification	O
results	O
were	O
validated	O
by	O
electrophoresis	B-P
and	O
real-time	O
quantitative	O
PCR	O
.	O

Our	O
PCR	B-P
-based	I-P
enrichment	I-P
efficiently	O
amplified	O
all	O
DNA	O
fragments	O
with	O
differing	O
lengths	O
within	O
a	O
single	O
reaction	O
system	O
,	O
as	O
well	O
as	O
preserving	O
the	O
integrity	O
of	O
the	O
DNA	O
fragments	O
.	O

cffDNA	B-P
was	O
significantly	O
amplified	O
along	O
with	O
the	O
selective	O
amplification	O
of	O
small	O
fragment	O
maternal	O
plasma	O
DNA	O
in	O
an	O
appropriate	O
range	O
of	O
denaturation	O
temperatures	O
.	O

We	O
have	O
established	O
a	O
PCR-based	O
method	O
for	O
the	O
simultaneous	O
enrichment	B-P
and	O
amplification	O
of	O
cffDNA	B-P
in	O
order	O
to	O
meet	O
the	O
requirements	O
of	O
high	O
cffDNA	B-P
quantity	O
for	O
routine	O
non-invasive	O
prenatal	O
testing	O
.	O

Pattern	O
recognition	O
of	O
enrichment	O
levels	O
of	O
SELEX	O
-based	O
candidate	O
aptamers	O
for	O
human	O
C-reactive	O
protein	O
.	O

Selecting	O
aptamers	O
for	O
human	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
would	O
be	O
of	O
critical	O
importance	O
in	O
predicting	O
the	O
risk	O
for	O
cardiovascular	O
disease	O
.	O

The	O
enrichment	O
level	O
of	O
DNA	O
aptamers	O
is	O
an	O
important	O
parameter	O
for	O
selecting	O
candidate	O
aptamers	O
for	O
further	O
affinity	O
and	O
specificity	O
determination	B-P
.	O

This	O
paper	O
is	O
the	O
first	O
report	O
on	O
pattern	O
recognition	O
used	O
for	O
CRP	O
aptamer	O
enrichment	O
levels	O
in	O
the	O
systematic	O
evolution	O
of	O
ligands	O
by	O
exponential	O
enrichment	O
(	O
SELEX	O
)	O
process	O
,	O
by	O
applying	O
structure-activity	O
relationship	O
models	O
.	O

After	O
generating	O
10	O
rounds	O
of	O
graphene	O
oxide	O
(	O
GO	O
)	O
-	O
SELEX	O
and	O
1670	O
molecular	O
descriptors	O
,	O
eight	O
molecular	O
descriptors	O
were	O
selected	O
and	O
five	O
latent	O
variables	O
were	O
then	O
obtained	O
with	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
to	O
develop	O
a	O
support	O
vector	O
classification	O
(	O
SVC	O
)	O
model	O
.	O

The	O
SVC	O
model	O
(	O
C=8.1728	O
and	O
γ=0.2333	O
)	O
optimized	O
by	O
the	O
particle	O
swarm	O
optimization	O
(	O
PSO	O
)	O
algorithm	O
possesses	O
an	O
accuracy	O
of	O
88.15	O
%	O
for	O
the	O
training	O
set	O
.	O

Prediction	O
results	O
of	O
enrichment	O
levels	O
for	O
the	O
sequences	O
with	O
the	O
frequencies	O
of	O
6	O
and	O
5	O
are	O
reasonable	O
and	O
acceptable	O
,	O
with	O
accuracies	O
of	O
70.59	O
%	O
and	O
76.37	O
%	O
,	O
respectively	O
.	O

EEG	B-P
Monitoring	O
Technique	O
Influences	O
the	O
Management	O
of	O
Hypoxic-Ischemic	O
Seizures	O
in	O
Neonates	O
Undergoing	O
Therapeutic	B-P
Hypothermia	I-P
.	O

Electroencephalogram	O
(	O
EEG	O
)	O
monitoring	O
techniques	O
for	O
neonatal	O
hypoxia-ischemia	O
(	O
HI	O
)	O
are	O
evolving	O
over	O
time	O
,	O
and	O
the	O
specific	O
type	O
of	O
EEG	O
utilized	O
could	O
influence	O
seizure	O
diagnosis	O
and	O
management	O
.	O

We	O
examined	O
whether	O
the	O
type	O
of	O
EEG	B-P
performed	O
affected	O
seizure	O
treatment	O
decisions	O
(	O
e.g.	O
,	O
the	O
choice	O
and	O
number	O
of	O
antiseizure	O
drugs	O
[	O
ASDs	O
]	O
)	O
in	O
therapeutic	O
hypothermia-treated	B-P
neonates	O
with	O
HI	O
from	O
2007	O
to	O
2015	O
in	O
the	O
Johns	O
Hopkins	O
Hospital	O
Neonatal	O
Intensive	O
Care	O
Unit	O
.	O

During	O
this	O
period	O
,	O
3	O
different	O
EEG	O
monitoring	O
protocols	B-P
were	O
utilized	O
:	O
Period	O
1	O
(	O
2007-2009	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
(	O
1	O
h	O
duration	O
)	O
at	O
a	O
variable	O
time	O
during	O
therapeutic	O
hypothermia	B-P
treatment	I-P
,	O
i.e.	O
,	O
ordered	O
when	O
a	O
seizure	O
was	O
suspected	O
;	O
Period	O
2	O
(	O
2009-2013	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
followed	O
by	O
amplitude-integrated	B-P
EEG	I-P
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	B-P
treatment	I-P
and	O
another	O
brief	O
conventional	O
EEG	B-P
after	O
rewarming	B-P
;	O
and	O
Period	O
3	O
(	O
2014-2015	O
)	O
,	O
continuous	B-P
video-EEG	I-P
(	O
cEEG	B-P
)	O
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	B-P
treatment	I-P
(	O
72	O
h	O
)	O
plus	O
for	O
an	O
additional	O
12	O
h	O
during	O
and	O
after	O
rewarming	B-P
.	O

One	O
hundred	O
and	O
sixty-two	O
newborns	O
were	O
included	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

As	O
a	O
function	O
of	O
the	O
type	O
and	O
duration	O
of	O
EEG	O
monitoring	O
,	O
we	O
assessed	O
the	O
risk	O
(	O
likelihood	O
)	O
of	O
receiving	O
no	O
ASD	O
,	O
at	O
least	O
1	O
ASD	O
,	O
or	O
≥2	O
ASDs	O
.	O

We	O
found	O
that	O
the	O
risk	O
of	O
a	O
neonate	O
being	O
prescribed	O
an	O
ASD	O
was	O
46	O
%	O
less	O
during	O
Period	O
3	O
(	O
cEEG	B-P
)	O
than	O
during	O
Period	O
1	O
(	O
brief	O
conventional	O
EEG	B-P
only	O
)	O
(	O
95	O
%	O
CI	O
6-69	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

After	O
adjusting	O
for	O
initial	O
EEG	B-P
and	O
MRI	B-P
results	O
,	O
compared	O
with	O
Period	O
1	O
,	O
there	O
was	O
a	O
38	O
%	O
lower	O
risk	O
of	O
receiving	O
an	O
ASD	O
during	O
Period	O
2	O
(	O
95	O
%	O
CI	O
:	O
9-58	O
%	O
,	O
p	O
=	O
0.02	O
)	O
and	O
a	O
67	O
%	O
lower	O
risk	O
during	O
Period	O
3	O
(	O
95	O
%	O
CI	O
:	O
23-86	O
%	O
,	O
p	O
=	O
0.01	O
)	O
.	O

The	O
risk	O
ratio	O
of	O
receiving	O
≥2	O
ASDs	O
was	O
not	O
significantly	O
different	O
across	O
the	O
3	O
periods	O
.	O

In	O
conclusion	O
,	O
in	O
addition	O
to	O
the	O
higher	O
sensitivity	O
and	O
specificity	O
of	O
continuous	B-P
video-EEG	I-P
monitoring	O
,	O
fewer	O
infants	O
are	O
prescribed	O
an	O
ASD	O
when	O
undergoing	O
continuous	O
forms	O
of	O
EEG	O
monitoring	O
(	O
aEEG	B-P
or	O
cEEG	B-P
)	O
than	O
those	O
receiving	O
conventional	O
EEG	B-P
.	O

We	O
recommend	O
that	O
use	O
of	O
continuous	B-P
video-EEG	I-P
be	O
considered	O
whenever	O
possible	O
,	O
both	O
to	O
treat	O
seizures	O
more	O
specifically	O
and	O
to	O
avoid	O
overtreatment	O
.	O

Undiagnosed	O
Primary	O
Open-Angle	O
Glaucoma	O
in	O
Korea	O
:	O
The	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
2008-2009	O
.	O

To	O
evaluate	O
the	O
characteristics	O
of	O
patients	O
with	O
previously	O
undiagnosed	O
primary	O
open-angle	O
glaucoma	O
(	O
POAG	O
)	O
in	O
Korea	O
.	O

This	O
study	O
examined	O
data	O
from	O
391	O
subjects	O
obtained	O
from	O
the	O
2008-2009	O
Korean	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
KNHANES	O
)	O
.	O

The	O
KNHANES	O
is	O
a	O
population-based	O
,	O
cross-sectional	O
epidemiological	O
survey	O
.	O

Participants	O
aged	O
19	O
years	O
or	O
older	O
completed	O
standardized	O
interviews	O
and	O
dilated	O
ocular	O
examinations	O
,	O
including	O
measurement	O
of	O
intraocular	O
pressure	O
,	O
visual	O
fields	O
with	O
frequency	B-P
doubling	I-P
perimetry	I-P
,	O
and	O
fundus	B-P
photography	I-P
.	O

Data	O
from	O
the	O
361	O
patients	O
with	O
previously	O
undiagnosed	O
POAG	O
were	O
analyzed	O
and	O
compared	O
with	O
data	O
from	O
the	O
30	O
patients	O
with	O
previously	O
diagnosed	O
glaucoma	O
.	O

A	O
total	O
of	O
92.3	O
%	O
of	O
POAG	O
cases	O
were	O
undiagnosed	O
before	O
this	O
study	O
.	O

Adjusted	O
for	O
age	O
and	O
sex	O
,	O
the	O
strongest	O
risk	O
factor	O
for	O
undiagnosed	O
glaucoma	O
was	O
longer	O
elapsed	O
time	O
since	O
last	O
eye	B-P
doctor	I-P
visit	I-P
.	O

Glaucoma	O
patients	O
who	O
had	O
not	O
visited	B-P
an	I-P
eye	I-P
specialist	I-P
in	O
the	O
last	O
3	O
years	O
were	O
22	O
times	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
,	O
4.49-105.64	O
,	O
p	O
<	O
0.001	O
)	O
more	O
likely	O
to	O
have	O
undiagnosed	O
disease	O
compared	O
with	O
patients	O
who	O
had	O
visited	B-P
an	I-P
eye	I-P
specialist	I-P
in	O
the	O
last	O
month	O
.	O

Another	O
significant	O
factor	O
for	O
previously	O
undiagnosed	O
glaucoma	O
was	O
smaller	O
cup-to-disc	O
ratio	O
(	O
odds	O
ratio	O
,	O
OR	O
,	O
0.60/0.1	O
units	O
,	O
95	O
%	O
CI	O
0.43-0.85/0.1	O
units	O
,	O
p	O
=	O
0.004	O
)	O
.	O

The	O
higher	O
vertical	O
cup-to-disc	O
ratio	O
of	O
a	O
subject	O
's	O
two	O
eyes	O
was	O
significantly	O
different	O
between	O
those	O
with	O
previously	O
undiagnosed	O
(	O
0.69	O
)	O
and	O
diagnosed	O
(	O
0.78	O
)	O
POAG	O
(	O
p	O
=	O
0.001	O
)	O
.	O

The	O
undiagnosed	O
POAG	O
group	O
had	O
a	O
longer	O
interval	O
from	O
last	O
eye	B-P
doctor	I-P
visit	I-P
and	O
smaller	O
vertical	O
cup-to-disc	O
ratio	O
compared	O
to	O
the	O
diagnosed	O
group	O
.	O

Identification	O
of	O
a	O
peroxisomal	O
-targeted	O
aldolase	O
involved	O
in	O
chlorophyll	O
biosynthesis	O
and	O
sugar	O
metabolism	O
in	O
rice	O
.	O

Chlorophyll	O
plays	O
remarkable	O
and	O
critical	O
roles	O
in	O
photosynthetic	O
light-harvesting	O
,	O
energy	O
transduction	O
and	O
plant	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
rice	O
Chl	O
-deficient	O
mutant	O
,	O
ygdl-1	O
(	O
yellow	O
green	O
and	O
droopy	O
leaf-1	O
)	O
,	O
which	O
showed	O
yellow-green	O
leaves	O
throughout	O
plant	O
development	O
with	O
decreased	O
content	O
of	O
Chls	O
and	O
carotene	O
and	O
an	O
increased	O
Chl	O
a/b	O
ratio	O
.	O

The	O
ygdl-1	O
mutant	O
also	O
exhibited	O
severe	O
defects	O
in	O
chloroplast	O
development	O
,	O
including	O
disorganized	O
grana	O
stacks	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
mutant	O
contained	O
a	O
T-DNA	O
insertion	O
within	O
the	O
promoter	O
of	O
a	O
fructose-1,6-bisphosphate	O
aldolase	O
(	O
OsAld-Y	O
)	O
,	O
which	O
dramatically	O
reduced	O
the	O
OsAld-Y	O
mRNA	O
level	O
,	O
and	O
its	O
identity	O
was	O
verified	O
by	O
transgenic	O
complementation	O
.	O

Real-time	B-P
PCR	I-P
analysis	I-P
showed	O
that	O
the	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
chlorophyll	O
biosynthesis	O
and	O
chloroplast	O
development	O
were	O
concurrently	O
altered	O
in	O
the	O
ygdl-1	O
mutant	O
.	O

The	O
expression	O
of	O
OsAld-Y	O
-	O
GFP	O
fusion	O
protein	O
in	O
tobacco	O
epidermal	O
cells	O
showed	O
that	O
OsAld-Y	O
was	O
localized	O
to	O
the	O
peroxisome	O
.	O

In	O
addition	O
,	O
the	O
analysis	O
of	O
primary	O
carbon	O
metabolites	O
revealed	O
the	O
significantly	O
reduced	O
levels	O
of	O
sucrose	O
and	O
fructose	O
in	O
the	O
mutant	O
leaves	O
,	O
while	O
the	O
glucose	O
content	O
was	O
similar	O
to	O
wild-type	O
plants	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
OsAld-Y	O
participates	O
in	O
Chl	O
accumulation	O
,	O
chloroplast	O
development	O
and	O
plant	O
growth	O
by	O
influencing	O
the	O
photosynthetic	O
rate	O
of	O
leaves	O
and	O
the	O
sugar	O
metabolism	O
of	O
rice	O
.	O

Environmental	O
Exposure	O
to	O
Cadmium	O
:	O
Health	B-P
Risk	I-P
Assessment	I-P
and	O
its	O
Associations	O
with	O
Hypertension	O
and	O
Impaired	O
Kidney	O
Function	O
.	O

Cadmium	O
(	O
Cd	O
)	O
is	O
a	O
toxic	O
metal	O
.	O

This	O
study	O
was	O
aimed	O
to	O
estimate	O
the	O
potential	O
health	O
risks	O
in	O
a	O
Cd	O
-	O
polluted	O
district	O
in	O
China	O
,	O
and	O
examine	O
the	O
relationship	O
between	O
urinary	O
cadmium	O
(	O
UCd	O
)	O
and	O
hypertension	O
and	O
impaired	O
kidney	O
function	O
at	O
low	O
exposure	O
levels	O
(	O
UCd	O
:	O
GM	O
1.3	O
μg/g	O
creatinine	O
)	O
.	O

Blood	O
pressure	O
measurement	O
,	O
questionnaires	O
,	O
and	O
collection	O
of	O
urinary	O
samples	O
were	O
conducted	O
from	O
217	O
residents	O
.	O

Environmental	O
samples	O
,	O
food	O
,	O
and	O
cigarette	O
samples	O
were	O
collected	O
and	O
detected	O
to	O
estimate	O
the	O
risks	O
posed	O
by	O
Cd	O
and	O
the	O
contribution	O
of	O
inhalation	O
,	O
ingestion	O
,	O
and	O
dermal	O
contact	O
pathways	O
to	O
these	O
risks	O
.	O

A	O
logistic	O
regression	O
model	O
was	O
used	O
in	O
examining	O
associations	O
between	O
exposure	O
and	O
hypertension	O
and	O
impaired	O
kidney	O
function	O
.	O

Results	O
show	O
that	O
this	O
population	O
is	O
at	O
high	O
risk	O
.	O

For	O
non-smokers	O
,	O
incremental	O
lifetime	O
cancer	O
risk	O
(	O
ILCR	O
)	O
and	O
hazard	O
quotient	O
(	O
HQ	O
)	O
are	O
1.74E-04	O
and	O
2.96	O
,	O
and	O
for	O
smokers	O
,	O
they	O
are	O
1.07E-03	O
and	O
52.5	O
,	O
respectively	O
.	O

Among	O
all	O
exposure	O
pathways	O
,	O
smoking	O
and	O
foods	O
cause	O
the	O
major	O
increases	O
in	O
ILCR	O
and	O
HQ	O
.	O

UCd	O
is	O
significantly	O
associated	O
with	O
hypertension	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.468	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.104	O
,	O
1.953	O
;	O
P	O
=	O
0.008	O
)	O
and	O
impaired	O
kidney	O
function	O
(	O
OR	O
=	O
1.902	O
,	O
95	O
%	O
CI	O
:	O
1.054	O
,	O
3.432	O
;	O
P	O
=	O
0.033	O
)	O
.	O

The	O
results	O
demonstrate	O
that	O
Cd	O
can	O
potentially	O
lead	O
to	O
adverse	O
health	O
effects	O
.	O

Spine	O
fracture	O
prevalence	O
in	O
a	O
nationally	O
representative	O
sample	O
of	O
US	O
women	O
and	O
men	O
aged	O
≥40	O
years	O
:	O
results	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
2013-2014	O
.	O

Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
men	O
and	O
women	O
,	O
increasing	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Prevalence	O
was	O
higher	O
with	O
age	O
,	O
lower	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
,	O
and	O
in	O
those	O
meeting	O
criteria	O
for	O
spine	B-P
imaging	I-P
.	O

Most	O
subjects	O
with	O
spine	O
fractures	O
were	O
unaware	O
of	O
them	O
.	O

Spine	O
fractures	O
have	O
substantial	O
medical	O
significance	O
but	O
are	O
seldom	O
recognized	O
.	O

This	O
study	O
collected	O
contemporary	O
nationally	O
representative	O
spine	O
fracture	O
prevalence	O
data	O
.	O

Cross-sectional	O
analysis	O
of	O
3330	O
US	O
adults	O
aged	O
≥40	O
years	O
participating	O
in	O
NHANES	O
2013-2014	O
with	O
evaluable	O
Vertebral	O
Fracture	O
Assessment	O
(	O
VFA	B-P
)	O
.	O

VFA	B-P
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O

BMD	O
and	O
an	O
osteoporosis	O
questionnaire	O
were	O
collected	O
.	O

Overall	O
spine	O
fracture	O
prevalence	O
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	O
and	O
women	O
.	O

Prevalence	O
increased	O
with	O
age	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Fractures	O
were	O
more	O
common	O
in	O
non-Hispanic	O
whites	O
and	O
in	O
people	O
with	O
lower	O
body	O
mass	O
index	O
and	O
BMD	O
.	O

Among	O
subjects	O
with	O
spine	O
fracture	O
,	O
26	O
%	O
met	O
BMD	O
criteria	O
for	O
osteoporosis	O
.	O

Prevalence	O
was	O
higher	O
in	O
subjects	O
who	O
met	O
National	O
Osteoporosis	O
Foundation	O
(	O
NOF	O
)	O
criteria	O
for	O
spine	B-P
imaging	I-P
(	O
14	O
vs	O
4.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	O
fracture	O
diagnosed	O
by	O
VFA	B-P
had	O
a	O
self-reported	O
fracture	O
,	O
and	O
among	O
those	O
who	O
self-reported	O
a	O
spine	O
fracture	O
,	O
only	O
21	O
%	O
were	O
diagnosed	O
with	O
fracture	O
by	O
VFA	B-P
.	O

Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
women	O
and	O
men	O
and	O
increases	O
with	O
age	O
and	O
lower	O
BMD	O
,	O
although	O
most	O
subjects	O
with	O
spine	O
fracture	O
do	O
not	O
meet	O
BMD	O
criteria	O
for	O
osteoporosis	O
.	O

Since	O
most	O
(	O
>	O
90	O
%	O
)	O
individuals	O
were	O
unaware	O
of	O
their	O
spine	O
fractures	O
,	O
lateral	O
spine	B-P
imaging	I-P
is	O
needed	O
to	O
identify	O
these	O
women	O
and	O
men	O
.	O

Spine	O
fracture	O
prevalence	O
was	O
threefold	O
higher	O
in	O
individuals	O
meeting	O
NOF	O
criteria	O
for	O
spine	B-P
imaging	I-P
(	O
∼1	O
in	O
7	O
undergoing	O
VFA	B-P
)	O
.	O

Identifying	O
spine	O
fractures	O
as	O
part	O
of	O
comprehensive	O
risk	O
assessment	O
may	O
improve	O
clinical	B-P
decision	I-P
making	I-P
.	O

Lignin	O
-derived	O
inhibition	O
of	O
monocomponent	O
cellulases	O
and	O
a	O
xylanase	O
in	O
the	O
hydrolysis	O
of	O
lignocellulosics	O
.	O

Non-productive	O
enzyme	O
binding	O
onto	O
lignin	O
is	O
the	O
major	O
inhibitory	O
mechanism	O
,	O
which	O
reduces	O
hydrolysis	O
rates	O
and	O
yields	O
and	O
prevents	O
efficient	O
enzyme	O
recycling	O
in	O
the	O
hydrolysis	O
of	O
lignocellulosics	O
.	O

The	O
detailed	O
mechanisms	O
of	O
binding	O
are	O
still	O
poorly	O
understood	O
.	O

Enzyme	O
-	O
lignin	O
interactions	O
were	O
investigated	O
by	O
comparing	O
the	O
structural	O
properties	O
and	O
binding	O
behaviour	O
of	O
fungal	O
monocomponent	O
enzymes	O
,	O
cellobiohydrolases	O
TrCel7A	O
and	O
TrCel6A	O
,	O
endoglucanases	O
TrCel7B	O
and	O
TrCel5A	O
,	O
a	O
xylanase	O
TrXyn11	O
and	O
a	O
β-glucosidase	O
AnCel3A	O
,	O
onto	O
lignins	O
isolated	O
from	O
steam	O
pretreated	O
spruce	O
and	O
wheat	O
straw	O
.	O

The	O
enzymes	O
exhibited	O
decreasing	O
affinity	O
onto	O
lignin	O
model	O
films	O
in	O
the	O
following	O
order	O
:	O
TrCel7B	O
>	O
TrCel6A	O
>	O
TrCel5A	O
>	O
AnCel3A	O
>	O
TrCel7A	O
>	O
TrXyn11	O
.	O

As	O
analysed	O
in	O
Avicel	O
hydrolysis	O
,	O
TrCel6A	O
and	O
TrCel7B	O
were	O
most	O
inhibited	O
by	O
lignin	O
isolated	O
from	O
pretreated	O
spruce	O
.	O

This	O
could	O
be	O
partially	O
explained	O
by	O
adsorption	B-P
of	O
the	O
enzyme	O
onto	O
the	O
lignin	O
surface	O
.	O

Enzyme	O
properties	O
,	O
such	O
as	O
enzyme	O
surface	O
charge	O
,	O
thermal	B-P
stability	I-P
or	O
surface	O
hydrophobicity	O
could	O
not	O
alone	O
explain	O
the	O
adsorption	B-P
behaviour	O
.	O

Joint	O
model	O
imputation	O
to	O
estimate	O
the	O
treatment	O
effect	O
on	O
long-term	O
survival	O
using	O
auxiliary	O
events	O
.	O

Clinical	O
trial	O
duration	O
may	O
be	O
a	O
concern	O
in	O
clinical	O
research	O
,	O
especially	O
in	O
cancer	O
trials	O
where	O
the	O
endpoint	O
is	O
overall	O
survival	O
.	O

A	O
surrogate	O
endpoint	O
can	O
be	O
used	O
as	O
an	O
auxiliary	O
variable	O
to	O
analyze	O
the	O
treatment	O
effect	O
earlier	O
.	O

At	O
an	O
early	O
time	O
point	O
,	O
the	O
high	O
number	O
of	O
censored	O
observations	O
can	O
be	O
compensated	O
by	O
the	O
imputation	O
of	O
the	O
unobserved	O
deaths	O
times	O
.	O

We	O
propose	O
to	O
use	O
predictions	O
of	O
the	O
risk	O
of	O
death	O
from	O
a	O
joint	O
model	O
for	O
a	O
recurrent	O
event	O
and	O
a	O
terminal	O
event	O
,	O
which	O
account	O
for	O
disease	O
relapse	O
information	O
.	O

Two	O
imputation	O
methods	O
were	O
compared	O
:	O
sampling	O
from	O
the	O
estimated	O
parametric	O
distribution	O
of	O
the	O
survival	O
time	O
and	O
sampling	O
using	O
its	O
nonparametric	O
estimation	O
.	O

The	O
treatment	O
effect	O
and	O
its	O
standard	O
error	O
were	O
estimated	O
via	O
multiple	O
imputations	O
.	O

The	O
performances	O
of	O
the	O
two	O
methods	O
were	O
compared	O
in	O
terms	O
of	O
bias	O
in	O
the	O
estimates	O
,	O
standard	O
errors	O
,	O
and	O
coverage	O
probability	O
.	O

Both	O
methods	O
were	O
then	O
retrospectively	O
applied	O
to	O
two	O
randomized	O
clinical	O
trials	O
studying	O
the	O
effect	O
of	O
adjuvant	O
chemotherapy	B-P
in	O
breast	O
cancer	O
patients	O
.	O

An	O
Accessible	O
and	O
Pragmatic	O
Experimental	O
Model	O
of	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
.	O

BACKGROUND	O
There	O
is	O
no	O
convenient	O
cheap	O
pragmatic	O
experimental	O
model	O
for	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
(	O
NAFLD	O
)	O
/	O
Nonalcoholic	O
Steatohepatitis	O
(	O
NASH	O
)	O
.	O

Our	O
objective	O
was	O
to	O
create	O
a	O
pragmatic	O
model	O
of	O
NAFLD	O
/	O
NASH	O
.	O

METHODS	O
Sprague-Dawley	O
rats	O
were	O
fed	O
a	O
high-fat	B-P
,	O
high	B-P
sugar	I-P
homemade	I-P
diet	I-P
ad	O
libitum	O
for	O
seven	O
weeks	O
.	O

The	O
high-fat	B-P
,	O
high	B-P
sugar	I-P
diet	I-P
included	O
59	O
%	O
of	O
energy	O
derived	O
from	O
fat	O
,	O
30	O
%	O
from	O
carbohydrates	O
,	O
and	O
11	O
%	O
from	O
protein	O
.	O

Serum	B-P
levels	I-P
of	I-P
fasting	I-P
glucose	I-P
,	O
triglyceride	B-P
,	O
cholesterol	B-P
,	O
liver	B-P
enzymes	I-P
,	O
insulin	B-P
,	O
and	O
hepatic	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-α	O
)	O
gene	O
expression	O
were	O
determined	O
.	O

Hepatic	O
histology	B-P
was	O
examined	O
by	O
H	B-P
&	I-P
E	I-P
stain	I-P
.	O

RESULTS	O
Rats	O
fed	O
the	O
high-fat	B-P
,	O
high	B-P
sugar	I-P
diet	I-P
developed	O
hepatic	O
steatosis	O
,	O
and	O
a	O
moderate	O
inflammation	O
,	O
which	O
was	O
associated	O
with	O
increased	O
serum	O
levels	O
of	O
liver	O
enzymes	O
,	O
glucose	O
,	O
insulin	O
,	O
triglyceride	O
,	O
cholesterol	O
,	O
and	O
hepatic	O
TNF-α	O
gene	O
expression	O
.	O

CONCLUSION	O
This	O
rat	O
model	O
resembles	O
the	O
key	O
features	O
of	O
human	O
NAFLD	O
/	O
NASH	O
and	O
provides	O
a	O
simple	O
pragmatic	O
experimental	O
model	O
for	O
elucidating	O
the	O
disease	B-P
prevention	I-P
and	O
treatment	B-P
.	O

From	O
Homology	O
Models	O
to	O
a	O
Set	O
of	O
Predictive	O
Binding	O
Pockets	O
-a	O
5-HT1A	O
Receptor	O
Case	O
Study	O
.	O

Despite	O
its	O
remarkable	O
importance	O
in	O
the	O
arena	O
of	O
drug	O
design	O
,	O
serotonin	O
1A	O
receptor	O
(	O
5-HT1A	O
)	O
has	O
been	O
elusive	O
to	O
the	O
X-ray	B-P
crystallography	I-P
community	O
.	O

This	O
lack	O
of	O
direct	O
structural	O
information	O
not	O
only	O
hampers	O
our	O
knowledge	O
regarding	O
the	O
binding	O
modes	O
of	O
many	O
popular	O
ligands	O
(	O
including	O
the	O
endogenous	O
neurotransmitter	O
-	O
serotonin	O
)	O
,	O
but	O
also	O
limits	O
the	O
search	O
for	O
more	O
potent	O
compounds	O
.	O

In	O
this	O
paper	O
we	O
shed	O
new	O
light	O
on	O
the	O
3D	O
pharmacological	O
properties	O
of	O
the	O
5-HT1A	O
receptor	O
by	O
using	O
a	O
ligand-guided	O
approach	O
(	O
ALiBERO	O
)	O
grounded	O
in	O
the	O
Internal	O
Coordinate	O
Mechanics	O
(	O
ICM	O
)	O
docking	O
platform	O
.	O

Starting	O
from	O
a	O
homology	O
template	O
and	O
set	O
of	O
known	O
actives	O
,	O
the	O
method	O
introduces	O
receptor	O
flexibility	O
via	O
Normal	O
Mode	O
Analysis	O
and	O
Monte	O
Carlo	O
sampling	O
,	O
to	O
generate	O
a	O
subset	O
of	O
pockets	O
that	O
display	O
enriched	O
discrimination	O
of	O
actives	O
from	O
inactives	O
in	O
retrospective	O
docking	O
.	O

Here	O
,	O
we	O
thoroughly	O
investigated	O
the	O
repercussions	O
of	O
using	O
different	O
protein	O
templates	O
and	O
the	O
effect	O
of	O
compound	O
selection	O
on	O
screening	O
performance	O
.	O

Finally	O
,	O
the	O
best	O
resulting	O
protein	O
models	O
were	O
applied	O
prospectively	O
in	O
a	O
large	O
virtual	O
screening	O
campaign	O
,	O
in	O
which	O
two	O
new	O
active	O
compounds	O
were	O
identified	O
that	O
were	O
chemically	O
distinct	O
from	O
those	O
described	O
in	O
the	O
literature	O
.	O

Preparation	O
and	O
characterization	O
of	O
gastrointestinal	O
wafer	O
formulations	O
.	O

Many	O
active	O
pharmaceutical	O
ingredients	O
(	O
API	O
)	O
have	O
a	O
very	O
poor	O
or	O
highly	O
variable	O
bioavailability	O
after	O
oral	B-P
administration	I-P
.	O

One	O
possibility	O
to	O
overcome	O
this	O
problem	O
might	O
be	O
found	O
in	O
the	O
application	O
of	O
mucoadhesive	O
dosage	O
forms	O
like	O
gastrointestinal	O
wafers	O
.	O

However	O
,	O
a	O
currently	O
unsolved	O
challenge	O
is	O
the	O
control	O
of	O
the	O
adhesion	O
of	O
the	O
wafer	O
to	O
the	O
intestinal	O
mucus	O
.	O

One	O
suggested	O
solution	O
might	O
be	O
the	O
combination	O
of	O
gastrointestinal	O
wafers	O
and	O
expanding	O
systems	O
.	O

Such	O
a	O
combination	O
requires	O
thin	O
and	O
elastic	O
wafers	O
which	O
are	O
further	O
characterized	O
by	O
an	O
unidirectional	O
drug	O
release	O
.	O

In	O
this	O
study	O
gastrointestinal	O
,	O
twolayered	O
wafers	O
containing	O
a	O
water-insoluble	O
backing	O
layer	O
and	O
a	O
drug-loaded	O
,	O
mucoadhesive	O
layer	O
were	O
fabricated	O
by	O
casting	O
solvent	O
technique	O
.	O

The	O
backing	O
layer	O
consists	O
of	O
Ethocel™	O
Standard	O
10	O
Premium	O
and	O
the	O
mucoadhesive	O
layer	O
was	O
prepared	O
using	O
a	O
mixture	O
of	O
Methocel™	O
E15	O
Premium	O
LV	O
,	O
polyvinyl	O
alcohol	O
and	O
Macrogol	O
400	O
.	O

The	O
wafers	O
were	O
characterized	O
regarding	O
their	O
appearance	O
,	O
mechanical	O
properties	O
and	O
dissolution	O
profiles	O
as	O
well	O
as	O
the	O
influence	O
of	O
backing	O
layer	O
thickness	O
on	O
drug	O
transfer	O
and	O
their	O
ability	O
of	O
unidirectional	O
drug	O
release	O
.	O

The	O
wafers	O
with	O
backing	O
layer	O
thickness	O
of	O
500μg	O
Ethocel	O
™/cm	O
(	O
2	O
)	O
presented	O
adequate	O
mechanical	O
properties	O
,	O
a	O
drug	O
transfer	O
about	O
73	O
%	O
and	O
unidirectional	O
drug	O
release	O
.	O

Decoding	O
the	O
Interactions	O
Regulating	O
the	O
Active	O
State	O
Mechanics	O
of	O
Eukaryotic	O
Protein	O
Kinases	O
.	O

Eukaryotic	O
protein	O
kinases	O
regulate	O
most	O
cellular	O
functions	O
by	O
phosphorylating	O
targeted	O
protein	O
substrates	O
through	O
a	O
highly	O
conserved	O
catalytic	O
core	O
.	O

In	O
the	O
active	O
state	O
,	O
the	O
catalytic	O
core	O
oscillates	B-P
between	O
open	O
,	O
intermediate	O
,	O
and	O
closed	O
conformations	O
.	O

Currently	O
,	O
the	O
intramolecular	O
interactions	O
that	O
regulate	O
the	O
active	O
state	O
mechanics	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
using	O
cAMP-dependent	O
protein	O
kinase	O
as	O
a	O
representative	O
model	O
coupled	O
with	O
biochemical	O
,	O
biophysical	O
,	O
and	O
computational	O
techniques	O
,	O
we	O
define	O
a	O
set	O
of	O
highly	O
conserved	O
electrostatic	O
and	O
hydrophobic	O
interactions	O
working	O
harmoniously	O
to	O
regulate	O
these	O
mechanics	O
.	O

These	O
include	O
the	O
previously	O
identified	O
salt	O
bridge	O
between	O
a	O
lysine	O
from	O
the	O
β3-strand	O
and	O
a	O
glutamate	O
from	O
the	O
αC-helix	O
as	O
well	O
as	O
an	O
electrostatic	O
interaction	O
between	O
the	O
phosphorylated	O
activation	O
loop	O
and	O
αC-helix	O
and	O
an	O
ensemble	O
of	O
hydrophobic	O
residues	O
of	O
the	O
Regulatory	O
spine	O
and	O
Shell	O
.	O

Moreover	O
,	O
for	O
over	O
three	O
decades	O
it	O
was	O
thought	O
that	O
the	O
highly	O
conserved	O
β3	O
-lysine	O
was	O
essential	O
for	O
phosphoryl	O
transfer	O
,	O
but	O
our	O
findings	O
show	O
that	O
the	O
β3	O
-lysine	O
is	O
not	O
required	O
for	O
phosphoryl	O
transfer	O
but	O
is	O
essential	O
for	O
the	O
active	O
state	O
mechanics	O
.	O

MRI	B-P
-based	O
prostate	O
cancer	O
detection	O
with	O
high-level	O
representation	O
and	O
hierarchical	O
classification	O
.	O

Extracting	O
the	O
high-level	O
feature	O
representation	O
by	O
using	O
deep	O
neural	O
networks	O
for	O
detection	O
of	O
prostate	O
cancer	O
,	O
and	O
then	O
based	O
on	O
high-level	O
feature	O
representation	O
constructing	O
hierarchical	O
classification	O
to	O
refine	O
the	O
detection	O
results	O
.	O

High-level	O
feature	O
representation	O
is	O
first	O
learned	O
by	O
a	O
deep	O
learning	O
network	O
,	O
where	O
multiparametric	B-P
MR	I-P
images	O
are	O
used	O
as	O
the	O
input	O
data	O
.	O

Then	O
,	O
based	O
on	O
the	O
learned	O
high-level	O
features	O
,	O
a	O
hierarchical	O
classification	O
method	O
is	O
developed	O
,	O
where	O
multiple	O
random	O
forest	O
classifiers	O
are	O
iteratively	O
constructed	O
to	O
refine	O
the	O
detection	O
results	O
of	O
prostate	O
cancer	O
.	O

The	O
experiments	O
were	O
carried	O
on	O
21	O
real	O
patient	O
subjects	O
,	O
and	O
the	O
proposed	O
method	O
achieves	O
an	O
averaged	O
section-based	O
evaluation	O
(	O
SBE	O
)	O
of	O
89.90	O
%	O
,	O
an	O
averaged	O
sensitivity	O
of	O
91.51	O
%	O
,	O
and	O
an	O
averaged	O
specificity	O
of	O
88.47	O
%	O
.	O

The	O
high-level	O
features	O
learned	O
from	O
our	O
proposed	O
method	O
can	O
achieve	O
better	O
performance	O
than	O
the	O
conventional	O
handcrafted	O
features	O
(	O
e.g.	O
,	O
LBP	O
and	O
Haar-like	O
features	O
)	O
in	O
detecting	O
prostate	O
cancer	O
regions	O
,	O
also	O
the	O
context	O
features	O
obtained	O
from	O
the	O
proposed	O
hierarchical	O
classification	O
approach	O
are	O
effective	O
in	O
refining	O
cancer	O
detection	O
result	O
.	O

Lipidomic	B-P
Signatures	I-P
and	O
Associated	O
Transcriptomic	O
Profiles	O
of	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
.	O

Renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
is	O
the	O
most	O
common	O
histological	O
type	O
of	O
adult	O
kidney	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
lipidomic	B-P
profiles	I-P
of	O
clear	O
cell	O
RCC	O
(	O
ccRCC	O
)	O
,	O
a	O
major	O
RCC	O
subtype	O
,	O
by	O
performing	O
a	O
lipidomic	B-P
analysis	I-P
of	O
specimens	O
of	O
cancerous	O
tissue	O
and	O
the	O
surrounding	O
normal	O
renal	O
cortex	O
obtained	O
from	O
the	O
same	O
patients	O
(	O
N	O
=	O
49	O
)	O
.	O

We	O
also	O
compared	O
the	O
lipidomic	B-P
profiles	I-P
with	O
the	O
lipogenic	O
transcriptome	O
of	O
specimens	O
of	O
cancerous	O
tissue	O
and	O
the	O
surrounding	O
normal	O
renal	O
cortex	O
for	O
an	O
additional	O
set	O
of	O
patient	O
samples	O
(	O
N	O
=	O
95	O
)	O
.	O

Overall	O
,	O
we	O
detected	O
326	O
lipids	O
,	O
including	O
phospholipids	O
,	O
sphingolipids	O
,	O
neutral	O
lipids	O
,	O
and	O
eicosanoids	O
.	O

The	O
levels	O
of	O
more	O
than	O
70	O
%	O
of	O
the	O
detected	O
lipids	O
were	O
significantly	O
different	O
(	O
P	O
<	O
0.01	O
,	O
corrected	O
by	O
the	O
false	O
discovery	O
rate	O
)	O
.	O

The	O
cancerous	O
tissue	O
was	O
distinguished	O
by	O
higher	O
levels	O
of	O
ether-type	O
phospholipids	O
,	O
cholesterol	O
esters	O
,	O
and	O
triacylglycerols	O
,	O
as	O
well	O
as	O
by	O
lower	O
levels	O
of	O
phospholipids	O
(	O
except	O
for	O
phosphatidylcholines	O
)	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

Characteristic	O
changes	O
in	O
the	O
levels	O
of	O
mRNAs	O
and	O
metabolites	O
suggested	O
that	O
the	O
phosphatidylethanolamine	O
(	O
PE	O
)	O
synthesis	O
pathway	O
is	O
suppressed	O
in	O
ccRCC	O
and	O
associated	O
with	O
cell	O
proliferation	O
.	O

The	O
present	O
study	O
represents	O
the	O
lipidomic	B-P
profiles	I-P
of	O
ccRCC	O
,	O
which	O
provides	O
novel	O
information	O
about	O
the	O
metabolic	O
changes	O
in	O
renal	O
cancerous	O
tissue	O
and	O
RCC	O
pathophysiology	O
.	O

Comparison	O
of	O
therapy	B-P
persistence	O
for	O
fixed	O
versus	O
free	O
combination	O
antihypertensives	O
:	O
a	O
retrospective	O
cohort	O
study	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
therapy	B-P
persistence	O
among	O
patients	O
who	O
started	O
with	O
one	O
of	O
three	O
drug	O
regimens	B-P
:	O
a	O
monotherapy	B-P
,	O
or	O
combination	O
therapy	B-P
either	O
as	O
a	O
fixed	O
combination	O
(	O
ie	O
,	O
'single	O
pill	O
'	O
)	O
or	O
as	O
a	O
free	O
combination	O
(	O
ie	O
,	O
two	O
separate	O
antihypertensive	O
agents	O
)	O
.	O

In	O
a	O
secondary	O
data	O
analysis	O
,	O
we	O
used	O
descriptive	O
statistics	O
and	O
multivariate	O
logistic	O
regression	O
to	O
measure	O
the	O
effect	O
of	O
the	O
three	O
therapy	B-P
regimens	B-P
on	O
therapy	B-P
persistence	O
over	O
4	O
years	O
.	O

Prescription	O
data	O
from	O
a	O
large	O
German	O
statutory	O
health	O
insurance	O
provider	O
.	O

All	O
patients	O
who	O
started	O
with	O
a	O
new	O
antihypertensive	O
therapy	B-P
in	O
2007	O
or	O
2008	O
(	O
n=8032	O
)	O
were	O
included	O
and	O
followed	O
for	O
4	O
years	O
.	O

Therapy	B-P
persistence	O
,	O
defined	O
as	O
receiving	O
a	O
refill	O
prescription	O
no	O
later	O
than	O
within	O
180	O
days	O
.	O

The	O
persistence	O
rates	O
after	O
4	O
years	O
were	O
nearly	O
identical	O
among	O
patients	O
who	O
started	O
with	O
a	O
monotherapy	B-P
(	O
40.3	O
%	O
)	O
or	O
a	O
fixed	O
combination	O
of	O
two	O
drugs	O
(	O
39.8	O
%	O
)	O
.	O

However	O
,	O
significantly	O
more	O
patients	O
who	O
started	O
with	O
free	O
-	O
drug	O
combinations	O
remained	O
therapy	B-P
persistent	O
(	O
56.4	O
%	O
)	O
,	O
resulting	O
in	O
an	O
OR	O
of	O
2.00	O
(	O
95	O
%	O
CI	O
1.6	O
to	O
2.5	O
;	O
p	O
<	O
0.0001	O
)	O
for	O
free	O
combinations	O
versus	O
fixed	O
combinations	O
.	O

This	O
trend	O
was	O
observed	O
in	O
all	O
age	O
groups	O
and	O
for	O
men	O
and	O
women	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
period	O
,	O
the	O
number	O
of	O
different	O
antihypertensive	O
agents	O
was	O
still	O
similar	O
between	O
patients	O
who	O
started	O
with	O
a	O
fixed	O
combination	O
(	O
2.41	O
)	O
and	O
patients	O
who	O
started	O
with	O
a	O
free	O
combination	O
(	O
2.28	O
)	O
.	O

While	O
single-	O
pill	O
combination	O
s	O
make	O
it	O
easier	O
to	O
take	O
different	O
drugs	O
at	O
once	O
,	O
the	O
risk	O
is	O
high	O
that	O
these	O
several	O
substances	O
are	O
stopped	O
at	O
once	O
.	O

Therapy	B-P
persistence	O
was	O
significantly	O
better	O
for	O
patients	O
who	O
started	O
with	O
a	O
free	O
-	O
drug	O
combination	O
without	O
taking	O
much	O
fewer	O
different	O
antihypertensive	O
drugs	O
as	O
those	O
with	O
a	O
fixed	O
combination	O
.	O

Recovery	O
of	O
orthographic	O
processing	O
after	O
stroke	O
:	O
A	O
longitudinal	O
fMRI	B-P
study	O
.	O

An	O
intact	O
orthographic	O
processing	O
system	O
is	O
critical	O
for	O
normal	O
reading	O
and	O
spelling	O
.	O

Here	O
we	O
investigate	O
the	O
neural	O
changes	O
associated	O
with	O
impairment	O
and	O
subsequent	O
recovery	O
of	O
the	O
orthographic	O
lexical	O
processing	O
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	O
left	O
posterior	O
cerebral	O
artery	O
(	O
PCA	O
)	O
stroke	O
.	O

This	O
work	O
describes	O
a	O
longitudinal	O
case	O
study	O
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
MMY	O
,	O
with	O
impairments	O
in	O
orthographic	O
lexical	O
processing	O
for	O
reading	O
and	O
spelling	O
at	O
stroke	O
onset	O
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
this	O
acute	O
impairment	O
to	O
reading	O
and	O
spelling	O
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
neural	O
activation	O
in	O
the	O
left	O
fusiform	O
gyrus	O
(	O
FG	O
)	O
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	O
of	O
neural	O
activation	O
in	O
this	O
region	O
.	O

MMY	O
's	O
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	O
changes	O
because	O
she	O
demonstrated	O
a	O
behavioral	O
recovery	O
of	O
naming	O
as	O
well	O
;	O
i.e.	O
,	O
if	O
there	O
is	O
neural	O
recovery	O
for	O
reading	O
and	O
spelling	O
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	O
changes	O
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	O
processing	O
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	O
behavioral	O
and	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
data	O
of	O
reading	O
,	O
spelling	O
,	O
and	O
visual	O
object	O
naming	O
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	O
.	O

In	O
confirmation	O
of	O
our	O
hypothesis	O
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	O
lexical	O
processing	O
was	O
associated	O
with	O
up-regulation	O
of	O
neural	O
activation	O
in	O
areas	O
previously	O
associated	O
with	O
orthographic	O
lexical	O
processing	O
:	O
i.e.	O
,	O
the	O
left	O
mid-FG	O
and	O
inferior	O
frontal	O
junction	O
(	O
IFJ	O
)	O
.	O

Furthermore	O
,	O
these	O
neural	O
changes	O
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	O
processing	O
,	O
as	O
they	O
were	O
observed	O
for	O
reading	O
and	O
spelling	O
,	O
but	O
not	O
for	O
visual	O
object	O
naming	O
within	O
the	O
left	O
mid-FG	O
.	O

This	O
work	O
shows	O
that	O
left	O
PCA	O
stroke	O
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	O
lexical	O
processing	O
system	O
,	O
not	O
only	O
in	O
the	O
posterior	O
region	O
adjacent	O
to	O
the	O
stroke	O
,	O
but	O
also	O
in	O
relatively	O
distant	O
frontal	O
orthographic	O
processing	O
regions	O
.	O

MyHEART	O
:	O
A	O
Non	O
Randomized	O
Feasibility	O
Study	O
of	O
a	O
Young	O
Adult	O
Hypertension	O
Intervention	B-P
.	O

In	O
the	O
United	O
States	O
,	O
young	O
adults	O
(	O
18-39	O
year-olds	O
)	O
have	O
the	O
lowest	O
hypertension	O
control	O
rates	O
(	O
35	O
%	O
)	O
compared	O
to	O
middle-aged	O
(	O
58	O
%	O
)	O
and	O
older	O
(	O
54	O
%	O
)	O
adults	O
.	O

Ambulatory	O
care	O
for	O
hypertension	O
management	O
often	O
focuses	O
on	O
medication	O
with	O
little	O
time	O
for	O
self-management	O
and	O
behavioral	B-P
counseling	I-P
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
feasibility	O
of	O
MyHEART	O
,	O
a	O
telephone-based	O
health	O
coach	O
self-management	O
intervention	O
for	O
young	O
adults	O
.	O

The	O
goals	O
were	O
to	O
determine	O
the	O
intervention	B-P
's	I-P
ability	O
to	O
:	O
1	O
)	O
recruit	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
,	O
2	O
)	O
maintain	O
ongoing	O
communication	O
between	O
the	O
coach	O
and	O
participants	O
,	O
3	O
)	O
increase	O
participants	O
'	O
engagement	O
in	O
self-management	O
,	O
4	O
)	O
document	O
coach	O
-	O
patient	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
5	O
)	O
assess	O
patient	O
acceptability	O
.	O

Eligible	O
participants	O
were	O
identified	O
through	O
the	O
electronic	O
health	O
record	O
.	O

Inclusion	O
criteria	O
included	O
18-39	O
year-olds	O
,	O
with	O
ICD-9	O
hypertension	O
diagnoses	O
and	O
uncontrolled	O
hypertension	O
(	O
≥	O
140/90	O
mmHg	O
)	O
,	O
receiving	O
regular	O
primary	O
care	O
at	O
a	O
large	O
multispecialty	O
group	O
practice	O
.	O

The	O
intervention	B-P
consisted	O
of	O
6	O
telephone	O
self-management	O
sessions	O
by	O
a	O
health	O
coach	O
targeting	O
lifestyle	O
modifications	O
.	O

Patients	O
completed	O
an	O
open-ended	O
acceptability	O
survey	O
.	O

Study	O
uptake	O
was	O
47	O
%	O
(	O
9	O
enrolled/19	O
eligible	O
)	O
.	O

Mean	O
(	O
SD	O
)	O
age	O
was	O
35.8	O
(	O
2.6	O
)	O
years	O
,	O
78	O
%	O
male	O
,	O
and	O
33	O
%	O
Black	O
.	O

Over	O
85	O
%	O
of	O
enrolled	O
young	O
adults	O
maintained	O
communication	O
with	O
their	O
health	O
coach	O
.	O

At	O
baseline	O
,	O
11	O
%	O
reported	O
checking	O
their	O
blood	O
pressure	O
outside	O
of	O
clinic	O
;	O
44	O
%	O
reported	O
blood	O
pressure	O
monitoring	O
after	O
the	O
study	O
.	O

All	O
coach	O
-	O
patient	O
encounters	O
were	O
successfully	O
documented	O
in	O
the	O
electronic	O
health	O
record	O
for	O
primary	O
care	O
provider	O
review	O
.	O

Open-ended	O
responses	O
from	O
all	O
surveys	O
indicated	O
that	O
participants	O
had	O
a	O
positive	O
experience	O
with	O
the	O
MyHEART	O
intervention	B-P
.	O

This	O
study	O
demonstrated	O
that	O
MyHEART	O
was	O
feasible	O
and	O
acceptable	O
to	O
young	O
adults	O
with	O
uncontrolled	O
hypertension	O
.	O

Health	O
coaches	O
can	O
effectively	O
maintain	O
ongoing	O
communication	O
with	O
young	O
adults	O
,	O
document	O
communication	O
in	O
the	O
electronic	O
health	O
record	O
,	O
and	O
increase	O
engagement	O
with	O
home	B-P
blood	I-P
pressure	I-P
monitoring	I-P
.	O

The	O
results	O
of	O
this	O
study	O
will	O
inform	O
a	O
multi-center	O
young	O
adult	O
randomized	O
controlled	O
trial	O
of	O
MyHEART	O
.	O

Biochemical	O
and	O
proteomic	O
analyses	O
of	O
the	O
physiological	O
response	O
induced	O
by	O
individual	O
housing	O
in	O
gilts	O
provide	O
new	O
potential	O
stress	O
markers	O
.	O

The	O
objective	O
assessment	O
of	O
animal	O
stress	O
and	O
welfare	O
requires	O
proper	O
laboratory	O
biomarkers	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	O
composition	O
in	O
gilts	O
after	O
switching	O
their	O
housing	O
,	O
from	O
pen	O
to	O
individual	O
stalls	O
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	O
discomfort	O
.	O

Blood	O
and	O
saliva	O
samples	O
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	O
system	O
.	O

Biochemical	O
analyses	O
showed	O
adaptive	O
changes	O
in	O
lipid	O
and	O
protein	O
metabolism	O
after	O
the	O
housing	O
switch	O
,	O
whereas	O
cortisol	O
and	O
muscular	O
markers	O
showed	O
a	O
large	O
variability	O
between	O
animals	O
.	O

2D-DIGE	B-P
and	O
iTRAQ	O
proteomic	O
approaches	O
revealed	O
variations	O
in	O
serum	O
protein	O
composition	O
after	O
changing	O
housing	O
and	O
diet	O
of	O
gilts	O
.	O

Both	O
techniques	O
showed	O
alterations	O
in	O
two	O
main	O
homeostatic	O
mechanisms	O
:	O
the	O
innate	O
immune	O
and	O
redox	O
systems	O
.	O

The	O
acute	O
phase	O
proteins	O
haptoglobin	O
,	O
apolipoprotein	O
A-I	O
and	O
α1-antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	O
enzyme	O
peroxiredoxin	O
2	O
were	O
found	O
differentially	O
expressed	O
by	O
2D-DIGE	B-P
.	O

Other	O
proteins	O
related	O
to	O
the	O
innate	O
immune	O
system	O
,	O
including	O
lactotransferrin	O
,	O
protegrin	O
3	O
and	O
galectin	O
1	O
were	O
also	O
identified	O
by	O
iTRAQ	O
,	O
as	O
well	O
as	O
oxidative	O
stress	O
enzymes	O
such	O
as	O
peroxiredoxin	O
2	O
and	O
glutathione	O
peroxidase	O
3	O
.	O

Proteomics	O
also	O
revealed	O
the	O
decrease	O
of	O
apolipoproteins	O
,	O
and	O
the	O
presence	O
of	O
intracellular	O
proteins	O
in	O
serum	O
,	O
which	O
may	O
indicate	O
physical	O
injury	O
to	O
tissues	O
.	O

Housing	O
of	O
gilts	O
in	O
individual	O
stalls	O
and	O
diet	O
change	O
increase	O
lipid	O
and	O
protein	O
catabolism	O
,	O
oxidative	O
stress	O
,	O
activate	O
the	O
innate	O
immune	O
system	O
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	O
damage	O
.	O

We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-P
assessment	I-P
in	O
gilts	O
may	O
be	O
based	O
on	O
a	O
score	O
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	O
metabolites	O
,	O
innate	O
immunity	O
and	O
oxidative	O
stress	O
markers	O
and	O
intracellular	O
proteins	O
.	O

Adequacy	O
criteria	O
for	O
thyroid	B-P
FNA	I-P
evaluated	O
by	O
ThinPrep	B-P
slides	I-P
only	O
.	O

Adequacy	O
criteria	O
for	O
thyroid	B-P
fine-needle	I-P
aspiration	I-P
(	O
FNA	B-P
)	O
recommended	O
by	O
The	O
Bethesda	B-P
System	I-P
for	I-P
Reporting	I-P
Thyroid	I-P
Cytopathology	I-P
(	O
TBS	B-P
)	O
were	O
developed	O
with	O
smears	B-P
,	O
but	O
they	O
are	O
commonly	O
applied	O
to	O
ThinPreps	B-P
(	O
TPs	B-P
)	O
.	O

This	O
study	O
evaluated	O
adequacy	O
in	O
TPs	B-P
at	O
different	O
diagnostic	O
thresholds	O
.	O

All	O
FNA	B-P
procedures	I-P
performed	O
between	O
2010	O
and	O
2015	O
with	O
matched	O
surgical	O
specimens	O
were	O
analyzed	O
.	O

Cell	B-P
counts	I-P
and	O
cytological	O
features	O
were	O
evaluated	O
in	O
all	O
initially	O
nondiagnostic	O
(	O
ND	O
)	O
cases	O
.	O

ND	O
cases	O
were	O
reclassified	O
into	O
TBS	B-P
categories	O
by	O
2	O
pathologists	O
,	O
and	O
the	O
results	O
were	O
compared	O
with	O
surgical	O
outcomes	O
.	O

One	O
hundred	O
forty-six	O
of	O
the	O
151	O
cases	O
initially	O
classified	O
as	O
ND	O
were	O
available	O
for	O
review	O
,	O
and	O
they	O
had	O
a	O
mean	O
cell	B-P
count	I-P
of	O
60.5	O
(	O
standard	O
deviation	O
,	O
71.4	O
)	O
.	O

Interobserver	O
agreement	O
on	O
the	O
reclassification	O
of	O
ND	O
cases	O
was	O
moderate	O
(	O
k	O
=	O
0.57	O
)	O
,	O
and	O
consensus	O
yielded	O
48	O
ND	O
cases	O
(	O
33	O
%	O
)	O
,	O
72	O
benign	O
cases	O
(	O
49	O
%	O
)	O
,	O
24	O
cases	O
of	O
atypia	O
of	O
undetermined	O
significance	O
(	O
16	O
%	O
)	O
,	O
and	O
2	O
cases	O
suspicious	O
for	O
malignancy	O
(	O
1	O
%	O
)	O
.	O

Lowering	O
the	O
diagnostic	O
threshold	O
to	O
any	O
follicular	O
cells	O
yielded	O
a	O
sensitivity	O
of	O
92	O
%	O
,	O
a	O
specificity	O
of	O
60	O
%	O
,	O
a	O
positive	O
predictive	O
value	O
of	O
59	O
%	O
,	O
a	O
negative	O
predictive	O
value	O
of	O
92	O
%	O
,	O
and	O
a	O
false-negative	O
rate	O
of	O
7.7	O
%	O
,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	O
cases	O
were	O
93	O
%	O
,	O
58	O
%	O
,	O
59	O
%	O
,	O
93	O
%	O
,	O
and	O
7.7	O
%	O
,	O
respectively	O
.	O

Including	O
cases	O
with	O
>	O
60	O
cells	O
but	O
lacking	O
6	O
groups	O
containing	O
at	O
least	O
10	O
cells	O
did	O
not	O
affect	O
test	B-P
performance	I-P
.	O

Nuclear	O
enlargement	O
,	O
pallor	O
,	O
grooves	O
,	O
and	O
the	O
presence	O
of	O
histiocytoid	O
cells	O
in	O
initially	O
ND	O
FNA	B-P
correlated	O
with	O
malignancy	O
.	O

In	O
thyroid	B-P
FNA	I-P
examined	O
with	O
TP	B-P
only	O
,	O
lowering	O
the	O
adequacy	O
threshold	O
and	O
eliminating	O
the	O
requirement	O
of	O
6	O
groups	O
of	O
at	O
least	O
10	O
cells	O
did	O
not	O
significantly	O
affect	O
test	B-P
performance	I-P
if	O
cytological	O
features	O
associated	O
with	O
malignancy	O
were	O
absent	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

Electrochemically	O
assisted	O
deposition	O
of	O
strontium	O
modified	O
magnesium	O
phosphate	O
on	O
titanium	O
surfaces	O
.	O

Electrochemically	O
assisted	O
deposition	O
was	O
utilized	O
to	O
produce	O
ceramic	O
coatings	O
on	O
the	O
basis	O
of	O
magnesium	O
ammonium	O
phosphate	O
(	O
struvite	O
)	O
on	O
corundum	O
-	O
blasted	O
titanium	O
surfaces	O
.	O

By	O
the	O
addition	O
of	O
defined	O
concentrations	O
of	O
strontium	O
nitrate	O
to	O
the	O
coating	O
electrolyte	O
Sr	O
(	O
2+	O
)	O
ions	O
were	O
successfully	O
incorporated	O
into	O
the	O
struvite	O
matrix	O
.	O

By	O
variation	O
of	O
deposition	O
parameters	O
it	O
was	O
possible	O
to	O
fabricate	O
coatings	O
with	O
different	O
kinetics	O
of	O
Sr	O
(	O
2+	O
)	O
into	O
physiological	O
media	O
,	O
whereas	O
the	O
release	O
of	O
therapeutically	O
relevant	O
strontium	O
doses	O
could	O
be	O
sustained	O
over	O
several	O
weeks	O
.	O

Morphological	O
and	O
crystallographic	B-P
examinations	I-P
of	O
the	O
immersed	O
coatings	O
revealed	O
that	O
the	O
degradation	O
of	O
struvite	O
and	O
the	O
release	O
of	O
Sr	O
(	O
2+	O
)	O
ions	O
were	O
accompanied	O
by	O
a	O
transformation	O
of	O
the	O
coating	O
to	O
a	O
calcium	O
phosphate	O
based	O
phase	O
similar	O
to	O
low-crystalline	O
hydroxyapatite	O
.	O

These	O
findings	O
showed	O
that	O
strontium	O
doped	O
struvite	O
coatings	O
may	O
provide	O
a	O
promising	O
degradable	O
coating	O
system	O
for	O
the	O
local	O
application	O
of	O
strontium	O
or	O
other	O
biologically	O
active	O
metal	O
ions	O
in	O
the	O
implant-bone	O
interface	O
.	O

Multicentric	O
Castleman	O
disease	O
of	O
hyaline	O
vascular	O
variant	O
presenting	O
with	O
unusual	O
systemic	O
manifestations	O
:	O
a	O
case	O
report	O
.	O

Castleman	O
disease	O
is	O
a	O
rare	O
lymphoproliferative	O
disorder	O
presenting	O
with	O
localized	O
or	O
disseminated	O
lymphadenopathy	O
and	O
systemic	O
manifestations	O
.	O

It	O
can	O
be	O
categorized	O
in	O
numerous	O
ways	O
,	O
such	O
as	O
unicentric	O
versus	O
multicentric	O
,	O
histopathological	O
variants	O
(	O
hyaline	O
-	O
vascular	O
,	O
plasma	O
cell	O
,	O
and	O
mixed	O
)	O
,	O
or	O
subtypes	O
based	O
on	O
causative	O
viral	O
infections	O
(	O
human	O
immunodeficiency	O
virus	O
,	O
human	O
herpesvirus-8	O
,	O
or	O
Kaposi	O
sarcoma	O
herpesvirus	O
)	O
.	O

Presentation	O
ranges	O
from	O
asymptomatic	O
to	O
symptoms	O
involving	O
multiple	O
organs	O
.	O

Even	O
though	O
the	O
exact	O
mechanism	O
of	O
pathogenesis	O
is	O
unknown	O
,	O
treatment	O
is	O
directed	O
toward	O
possible	O
etiologies	O
such	O
as	O
interleukin-6	O
,	O
cluster	O
of	O
differentiation	O
20	O
,	O
and	O
viral	O
agents	O
.	O

A	O
36-	O
year	O
-old	O
Sri	O
Lankan	O
woman	O
presented	O
with	O
generalized	O
body	O
swelling	O
and	O
foamy	O
urine	O
of	O
2	O
weeks	O
'	O
duration	O
.	O

Examination	O
revealed	O
pallor	O
;	O
generalized	O
edema	O
;	O
axillary	O
,	O
cervical	O
,	O
and	O
inguinal	O
lymphadenopathy	O
;	O
hypertension	O
;	O
and	O
hepatomegaly	O
.	O

Investigations	O
showed	O
bicytopenia	O
,	O
nephrotic	O
range	O
proteinuria	O
with	O
hypoalbuminemia	O
,	O
hypogammaglobulinemia	O
,	O
and	O
features	O
of	O
hyaline	O
-	O
vascular	O
type	O
Castleman	O
disease	O
in	O
a	O
lymph	B-P
node	I-P
biopsy	I-P
.	O

She	O
was	O
managed	O
with	O
rituximab	O
and	O
had	O
good	O
clinical	O
improvement	O
.	O

Castleman	O
disease	O
has	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
,	O
disease	O
pathogeneses	O
,	O
and	O
associations	O
and/or	O
complications	O
.	O

Medical	O
professionals	O
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	O
because	O
timely	O
diagnosis	O
and	O
aggressive	B-P
targeted	I-P
therapy	I-P
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
patients	O
.	O

Metabolomics	O
analysis	O
of	O
anaphylactoid	O
reaction	O
reveals	O
its	O
mechanism	O
in	O
a	O
rat	O
model	O
.	O

Anaphylactoid	O
reactions	O
,	O
accounting	O
for	O
more	O
than	O
77	O
%	O
of	O
all	O
immune-mediated	O
immediate	O
hypersensitivity	O
reactions	O
,	O
have	O
become	O
a	O
serious	O
threat	O
to	O
public	O
health	O
,	O
but	O
their	O
effect	O
mechanism	O
is	O
not	O
clear	O
and	O
diagnostic	B-P
tests	I-P
are	O
limited	O
.	O

Comprehensive	O
metabolite	O
analysis	O
may	O
reveal	O
the	O
anaphylactoid	O
effect	O
mechanism	O
systematically	O
and	O
provide	O
reference	O
for	O
future	O
diagnostic	O
purposes	O
.	O

Plasma	O
from	O
Brown	O
Norway	O
rats	O
given	O
intravenous	O
injection	O
of	O
saline	O
,	O
compound	O
48/80	O
(	O
2.5	O
mL/kg	O
)	O
or	O
ovalbumin	O
(	O
20	O
mL/kg	O
)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	O
to	O
study	O
the	O
effect	O
mechanism	O
of	O
anaphylactoid	O
reactions	O
through	O
metabolomics	O
(	O
UPLC-qTOF-MS/MS	O
)	O
.	O

Metabolomics	O
integrated	O
with	O
proteomics	O
data	O
were	O
used	O
to	O
analyze	O
the	O
anaphylactoid	O
pathways	O
by	O
MetaboAnalyst	O
followed	O
by	O
integrated	O
pathway	O
analysis	O
.	O

Thirty	O
metabolites	O
were	O
identified	O
through	O
the	O
METLIN	O
database	O
by	O
MS/MS	O
and	O
18	O
of	O
them	O
were	O
confirmed	O
by	O
authentic	O
standards	O
.	O

The	O
results	O
showed	O
that	O
adenosine	O
,	O
histamine	O
,	O
N-acetylhistamine	O
,	O
N	O
(	O
α	O
)	O
-γ-glutamylhistamine	O
,	O
malate	O
and	O
xanthine	O
are	O
important	O
indices	O
for	O
anaphylactoid	O
reactions	O
.	O

It	O
could	O
be	O
concluded	O
that	O
the	O
effect	O
mechanism	O
is	O
mainly	O
composed	O
of	O
histidine	O
metabolism	O
,	O
arachidonic	O
acid	O
metabolism	O
,	O
energy	O
metabolism	O
,	O
purine	O
metabolism	O
and	O
other	O
small	O
molecules	O
through	O
30	O
metabolites	O
.	O

Multiple	O
linear	O
regression	O
analysis	O
indicated	O
that	O
not	O
only	O
histamine	O
but	O
also	O
N	O
(	O
α	O
)	O
-γ-glutamylhistamine	O
and	O
arachidonic	O
acid	O
could	O
be	O
used	O
to	O
evaluate	O
anaphylactoid	O
symptoms	O
of	O
animals	O
.	O

Furthermore	O
,	O
the	O
citrate	O
cycle	O
,	O
histidine	O
metabolism	O
and	O
arachidonic	O
acid	O
metabolism	O
could	O
be	O
the	O
main	O
pathways	O
of	O
anaphylactoid	O
reactions	O
as	O
determined	O
by	O
MetaboAnalyst	O
.	O

The	O
results	O
may	O
provide	O
a	O
reference	O
to	O
improve	O
diagnostic	O
accuracy	O
and	O
predict	O
and	O
monitor	O
treatment	O
efficacy	O
in	O
anaphylactoid	O
reactions	O
in	O
the	O
clinical	O
setting	O
.	O

Effect	O
of	O
ultrasonic	O
processing	O
on	O
the	O
changes	O
in	O
activity	O
,	O
aggregation	O
and	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
polyphenol	O
oxidase	O
in	O
oriental	O
sweet	O
melon	O
(	O
Cucumis	O
melo	O
var	O
.	O

makuwa	O
Makino	O
)	O
.	O

Polyphenol	O
oxidase	O
(	O
PPO	O
)	O
mainly	O
contributes	O
to	O
the	O
browning	O
reaction	O
of	O
fruits	O
and	O
vegetables	O
and	O
causes	O
serious	O
damage	O
to	O
the	O
quality	O
of	O
sweet	O
melon	O
products	O
.	O

However	O
,	O
traditional	O
methods	O
to	O
inactivate	O
browning	O
may	O
induce	O
more	O
unexpected	O
risks	O
than	O
ultrasonic	O
processing	O
.	O

Meanwhile	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
effect	O
of	O
ultrasound	O
on	O
PPO	O
directly	O
purified	O
from	O
sweet	O
melon	O
.	O

The	O
PPO	O
in	O
the	O
original	O
juice	O
was	O
less	O
inactivated	O
than	O
the	O
purified	O
form	O
when	O
treated	B-P
with	I-P
ultrasound	O
.	O

As	O
for	O
purified	O
PPO	O
,	O
superior	O
to	O
thermal	B-P
treatment	I-P
,	O
less	O
heat	O
was	O
needed	O
to	O
inactivate	O
the	O
PPO	O
with	O
ultrasonic	O
treatment	B-P
.	O

At	O
intensity	O
lower	O
than	O
200	O
W	O
,	O
ultrasound	O
did	O
not	O
significantly	O
affect	O
the	O
structure	O
and	O
activity	O
of	O
PPO	O
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
latent	O
PPO	O
was	O
activated	O
.	O

At	O
intensity	O
higher	O
than	O
200	O
W	O
,	O
ultrasound	O
inactivated	O
PPO	O
,	O
induced	O
aggregation	O
and	O
dissociation	O
of	O
PPO	O
particles	O
and	O
significantly	O
decreased	O
the	O
α-helix	O
structure	O
content	O
.	O

Low-frequency	O
high-intensity	O
ultrasound	O
caused	O
an	O
inactivation	O
effect	O
and	O
conformational	O
changes	O
of	O
purified	O
PPO	O
from	O
oriental	O
sweet	O
melons	O
.	O

Changes	O
in	O
the	O
PPO	O
structure	O
induced	O
by	O
ultrasound	O
eventually	O
inactivated	O
the	O
enzyme	O
.	O

Ultrasound	O
may	O
be	O
a	O
potential	O
method	O
to	O
inactivate	O
PPO	O
in	O
oriental	O
sweet	O
melons	O
.	O

©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Effects	O
of	O
robot-assisted	B-P
upper	I-P
limb	I-P
rehabilitation	I-P
in	O
stroke	O
patients	O
:	O
a	O
systematic	O
review	O
with	O
meta-analysis	O
.	O

Technology-supported	O
training	O
is	O
emerging	O
as	O
a	O
solution	O
to	O
support	O
therapists	O
in	O
their	O
efforts	O
providing	O
high-intensity	O
,	O
repetitive	O
,	O
and	O
task-specific	B-P
treatment	I-P
,	O
in	O
order	O
to	O
enhance	O
the	O
recovery	O
process	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
assess	O
the	O
effectiveness	O
of	O
different	O
robotic	O
devices	O
(	O
end-effector	O
and	O
exoskeleton	O
robots	O
)	O
in	O
comparison	O
with	O
any	O
other	O
type	O
of	O
intervention	B-P
.	O

Furthermore	O
,	O
we	O
aim	O
to	O
assess	O
whether	O
or	O
not	O
better	O
improvements	O
are	O
obtained	O
in	O
the	O
sub-acute	O
phase	O
after	O
stroke	O
onset	O
than	O
in	O
the	O
chronic	O
phase	O
.	O

A	O
research	O
was	O
conducted	O
in	O
the	O
electronic	O
bibliographic	O
databases	O
Cochrane	O
,	O
MEDLINE	O
,	O
and	O
EMBASE	O
.	O

A	O
total	O
of	O
17	O
studies	O
were	O
included	O
:	O
14	O
randomized	O
controlled	O
trials	O
,	O
2	O
systematic	O
reviews	O
,	O
and	O
one	O
meta-analysis	O
.	O

Fugl-Meyer	O
and	O
modified	O
Ashworth	O
scale	O
were	O
selected	O
to	O
measure	O
primary	O
outcomes	O
,	O
i.e.	O
,	O
motor	O
function	O
and	O
muscle	O
tone	O
.	O

Functional	O
independence	O
measure	O
and	O
motor	O
activity	O
log	O
were	O
selected	O
to	O
measure	O
secondary	O
outcomes	O
,	O
i.e.	O
,	O
activities	O
of	O
daily	O
living	O
.	O

In	O
comparison	O
with	O
conventional	B-P
therapy	I-P
,	O
the	O
robot-assisted	B-P
rehabilitation	I-P
is	O
more	O
effective	O
in	O
improving	O
upper	O
limb	O
motor	O
function	O
recovery	O
,	O
especially	O
in	O
chronic	O
stroke	O
patients	O
.	O

No	O
significant	O
improvements	O
are	O
observed	O
in	O
the	O
reduction	O
of	O
muscle	O
tone	O
or	O
daily	O
living	O
activities	O
.	O

The	O
present	O
systematic	O
review	O
shows	O
that	O
the	O
use	O
of	O
robotic	O
devices	O
can	O
positively	O
affect	O
the	O
recovery	O
of	O
arm	O
function	O
in	O
patients	O
with	O
stroke	O
.	O

Heavy	B-P
Resistance	I-P
Training	I-P
in	O
Hypoxia	O
Enhances	O
1RM	O
Squat	O
Performance	O
.	O

Purpose	O
:	O
To	O
determine	O
if	O
heavy	B-P
resistance	I-P
training	I-P
in	O
hypoxia	O
(	O
IHRT	B-P
)	O
is	O
more	O
effective	O
at	O
improving	O
strength	O
,	O
power	O
,	O
and	O
increasing	O
lean	O
mass	O
than	O
the	O
same	O
training	O
in	O
normoxia	O
.	O

Methods	O
:	O
A	O
pair-matched	O
,	O
placebo-controlled	O
study	O
design	O
included	O
20	O
resistance-trained	B-P
participants	O
assigned	O
to	O
IHRT	B-P
(	O
FIO2	B-P
0.143	O
)	O
or	O
placebo	O
(	O
FIO2	B-P
0.20	O
)	O
,	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
.	O

Participants	O
were	O
matched	O
for	O
strength	O
and	O
training	B-P
.	O

Both	O
groups	O
performed	O
20	O
sessions	O
over	O
7	O
weeks	O
either	O
with	O
IHRT	B-P
or	O
placebo	O
.	O

All	O
participants	O
were	O
tested	O
for	O
1RM	O
,	O
20-m	O
sprint	B-P
,	O
body	O
composition	O
,	O
and	O
countermovement	O
jump	O
pre	O
-	O
,	O
mid	O
-	O
,	O
and	O
post	O
-	O
training	B-P
and	O
compared	O
via	O
magnitude	O
-	O
based	O
inferences	O
.	O

Presentation	O
of	O
Results	O
:	O
Groups	O
were	O
not	O
clearly	O
different	O
for	O
any	O
test	O
at	O
baseline	O
.	O

Training	B-P
improved	O
both	O
absolute	O
(	O
IHRT	B-P
:	O
13.1	O
±	O
3.9	O
%	O
,	O
effect	O
size	O
(	O
ES	O
)	O
0.60	O
,	O
placebo	O
9.8	O
±	O
4.7	O
%	O
,	O
ES	O
0.31	O
)	O
and	O
relative	O
1RM	O
(	O
IHRT	B-P
:	O
13.4	O
±	O
5.1	O
%	O
,	O
ES	O
0.76	O
,	O
placebo	O
9.7	O
±	O
5.3	O
%	O
,	O
ES	O
0.48	O
)	O
at	O
mid	O
.	O

Similarly	O
,	O
at	O
post	O
both	O
groups	O
increased	O
absolute	O
(	O
IHRT	B-P
:	O
20.7	O
±	O
7.6	O
%	O
,	O
ES	O
0.74	O
,	O
placebo	O
14.1	O
±	O
6.0	O
%	O
,	O
ES	O
0.58	O
)	O
and	O
relative	O
1RM	O
(	O
IHRT	B-P
:	O
21.6	O
±	O
8.5	O
%	O
,	O
ES	O
1.08	O
,	O
placebo	O
13.2	O
±	O
6.4	O
%	O
,	O
ES	O
0.78	O
)	O
.	O

Importantly	O
,	O
the	O
change	O
in	O
IHRT	B-P
was	O
greater	O
than	O
placebo	O
at	O
mid	O
for	O
both	O
absolute	O
[	O
4.4	O
%	O
greater	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
1.0:8.0	O
%	O
,	O
ES	O
0.21	O
,	O
and	O
relative	O
strength	O
(	O
5.6	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1.0:9.4	O
%	O
,	O
ES	O
0.31	O
(	O
relative	O
)	O
]	O
.	O

There	O
was	O
also	O
a	O
greater	O
change	O
for	O
IHRT	B-P
at	O
post	O
for	O
both	O
absolute	O
(	O
7.0	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1.3:13	O
%	O
,	O
ES	O
0.33	O
)	O
,	O
and	O
relative	O
1RM	O
(	O
9.2	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1.6:14.9	O
%	O
,	O
ES	O
0.49	O
)	O
.	O

Only	O
IHRT	B-P
increased	O
countermovement	O
jump	O
peak	O
power	O
at	O
Post	O
(	O
4.9	O
%	O
,	O
ES	O
0.35	O
)	O
,	O
however	O
the	O
difference	O
between	O
IHRT	B-P
and	O
placebo	O
was	O
unclear	O
(	O
2.7	O
,	O
90	O
%	O
CI	O
-2.0:7.6	O
%	O
,	O
ES	O
0.20	O
)	O
with	O
no	O
clear	O
differences	O
in	O
speed	O
or	O
body	O
composition	O
throughout	O
.	O

Conclusion	O
:	O
Heavy	B-P
resistance	I-P
training	I-P
in	O
hypoxia	O
is	O
more	O
effective	O
than	O
placebo	O
for	O
improving	O
absolute	O
and	O
relative	O
strength	O
.	O

Juvenile	O
dermatomyositis	O
with	O
anti-signal	O
recognition	O
particle	O
antibodies	O
:	O
a	O
case	O
report	O
.	O

Serologic	O
investigation	O
has	O
been	O
explored	O
in	O
inflammatory	O
myopathies	O
in	O
order	O
to	O
define	O
subgroups	O
that	O
can	O
help	O
us	O
predict	O
clinical	O
course	O
,	O
treatment	B-P
and	O
prognosis	O
.	O

The	O
level	O
of	O
similarity	O
between	O
juvenile	O
and	O
adult	O
myopathies	O
regarding	O
the	O
presence	O
of	O
myositis	O
-	O
specific	O
autoantibodies	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
8-year-old	O
girl	O
who	O
presented	O
with	O
a	O
rapid	O
progression	O
of	O
muscle	O
weakness	O
and	O
cutaneous	O
signs	O
consistent	O
with	O
the	O
diagnosis	O
of	O
juvenile	O
dermatomyositis	O
and	O
whose	O
serologic	O
testing	O
revealed	O
the	O
presence	O
of	O
anti-signal	O
recognition	O
particle	O
(	O
SRP	O
)	O
antibodies	O
.	O

So	O
far	O
these	O
antibodies	O
have	O
been	O
described	O
mostly	O
in	O
adult	O
subsets	O
,	O
frequently	O
associated	O
with	O
poorer	O
outcomes	O
and	O
rarely	O
related	O
to	O
cutaneous	O
manifestations	O
.	O

The	O
knowledge	O
of	O
the	O
degree	O
of	O
overlap	O
between	O
paediatric	O
and	O
adult	O
SRP	O
positive	O
myopathies	O
may	O
improve	O
the	O
medical	O
care	O
we	O
provide	O
to	O
these	O
children	O
.	O

Radiolabeled	O
B9958	O
Derivatives	O
for	O
Imaging	B-P
Bradykinin	O
B1	O
Receptor	O
Expression	O
with	O
Positron	B-P
Emission	I-P
Tomography	I-P
:	O
Effect	O
of	O
the	O
Radiolabel	O
-	O
Chelator	O
Complex	O
on	O
Biodistribution	O
and	O
Tumor	O
Uptake	O
.	O

Bradykinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
,	O
which	O
is	O
upregulated	O
in	O
a	O
variety	O
of	O
malignancies	O
,	O
is	O
an	O
attractive	O
cancer	B-P
imaging	I-P
biomarker	O
.	O

In	O
this	O
study	O
we	O
optimized	O
the	O
selection	O
of	O
radiolabel	O
-	O
chelator	O
complex	O
to	O
improve	O
tumor	O
uptake	O
and	O
tumor	O
-to-background	O
contrast	O
of	O
radiolabeled	O
analogues	O
of	O
B9958	O
(	O
Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg	O
)	O
,	O
a	O
potent	O
B1R	O
antagonist	O
.	O

Peptide	O
sequences	O
were	O
assembled	O
on	O
solid	O
phase	O
.	O

Cold	O
standards	O
were	O
prepared	O
by	O
incubating	O
DOTA	O
-/	O
NODA	O
-	O
conjugated	O
peptides	O
with	O
GaCl3	O
,	O
and	O
by	O
incubating	O
AlOH	O
-	O
NODA	O
-conjugated	O
peptide	O
with	O
NaF	O
.	O

Binding	O
affinities	O
were	O
measured	O
via	O
in	B-P
vitro	I-P
competition	I-P
binding	I-P
assays	I-P
.	O

(	O
68	O
)	O
Ga	O
and	O
(	O
18	O
)	O
F	O
labeling	O
experiments	O
were	O
performed	O
in	O
acidic	O
buffer	O
and	O
purified	O
by	O
HPLC	B-P
.	O

Imaging	B-P
/	O
biodistribution	O
studies	O
were	O
performed	O
in	O
mice	O
bearing	O
both	O
B1R-positive	O
(	O
B1R+	O
)	O
HEK293T	O
:	O
:	O
hB1R	O
and	O
B1R-negative	O
(	O
B1R-	O
)	O
HEK293T	O
tumors	O
.	O

Z02176	O
(	O
Ga-DOTA-Pip-B9958	O
;	O
Pip	O
:	O
4-amino-	O
(	O
1-carboxymethyl	O
)	O
piperidine	O
)	O
,	O
Z02137	O
(	O
Ga-NODA-Mpaa-Pip-B9958	O
;	O
Mpaa	O
:	O
4-methylphenylacetic	O
acid	O
)	O
,	O
and	O
Z04139	O
(	O
AlF-NODA-Mpaa-Pip-B9958	O
)	O
bound	O
h	O
B1R	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
1.4-2.5	O
nM	O
)	O
.	O

(	O
68	O
)	O
Ga	O
-/	O
(	O
18	O
)	O
F	O
-	O
labeled	O
peptides	O
were	O
obtained	O
on	O
average	O
in	O
≥32	O
%	O
decay-corrected	O
radiochemical	O
yield	O
with	O
>	O
99	O
%	O
radiochemical	O
purity	O
and	O
100-261	O
GBq/μmol	O
specific	O
activity	O
.	O

Biodistribution	O
/	O
imaging	B-P
studies	O
at	O
1	O
h	O
postinjection	O
showed	O
that	O
all	O
tracers	O
cleared	O
rapidly	O
from	O
background	O
tissues	O
(	O
except	O
kidneys	O
)	O
and	O
were	O
excreted	O
predominantly	O
via	O
the	O
renal	O
pathway	O
.	O

Only	O
kidneys	O
,	O
bladders	O
,	O
and	O
B1R+	O
tumors	O
were	O
clearly	O
visualized	O
in	O
PET	B-P
images	O
.	O

Uptake	O
in	O
B1R+	O
tumor	O
was	O
higher	O
by	O
using	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
(	O
28.9	O
±	O
6.21	O
%	O
ID/g	O
)	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
(	O
22.6	O
±	O
3.41	O
%	O
ID/g	O
)	O
than	O
(	O
68	O
)	O
Ga	O
-	O
Z02137	O
(	O
14.0	O
±	O
4.86	O
%	O
ID/g	O
)	O
.	O

The	O
B1R+	O
tumor-to-blood	O
and	O
B1R+	O
tumor-to-muscle	O
contrast	O
ratios	O
were	O
also	O
higher	O
for	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
(	O
56.1	O
±	O
17.3	O
and	O
167	O
±	O
57.6	O
)	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
(	O
58.0	O
±	O
20.9	O
and	O
173	O
±	O
42.9	O
)	O
than	O
(	O
68	O
)	O
Ga	O
-	O
Z02137	O
(	O
34.3	O
±	O
15.2	O
and	O
103	O
±	O
30.2	O
)	O
.	O

With	O
improved	O
target-to-background	O
contrast	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
are	O
promising	O
for	O
imaging	B-P
B1R	O
expression	O
in	O
cancers	O
with	O
PET	B-P
.	O

Survey	O
of	O
Neonatal	O
Intensive	O
Care	O
Unit	O
Nurse	O
Attitudes	O
Toward	O
Therapeutic	B-P
Hypothermia	I-P
Treatment	I-P
.	O

The	O
traumatic	O
experiences	O
of	O
parent	O
s	O
of	O
babies	O
treated	B-P
with	I-P
therapeutic	B-P
hypothermia	I-P
(	O
TH	B-P
)	O
have	O
been	O
described	O
.	O

No	O
research	O
has	O
assessed	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
nurse	O
experience	O
in	O
providing	O
care	O
to	O
hypothermic	O
babies	O
and	O
emotional	O
support	O
to	O
their	O
parents	O
.	O

To	O
assess	O
NICU	O
nurse	O
attitudes	O
to	O
the	O
provision	O
of	O
TH	B-P
with	O
respect	O
to	O
perceptions	O
about	O
baby	O
pain	O
/	O
sedation	B-P
,	O
need	O
for	O
nurse	O
and	O
parent	O
education	O
,	O
decision	O
making	O
about	O
initiation	O
of	O
TH	B-P
,	O
and	O
barriers	O
to	O
best	O
care	O
.	O

A	O
survey	O
was	O
electronically	O
sent	O
to	O
219	O
nurses	O
at	O
2	O
affiliated	O
academic	O
level	O
III	O
NICUs	O
:	O
1	O
rural	O
and	O
1	O
urban	O
location	O
.	O

There	O
were	O
17	O
questions	O
where	O
responses	O
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	O
to	O
provide	O
free	O
text	O
responses	O
.	O

The	O
response	O
rate	O
was	O
38	O
%	O
(	O
N	O
=	O
83	O
)	O
.	O

Overwhelming	O
similarities	O
between	O
the	O
urban	O
and	O
rural	O
institutions	O
were	O
found	O
with	O
NICU	O
nurses	O
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
TH	B-P
,	O
agreement	O
that	O
TH	B-P
improves	O
long-term	O
outcomes	O
and	O
that	O
the	O
benefits	O
of	O
TH	B-P
outweigh	O
the	O
risks	O
.	O

Nurses	O
at	O
the	O
urban	O
institution	O
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-P
of	O
baby	O
pain	O
/	O
sedation	B-P
,	O
and	O
nurses	O
at	O
both	O
institutions	O
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	O
and	O
parent	O
education	O
about	O
TH	B-P
and	O
improved	O
timeliness	O
of	O
decision	O
making	O
for	O
initiation	O
of	O
TH	B-P
.	O

NICU	O
nurses	O
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	O
of	O
babies	O
after	O
treatment	B-P
with	O
TH	B-P
and	O
feel	O
that	O
parents	O
need	O
more	O
education	O
about	O
TH	B-P
.	O

Research	O
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
TH	B-P
treatment	I-P
for	O
parent	O
-	O
baby	O
bonding	O
.	O

Large-scale	O
synthesis	O
and	O
structural	O
analysis	O
of	O
a	O
synthetic	O
glycopeptide	O
dendrimer	O
as	O
an	O
anti-cancer	O
vaccine	O
candidate	O
.	O

Herein	O
,	O
we	O
report	O
a	O
new	O
process	O
that	O
enables	O
the	O
gram-scale	O
production	O
of	O
a	O
fully	O
synthetic	O
anti-cancer	O
vaccine	O
for	O
human	O
use	O
.	O

This	O
therapeutic	O
vaccine	O
candidate	O
,	O
named	O
MAG-Tn3	O
,	O
is	O
a	O
high-molecular-weight	O
tetrameric	O
glycopeptide	O
encompassing	O
carbohydrate	O
tumor-associated	O
Tn	O
antigen	O
clusters	O
and	O
peptidic	O
CD4	O
(	O
+	O
)	O
T-cell	O
epitopes	O
.	O

The	O
synthetic	O
process	O
involves	O
(	O
i	O
)	O
the	O
stepwise	O
solid-phase	O
assembly	O
of	O
protected	O
amino	O
acids	O
,	O
including	O
the	O
high	O
value-added	O
Tn	O
building	O
blocks	O
with	O
only	O
1.5	O
equivalents	O
,	O
(	O
ii	O
)	O
a	O
single	O
isolated	O
intermediate	O
,	O
and	O
(	O
iii	O
)	O
the	O
simultaneous	O
deprotection	O
of	O
36	O
hindered	O
protective	O
groups	O
.	O

The	O
resulting	O
MAG-Tn3	O
was	O
unambiguously	O
characterized	O
using	O
a	O
combination	O
of	O
techniques	O
,	O
including	O
a	O
structural	O
analysis	O
by	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
.	O

The	O
four	O
peptidic	O
chains	O
are	O
flexible	O
in	O
solution	O
,	O
with	O
a	O
more	O
constrained	O
but	O
extended	O
conformation	O
at	O
the	O
Tn3	O
antigen	O
motif	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
,	O
when	O
injected	O
into	O
HLA-DR1	O
-	O
expressing	O
transgenic	O
mice	O
,	O
this	O
vaccine	O
induces	O
Tn-specific	O
antibodies	O
that	O
mediate	O
the	O
killing	O
of	O
human	O
Tn-positive	O
tumor	O
cells	O
.	O

These	O
studies	O
led	O
to	O
a	O
clinical	O
batch	O
of	O
the	O
MAG-Tn3	O
,	O
currently	O
investigated	O
in	O
breast	O
cancer	O
patients	O
(	O
phase	O
I	O
clinical	O
trial	O
)	O
.	O

The	O
current	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
the	O
multigram-scale	O
synthesis	O
of	O
a	O
highly	O
pure	O
complex	O
glycopeptide	O
,	O
and	O
it	O
opens	O
new	O
avenues	O
for	O
the	O
use	O
of	O
synthetic	O
glycopeptides	O
as	O
drugs	O
in	O
humans	O
.	O

Serum	B-P
C-Reactive	I-P
Protein	I-P
in	O
Children	O
with	O
Liver	O
Disease	O
and	O
Ascites	O
.	O

The	O
diagnosis	O
of	O
peritonitis	O
as	O
a	O
complication	O
of	O
cirrhosis	O
is	O
an	O
important	O
clinical	O
problem	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
serum	B-P
C-reactive	I-P
protein	I-P
levels	I-P
as	O
a	O
diagnostic	O
factor	O
for	O
spontaneous	O
bacterial	O
peritonitis	O
(	O
SBP	O
)	O
in	O
child	O
patients	O
with	O
liver	O
disease	O
.	O

In	O
this	O
study	O
,	O
150	O
children	O
diagnosed	O
with	O
liver	O
disease	O
and	O
ascites	O
upon	O
admission	O
to	O
Nemazee	O
Teaching	O
Hospital	O
(	O
Shiraz	O
,	O
Iran	O
)	O
were	O
examined	O
.	O

Patients	O
were	O
divided	O
into	O
spontaneous	O
bacterial	O
peritonitis	O
and	O
sterile	O
ascetic	O
fluid	O
groups	O
according	O
to	O
the	O
PMN	B-P
count	I-P
≥	O
250/mm	O
(	O
3	O
)	O
in	O
the	O
ascetic	O
fluids	O
.	O

Routine	B-P
laboratory	I-P
tests	I-P
were	O
conducted	O
and	O
quantitative	O
C-reactive	B-P
protein	I-P
(	I-P
CRP	I-P
)	I-P
levels	I-P
were	O
measured	O
for	O
all	O
of	O
the	O
patients	O
.	O

Accuracy	O
,	O
sensitivity	O
,	O
and	O
specificity	O
of	O
CRP	B-P
was	O
evaluated	O
for	O
diagnosis	O
of	O
SBP	O
.	O

Of	O
150	O
cirrhotic	O
patients	O
,	O
109	O
patients	O
presented	O
without	O
SBP	O
(	O
52.29	O
%	O
male	O
,	O
mean	O
age	O
:	O
5.02	O
±	O
4.49	O
years	O
)	O
and	O
41	O
patients	O
presented	O
with	O
SBP	O
(	O
51.21	O
%	O
male	O
,	O
mean	O
age	O
:	O
4.71	O
years	O
)	O
.	O

Cell	B-P
counts	I-P
,	O
protein	O
levels	O
,	O
albumin	O
levels	O
,	O
and	O
lactate	B-P
dehydrogenize	I-P
(	I-P
LDH	I-P
)	I-P
levels	I-P
of	O
the	O
ascetic	O
fluid	O
and	O
serum	O
samples	O
in	O
the	O
SBP	O
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	O
(	O
P	O
<	O
0.05	O
(	O
.	O

The	O
mean	O
±	O
SD	O
of	O
CRP	B-P
in	O
the	O
SBP	O
group	O
(	O
36.89	O
±	O
23.43	O
)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	O
(	O
21.59	O
±	O
15.43	O
,	O
P	O
=	O
0.001	O
)	O
.	O

The	O
percentages	O
for	O
sensitivity	O
and	O
specificity	O
of	O
CRP	B-P
,	O
the	O
diagnosis	O
of	O
SBP	O
based	O
on	O
the	O
PMN	B-P
count	I-P
≥	O
250/mm	O
(	O
3	O
)	O
,	O
and	O
cultured	O
ascites	O
were	O
69.23	O
%	O
,	O
90.25	O
%	O
,	O
88.43	O
%	O
,	O
and	O
84.32	O
%	O
,	O
respectively	O
.	O

The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-P
for	O
SBP	O
based	O
on	O
the	O
PMN	B-P
count	I-P
≥	O
250/mm	O
(	O
3	O
)	O
and	O
cultured	O
ascites	O
was	O
0.94	O
(	O
CI	O
95	O
%	O
:	O
0.90	O
to	O
0.96	O
)	O
and	O
0.85	O
(	O
CI	O
95	O
%	O
:	O
0.84	O
to	O
0.92	O
)	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Our	O
study	O
showed	O
that	O
CRP	B-P
is	O
a	O
marker	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
the	O
diagnosis	O
of	O
SBP	O
in	O
cirrhotic	O
children	O
.	O

Safety	O
and	O
function	O
of	O
a	O
prototype	O
microprocessor	O
-controlled	O
knee	B-P
prosthesis	I-P
for	O
low	O
active	O
transfemoral	B-P
amputees	I-P
switching	O
from	O
a	O
mechanic	O
knee	B-P
prosthesis	I-P
:	O
a	O
pilot	O
study	O
.	O

Aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
assess	O
safety	O
and	O
functioning	O
of	O
a	O
microprocessor	O
-controlled	O
knee	B-P
prosthesis	I-P
(	O
MPK	B-P
)	O
after	O
a	O
short	O
familiarization	O
time	O
and	O
no	O
structured	O
physical	B-P
therapy	I-P
.	O

Five	O
elderly	O
,	O
low-active	O
transfemoral	B-P
amputees	I-P
who	O
were	O
fitted	O
with	O
a	O
standard	O
non-microprocessor	O
controlled	O
knee	B-P
prosthesis	I-P
(	O
NMPK	B-P
)	O
performed	O
a	O
baseline	O
measurement	O
consisting	O
of	O
a	O
3	B-P
D	I-P
gait	I-P
analysis	I-P
,	O
functional	O
tests	O
and	O
questionnaires	O
.	O

The	O
first	O
follow-up	O
consisted	O
of	O
the	O
same	O
test	B-P
procedure	I-P
and	O
was	O
performed	O
with	O
the	O
MPK	B-P
after	O
4	O
to	O
6	O
weeks	O
of	O
familiarization	O
.	O

After	O
being	O
refitted	O
to	O
their	O
standard	O
NMPK	B-P
again	O
,	O
the	O
subjects	O
undertook	O
the	O
second	O
follow-up	O
which	O
consisted	O
of	O
solely	O
questionnaires	O
4	O
weeks	O
later	O
.	O

Questionnaires	O
and	O
functional	O
tests	O
showed	O
an	O
increase	O
in	O
the	O
perception	O
of	O
safety	O
.	O

Moreover	O
,	O
gait	B-P
analysis	I-P
revealed	O
more	O
physiologic	O
knee	O
and	O
hip	O
extension/flexion	O
patterns	O
when	O
using	O
the	O
MPK	B-P
.	O

Our	O
results	O
showed	O
that	O
although	O
the	O
Genium	B-P
with	I-P
Cenior-Leg	I-P
ruleset-MPK	I-P
(	O
GCL-MPK	B-P
)	O
might	O
help	O
to	O
improve	O
several	O
safety	O
-related	O
outcomes	O
as	O
well	O
as	O
gait	O
biomechanics	O
the	O
functional	O
potential	O
of	O
the	O
GCL-MPK	B-P
may	O
have	O
been	O
limited	O
without	O
specific	O
training	O
and	O
a	O
sufficient	O
acclimation	O
period	O
.	O

Implications	O
for	O
Rehabilitation	O
Elderly	O
transfemoral	B-P
amputees	I-P
are	O
often	O
limited	O
in	O
their	O
activity	O
by	O
safety	O
issues	O
as	O
well	O
as	O
insufficient	O
functioning	O
regarding	O
the	O
non	O
microprocessor	O
-controlled	O
knee	B-P
prostheses	I-P
(	O
NMPK	B-P
)	O
,	O
thing	O
that	O
could	O
be	O
eliminated	O
with	O
the	O
use	O
of	O
suitable	O
microprocessor	O
-controlled	O
prostheses	B-P
(	O
MPK	B-P
)	O
.	O

The	O
safety	O
and	O
functioning	O
of	O
a	O
prototype	O
MPK	B-P
(	O
GCL-MPK	B-P
)	O
specifically	O
designed	O
for	O
the	O
needs	O
of	O
older	O
and	O
low-active	O
transfemoral	B-P
amputees	I-P
was	O
assessed	O
in	O
this	O
pilot	O
study	O
.	O

The	O
GCL-MPK	B-P
showed	O
indicators	O
of	O
increased	O
safety	O
and	O
more	O
natural	O
walking	O
patterns	O
in	O
older	O
and	O
low-active	O
transfemoral	B-P
amputees	I-P
in	O
comparison	O
to	O
the	O
standard	O
NMPK	B-P
already	O
after	O
a	O
short	O
acclimatisation	O
time	O
and	O
no	O
structured	O
physical	B-P
therapy	I-P
.	O

Regarding	O
functional	O
performance	O
it	O
seems	O
as	O
if	O
providing	O
older	O
and	O
low-active	O
transfemoral	B-P
amputees	I-P
with	O
the	O
GCL-MPK	B-P
alone	O
without	O
prescribing	O
structured	O
prosthesis	B-P
training	I-P
might	O
be	O
insufficient	O
to	O
achieve	O
improvements	O
over	O
the	O
standard	O
NMPKs	B-P
.	O

Open-label	O
,	O
multicentre	O
safety	O
study	O
of	O
vemurafenib	O
in	O
3219	O
patients	O
with	O
BRAF	O
(	O
V600	O
)	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
:	O
2-year	O
follow-up	O
data	O
and	O
long-term	O
responders	O
'	O
analysis	O
.	O

The	O
orally	O
available	O
BRAF	O
kinase	O
inhibitor	O
vemurafenib	O
is	O
an	O
effective	O
and	O
tolerable	O
treatment	B-P
option	I-P
for	O
patients	O
with	O
metastatic	O
melanoma	O
harbouring	O
BRAF	O
(	O
V600	O
)	O
mutations	O
.	O

We	O
assessed	O
the	O
safety	O
of	O
vemurafenib	O
in	O
a	O
large	O
population	O
of	O
patients	O
with	O
few	O
alternative	O
treatment	B-P
options	I-P
;	O
we	O
report	O
updated	O
2-year	O
safety	O
.	O

This	O
was	O
an	O
open-label	O
,	O
multicentre	O
study	O
of	O
vemurafenib	O
(	O
960	O
mg	O
bid	O
)	O
in	O
patients	O
with	O
previously	O
treated	O
or	O
untreated	O
BRAF	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
(	O
cobas	O
(	O
®	O
)	O
4800	O
BRAF	B-P
V600	I-P
Mutation	I-P
Test	I-P
)	O
.	O

The	O
primary	O
end-point	O
was	O
safety	O
;	O
efficacy	O
end-points	O
were	O
secondary	O
.	O

An	O
exploratory	O
analysis	O
was	O
performed	O
to	O
assess	O
safety	O
outcomes	O
in	O
patients	O
with	O
long	O
duration	O
of	O
response	O
(	O
DOR	O
)	O
(	O
≥12	O
or	O
≥24	O
months	O
)	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
32.2	O
months	O
(	O
95	O
%	O
CI	O
,	O
31.1-33.2	O
months	O
)	O
,	O
3079/3219	O
patients	O
(	O
96	O
%	O
)	O
had	O
discontinued	O
treatment	O
.	O

Adverse	O
events	O
(	O
AEs	O
)	O
were	O
largely	O
consistent	O
with	O
previous	O
reports	O
;	O
the	O
most	O
common	O
all-grade	O
treatment	O
-related	O
AEs	O
were	O
arthralgia	O
(	O
37	O
%	O
)	O
,	O
alopecia	O
(	O
25	O
%	O
)	O
and	O
hyperkeratosis	O
(	O
23	O
%	O
)	O
;	O
the	O
most	O
common	O
grade	O
3/4	O
treatment	O
-related	O
AEs	O
were	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
skin	O
(	O
8	O
%	O
)	O
and	O
keratoacanthoma	O
(	O
8	O
%	O
)	O
.	O

In	O
the	O
exploratory	O
analysis	O
,	O
patients	O
with	O
DOR	O
≥12	O
months	O
(	O
n	O
=	O
287	O
)	O
or	O
≥24	O
months	O
(	O
n	O
=	O
133	O
)	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3/4	O
AEs	O
than	O
the	O
overall	O
population	O
.	O

No	O
new	O
specific	O
safety	O
signals	O
were	O
observed	O
with	O
longer	O
vemurafenib	O
exposure	O
.	O

After	O
2	O
years	O
'	O
follow-up	O
,	O
safety	O
was	O
maintained	O
in	O
this	O
large	O
group	O
of	O
patients	O
with	O
BRAF	O
(	O
V600	O
)	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical	O
practice	O
than	O
typical	O
clinical	O
trial	O
populations	O
.	O

These	O
data	O
suggest	O
that	O
long-term	O
vemurafenib	O
treatment	O
is	O
effective	O
and	O
tolerable	O
without	O
the	O
development	O
of	O
new	O
safety	O
signals	O
.	O

A	O
Novel	O
Multiplex	O
PCR	O
Assay	B-P
for	O
the	O
Detection	B-P
of	O
Chlorhexidine	O
/	O
Quaternary	O
Ammonium	O
,	O
Mupirocin	O
and	O
Methicillin	O
Resistance	O
Genes	O
with	O
Simultaneous	O
Discrimination	O
of	O
Staphylococcus	O
aureus	O
from	O
Coagulase-Negative	O
Staphylococci	O
.	O

Methicillin-resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
is	O
a	O
clinically	O
significant	O
pathogen	O
resistant	O
to	O
a	O
wide	O
variety	O
of	O
antibiotics	O
and	O
responsible	O
for	O
a	O
large	O
number	O
of	O
nosocomial	O
infections	O
worldwide	O
.	O

The	O
Agency	O
for	O
Healthcare	O
Research	O
and	O
Quality	O
and	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
recently	O
recommended	O
to	O
adopt	O
universal	O
mupirocin	O
/	O
chlorhexidine	O
decolonization	O
of	O
all	O
admitted	O
intensive	O
care	O
unit	O
patients	O
,	O
rather	O
than	O
MRSA	O
screening	O
with	O
targeted	O
treatments	B-P
,	O
which	O
raises	O
the	O
serious	O
concern	O
about	O
the	O
selection	O
of	O
resistance	O
to	O
mupirocin	O
and	O
chlorhexidine	O
in	O
strains	O
of	O
staphylococci	O
.	O

Thus	O
,	O
a	O
simple	O
,	O
rapid	O
,	O
and	O
reliable	O
approach	O
will	O
be	O
paramount	O
in	O
monitoring	O
the	O
resistance	O
prevalence	O
to	O
these	O
agents	O
.	O

We	O
developed	O
a	O
simple	O
multiplex	O
PCR	O
assay	B-P
capable	O
of	O
screening	O
Staphylococcus	O
isolates	O
for	O
the	O
presence	O
of	O
antiseptic	O
resistance	O
genes	O
for	O
chlorhexidine	O
and	O
quaternary	O
ammonium	O
compounds	O
,	O
as	O
well	O
as	O
mupirocin	O
-	O
and	O
methicillin-resistance	O
genes	O
,	O
while	O
simultaneously	O
discriminating	O
S.	O
aureus	O
from	O
coagulase-negative	O
staphylococci	O
(	O
CoNS	O
)	O
.	O

The	O
assay	B-P
incorporates	O
7	O
PCR	O
targets	O
,	O
including	O
staph	O
16S-rRNA	O
(	O
specifically	O
detecting	O
Staphylococcus	O
sp	O
.	O

)	O
,	O
nuc	O
(	O
distinguishing	O
S.	O
aureus	O
from	O
CoNS	O
)	O
,	O
mecA	O
(	O
distinguishing	O
MRSA	O
from	O
methicillin-susceptible	O
S.	O
aureus	O
)	O
,	O
mupA	O
and	O
mupB	O
(	O
identifying	O
high-level	O
mupirocin	O
resistance	O
)	O
,	O
qac	O
and	O
smr	O
(	O
identifying	O
chlorhexidine	O
and	O
quaternary	O
ammonium	O
resistance	O
)	O
.	O

Our	O
assay	O
demonstrated	O
100	O
%	O
sensitivity	O
,	O
specificity	O
and	O
accuracy	O
in	O
a	O
total	O
of	O
23	O
variant	O
antiseptic	O
/	O
antibiotic-resistant	O
control	O
strains	O
.	O

Further	O
validation	O
of	O
our	O
assay	O
using	O
378	O
randomly	O
selected	O
and	O
previously	O
well-characterized	O
local	O
clinical	O
isolates	O
confirmed	O
its	O
feasibility	O
and	O
practicality	O
.	O

This	O
may	O
prove	O
to	O
be	O
a	O
useful	O
tool	O
for	O
multidrug-resistant	O
staphylococci	O
monitoring	O
in	O
clinical	O
laboratories	O
,	O
particularly	O
in	O
the	O
wake	O
of	O
increased	O
chlorhexidine	O
and	O
mupirocin	O
treatments	O
.	O

Role	O
of	O
endoscopy	B-P
in	O
primary	O
sclerosing	O
cholangitis	O
:	O
European	O
Society	O
of	O
Gastrointestinal	O
Endoscopy	O
(	O
ESGE	O
)	O
and	O
European	O
Association	O
for	O
the	O
Study	O
of	O
the	O
Liver	O
(	O
EASL	O
)	O
Clinical	O
Guideline	O
.	O

1	O
ESGE	O
/	O
EASL	O
recommend	O
that	O
,	O
as	O
the	O
primary	O
diagnostic	B-P
modality	O
for	O
PSC	O
,	O
magnetic	B-P
resonance	I-P
cholangiography	I-P
(	O
MRC	B-P
)	O
should	O
be	O
preferred	O
over	O
endoscopic	B-P
retrograde	I-P
cholangiopancreatography	I-P
(	O
ERCP	B-P
)	O
.	O

Moderate	O
quality	O
evidence	O
,	O
strong	O
recommendation	O
.	O

2	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
ERCP	B-P
can	O
be	O
considered	O
if	O
MRC	B-P
plus	O
liver	B-P
biopsy	I-P
is	O
equivocal	O
or	O
contraindicated	O
in	O
patients	O
with	O
persisting	O
clinical	O
suspicion	O
of	O
PSC	O
.	O

The	O
risks	O
of	O
ERCP	B-P
have	O
to	O
be	O
weighed	O
against	O
the	O
potential	O
benefit	O
with	O
regard	O
to	O
surveillance	O
and	O
treatment	B-P
recommendations	O
.	O

Low	O
quality	O
evidence	O
,	O
weak	O
recommendation	O
.	O

6	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
,	O
in	O
patients	O
with	O
an	O
established	O
diagnosis	O
of	O
PSC	O
,	O
MRC	B-P
should	O
be	O
considered	O
before	O
therapeutic	B-P
ERCP	B-P
.	O

Weak	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

7	O
ESGE	O
/	O
EASL	O
suggest	O
performing	O
endoscopic	B-P
treatment	B-P
with	O
concomitant	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
of	O
suspected	O
significant	O
strictures	O
identified	O
at	O
MRC	B-P
in	O
PSC	O
patients	O
who	O
present	O
with	O
symptoms	O
likely	O
to	O
improve	O
following	O
endoscopic	B-P
treatment	B-P
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

9	O
ESGE	O
/	O
EASL	O
recommend	O
weighing	O
the	O
anticipated	O
benefits	O
of	O
biliary	B-P
papillotomy	I-P
/	O
sphincterotomy	B-P
against	O
its	O
risks	O
on	O
a	O
case-by-case	O
basis	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

Biliary	B-P
papillotomy	I-P
/	O
sphincterotomy	B-P
should	O
be	O
considered	O
especially	O
after	O
difficult	O
cannulation	B-P
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

16	O
ESGE	O
/	O
EASL	O
suggest	O
routine	B-P
administration	I-P
of	O
prophylactic	B-P
antibiotics	I-P
before	O
ERCP	B-P
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

17	O
EASL	O
/	O
ESGE	O
recommend	O
that	O
cholangiocarcinoma	O
(	O
CCA	O
)	O
should	O
be	O
suspected	O
in	O
any	O
patient	O
with	O
worsening	O
cholestasis	O
,	O
weight	O
loss	O
,	O
raised	O
serum	O
CA19-9	B-P
,	O
and/or	O
new	O
or	O
progressive	O
dominant	O
stricture	O
,	O
particularly	O
with	O
an	O
associated	O
enhancing	O
mass	O
lesion	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

19	O
ESGE	O
/	O
EASL	O
recommend	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
as	O
part	O
of	O
the	O
initial	O
investigation	O
for	O
the	O
diagnosis	O
and	O
staging	B-P
of	O
suspected	O
CCA	O
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
high	O
quality	O
evidence	O
.	O

Right	O
Ventricular	O
Response	O
During	O
Exercise	O
in	O
Patients	O
with	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
.	O

Right	O
ventricular	O
(	O
RV	O
)	O
pump	O
function	O
is	O
of	O
essential	O
clinical	O
and	O
prognostic	O
importance	O
in	O
a	O
variety	O
of	O
heart	O
and	O
lung	O
diseases	O
.	O

While	O
the	O
evaluation	O
of	O
RV	O
performance	O
at	O
rest	O
has	O
been	O
implemented	O
in	O
the	O
clinical	O
setting	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	O
during	O
exercise	O
may	O
provide	O
additional	O
benefit	O
.	O

With	O
this	O
aim	O
,	O
we	O
evaluated	O
the	O
exercise	O
-	O
induced	O
pulmonary	B-P
arterial	I-P
systolic	I-P
pressure	I-P
(	O
PASP	B-P
)	O
increase	O
during	O
exercise	O
in	O
patients	O
with	O
severe	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
as	O
an	O
expression	O
of	O
RV	O
contractile	O
reserve	O
.	O

Cardiopulmonary	B-P
exercise	I-P
testing	I-P
(	O
CPET	B-P
)	O
with	O
synchronic	B-P
echocardiography	I-P
was	O
performed	O
in	O
81	O
patients	O
.	O

Patients	O
were	O
classified	O
into	O
two	O
groups	O
according	O
to	O
an	O
exercise	O
-	O
induced	O
PASP	B-P
increase	O
above	O
30mmHg	O
(	O
High	O
PSAP	B-P
)	O
or	O
below	O
30mmHg	O
(	O
Low	O
PSAP	B-P
)	O
during	O
maximal	O
exercise	O
.	O

Patients	O
were	O
then	O
followed	O
for	O
three	O
years	O
.	O

Sixteen	O
patients	O
(	O
20	O
%	O
)	O
had	O
low	O
PSAP	B-P
and	O
65	O
(	O
80	O
%	O
)	O
showed	O
high	O
PSAP	B-P
.	O

These	O
were	O
not	O
significant	O
clinical	O
and	O
functional	O
differences	O
.	O

Low	O
PSAP	B-P
was	O
associated	O
with	O
a	O
significantly	O
lower	O
peak	O
VO2	O
(	O
mean	O
(	O
SD	O
)	O
,	O
35	O
(	O
2	O
)	O
%	O
predicted	O
)	O
compared	O
to	O
high	O
PSAP	B-P
response	O
(	O
peak	O
VO2	O
45	O
(	O
3	O
)	O
%	O
predicted	O
)	O
,	O
p=0.045	O
.	O

Factors	O
associated	O
with	O
mortality	O
were	O
age	O
and	O
exercise	O
-	O
induced	O
PASP	B-P
.	O

Seventeen	O
patients	O
died	O
during	O
the	O
three	O
years	O
of	O
follow-up	O
(	O
7	O
(	O
39	O
%	O
)	O
in	O
the	O
low	O
PSAP	B-P
group	O
and	O
only	O
10	O
(	O
1	O
%	O
)	O
in	O
the	O
high	O
PSAP	B-P
group	O
,	O
p=0.041	O
)	O
.	O

Cardiopulmonary	B-P
exercise	I-P
testing	I-P
with	O
a	O
synchronic	B-P
echocardiography	I-P
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	O
of	O
RV	O
contractile	O
reserve	O
in	O
severe	O
COPD	O
patients	O
.	O

Exercise	O
-	O
induced	O
PSAP	B-P
emerges	O
as	O
a	O
possible	O
prognostic	O
factor	O
in	O
these	O
patients	O
.	O

Uncoupling	O
protein	O
2	O
downregulation	O
by	O
hypoxia	O
through	O
repression	O
of	O
peroxisome	O
proliferator-activated	O
receptor	O
γ	O
promotes	O
chemoresistance	O
of	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Hypoxic	O
microenvironment	O
is	O
critically	O
involved	O
in	O
the	O
response	O
of	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
to	O
chemotherapy	B-P
,	O
the	O
mechanisms	O
of	O
which	O
remain	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
found	O
that	O
NSCLC	O
patients	O
exhibited	O
increased	O
chemotherapeutic	O
resistance	O
when	O
complicated	O
by	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
a	O
critical	O
cause	O
of	O
chronic	O
hypoxemia	O
.	O

The	O
downregulation	O
of	O
uncoupling	O
protein	O
2	O
(	O
UCP2	O
)	O
,	O
which	O
is	O
attributed	O
to	O
hypoxia-inducible	O
factor	O
1	O
(	O
HIF-1	O
)	O
-mediated	O
suppression	O
of	O
the	O
transcriptional	O
factor	O
peroxisome	O
proliferator-activated	O
receptor	O
γ	O
(	O
PPARγ	O
)	O
,	O
was	O
involved	O
in	O
NSCLC	O
chemoresistance	O
,	O
and	O
predicted	O
a	O
poor	O
survival	O
rate	O
of	O
patients	O
receiving	O
routine	O
chemotherapy	B-P
.	O

UCP2	O
suppression	O
induced	O
reactive	O
oxygen	O
species	O
production	O
and	O
upregulation	O
of	O
the	O
ABC	O
transporter	O
protein	O
ABCG2	O
,	O
which	O
leads	O
to	O
chemoresistance	O
by	O
promoting	O
drug	O
efflux	O
.	O

UCP2	O
downregulation	O
also	O
altered	O
metabolic	O
rates	O
as	O
shown	O
by	O
elevated	O
glucose	O
uptake	O
and	O
reduced	O
oxygen	O
consumption	O
.	O

These	O
data	O
suggest	O
that	O
UCP2	O
is	O
a	O
key	O
mediator	O
of	O
hypoxia	O
-triggered	O
chemoresistance	O
of	O
NSCLCs	O
,	O
which	O
can	O
be	O
potentially	O
targeted	O
in	O
clinical	B-P
treatment	I-P
of	O
chemo-refractory	O
NSCLCs	O
.	O

The	O
construction	O
of	O
three-dimensional	O
composite	O
fibrous	O
macrostructures	O
with	O
nanotextures	O
for	O
biomedical	O
applications	O
.	O

The	O
development	O
of	O
modern	O
biomedical	O
nanotechnology	O
requires	O
three-dimensional	O
macrostructures	O
with	O
nanotextures	O
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	O
in	O
intricate	O
biological	O
systems	O
.	O

Additionally	O
,	O
the	O
restoration	O
and	O
regeneration	O
of	O
some	O
specific	O
body	O
tissues	O
and	O
organs	O
rely	O
on	O
the	O
function	O
of	O
conductive	O
polymers	O
,	O
which	O
can	O
provide	O
electrical	O
cues	O
for	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
fabricated	O
three-dimensional	O
composite	O
nanofibre	O
macrostructures	O
of	O
polycaprolactone	O
(	O
PCL	O
)	O
with	O
different	O
concentrations	O
of	O
polyaniline	O
(	O
PANi	O
)	O
by	O
employing	O
an	O
improved	O
electrospinning	O
technology	O
with	O
a	O
specially	O
designed	O
collector	O
.	O

The	O
3D	O
structures	O
possessed	O
cap-like	O
macrostructures	O
with	O
centimetre-scale	O
thickness	O
and	O
interconnected	O
pore	O
nanotextures	O
with	O
nanometre-scale	O
nanofibres	O
.	O

To	O
estimate	O
the	O
biocompatibility	O
of	O
the	O
3D	O
PCL	O
/	O
PANi	O
composite	O
nanofibre	O
macrostructures	O
,	O
mouse	O
myoblasts	O
(	O
C2C12	O
cells	O
)	O
were	O
cultured	O
as	O
model	O
cells	O
.	O

The	O
initial	O
responses	O
of	O
C2C12	O
cells	O
to	O
the	O
3D	O
PCL	O
/	O
PANi	O
composite	O
macrostructures	O
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
PCL	O
,	O
that	O
is	O
,	O
the	O
cells	O
exhibited	O
typical	O
myoblast-like	O
morphologies	O
with	O
obvious	O
pseudopodia	O
and	O
the	O
moderate	O
incorporation	O
(	O
less	O
than	O
2.0	O
wt	O
%	O
)	O
of	O
conductive	O
PANi	O
facilitated	O
cell	O
proliferation	O
,	O
which	O
indicated	O
that	O
PANi	O
has	O
appreciable	O
cell	O
affinity	O
.	O

Moreover	O
,	O
the	O
addition	O
of	O
conductive	O
PANi	O
to	O
the	O
3D	O
composite	O
nanofibre	O
macrostructures	O
considerably	O
enhanced	O
myoblast	O
differentiation	O
and	O
myotube	O
maturation	O
.	O

These	O
results	O
suggest	O
that	O
electrospun	O
3D	O
PCL	O
/	O
PANi	O
composite	O
nanofibre	O
macrostructures	O
would	O
have	O
promising	O
applications	O
in	O
tissue	B-P
engineering	I-P
.	O

Semianalytical	O
Solution	O
for	O
the	O
Deformation	O
of	O
an	O
Elastic	O
Layer	O
under	O
an	O
Axisymmetrically	O
Distributed	O
Power-Form	O
Load	O
:	O
Application	O
to	O
Fluid-Jet-Induced	B-P
Indentation	I-P
of	O
Biological	O
Soft	O
Tissues	O
.	O

Fluid-jet-based	B-P
indentation	I-P
is	O
used	O
as	O
a	O
noncontact	O
excitation	O
technique	O
by	O
systems	O
measuring	O
the	O
mechanical	O
properties	O
of	O
soft	O
tissues	O
.	O

However	O
,	O
the	O
application	O
of	O
these	O
devices	O
has	O
been	O
hindered	O
by	O
the	O
lack	O
of	O
theoretical	O
solutions	O
.	O

This	O
study	O
developed	O
a	O
mathematical	O
model	O
for	O
testing	O
the	O
indentation	B-P
induced	O
by	O
a	O
fluid	O
jet	O
and	O
determined	O
a	O
semianalytical	O
solution	O
.	O

The	O
soft	O
tissue	O
was	O
modeled	O
as	O
an	O
elastic	O
layer	O
bonded	O
to	O
a	O
rigid	O
base	O
.	O

The	O
pressure	O
of	O
the	O
fluid	O
jet	O
impinging	O
on	O
the	O
soft	O
tissue	O
was	O
assumed	O
to	O
have	O
a	O
power-form	O
function	O
.	O

The	O
semianalytical	O
solution	O
was	O
verified	O
in	O
detail	O
using	O
finite-element	O
modeling	O
,	O
with	O
excellent	O
agreement	O
being	O
achieved	O
.	O

The	O
effects	O
of	O
several	O
parameters	O
on	O
the	O
solution	O
behaviors	O
are	O
reported	O
,	O
and	O
a	O
method	O
for	O
applying	O
the	O
solution	O
to	O
determine	O
the	O
mechanical	O
properties	O
of	O
soft	O
tissues	O
is	O
suggested	O
.	O

A	O
scoping	O
review	O
of	O
Australian	O
allied	O
health	O
research	O
in	O
ehealth	O
.	O

Uptake	O
of	O
e-health	O
,	O
the	O
use	O
of	O
information	O
communication	O
technologies	O
(	O
ICT	O
)	O
for	O
health	O
service	O
delivery	O
,	O
in	O
allied	O
health	O
appears	O
to	O
be	O
lagging	O
behind	O
other	O
health	O
care	O
areas	O
,	O
despite	O
offering	O
the	O
potential	O
to	O
address	O
problems	O
with	O
service	O
access	O
by	O
rural	O
and	O
remote	O
Australians	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
conduct	O
a	O
scoping	O
review	O
of	O
studies	O
into	O
the	O
application	O
of	O
or	O
attitudes	O
towards	O
ehealth	O
amongst	O
allied	O
health	O
professionals	O
conducted	O
in	O
Australia	O
.	O

Studies	O
meeting	O
inclusion	O
criteria	O
published	O
from	O
January	O
2004	O
to	O
June	O
2015	O
were	O
reviewed	O
.	O

Professions	O
included	O
were	O
audiology	O
,	O
dietetics	O
,	O
exercise	O
physiology	O
,	O
occupational	O
therapy	O
,	O
physiotherapy	B-P
,	O
podiatry	O
,	O
social	O
work	O
,	O
and	O
speech	O
pathology	O
.	O

Terms	O
for	O
these	O
professions	O
and	O
forms	O
of	O
ehealth	O
were	O
combined	O
in	O
databases	O
of	O
CINAHL	O
(	O
EBSCO	O
)	O
,	O
Cochrane	O
Library	O
,	O
PsycINFO	O
(	O
1806	O
-	O
Ovid	O
)	O
,	O
MEDLINE	O
(	O
Ovid	O
)	O
and	O
AMED	O
(	O
Ovid	O
)	O
.	O

Forty-four	O
studies	O
meeting	O
inclusion	O
criteria	O
were	O
summarised	O
.	O

They	O
were	O
either	O
trials	O
of	O
aspects	O
of	O
ehealth	O
service	O
delivery	O
,	O
or	O
clinician	O
and/or	O
client	O
use	O
of	O
and	O
attitudes	O
towards	O
ehealth	O
.	O

Trials	O
of	O
ehealth	O
were	O
largely	O
from	O
two	O
research	O
groups	O
located	O
at	O
the	O
Universities	O
of	O
Sydney	O
and	O
Queensland	O
;	O
most	O
involved	O
speech	O
pathology	O
and	O
physiotherapy	B-P
.	O

Assessments	O
through	O
ehealth	O
and	O
intervention	B-P
outcomes	O
through	O
ehealth	O
were	O
comparable	O
with	O
face-to-face	O
delivery	O
.	O

Clinicians	O
used	O
ICT	O
mostly	O
for	O
managing	O
their	O
work	O
and	O
for	O
professional	O
development	O
,	O
but	O
were	O
reticent	O
about	O
its	O
use	O
in	O
service	O
delivery	O
,	O
which	O
contrasted	O
with	O
the	O
more	O
positive	O
attitudes	O
and	O
experiences	O
of	O
clients	O
.	O

The	O
potential	O
of	O
ehealth	O
to	O
address	O
allied	O
health	O
needs	O
of	O
Australians	O
living	O
in	O
rural	O
and	O
remote	O
Australia	O
appears	O
unrealised	O
.	O

Clinicians	O
may	O
need	O
to	O
embrace	O
ehealth	O
as	O
a	O
means	O
to	O
radicalise	O
practice	O
,	O
rather	O
than	O
replicate	O
existing	O
practices	O
through	O
a	O
different	O
mode	O
of	O
delivery	O
.	O

Discovery	O
of	O
novel	O
antagonists	O
of	O
human	O
neurotensin	O
receptor	O
1	O
on	O
the	O
basis	O
of	O
ligand	O
and	O
protein	O
structure	O
.	O

Neurotensin	O
receptor	O
1	O
(	O
NTR1	O
)	O
is	O
a	O
cell	O
surface	O
receptor	O
belonging	O
to	O
the	O
G	O
protein-coupled	O
receptor	O
(	O
GPCR	O
)	O
A	O
superfamily	O
.	O

NTR1	O
plays	O
an	O
important	O
role	O
in	O
neuronal	O
and	O
non	O
-	O
neuronal	O
systems	O
.	O

Using	O
the	O
previously	O
identified	O
crystal	O
structure	O
of	O
rat	O
NTR1	O
(	O
rNTR1	O
)	O
,	O
we	O
screened	O
for	O
potential	O
candidates	O
of	O
human	O
NTR1	O
(	O
hNTR1	O
)	O
ligand	O
.	O

Approximately	O
10,000	O
compounds	O
were	O
selected	O
using	O
the	O
docking	O
score	O
,	O
followed	O
by	O
pharmacophore	O
-based	O
virtual	O
screening	O
and	O
a	O
two-dimensional	O
(	B-P
2D	I-P
)	I-P
-fingerprint	I-P
structural	I-P
similarity	I-P
search	I-P
.	O

The	O
identified	O
molecules	O
were	O
tested	O
by	O
in	O
vitro	O
calcium	B-P
flux	I-P
assay	I-P
.	O

Four	O
compounds	O
showed	O
micromolar	O
level	O
affinity	O
,	O
of	O
which	O
,	O
one	O
compound	O
can	O
inhibit	O
hNTR1	O
/	O
CHO	O
cells	O
'	O
proliferation	O
by	O
cell	O
viability	O
assays	O
.	O

To	O
improve	O
the	O
affinity	O
of	O
these	O
positive	O
hit	O
compounds	O
,	O
a	O
homology	O
model	O
of	O
hNTR1	O
was	O
built	O
on	O
the	O
basis	O
of	O
the	O
crystal	O
structure	O
of	O
rNTR1	O
.	O

The	O
hit	O
compounds	O
will	O
be	O
further	O
optimized	O
on	O
the	O
basis	O
of	O
the	O
structure	O
of	O
the	O
hNTR1	O
receptor	O
to	O
be	O
the	O
targets	O
for	O
drugs	O
directed	O
against	O
diseases	O
associated	O
with	O
hNTR1	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
method	O
we	O
used	O
is	O
valid	O
,	O
which	O
will	O
be	O
treated	O
as	O
a	O
useful	O
tool	O
to	O
search	O
for	O
the	O
agonists	O
or	O
antagonists	O
of	O
our	O
interested	O
target	O
protein	O
.	O

Moreover	O
,	O
the	O
compound	O
we	O
tested	O
may	O
provide	O
a	O
hopeful	O
clue	O
for	O
treating	O
the	O
diseases	O
related	O
with	O
hNTR1	O
.	O

The	O
Netherlands	O
Chlamydia	O
cohort	O
study	O
(	O
NECCST	O
)	O
protocol	O
to	O
assess	O
the	O
risk	O
of	O
late	O
complications	O
following	O
Chlamydia	O
trachomatis	O
infection	O
in	O
women	O
.	O

Chlamydia	O
trachomatis	O
(	O
CT	O
)	O
,	O
the	O
most	O
common	O
bacterial	O
sexually	O
transmitted	O
infection	O
(	O
STI	O
)	O
among	O
young	O
women	O
,	O
can	O
result	O
in	O
serious	O
sequelae	O
.	O

Although	O
the	O
course	O
of	O
infection	O
is	O
often	O
asymptomatic	O
,	O
CT	O
may	O
cause	O
pelvic	O
inflammatory	O
disease	O
(	O
PID	O
)	O
,	O
leading	O
to	O
severe	O
complications	O
,	O
such	O
as	O
prolonged	O
time	O
to	O
pregnancy	O
,	O
ectopic	O
pregnancy	O
,	O
and	O
tubal	O
factor	O
subfertility	O
.	O

The	O
risk	O
of	O
and	O
risk	O
factors	O
for	O
complications	O
following	O
CT-infection	O
have	O
not	O
been	O
assessed	O
in	O
a	O
long-term	O
prospective	O
cohort	O
study	O
,	O
the	O
preferred	O
design	O
to	O
define	O
infections	O
and	O
complications	O
adequately	O
.	O

In	O
the	O
Netherlands	O
Chlamydia	O
Cohort	O
Study	O
(	O
NECCST	O
)	O
,	O
a	O
cohort	O
of	O
women	O
of	O
reproductive	O
age	O
with	O
and	O
without	O
a	O
history	O
of	O
CT-infection	O
is	O
followed	O
over	O
a	O
minimum	O
of	O
ten	O
years	O
to	O
investigate	O
(	O
CT	O
-related	O
)	O
reproductive	O
tract	O
complications	O
.	O

This	O
study	O
is	O
a	O
follow-up	O
of	O
the	O
Chlamydia	B-P
Screening	I-P
Implementation	I-P
(	I-P
CSI	I-P
)	I-P
study	I-P
,	O
executed	O
between	O
2008	O
and	O
2011	O
in	O
the	O
Netherlands	O
.	O

For	O
NECCST	O
,	O
female	O
CSI	B-P
participants	O
who	O
consented	O
to	O
be	O
approached	O
for	O
follow-up	O
studies	O
(	O
n	O
=	O
14,685	O
)	O
are	O
invited	O
,	O
and	O
prospectively	O
followed	O
until	O
2022	O
.	O

Four	O
data	O
collection	O
moments	O
are	O
foreseen	O
every	O
two	O
consecutive	O
years	O
.	O

Questionnaire	O
data	O
and	O
blood	O
samples	O
for	O
CT	O
-	O
Immunoglobulin	B-P
G	I-P
(	I-P
IgG	I-P
)	I-P
measurement	I-P
are	O
obtained	O
as	O
well	O
as	O
host	O
DNA	O
to	O
determine	O
specific	O
genetic	O
biomarkers	O
related	O
to	O
susceptibility	O
and	O
severity	O
of	O
infection	O
.	O

CT	O
-	O
history	O
will	O
be	O
based	O
on	O
CSI	B-P
test	I-P
outcomes	O
,	O
self-reported	O
infections	O
and	O
CT	O
-	O
IgG	O
presence	O
.	O

Information	O
on	O
(	O
time	O
to	O
)	O
pregnancies	O
and	O
the	O
potential	O
long-term	O
complications	O
(	O
i.e	O
.	O

PID	O
,	O
ectopic	O
pregnancy	O
and	O
(	O
tubal	O
factor	O
)	O
subfertility	O
)	O
,	O
will	O
be	O
acquired	O
by	O
questionnaires	O
.	O

Reported	O
subfertility	O
will	O
be	O
verified	O
in	O
medical	O
registers	O
.	O

Occurrence	O
of	O
these	O
late	O
complications	O
and	O
prolonged	O
time	O
to	O
pregnancy	O
,	O
as	O
a	O
proxy	O
for	O
reduced	O
fertility	O
due	O
to	O
a	O
previous	O
CT-infection	O
,	O
or	O
other	O
risk	O
factors	O
,	O
will	O
be	O
investigated	O
using	O
longitudinal	O
statistical	O
procedures	O
.	O

In	O
the	O
proposed	O
study	O
,	O
the	O
occurrence	O
of	O
late	O
complications	O
following	O
CT-infection	O
and	O
its	O
risk	O
factors	O
will	O
be	O
assessed	O
.	O

Ultimately	O
,	O
provided	O
reliable	O
risk	O
factors	O
and/or	O
markers	O
can	O
be	O
identified	O
for	O
such	O
late	O
complications	O
.	O

This	O
will	O
contribute	O
to	O
the	O
development	O
of	O
a	O
prognostic	O
tool	O
to	O
estimate	O
the	O
risk	O
of	O
CT	O
-related	O
complications	O
at	O
an	O
early	O
time	O
point	O
,	O
enabling	O
targeted	O
prevention	O
and	O
care	O
towards	O
women	O
at	O
risk	O
for	O
late	O
complications	O
.	O

Dutch	O
Trial	O
Register	O
NTR-5597	O
.	O

Retrospectively	O
registered	O
14	O
February	O
2016	O
.	O

Comparison	O
of	O
270	O
Versus	O
320	O
mg	O
I/mL	O
of	O
Iodixanol	O
in	O
1	O
Image	O
Assessment	O
of	O
Both	O
Renal	O
Arteries	O
and	O
Veins	O
With	O
Dual-Energy	B-P
Spectral	I-P
CT	I-P
Imaging	I-P
in	O
Late	O
Arterial	O
Phase	O
and	O
Their	O
Influence	O
on	O
Renal	O
Function	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
image	O
quality	O
of	O
renal	O
arteries	O
and	O
veins	O
with	O
dual-energy	B-P
spectral	I-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
imaging	I-P
in	O
late	O
arterial	O
phase	O
using	O
270	O
and	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
and	O
their	O
influence	O
on	O
renal	O
function	O
.	O

A	O
total	O
of	O
1062	O
patients	O
underwent	O
renal	B-P
CT	I-P
angiography	I-P
with	O
270	O
or	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
with	O
dual-energy	B-P
spectral	I-P
CT	I-P
imaging	I-P
in	O
late	O
arterial	O
phase	O
.	O

Image	O
quality	O
and	O
their	O
influence	O
on	O
renal	O
function	O
were	O
compared	O
.	O

There	O
were	O
no	O
significant	O
differences	O
of	O
CT	O
value	O
,	O
signal-to-noise	O
ratio	O
,	O
contrast-to-noise	O
ratio	O
,	O
and	O
subjective	O
score	O
of	O
renal	O
vessels	O
between	O
2	O
groups	O
(	O
all	O
P	O
>	O
0.05	O
)	O
.	O

The	O
incidence	O
of	O
contrast-induced	O
nephropathy	O
in	O
patients	O
with	O
abnormal	O
renal	O
function	O
using	O
320	O
mg	O
I/mL	O
of	O
iodixanol	O
was	O
significantly	O
higher	O
than	O
using	O
270	O
mg	O
I/mL	O
of	O
iodixanol	O
(	O
P	O
=	O
0.043	O
)	O
.	O

The	O
renal	O
arteries	O
and	O
veins	O
can	O
be	O
fully	O
assessed	O
in	O
late	O
arterial	O
phase	O
with	O
270	O
mg	O
I/mL	O
of	O
iodixanol	O
using	O
dual-energy	B-P
spectral	I-P
CT	I-P
scan	I-P
with	O
better	O
preserved	O
renal	O
function	O
.	O

Evaluation	O
of	O
analytical	O
methods	O
for	O
the	O
determination	B-P
of	O
the	O
physicochemical	O
properties	O
of	O
fermented	O
,	O
granulated	O
,	O
and	O
roasted	O
cassava	O
pulp	O
-	O
gari	O
.	O

Simple	O
but	O
reliable	O
methods	O
for	O
the	O
determination	B-P
of	O
the	O
physicochemical	O
properties	O
of	O
gari	O
were	O
evaluated	O
for	O
the	O
parameters	O
,	O
such	O
as	O
grain	O
size	O
,	O
bulk	O
density	O
,	O
swelling	O
index	O
,	O
moisture	O
content	O
,	O
gross	O
calorific	O
value	O
,	O
cyanide	O
content	O
,	O
and	O
acidity	O
content	O
.	O

The	O
grain	O
sizes	O
were	O
between	O
525	O
and	O
928	O
μm	O
(	O
weighted	O
means	O
)	O
,	O
the	O
bulk	O
densities	O
between	O
0.541	O
and	O
0.699	O
g/cm³	O
,	O
and	O
the	O
swelling	O
indices	O
between	O
3.21	O
and	O
4.33	O
.	O

The	O
moisture	O
contents	O
ranged	O
from	O
4.30	O
to	O
9.19	O
%	O
.	O

The	O
gross	O
calorific	O
values	O
were	O
found	O
between	O
15.45	O
and	O
15.82	O
kJ/g	O
.	O

The	O
cyanide	O
contents	O
were	O
between	O
0	O
and	O
4.8	O
ppm	O
.	O

The	O
acidity	O
contents	O
varied	O
among	O
0.55	O
and	O
1.62	O
%	O
.	O

Correlation	O
tests	O
verified	O
the	O
influences	O
of	O
the	O
grain	O
size	O
and	O
the	O
moisture	O
content	O
on	O
the	O
acidity	O
content	O
with	O
a	O
probability	O
of	O
99.9	O
%	O
.	O

The	O
methods	O
were	O
regarded	O
as	O
suitable	O
and	O
adaptable	O
for	O
the	O
application	O
in	O
small	O
and	O
medium	O
cassava	O
-	O
processing	O
industries	O
with	O
special	O
regard	O
to	O
the	O
respect	O
of	O
the	O
consumer	O
`	O
s	O
health	O
safety	O
.	O

Identification	O
and	O
SAR	O
Evaluation	O
of	O
Hemozoin	O
-	O
Inhibiting	O
Benzamides	O
Active	O
against	O
Plasmodium	O
falciparum	O
.	O

Quinoline	O
antimalarials	O
target	O
hemozoin	O
formation	O
causing	O
a	O
cytotoxic	O
accumulation	O
of	O
ferriprotoporphyrin	O
IX	O
(	O
Fe	O
(	O
III	O
)	O
PPIX	O
)	O
.	O

Well-developed	O
SAR	O
models	O
exist	O
for	O
β-hematin	O
inhibition	O
,	O
parasite	O
activity	O
,	O
and	O
cellular	O
mechanisms	O
for	O
this	O
compound	O
class	O
,	O
but	O
no	O
comparably	O
detailed	O
investigations	O
exist	O
for	O
other	O
hemozoin	O
inhibiting	O
chemotypes	O
.	O

Here	O
,	O
benzamide	O
analogues	O
based	O
on	O
previous	O
HTS	B-P
hits	O
have	O
been	O
purchased	O
or	O
synthesized	O
.	O

Only	O
derivatives	O
containing	O
an	O
electron	O
deficient	O
aromatic	O
ring	O
and	O
capable	O
of	O
adopting	O
flat	O
conformations	O
,	O
optimal	O
for	O
π-π	O
interactions	O
with	O
Fe	O
(	O
III	O
)	O
PPIX	O
,	O
inhibited	O
β-hematin	O
formation	O
.	O

The	O
two	O
most	O
potent	O
analogues	O
showed	O
nanomolar	O
parasite	O
activity	O
,	O
with	O
little	O
CQ	O
cross-resistance	O
,	O
low	O
cytotoxicity	O
,	O
and	O
high	O
in	O
vitro	O
microsomal	O
stability	O
.	O

Selected	O
analogues	O
inhibited	O
hemozoin	O
formation	O
in	O
Plasmodium	O
falciparum	O
causing	O
high	O
levels	O
of	O
free	O
heme	O
.	O

In	O
contrast	O
to	O
quinolines	O
,	O
introduction	O
of	O
amine	O
side	O
chains	O
did	O
not	O
lead	O
to	O
benzamide	O
accumulation	O
in	O
the	O
parasite	O
.	O

These	O
data	O
reveal	O
complex	O
relationships	O
between	O
heme	O
binding	O
,	O
free	O
heme	O
levels	O
,	O
cellular	O
accumulation	O
,	O
and	O
in	O
vitro	O
activity	O
of	O
potential	O
novel	O
antimalarials	O
.	O

Nucleic	B-P
acid	I-P
detection	I-P
with	O
CRISPR	O
-	O
Cas13a	O
/	O
C2c2	O
.	O

Rapid	O
,	O
inexpensive	O
,	O
and	O
sensitive	O
nucleic	B-P
acid	I-P
detection	I-P
may	O
aid	O
point-of-care	O
pathogen	O
detection	B-P
,	O
genotyping	B-P
,	O
and	O
disease	O
monitoring	O
.	O

The	O
RNA	O
-guided	O
,	O
RNA	O
-	O
targeting	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
effector	O
Cas13a	O
(	O
previously	O
known	O
as	O
C2c2	O
)	O
exhibits	O
a	O
``	O
collateral	O
effect	O
``	O
of	O
promiscuous	O
ribonuclease	O
activity	O
upon	O
target	O
recognition	O
.	O

We	O
combine	O
the	O
collateral	O
effect	O
of	O
Cas13a	O
with	O
isothermal	B-P
amplification	I-P
to	O
establish	O
a	O
CRISPR	O
-based	O
diagnostic	O
(	O
CRISPR	O
-	O
Dx	O
)	O
,	O
providing	O
rapid	O
DNA	O
or	O
RNA	O
detection	B-P
with	O
attomolar	O
sensitivity	O
and	O
single-base	O
mismatch	O
specificity	O
.	O

We	O
use	O
this	O
Cas13a	O
-based	O
molecular	O
detection	B-P
platform	O
,	O
termed	O
Specific	O
High-Sensitivity	O
Enzymatic	O
Reporter	O
UnLOCKing	O
(	O
SHERLOCK	O
)	O
,	O
to	O
detect	O
specific	O
strains	O
of	O
Zika	O
and	O
Dengue	O
virus	O
,	O
distinguish	O
pathogenic	O
bacteria	O
,	O
genotype	O
human	O
DNA	O
,	O
and	O
identify	O
mutations	O
in	O
cell-free	O
tumor	O
DNA	O
.	O

Furthermore	O
,	O
SHERLOCK	O
reaction	O
reagents	O
can	O
be	O
lyophilized	B-P
for	O
cold-chain	O
independence	O
and	O
long-term	O
storage	O
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	O
applications	O
.	O

Asenapine	O
for	O
the	O
treatment	O
of	O
adults	O
with	O
an	O
acute	O
exacerbation	O
of	O
schizophrenia	O
:	O
results	O
from	O
a	O
randomized	O
,	O
double-blind	O
,	O
fixed-dose	O
,	O
placebo-controlled	O
trial	O
with	O
olanzapine	O
as	O
an	O
active	O
control	O
.	O

Evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
asenapine	O
2.5	O
mg	O
twice	O
daily	O
(	O
bid	O
;	O
n=97	O
)	O
or	O
5	O
mg	O
bid	O
(	O
n=113	O
)	O
versus	O
placebo	B-P
(	O
n=101	O
)	O
in	O
adults	O
with	O
acute	O
exacerbation	O
of	O
schizophrenia	O
.	O

Adults	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
,	O
Text	O
Revision	O
(	O
DSM-IV-TR	O
)	O
schizophrenia	O
diagnosis	O
were	O
randomized	O
to	O
asenapine	O
2.5	O
mg	O
bid	O
,	O
5	O
mg	O
bid	O
,	O
placebo	B-P
,	O
or	O
olanzapine	O
15	O
mg	O
once	O
daily	O
.	O

The	O
primary	O
objective	O
was	O
to	O
test	O
superiority	O
of	O
asenapine	O
versus	O
placebo	B-P
as	O
measured	O
by	O
the	O
change	O
from	O
baseline	O
to	O
day	O
42	O
in	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
total	O
score	O
.	O

The	O
key	O
safety	O
objective	O
was	O
to	O
evaluate	O
weight	O
change	O
in	O
asenapine	O
versus	O
olanzapine	O
at	O
day	O
42	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
met	O
;	O
the	O
difference	O
in	O
least	O
squares	O
mean	O
change	O
from	O
baseline	O
to	O
day	O
42	O
in	O
PANSS	O
total	O
score	O
between	O
asenapine	O
5	O
mg	O
bid	O
and	O
placebo	B-P
was	O
-5.5	O
points	O
(	O
unadjusted	O
95	O
%	O
CI	O
:	O
-10.1	O
,	O
-1.0	O
;	O
multiplicity	O
adjusted	O
P=0.0356	O
)	O
.	O

Neither	O
asenapine	O
2.5	O
mg	O
bid	O
nor	O
olanzapine	O
15mg	O
were	O
superior	O
to	O
placebo	B-P
.	O

Both	O
asenapine	O
groups	O
demonstrated	O
significantly	O
less	O
weight	O
gain	O
than	O
olanzapine	O
at	O
day	O
42	O
.	O

Significantly	O
higher	O
incidences	O
of	O
oral	O
hypoesthesia	O
and	O
dysgeusia	O
(	O
combined	O
)	O
for	O
asenapine	O
2.5	O
mg	O
bid	O
(	O
5.2	O
%	O
vs	O
0.0	O
%	O
;	O
P=0.0217	O
)	O
and	O
5	O
mg	O
bid	O
(	O
7.1	O
%	O
vs	O
0.0	O
%	O
;	O
P=0.0033	O
)	O
were	O
observed	O
versus	O
placebo	B-P
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
asenapine	O
and	O
placebo	B-P
for	O
insomnia	O
,	O
extrapyramidal	O
symptoms	O
,	O
akathisia	O
,	O
dizziness	O
,	O
or	O
combination	O
of	O
somnolence	O
/	O
sedation	B-P
/	O
hypersomnia	O
.	O

This	O
study	O
supports	O
previous	O
efficacy	O
and	O
safety	O
findings	O
of	O
asenapine	O
;	O
asenapine	O
5	O
mg	O
bid	O
is	O
the	O
lowest	O
effective	O
dose	O
in	O
adults	O
with	O
schizophrenia	O
.	O

Asenapine	O
was	O
associated	O
with	O
significantly	O
less	O
weight	O
gain	O
than	O
olanzapine	O
at	O
day	O
42	O
.	O

Semimembranosus	O
tenosynovitis	O
:	O
Diagnosis	O
and	O
management	O
of	O
a	O
commonly	O
missed	O
cause	O
of	O
posteromedial	O
knee	O
pain	O
.	O

In	O
orthopedic	O
and	O
sports	O
medicine	O
literature	O
there	O
is	O
minimal	O
information	O
regarding	O
accurate	O
diagnosis	O
and	O
the	O
treatment	B-P
options	I-P
for	O
tenosynovitis	O
of	O
the	O
distal	O
semimembranosus	O
tendon	O
.	O

After	O
reviewing	O
the	O
literature	O
,	O
the	O
authors	O
question	O
both	O
the	O
etiology	O
and	O
treatment	B-P
of	O
this	O
condition	O
.	O

Previous	O
descriptions	O
have	O
associated	O
the	O
condition	O
primarily	O
with	O
the	O
endurance	O
athlete	O
but	O
we	O
have	O
noted	O
multiple	O
cases	O
in	O
which	O
this	O
is	O
a	O
condition	O
common	O
to	O
the	O
'sprinter	O
'	O
as	O
well	O
.	O

There	O
has	O
been	O
very	O
little	O
mention	O
of	O
this	O
condition	O
in	O
recent	O
literature	O
but	O
the	O
most	O
recent	O
complete	O
description	O
of	O
operative	O
treatment	B-P
for	O
this	O
condition	O
recommends	O
both	O
tendon	B-P
transfer	I-P
and	O
concomitant	O
arthroscopy	B-P
.	O

We	O
propose	O
this	O
condition	O
is	O
akin	O
to	O
De	O
Quervain	O
's	O
tenosynovitis	O
of	O
the	O
knee	O
,	O
with	O
sensitive	O
and	O
specific	O
signs	O
on	O
physical	O
examination	O
.	O

We	O
describe	O
a	O
case	O
series	O
of	O
six	O
cases	O
(	O
five	O
patients	O
)	O
,	O
that	O
underwent	O
open	B-P
surgical	I-P
release	O
for	O
semimembranosus	O
tenosynovitis	O
.	O

The	O
anatomy	O
and	O
the	O
treatment	B-P
options	I-P
for	O
the	O
condition	O
are	O
also	O
discussed	O
.	O

At	O
a	O
follow-up	O
period	O
of	O
18-64months	O
,	O
all	O
cases	O
showed	O
improvement	O
in	O
the	O
Tegner	O
activity	O
score	O
following	O
surgical	O
release	O
.	O

Diagnostic	O
confusion	O
can	O
be	O
decreased	O
with	O
more	O
modern	O
diagnostic	O
imaging	O
modalities	O
than	O
those	O
described	O
in	O
the	O
literature	O
.	O

The	O
authors	O
outline	O
an	O
alternative	O
operative	O
approach	O
significantly	O
decreasing	O
surgical	B-P
complexity	O
and	O
therefore	O
post-operative	O
morbidity	O
.	O

What	O
is	O
known	O
about	O
this	O
subject	O
:	O
This	O
is	O
a	O
rare	O
condition	O
and	O
the	O
surgical	B-P
treatment	B-P
is	O
seldom	O
performed	O
.	O

What	O
this	O
study	O
adds	O
to	O
existing	O
knowledge	O
:	O
We	O
describe	O
the	O
technique	O
for	O
surgical	B-P
decompression	B-P
and	O
reveal	O
positive	O
results	O
at	O
medium	O
term	O
follow-up	O
.	O

Nanocatalysts	O
promote	O
Streptococcus	O
mutans	O
biofilm	O
matrix	O
degradation	O
and	O
enhance	O
bacterial	O
killing	O
to	O
suppress	O
dental	O
caries	O
in	O
vivo	O
.	O

Dental	O
biofilms	O
(	O
known	O
as	O
plaque	O
)	O
are	O
notoriously	O
difficult	O
to	O
remove	O
or	O
treat	O
because	O
the	O
bacteria	O
can	O
be	O
enmeshed	O
in	O
a	O
protective	O
extracellular	O
matrix	O
.	O

It	O
can	O
also	O
create	O
highly	O
acidic	O
microenvironments	O
that	O
cause	O
acid-dissolution	O
of	O
enamel	O
-	O
apatite	O
on	O
teeth	O
,	O
leading	O
to	O
the	O
onset	O
of	O
dental	O
caries	O
.	O

Current	O
antimicrobial	O
agents	O
are	O
incapable	O
of	O
disrupting	O
the	O
matrix	O
and	O
thereby	O
fail	O
to	O
efficiently	O
kill	O
the	O
microbes	O
within	O
plaque	O
-	O
biofilms	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
strategy	O
to	O
control	O
plaque	O
-	O
biofilms	O
using	O
catalytic	O
nanoparticles	O
(	O
CAT-NP	O
)	O
with	O
peroxidase	O
-like	O
activity	O
that	O
trigger	O
extracellular	O
matrix	O
degradation	O
and	O
cause	O
bacterial	O
death	O
within	O
acidic	O
niches	O
of	O
caries	O
-causing	O
biofilm	O
.	O

CAT-NP	O
containing	O
biocompatible	O
Fe3O4	O
were	O
developed	O
to	O
catalyze	O
H2O2	O
to	O
generate	O
free-radicals	O
in	O
situ	O
that	O
simultaneously	O
degrade	O
the	O
biofilm	O
matrix	O
and	O
rapidly	O
kill	O
the	O
embedded	O
bacteria	O
with	O
exceptional	O
efficacy	O
(	O
>	O
5-log	O
reduction	O
of	O
cell-viability	O
)	O
.	O

Moreover	O
,	O
it	O
displays	O
an	O
additional	O
property	O
of	O
reducing	O
apatite	O
demineralization	O
in	O
acidic	O
conditions	O
.	O

Using	O
1-min	O
topical	O
daily	O
treatments	O
akin	O
to	O
a	O
clinical	O
situation	O
,	O
we	O
demonstrate	O
that	O
CAT-NP	O
in	O
combination	O
with	O
H2O2	O
effectively	O
suppress	O
the	O
onset	O
and	O
severity	O
of	O
dental	O
caries	O
while	O
sparing	O
normal	O
tissues	O
in	O
vivo	O
.	O

Our	O
results	O
reveal	O
the	O
potential	O
to	O
exploit	O
nanocatalysts	O
with	O
enzyme-like	O
activity	O
as	O
a	O
potent	O
alternative	O
approach	O
for	O
treatment	B-P
of	O
a	O
prevalent	O
biofilm	O
-associated	O
oral	O
disease	O
.	O

Repetitive	O
and	O
Prolonged	O
Omega-3	O
Fatty	O
Acid	O
Treatment	B-P
After	O
Traumatic	O
Brain	O
Injury	O
Enhances	O
Long-Term	O
Tissue	O
Restoration	B-P
and	O
Cognitive	B-P
Recovery	I-P
.	O

Traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
is	O
one	O
of	O
the	O
most	O
disabling	O
clinical	O
conditions	O
that	O
could	O
lead	O
to	O
neurocognitive	O
disorders	O
in	O
survivors	O
.	O

Our	O
group	O
and	O
others	O
previously	O
reported	O
that	O
prophylactic	B-P
enrichment	I-P
of	O
dietary	O
omega-3	O
polyunsaturated	O
fatty	O
acids	O
(	O
n-3	O
PUFAs	O
)	O
markedly	O
ameliorate	O
cognitive	O
deficits	O
after	O
TBI	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
a	O
clinically	O
relevant	O
therapeutic	B-P
regimen	I-P
with	O
n-3	O
PUFAs	O
administered	O
after	O
TBI	O
would	O
still	O
offer	O
significant	O
improvement	O
of	O
long-term	O
cognitive	B-P
recovery	I-P
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
the	O
decline	O
of	O
spatial	O
cognitive	O
function	O
as	O
a	O
main	O
outcome	O
after	O
TBI	O
to	O
investigate	O
the	O
therapeutic	O
efficacy	O
of	O
post	O
-	O
TBI	O
n-3	O
PUFA	O
treatment	B-P
and	O
the	O
underlying	O
mechanisms	O
.	O

Mice	O
were	O
subjected	O
to	O
sham	B-P
operation	I-P
or	O
controlled	O
cortical	O
impact	O
,	O
followed	O
by	O
random	O
assignment	O
to	O
receive	O
the	O
following	O
four	O
treatments	B-P
:	O
(	O
1	O
)	O
vehicle	O
control	O
;	O
(	O
2	O
)	O
daily	O
intraperitoneal	B-P
injections	I-P
of	O
n-3	O
PUFAs	O
for	O
2	O
weeks	O
,	O
beginning	O
2	O
h	O
after	O
TBI	O
;	O
(	O
3	O
)	O
fish	O
oil	O
dietary	O
supplementation	B-P
throughout	O
the	O
study	O
,	O
beginning	O
1	O
day	O
after	O
TBI	O
;	O
or	O
(	O
4	O
)	O
combination	O
of	O
treatments	B-P
(	O
2	O
)	O
and	O
(	O
3	O
)	O
.	O

Spatial	O
cognitive	O
deficits	O
and	O
chronic	O
brain	O
tissue	O
loss	O
,	O
as	O
well	O
as	O
endogenous	O
brain	B-P
repair	I-P
processes	I-P
such	O
as	O
neurogenesis	O
,	O
angiogenesis	O
,	O
and	O
oligodendrogenesis	O
,	O
were	O
evaluated	O
up	O
to	O
35	O
days	O
after	O
TBI	O
.	O

The	O
results	O
revealed	O
prominent	O
spatial	O
cognitive	O
deficits	O
and	O
massive	O
tissue	O
loss	O
caused	O
by	O
TBI	O
.	O

Among	O
all	O
mice	O
receiving	O
post-TBI	O
n-3	O
PUFA	O
treatments	B-P
,	O
the	O
combined	O
treatment	B-P
of	O
fish	O
oil	O
dietary	O
supplement	O
and	O
n-3	O
PUFA	O
injections	O
demonstrated	O
a	O
reproducible	O
beneficial	O
effect	O
in	O
attenuating	O
cognitive	O
deficits	O
although	O
without	O
reducing	O
gross	O
tissue	O
loss	O
.	O

Mechanistically	O
,	O
the	O
combined	O
treatment	B-P
promoted	O
post-TBI	O
restorative	B-P
processes	I-P
in	O
the	O
brain	O
,	O
including	O
generation	O
of	O
immature	O
neurons	O
,	O
microvessels	O
,	O
and	O
oligodendrocytes	O
,	O
each	O
of	O
which	O
was	O
significantly	O
correlated	O
with	O
the	O
improved	O
cognitive	O
recovery	O
.	O

These	O
results	O
indicated	O
that	O
repetitive	O
and	O
prolonged	O
n-3	O
PUFA	O
treatments	B-P
after	O
TBI	O
are	O
capable	O
of	O
enhancing	O
brain	O
remodeling	O
and	O
could	O
be	O
developed	O
as	O
a	O
potential	O
therapy	B-P
to	O
treat	O
TBI	O
victims	O
in	O
the	O
clinic	O
.	O

Preweaning	O
iron	O
deficiency	O
increases	O
non-contingent	O
responding	O
during	O
cocaine	O
self-administration	B-P
in	O
rats	O
.	O

Iron	O
deficiency	O
(	O
ID	O
)	O
is	O
the	O
most	O
prevalent	O
single-nutrient	O
deficiency	O
worldwide	O
.	O

There	O
is	O
evidence	O
that	O
ID	O
early	O
in	O
development	O
(	O
preweaning	O
in	O
rat	O
)	O
causes	O
irreversible	O
neurologic	O
,	O
behavioral	O
,	O
and	O
motor	O
development	O
deficits	O
.	O

Many	O
of	O
these	O
effects	O
have	O
been	O
attributed	O
to	O
damage	O
to	O
dopamine	O
systems	O
,	O
including	O
ID	O
-	O
induced	O
changes	O
in	O
transporter	O
and	O
receptor	O
numbers	O
in	O
the	O
striatum	O
and	O
nucleus	O
accumbens	O
.	O

These	O
mesolimbic	O
dopaminergic	O
neurons	O
are	O
,	O
in	O
part	O
,	O
responsible	O
for	O
mediating	O
reward	O
and	O
thus	O
play	O
a	O
key	O
role	O
in	O
addiction	O
.	O

However	O
,	O
there	O
has	O
been	O
relatively	O
little	O
investigation	O
into	O
the	O
behavioral	O
effects	O
of	O
ID	O
on	O
drug	O
addiction	O
.	O

In	O
2002	O
,	O
we	O
found	O
that	O
rats	O
made	O
ID	O
from	O
weaning	O
(	O
postnatal	O
day	O
21	O
)	O
and	O
throughout	O
the	O
experiment	O
acquired	O
cocaine	O
self-administration	B-P
significantly	O
more	O
slowly	O
than	O
controls	O
and	O
failed	O
to	O
increase	O
responding	O
when	O
the	O
dose	O
of	O
the	O
drug	O
was	O
decreased	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
addiction	O
for	O
self-administered	O
cocaine	O
in	O
rats	O
with	O
a	O
history	O
of	O
preweaning	O
ID	O
only	O
during	O
postnatal	O
days	O
4	O
through	O
21	O
,	O
and	O
iron	B-P
replete	I-P
thereafter	O
.	O

The	O
results	O
showed	O
that	O
while	O
ID	O
did	O
not	O
affect	O
the	O
number	O
of	O
cocaine	O
infusions	B-P
or	O
the	O
overall	O
addiction	O
-like	O
behavior	O
score	O
,	O
ID	O
rats	O
scored	O
higher	O
on	O
a	O
measure	O
of	O
continued	O
responding	O
for	O
drug	O
than	O
did	O
iron	B-P
replete	I-P
controls	O
.	O

This	O
increase	O
in	O
responding	O
,	O
however	O
,	O
was	O
less	O
goal-directed	O
as	O
ID	O
rats	O
also	O
responded	O
more	O
quickly	O
to	O
the	O
non-rewarded	O
manipulandum	O
than	O
did	O
control	O
rats	O
.	O

Thus	O
,	O
while	O
ID	O
early	O
in	O
infancy	O
did	O
not	O
significantly	O
increase	O
addiction	O
-like	O
behaviors	O
for	O
cocaine	O
in	O
this	O
small	O
study	O
,	O
the	O
pattern	O
of	O
data	O
suggests	O
a	O
possible	O
underlying	O
learning	O
or	O
performance	O
impairment	O
.	O

Future	O
studies	O
will	O
be	O
needed	O
to	O
elucidate	O
the	O
exact	O
neuro	O
-	O
behavioral	O
deficits	O
that	O
lead	O
to	O
the	O
increase	O
in	O
indiscriminate	O
responding	O
for	O
drug	O
in	O
rats	O
with	O
a	O
history	O
of	O
perinatal	O
ID	O
.	O

Relationship	O
Between	O
Frequent	O
Recreational	O
Cannabis	O
(	O
Marijuana	O
and	O
Hashish	O
)	O
Use	O
and	O
Periodontitis	O
in	O
Adults	O
in	O
the	O
United	O
States	O
:	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
2011	O
to	O
2012	O
.	O

Recreational	O
use	O
of	O
cannabis	O
,	O
following	O
its	O
legalization	O
in	O
some	O
countries	O
,	O
poses	O
emergent	O
oral	O
and	O
periodontal	O
health	O
concerns	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
relationship	O
between	O
frequent	O
recreational	O
cannabis	O
(	O
FRC	O
)	O
(	O
marijuana	O
and	O
hashish	O
)	O
use	O
and	O
periodontitis	O
prevalence	O
among	O
adults	O
in	O
the	O
United	O
States	O
.	O

Data	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
2011	O
to	O
2012	O
were	O
analyzed	O
.	O

Primary	O
outcome	O
(	O
periodontitis	O
)	O
was	O
defined	O
using	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
/	O
American	O
Academy	O
of	O
Periodontology	O
classification	O
as	O
well	O
as	O
continuous	O
measurements	O
of	O
probing	O
depth	O
(	O
PD	O
)	O
and	O
clinical	O
attachment	O
loss	O
(	O
AL	O
)	O
.	O

Exposure	O
of	O
interest	O
was	O
self-reported	O
cannabis	O
use	O
,	O
defined	O
as	O
``	O
FRC	O
use	O
``	O
versus	O
``	O
non-FRC	O
use	O
.	O
''	O

Bivariate	O
and	O
multivariable	O
regression	O
models	O
were	O
performed	O
using	O
the	O
entire	O
analytical	O
sample	O
(	O
model	O
1	O
)	O
as	O
well	O
as	O
those	O
who	O
had	O
never	O
used	O
tobacco	O
(	O
never-users	O
)	O
(	O
model	O
2	O
)	O
.	O

Of	O
1,938	O
participants	O
with	O
available	O
cannabis	O
use	O
data	O
and	O
essential	O
covariates	O
,	O
26.8	O
%	O
were	O
FRC	O
users	O
.	O

Mean	O
number	O
of	O
sites	O
per	O
participant	O
with	O
PD	O
≥4	O
,	O
≥6	O
,	O
and	O
≥8	O
mm	O
and	O
AL	O
≥3	O
,	O
≥5	O
,	O
and	O
≥8	O
mm	O
was	O
significantly	O
higher	O
among	O
FRC	O
users	O
than	O
among	O
non-FRC	O
users	O
(	O
mean	O
difference	O
in	O
number	O
of	O
PD	O
sites	O
:	O
6.9	O
,	O
5.6	O
,	O
and	O
5.6	O
;	O
P	O
<	O
0.05	O
;	O
mean	O
difference	O
in	O
number	O
of	O
AL	O
sites	O
:	O
12.7	O
,	O
7.6	O
,	O
and	O
5.6	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Average	O
AL	O
was	O
higher	O
among	O
FRC	O
users	O
than	O
among	O
non-FRC	O
users	O
(	O
1.8	O
versus	O
1.6	O
mm	O
;	O
P	O
=	O
0.004	O
)	O
.	O

Bivariate	O
analysis	O
revealed	O
positive	O
(	O
harmful	O
)	O
association	O
between	O
FRC	O
use	O
and	O
severe	O
periodontitis	O
in	O
the	O
entire	O
sample	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
:	O
1.7	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.3	O
to	O
2.4	O
;	O
P	O
=	O
0.002	O
)	O
as	O
well	O
as	O
in	O
never-smokers	O
(	O
OR	O
:	O
2.0	O
,	O
95	O
%	O
CI	O
:	O
1.2	O
to	O
3.5	O
;	O
P	O
=	O
0.01	O
)	O
.	O

This	O
association	O
was	O
retained	O
in	O
multivariable	O
models	O
adjusted	O
for	O
demographics	O
(	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
,	O
and	O
income	O
level	O
)	O
,	O
alcohol	O
and	O
tobacco	O
use	O
,	O
diabetes	O
mellitus	O
,	O
and	O
past	O
periodontal	B-P
treatment	I-P
(	O
model	O
1	O
:	O
adjusted	O
OR	O
[	O
aOR	O
]	O
:	O
1.4	O
,	O
95	O
%	O
CI	O
:	O
1.1	O
to	O
1.9	O
;	O
P	O
=	O
0.07	O
;	O
model	O
2	O
:	O
aOR	O
:	O
1.9	O
,	O
95	O
%	O
CI	O
:	O
1.1	O
to	O
3.2	O
;	O
P	O
=	O
0.03	O
)	O
.	O

FRC	O
use	O
is	O
associated	O
with	O
deeper	O
P	O
D	O
s	O
,	O
more	O
clinical	O
AL	O
,	O
and	O
higher	O
odds	O
of	O
having	O
severe	O
periodontitis	O
.	O

Evaluation	O
of	O
the	O
Effects	O
of	O
Intravenous	O
and	O
Percutaneous	O
Low	B-P
Level	I-P
Laser	I-P
Therapy	I-P
in	O
the	O
Management	B-P
of	O
Shoulder	O
Myofascial	O
Pain	O
Syndrome	O
.	O

Myofascial	O
pain	O
syndrome	O
(	O
MPS	O
)	O
treatment	B-P
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment	B-P
frame	I-P
.	O

Therefore	O
research	O
on	O
new	O
,	O
more	O
efficient	O
and	O
long	O
lasting	O
effect	O
treatment	B-P
modalities	O
is	O
necessary	O
.	O

This	O
study	O
looked	O
at	O
the	O
effects	O
of	O
intravenous	O
laser	B-P
therapy	I-P
(	O
IVL	B-P
)	O
and	O
percutaneous	O
low	B-P
level	I-P
laser	I-P
(	O
PLLL	B-P
)	O
in	O
the	O
management	B-P
of	O
shoulder	O
MPS	O
.	O

In	O
this	O
randomized	O
controlled	O
trial	O
,	O
30	O
patients	O
fulfilling	O
inclusion	O
criteria	O
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups	O
,	O
control	O
,	O
IVL	O
and	O
PLLL	O
.	O

Control	O
group	O
received	O
12	O
sessions	O
of	O
placebo	O
low	B-P
level	I-P
laser	I-P
,	O
IVL	O
group	O
received	O
12	O
sessions	O
of	O
IVL	B-P
therapy	I-P
,	O
and	O
PLLL	O
group	O
received	O
12	O
sessions	O
of	O
PLLL	B-P
therapy	I-P
.	O

All	O
patients	O
were	O
trained	O
for	O
better	O
body	O
posture	O
,	O
body	O
mechanics	O
,	O
gentle	B-P
massage	I-P
of	O
trigger	O
points	O
,	O
stretching	B-P
exercises	I-P
of	O
affected	O
muscle	O
(	O
trapezius	O
)	O
,	O
and	O
received	O
10	O
mg	O
of	O
oral	O
nortriptyline	O
regimen	B-P
every	O
night	O
for	O
3	O
months	O
.	O

Outcomes	O
included	O
pain	O
severity	O
,	O
functional	O
disability	O
,	O
and	O
quality	O
of	O
life	O
.	O

Patients	O
were	O
assessed	O
using	O
Numeric	O
Rating	O
Scale	O
(	O
NRS	O
)	O
,	O
Pain	O
Disability	O
Index	O
(	O
PDI	O
)	O
,	O
and	O
Short	O
Form	O
Health	O
Survey	O
(	O
SF-12	O
)	O
.	O

Data	O
collected	O
were	O
analyzed	O
using	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
Mann-Whitney	O
and	O
t	O
tests	O
.	O

The	O
mean	O
of	O
PDI	O
and	O
maximum	O
pain	O
intensity	O
during	O
day	O
and	O
night	O
significantly	O
reduced	O
in	O
both	O
PLLL	O
and	O
IVL	O
groups	O
compared	O
to	O
control	O
group	O
.	O

Although	O
pain	O
severity	O
and	O
PDI	O
reduction	O
was	O
more	O
pronounced	O
in	O
IVL	O
group	O
compared	O
to	O
PLLL	O
group	O
,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

Also	O
,	O
quality	O
of	O
life	O
statistically	O
significantly	O
improved	O
in	O
both	O
IVL	O
and	O
PLLL	O
groups	O
compared	O
to	O
control	O
group	O
was	O
more	O
,	O
and	O
although	O
higher	O
in	O
IVL	O
group	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
when	O
compared	O
to	O
PLLL	O
group	O
.	O

No	O
side	O
effects	O
were	O
observed	O
in	O
the	O
intervention	O
groups	O
.	O

Intravenous	O
laser	B-P
and	O
PLLL	B-P
therapy	I-P
had	O
a	O
positive	O
effect	O
on	O
pain	O
severity	O
and	O
PDI	O
reduction	O
,	O
and	O
quality	O
of	O
life	O
in	O
this	O
study	O
.	O

Also	O
no	O
adverse	O
event	O
was	O
recorded	O
.	O

Thus	O
,	O
intravenous	O
lasers	B-P
and	O
PLLL	B-P
therapy	I-P
seem	O
to	O
be	O
effective	O
complementary	O
modalities	O
in	O
managing	B-P
patients	O
with	O
shoulder	O
MPS	O
.	O

Extended	O
versus	O
standard	O
pelvic	B-P
lymphadenectomy	I-P
during	O
robot-assisted	B-P
radical	I-P
prostatectomy	I-P
:	O
the	O
role	O
of	O
extended	O
template	O
as	O
an	O
independent	O
predictor	O
of	O
lymph	O
node	O
invasion	O
with	O
comparable	O
morbidity	O
burden	O
.	O

To	O
assess	O
oncologic	O
and	O
surgical	B-P
outcomes	O
in	O
patients	O
subjected	O
to	O
standard	O
(	O
S	O
)	O
versus	O
extended	O
(	O
E	O
)	O
pelvic	B-P
lymph	I-P
node	I-P
dissection	I-P
(	O
PLND	B-P
)	O
during	O
robot-assisted	B-P
radical	I-P
prostatectomy	I-P
(	O
RARP	B-P
)	O
.	O

From	O
February	O
2009	O
to	O
December	O
2015	O
a	O
total	O
of	O
184	O
consecutive	O
patients	O
underwent	O
RARP	B-P
and	O
either	O
standard	O
or	O
extended	O
PLND	B-P
for	O
localized	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

Descriptive	O
statistics	O
compared	O
clinical	O
and	O
pathological	O
variables	O
between	O
groups	O
.	O

Logistic	O
regression	O
identified	O
potential	O
predictors	O
of	O
lymph	O
node	O
invasion	O
(	O
LNI	O
)	O
.	O

No	O
significant	O
preoperative	O
differences	O
were	O
found	O
between	O
the	O
EPLND	B-P
and	O
SPLND	B-P
groups	O
.	O

No	O
difference	O
in	O
complication	O
rates	O
was	O
observed	O
between	O
groups	O
.	O

No	O
group	O
differences	O
were	O
found	O
for	O
intraoperative	O
blood	O
loss	O
,	O
hospitalization	O
times	O
,	O
positive	O
surgical	O
margins	O
,	O
biochemical	O
recurrence	O
,	O
sexual	O
dysfunction	O
or	O
need	O
for	O
adjuvant	B-P
therapy	I-P
.	O

A	O
higher	O
median	O
range	O
of	O
LN	O
yield	O
was	O
found	O
for	O
the	O
EPLND	B-P
compared	O
to	O
SPLND	B-P
cohort	O
(	O
22.5	O
vs	O
12.8	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Of	O
the	O
36	O
patients	O
who	O
had	O
positive	O
LNs	O
at	O
the	O
final	O
pathology	O
,	O
22	O
were	O
in	O
the	O
EPLND	B-P
group	O
and	O
14	O
in	O
the	O
SPLND	B-P
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O

PSA	O
,	O
clinical	O
stage	O
and	O
both	O
number	O
of	O
nodes	O
removed	O
and	O
EPLND	B-P
were	O
significant	O
univariable	O
predictors	O
for	O
LNI	O
.	O

In	O
the	O
multivariable	O
model	O
,	O
PSA	O
,	O
clinical	O
stage	O
and	O
number	O
of	O
removed	O
nodes	O
were	O
independent	O
predictors	O
of	O
LNI	O
.	O

EPLND	B-P
was	O
an	O
independent	O
predictor	O
of	O
LNI	O
after	O
accounting	O
for	O
PSA	O
,	O
clinical	O
stage	O
and	O
Gleason	O
Score	O
stage	O
.	O

EPLND	B-P
during	O
RARP	B-P
is	O
safe	O
and	O
effective	O
.	O

It	O
results	O
in	O
more	O
removed	O
nodes	O
and	O
a	O
higher	O
LN	O
positivity	O
rate	O
compared	O
to	O
SPLND	B-P
,	O
predicting	O
LNI	O
without	O
increasing	O
complications	O
.	O

Sleep	O
Loss	O
Promotes	O
Astrocytic	O
Phagocytosis	O
and	O
Microglial	O
Activation	O
in	O
Mouse	O
Cerebral	O
Cortex	O
.	O

We	O
previously	O
found	O
that	O
Mertk	O
and	O
its	O
ligand	O
Gas6	O
,	O
astrocytic	O
genes	O
involved	O
in	O
phagocytosis	O
,	O
are	O
upregulated	O
after	O
acute	O
sleep	O
deprivation	O
.	O

These	O
results	O
suggested	O
that	O
astrocytes	O
may	O
engage	O
in	O
phagocytic	O
activity	O
during	O
extended	O
wake	O
,	O
but	O
direct	O
evidence	O
was	O
lacking	O
.	O

Studies	O
in	O
humans	O
and	O
rodents	O
also	O
found	O
that	O
sleep	O
loss	O
increases	O
peripheral	O
markers	O
of	O
inflammation	O
,	O
but	O
whether	O
these	O
changes	O
are	O
associated	O
with	O
neuroinflammation	O
and/or	O
activation	O
of	O
microglia	O
,	O
the	O
brain	O
's	O
resident	O
innate	O
immune	O
cells	O
,	O
was	O
unknown	O
.	O

Here	O
we	O
used	O
serial	B-P
block-face	I-P
scanning	I-P
electron	I-P
microscopy	I-P
to	O
obtain	O
3D	O
volume	O
measurements	O
of	O
synapses	O
and	O
surrounding	O
astrocytic	O
processes	O
in	O
mouse	O
frontal	O
cortex	O
after	O
6-8	O
h	O
of	O
sleep	O
,	O
spontaneous	O
wake	O
,	O
or	O
sleep	O
deprivation	O
(	O
SD	O
)	O
and	O
after	O
chronic	O
(	O
∼5	O
d	O
)	O
sleep	O
restriction	O
(	O
CSR	O
)	O
.	O

Astrocytic	O
phagocytosis	O
,	O
mainly	O
of	O
presynaptic	O
components	O
of	O
large	O
synapses	O
,	O
increased	O
after	O
both	O
acute	O
and	O
chronic	O
sleep	O
loss	O
relative	O
to	O
sleep	O
and	O
wake	O
.	O

MERTK	O
expression	O
and	O
lipid	O
peroxidation	O
in	O
synaptoneurosomes	O
also	O
increased	O
to	O
a	O
similar	O
extent	O
after	O
short	O
and	O
long	O
sleep	O
loss	O
,	O
suggesting	O
that	O
astrocytic	O
phagocytosis	O
may	O
represent	O
the	O
brain	O
's	O
response	O
to	O
the	O
increase	O
in	O
synaptic	O
activity	O
associated	O
with	O
prolonged	O
wake	O
,	O
clearing	O
worn	O
components	O
of	O
heavily	O
used	O
synapses	O
.	O

Using	O
confocal	B-P
microscopy	I-P
,	O
we	O
then	O
found	O
that	O
CSR	O
but	O
not	O
SD	O
mice	O
show	O
morphological	O
signs	O
of	O
microglial	O
activation	O
and	O
enhanced	O
microglial	O
phagocytosis	O
of	O
synaptic	O
elements	O
,	O
without	O
obvious	O
signs	O
of	O
neuroinflammation	O
in	O
the	O
CSF	O
.	O

Because	O
low	O
-	O
level	O
sustained	O
microglia	O
activation	O
can	O
lead	O
to	O
abnormal	O
responses	O
to	O
a	O
secondary	O
insult	O
,	O
these	O
results	O
suggest	O
that	O
chronic	O
sleep	O
loss	O
,	O
through	O
microglia	O
priming	O
,	O
may	O
predispose	O
the	O
brain	O
to	O
further	O
damage	O
.SIGNIFICANCE	O
STATEMENT	O
We	O
find	O
that	O
astrocytic	O
phagocytosis	O
of	O
synaptic	O
elements	O
,	O
mostly	O
of	O
presynaptic	O
origin	O
and	O
in	O
large	O
synapses	O
,	O
is	O
upregulated	O
already	O
after	O
a	O
few	O
hours	O
of	O
sleep	O
deprivation	O
and	O
shows	O
a	O
further	O
significant	O
increase	O
after	O
prolonged	O
and	O
severe	O
sleep	O
loss	O
,	O
suggesting	O
that	O
it	O
may	O
promote	O
the	O
housekeeping	O
of	O
heavily	O
used	O
and	O
strong	O
synapses	O
in	O
response	O
to	O
the	O
increased	O
neuronal	O
activity	O
of	O
extended	O
wake	O
.	O

By	O
contrast	O
,	O
chronic	O
sleep	O
restriction	O
but	O
not	O
acute	O
sleep	O
loss	O
activates	O
microglia	O
,	O
promotes	O
their	O
phagocytic	O
activity	O
,	O
and	O
does	O
so	O
in	O
the	O
absence	O
of	O
overt	O
signs	O
of	O
neuroinflammation	O
,	O
suggesting	O
that	O
like	O
many	O
other	O
stressors	O
,	O
extended	O
sleep	O
disruption	O
may	O
lead	O
to	O
a	O
state	O
of	O
sustained	O
microglia	O
activation	O
,	O
perhaps	O
increasing	O
the	O
brain	O
's	O
susceptibility	O
to	O
other	O
forms	O
of	O
damage	O
.	O

Polysaccharide	O
-	O
Specific	O
Memory	O
B	O
Cells	O
Predict	O
Protection	O
against	O
Experimental	O
Human	O
Pneumococcal	O
Carriage	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
pneumococcal	O
carriage	O
enhances	O
immunity	O
and	O
protects	O
healthy	O
adults	O
against	O
carriage	O
reacquisition	O
after	O
rechallenge	B-P
with	O
a	O
homologous	O
strain	O
.	O

To	O
investigate	O
the	O
role	O
of	O
naturally	O
acquired	O
pneumococcal	O
protein	O
and	O
polysaccharide	O
(	O
PS	O
)	O
-	O
specific	O
immunity	O
in	O
protection	O
against	O
carriage	O
acquisition	O
using	O
a	O
heterologous	O
challenge	O
model	O
.	O

We	O
identified	O
healthy	O
volunteers	O
that	O
were	O
naturally	O
colonized	O
with	O
pneumococcus	O
and	O
,	O
after	O
clearance	O
of	O
their	O
natural	O
carriage	O
episode	O
,	O
challenged	O
them	O
with	O
a	O
heterologous	O
6B	O
strain	O
.	O

In	O
another	O
cohort	O
of	O
volunteers	O
we	O
assessed	O
6BPS	O
-	O
specific	O
,	O
PspA	O
-	O
specific	O
,	O
and	O
PspC	O
-	O
specific	O
IgG	O
and	O
IgA	O
plasma	O
and	O
memory	O
B-cell	O
populations	O
before	O
and	O
7	O
,	O
14	O
,	O
and	O
35	O
days	O
after	O
experimental	O
pneumococcal	O
inoculation	B-P
.	O

Heterologous	O
challenge	O
with	O
6B	O
resulted	O
in	O
50	O
%	O
carriage	O
among	O
volunteers	O
with	O
previous	O
natural	O
pneumococcal	O
carriage	O
.	O

Protection	O
from	O
carriage	O
was	O
associated	O
with	O
a	O
high	O
number	O
of	O
circulating	O
6BPS	O
IgG	O
-	O
secreting	O
memory	O
B	O
cells	O
at	O
baseline	O
.	O

There	O
were	O
no	O
associations	O
between	O
protection	O
from	O
carriage	O
and	O
baseline	O
levels	O
of	O
6BPS	O
IgG	O
in	O
serum	O
or	O
nasal	O
wash	O
,	O
PspA	O
-	O
specific	O
,	O
or	O
PspC	O
-	O
specific	O
memory	O
B	O
cells	O
or	O
plasma	O
cells	O
.	O

In	O
volunteers	O
who	O
did	O
not	O
develop	O
carriage	O
,	O
the	O
number	O
of	O
circulating	O
6BPS	O
memory	O
B	O
cells	O
decreased	O
and	O
the	O
number	O
of	O
6BPS	O
plasma	O
cells	O
increased	O
postinoculation	O
.	O

Our	O
data	O
indicate	O
that	O
naturally	O
acquired	O
PS	O
-	O
specific	O
memory	O
B	O
cells	O
,	O
but	O
not	O
levels	O
of	O
circulating	O
IgG	O
at	O
time	O
of	O
pneumococcal	O
exposure	O
,	O
are	O
associated	O
with	O
protection	O
against	O
carriage	O
acquisition	O
.	O

Risk	O
stratification	O
for	O
major	O
adverse	O
cardiac	O
events	O
and	O
ventricular	O
tachyarrhythmias	O
by	O
cardiac	B-P
MRI	I-P
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
.	O

The	O
presence	O
of	O
myocardial	O
fibrosis	O
by	O
cardiac	B-P
MRI	I-P
has	O
prognostic	O
value	O
in	O
cardiac	O
sarcoidosis	O
,	O
and	O
localisation	O
may	O
be	O
equally	O
relevant	O
to	O
clinical	O
outcomes	O
.	O

We	O
aimed	O
to	O
analyse	O
cardiac	O
damage	O
and	O
function	O
in	O
detail	O
and	O
explore	O
the	O
relationship	O
with	O
clinical	O
outcomes	O
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
using	O
cardiac	B-P
MRI	I-P
.	O

We	O
included	O
81	O
consecutive	O
patients	O
with	O
cardiac	O
sarcoidosis	O
undergoing	O
cardiac	B-P
MR.	I-P
Left	O
ventricular	O
mass	O
and	O
fibrosis	O
mass	O
were	O
calculated	O
,	O
and	O
localisation	O
was	O
analysed	O
using	O
a	O
17-segment	O
model	O
.	O

Participants	O
underwent	O
follow-up	O
through	O
2015	O
,	O
and	O
the	O
development	O
of	O
major	O
adverse	O
cardiac	O
events	O
including	O
ventricular	O
tachyarrhythmias	O
was	O
recorded	O
.	O

Increased	O
left	O
ventricular	O
fibrosis	O
mass	O
was	O
associated	O
with	O
increased	O
prevalence	O
of	O
ventricular	O
tachyarrhythmias	O
(	O
p	O
<	O
0.001	O
)	O
.	O

When	O
localisation	O
was	O
defined	O
as	O
the	O
sum	O
of	O
late	O
gadolinium	O
enhancement	O
in	O
the	O
left	O
ventricular	O
basal	O
anterior	O
and	O
basal	O
anteroseptal	O
area	O
s	O
,	O
or	O
the	O
right	O
ventricular	O
area	O
,	O
it	O
was	O
associated	O
with	O
ventricular	O
tachyarrhythmias	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Kaplan-Meier	O
analysis	O
during	O
a	O
median	O
follow-up	O
of	O
22.1	O
months	O
showed	O
that	O
both	O
the	O
mass	O
and	O
localisation	O
groupings	O
for	O
fibrosis	O
were	O
significantly	O
associated	O
with	O
major	O
adverse	O
cardiac	O
events	O
or	O
ventricular	O
tachyarrhythmias	O
and	O
that	O
when	O
combined	O
,	O
the	O
risk	O
stratification	O
was	O
better	O
than	O
for	O
each	O
variable	O
alone	O
(	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

By	O
Cox-proportional	O
hazard	O
risk	O
analysis	O
,	O
the	O
localisation	O
grouping	O
was	O
an	O
independent	O
predictor	O
for	O
the	O
both	O
.	O

In	O
patients	O
with	O
cardiac	O
sarcoidosis	O
,	O
both	O
fibrosis	O
mass	O
and	O
its	O
localisation	O
to	O
the	O
basal	O
anterior	O
/	O
anteroseptal	O
left	O
ventricle	O
,	O
or	O
right	O
ventricle	O
was	O
associated	O
with	O
the	O
development	O
of	O
major	O
adverse	O
cardiac	O
events	O
or	O
ventricular	O
tachyarrhythmias	O
.	O

Cardiac	B-P
MR	I-P
with	O
late	O
gadolinium	O
enhancement	O
may	O
be	O
useful	O
for	O
improving	O
risk	O
stratification	O
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
.	O

A	O
Retrospective	O
Review	O
of	O
Forensic	O
Odontology	O
Reports	O
Written	O
by	O
the	O
Joint	O
POW/MIA	O
Accounting	O
Command	O
Central	O
Identification	O
Laboratory	O
for	O
Remains	O
Identified	O
from	O
the	O
Korean	O
War	O
.	O

As	O
of	O
August	O
2014	O
,	O
the	O
Joint	O
POW/MIA	O
Accounting	O
Command	O
has	O
identified	O
the	O
remains	O
of	O
1980	O
previously	O
unknown	O
U.S.	O
service	O
members	O
;	O
280	O
were	O
from	O
the	O
Korean	O
War	O
.	O

To	O
determine	O
the	O
accuracy	O
and	O
completeness	O
of	O
the	O
available	O
antemortem	O
(	O
AM	O
)	O
dental	O
records	O
,	O
a	O
review	O
of	O
the	O
AM	O
/	O
postmortem	O
(	O
AM	O
/	O
PM	O
)	O
dental	O
record	O
comparisons	O
from	O
233	O
Forensic	O
Odontology	O
Reports	O
written	O
in	O
support	O
of	O
remains	O
identified	O
from	O
the	O
Korean	O
War	O
was	O
performed	O
.	O

Seventy-two	O
AM	O
/	O
PM	O
comparisons	O
resulted	O
in	O
exact	O
dental	O
chartings	O
while	O
161	O
contained	O
discrepancies	O
which	O
were	O
explainable	O
.	O

Explainable	O
discrepancies	O
include	O
undocumented	O
treatment	B-P
(	O
103	O
)	O
,	O
incorrectly	O
charted	O
third	O
molars	O
as	O
missing	O
(	O
82	O
)	O
,	O
differing	O
opinions	O
of	O
specific	O
molars	O
present	O
/	O
missing	O
(	O
20	O
)	O
,	O
and	O
erroneous	O
treatment	B-P
documentation	O
and/or	O
misidentification	O
of	O
teeth	O
present	O
/	O
missing	O
(	O
22	O
,	O
other	O
than	O
molars	O
)	O
.	O

Reassessment	O
has	O
revealed	O
varying	O
levels	O
of	O
completeness	O
for	O
our	O
available	O
AM	O
dental	O
records	O
,	O
the	O
need	O
to	O
thoroughly	O
review	O
our	O
computerized	O
comparisons	O
,	O
adjust	O
our	O
comparisons	O
to	O
include	O
molar	O
pattern	O
variations	O
/	O
third	O
molars	O
,	O
and	O
updating	O
our	O
database	O
comparison	O
program	O
.	O

The	O
effect	O
of	O
total	B-P
hip	I-P
arthroplasty	I-P
on	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
and	O
low	O
back	O
pain	O
in	O
patients	O
with	O
severe	O
hip	O
osteoarthritis	O
.	O

Sagittal	O
spinopelvic	O
malalignment	O
has	O
been	O
reported	O
in	O
spinal	O
disorders	O
such	O
as	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
,	O
and	O
restoration	O
of	O
normal	O
alignment	O
is	O
targeted	O
when	O
treating	B-P
these	O
disorders	O
.	O

Abnormal	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
has	O
been	O
reported	O
in	O
patients	O
with	O
severe	O
hip	O
osteoarthritis	O
(	O
OA	O
)	O
,	O
who	O
have	O
a	O
high	O
prevalence	O
of	O
associated	O
LBP	O
.	O

This	O
prospective	O
longitudinal	O
study	O
aimed	O
to	O
investigate	O
changes	O
in	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
after	O
total	B-P
hip	I-P
arthroplasty	I-P
(	O
THA	B-P
)	O
in	O
patients	O
with	O
severe	O
hip	O
OA	O
,	O
and	O
whether	O
these	O
changes	O
contribute	O
to	O
LBP	O
relief	O
.	O

Patients	O
undergoing	O
primary	O
THA	B-P
due	O
to	O
severe	O
unilateral	O
hip	O
OA	O
were	O
recruited	O
.	O

Physical	O
examination	O
and	O
X-ray	O
films	O
were	O
taken	O
to	O
rule	O
out	O
any	O
spinal	O
disorder	O
.	O

Sagittal	O
alignment	O
of	O
pelvis	O
,	O
hip	O
,	O
and	O
spine	O
was	O
analyzed	O
on	O
lateral	B-P
radiographs	I-P
taken	O
before	O
(	O
baseline	O
)	O
and	O
1	O
year	O
after	O
(	O
follow-up	O
)	O
THA	B-P
.	O

Functional	O
instruments	O
were	O
completed	O
by	O
patients	O
including	O
:	O
visual	B-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
LBP	O
,	O
Roland-Morris	O
Disability	O
Questionnaire	O
(	O
RMDQ	O
)	O
,	O
and	O
Harris	O
Hip	O
Score	O
(	O
HHS	O
)	O
.	O

Comparisons	O
were	O
carried	O
out	O
at	O
baseline	O
and	O
follow-up	O
,	O
and	O
between	O
patients	O
with	O
and	O
without	O
LBP	O
.	O

The	O
recruited	O
69	O
patients	O
showed	O
significantly	O
reduced	O
hip	O
flexion	O
and	O
improved	O
global	O
spinal	O
balance	O
at	O
follow-up	O
compared	O
with	O
baseline	O
.	O

LBP	O
was	O
reported	O
by	O
39	O
patients	O
(	O
56.5	O
%	O
)	O
before	O
surgery	O
;	O
at	O
follow-up	O
,	O
17	O
reported	O
complete	O
resolution	O
,	O
while	O
22	O
reported	O
significant	O
relief	O
.	O

Significant	O
decreases	O
in	O
VAS	O
and	O
RMDQ	O
scores	O
in	O
lumbar	O
spine	O
and	O
increase	O
in	O
hip	O
HHS	O
were	O
observed	O
.	O

THA	B-P
in	O
patients	O
with	O
severe	O
hip	O
OA	O
could	O
help	O
correct	O
abnormal	O
sagittal	O
spinal	O
-	O
pelvic-leg	O
alignment	O
and	O
relieve	O
comorbid	O
LBP	O
.	O

Improvements	O
in	O
hip	O
flexion	O
and	O
global	O
spinal	O
balance	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
LBP	O
relief	O
.	O

Targeting	O
HIF2	O
in	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
.	O

Inactivation	O
of	O
the	O
von	O
Hippel-Lindau	O
tumor-suppressor	O
protein	O
(	O
pVHL	O
)	O
is	O
the	O
signature	O
``	O
truncal	O
''	O
event	O
in	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
,	O
which	O
is	O
the	O
most	O
common	O
form	O
of	O
kidney	O
cancer	O
.	O

pVHL	O
is	O
part	O
of	O
a	O
ubiquitin	O
ligase	O
the	O
targets	O
the	O
α	O
subunit	O
of	O
the	O
hypoxia-inducible	O
factor	O
(	O
HIF	O
)	O
transcription	O
factor	O
for	O
destruction	O
when	O
oxygen	O
is	O
available	O
.	O

Preclinical	O
studies	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
HIF	O
,	O
and	O
particularly	O
HIF2	O
,	O
drives	O
pVHL	O
-defective	O
renal	O
carcinogenesis	O
.	O

Although	O
HIF2α	O
was	O
classically	O
considered	O
undruggable	O
,	O
structural	O
and	O
chemical	O
work	O
by	O
Rick	O
Bruick	O
and	O
Kevin	O
Gardner	O
at	O
University	O
of	O
Texas	O
Southwestern	O
laid	O
the	O
foundation	O
for	O
the	O
development	O
of	O
small	O
molecule	O
direct	O
HIF2α	O
antagonists	O
(	O
PT2385	O
and	O
the	O
related	O
tool	O
compound	O
PT2399	O
)	O
by	O
Peloton	O
Therapeutics	O
that	O
block	O
the	O
dimerization	O
of	O
HIF2α	O
with	O
its	O
partner	O
protein	O
ARNT1	O
.	O

These	O
compounds	O
inhibit	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
growth	O
in	O
preclinical	O
models	O
,	O
and	O
PT2385	O
has	O
now	O
entered	O
the	O
clinic	O
.	O

Nonetheless	O
,	O
the	O
availability	O
of	O
such	O
compounds	O
,	O
together	O
with	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeat	O
(	O
CRISPR	O
)	O
-based	O
gene	O
editing	O
approaches	O
,	O
has	O
revealed	O
a	O
previously	O
unappreciated	O
heterogeneity	O
among	O
clear	O
cell	O
renal	O
carcinomas	O
and	O
patient	O
-derived	O
xenografts	B-P
with	O
respect	O
to	O
HIF2	O
dependence	O
,	O
suggesting	O
that	O
predictive	O
biomarkers	O
will	O
be	O
needed	O
to	O
optimize	O
the	O
use	O
of	O
such	O
agents	O
in	O
the	O
clinic	O
.	O

The	O
role	O
of	O
sub-hippocampal	O
versus	O
hippocampal	O
regions	O
in	O
bitemporal	O
lobe	O
epilepsies	O
.	O

We	O
aimed	O
at	O
better	O
delineating	O
the	O
functional	O
anatomical	O
organization	O
of	O
bitemporal	O
lobe	O
epilepsy	O
.	O

We	O
studied	O
the	O
epileptogenic	O
zone	O
(	O
EZ	O
)	O
by	O
quantifying	O
the	O
epileptogenicity	O
of	O
brain	O
structures	O
explored	O
by	O
depth	O
electrodes	O
in	O
patients	O
investigated	O
by	O
stereoelectroencephalography	B-P
(	O
SEEG	B-P
)	O
.	O

We	O
compared	O
15	O
patients	O
with	O
bilateral	O
mesial	O
temporal	O
lobe	O
epilepsy	O
(	O
BTLE	O
)	O
and	O
15	O
patients	O
with	O
unilateral	O
mesial	O
temporal	O
lobe	O
epilepsy	O
(	O
UTLE	O
)	O
.	O

This	O
quantification	O
was	O
performed	O
using	O
the	O
'	O
Epileptogenicity	O
Index	O
'	O
(	O
EI	O
)	O
.	O

Age	O
at	O
epilepsy	O
onset	O
,	O
and	O
epilepsy	O
duration	O
,	O
were	O
not	O
statistically	O
different	O
in	O
both	O
groups	O
.	O

UTLE	O
patients	O
more	O
frequently	O
displayed	O
maximal	O
epileptogenicity	O
in	O
hippocampal	O
structures	O
,	O
whereas	O
BTLE	O
patients	O
had	O
maximal	O
values	O
in	O
subhippocampal	O
areas	O
(	O
entorhinal	O
cortex	O
,	O
temporal	O
pole	O
,	O
parahippocampal	O
cortex	O
)	O
.	O

Our	O
results	O
suggest	O
different	O
organization	O
of	O
the	O
EZ	O
in	O
the	O
two	O
groups	O
.	O

BTLE	O
was	O
associated	O
with	O
more	O
involvement	O
of	O
subhippocampal	O
regions	O
,	O
a	O
result	O
in	O
agreement	O
with	O
known	O
anatomical	O
connections	O
between	O
the	O
two	O
temporal	O
lobes	O
.	O

The	O
cancer	O
Warburg	O
effect	O
may	O
be	O
a	O
testable	O
example	O
of	O
the	O
minimum	O
entropy	O
production	O
rate	O
principle	O
.	O

Cancer	O
cells	O
consume	O
more	O
glucose	O
by	O
glycolytic	O
fermentation	O
to	O
lactate	O
than	O
by	O
respiration	O
,	O
a	O
characteristic	O
known	O
as	O
the	O
Warburg	O
effect	O
.	O

In	O
contrast	O
with	O
the	O
34	O
moles	O
of	O
ATP	O
produced	O
by	O
respiration	O
,	O
fermentation	O
produces	O
two	O
moles	O
of	O
ATP	O
per	O
mole	O
of	O
glucose	O
consumed	O
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	O
of	O
the	O
Warburg	O
effect	O
.	O

Productions	O
of	O
free	O
energy	O
(	O
ΔG	O
)	O
,	O
enthalpy	O
(	O
ΔH	O
)	O
and	O
entropy	O
(	O
ΔS	O
)	O
per	O
mole	O
linearly	O
vary	O
with	O
the	O
fraction	O
(	O
x	O
)	O
of	O
glucose	O
consumed	O
by	O
fermentation	O
that	O
is	O
frequently	O
estimated	O
around	O
0.9	O
.	O

Hence	O
,	O
calculation	O
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	O
respiration	O
,	O
the	O
predominant	O
fermentative	O
metabolism	O
decreases	O
around	O
10	O
%	O
the	O
production	O
of	O
entropy	O
per	O
mole	O
of	O
glucose	O
consumed	O
in	O
cancer	O
cells	O
.	O

We	O
hypothesize	O
that	O
increased	O
fermentation	O
could	O
allow	O
cancer	O
cells	O
to	O
accomplish	O
the	O
Prigogine	O
theorem	O
of	O
the	O
trend	O
to	O
minimize	O
the	O
rate	O
of	O
production	O
of	O
entropy	O
.	O

According	O
the	O
theorem	O
,	O
open	O
cellular	O
systems	O
near	O
the	O
steady	O
state	O
could	O
evolve	O
to	O
minimize	O
the	O
rates	O
of	O
entropy	O
production	O
that	O
may	O
be	O
reached	O
by	O
modified	O
replicating	O
cells	O
producing	O
entropy	O
at	O
low	O
rate	O
.	O

Remarkably	O
,	O
at	O
CO2	O
concentrations	O
above	O
930	O
ppm	O
,	O
glucose	O
respiration	O
produces	O
less	O
entropy	O
than	O
fermentation	O
,	O
which	O
suggests	O
experimental	O
tests	B-P
to	O
validate	O
the	O
hypothesis	O
of	O
minimization	O
of	O
the	O
rate	O
of	O
entropy	O
production	O
through	O
the	O
Warburg	O
effect	O
.	O

Evaluation	O
and	O
Treatment	O
of	O
Anemia	O
in	O
Premature	O
Infants	O
.	O

Anemia	O
in	O
preterm	O
infants	O
is	O
the	O
pathophysiological	O
process	O
with	O
greater	O
and	O
more	O
rapid	O
decline	O
in	O
hemoglobin	O
compared	O
to	O
the	O
physiological	O
anemia	O
in	O
infants	O
.	O

There	O
is	O
a	O
need	O
for	O
transfusions	B-P
and	O
administration	B-P
of	O
human	O
recombinant	O
erythropoietin	O
.	O

To	O
determine	O
the	O
frequency	O
of	O
anemia	O
in	O
premature	O
infants	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
University	O
Clinical	O
Center	O
Sarajevo	O
,	O
as	O
well	O
as	O
parameter	O
values	O
in	O
the	O
blood	B-P
count	I-P
of	O
premature	O
infants	O
and	O
to	O
explore	O
a	O
relationship	O
between	O
blood	B-P
transfusions	I-P
with	O
the	O
advent	O
of	O
intraventricular	O
hemorrhage	O
(	O
determine	O
treatment	O
outcome	O
in	O
preterm	O
infants	O
)	O
.	O

Research	O
is	O
retrospective	O
study	O
and	O
it	O
included	O
the	O
period	O
of	O
six	O
months	O
in	O
year	O
2014	O
.	O

Research	O
included	O
100	O
patients	O
,	O
gestational	O
age	O
<	O
37	O
weeks	O
(	O
premature	O
infants	O
)	O
.	O

Data	O
were	O
collected	O
by	O
examining	O
the	O
medical	O
records	O
of	O
patients	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
UCCS	O
.	O

The	O
first	O
group	O
of	O
patients	O
were	O
premature	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
(	O
62/100	O
)	O
and	O
the	O
second	O
group	O
were	O
premature	O
infants	O
of	O
gestational	O
age	O
33-37	O
weeks	O
(	O
38/100	O
)	O
.	O

Among	O
the	O
patients	O
,	O
5	O
%	O
were	O
boys	O
and	O
46	O
%	O
girls	O
.	O

There	O
was	O
significant	O
difference	O
in	O
birth	O
weight	O
and	O
APGAR	O
score	O
among	O
the	O
groups	O
.	O

In	O
the	O
first	O
group	O
,	O
there	O
were	O
27.42	O
%	O
of	O
deaths	O
,	O
while	O
in	O
the	O
second	O
group	O
,	O
there	O
were	O
only	O
10.53	O
%	O
of	O
deaths	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
length	O
of	O
treatment	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
need	O
for	O
transfusion	B-P
among	O
the	O
groups	O
.	O

18	O
patients	O
in	O
the	O
first	O
group	O
required	O
a	O
transfusion	B-P
,	O
while	O
in	O
the	O
second	O
group	O
only	O
3	O
patients	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
are	O
likely	O
candidates	O
for	O
blood	B-P
transfusion	I-P
during	O
treatment	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
have	O
the	O
risk	O
of	O
intracranial	O
bleeding	O
associated	O
with	O
the	O
application	O
of	O
blood	B-P
transfusion	I-P
in	O
the	O
first	O
week	O
of	O
life	O
.	O

Sensitive	O
fluorescent	O
detection	O
of	O
DNA	O
methyltransferase	O
using	O
nicking	O
endonuclease	O
-mediated	O
multiple	O
primers	O
-like	O
rolling	O
circle	O
amplification	O
.	O

Sensitive	O
and	O
reliable	O
detection	O
of	O
DNA	O
methyltransferase	O
(	O
MTase	O
)	O
is	O
of	O
great	O
significance	O
for	O
both	O
early	O
tumor	O
diagnosis	O
and	O
therapy	B-P
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
,	O
label	O
-free	O
and	O
sensitive	O
DNA	O
MTase	O
-	O
sensing	B-P
method	I-P
was	O
developed	O
on	O
the	O
basis	O
of	O
a	O
nicking	O
endonuclease	O
-mediated	O
multiple	O
primers	O
-like	O
rolling	O
circle	O
amplification	O
(	O
RCA	O
)	O
strategy	B-P
.	O

In	O
this	O
method	B-P
,	O
a	O
dumbbell	O
RCA	O
template	O
was	O
prepared	O
by	O
blunt-end	O
ligation	O
of	O
two	O
molecules	O
of	O
hairpin	O
DNA	O
.	O

In	O
addition	O
to	O
the	O
primer	O
-	O
binding	O
sequence	O
,	O
the	O
dumbbell	O
template	O
contained	O
another	O
three	O
important	O
parts	O
:	O
5'-CCGG-3	O
'	O
sequences	O
in	O
double-stranded	O
stems	O
,	O
nicking	O
endonuclease	O
recognition	O
sites	O
and	O
C-rich	O
sequences	O
in	O
single-stranded	O
loops	O
.	O

The	O
introduction	O
of	O
5'-CCGG-3	O
'	O
sequences	O
allows	O
the	O
dumbbell	O
template	O
to	O
be	O
destroyed	O
by	O
the	O
restriction	O
endonuclease	O
,	O
HpaII	O
,	O
but	O
is	O
not	O
destroyed	O
in	O
the	O
presence	O
of	O
the	O
target	O
MTase	O
-	O
M.SssI	O
MTase	O
.	O

The	O
introduction	O
of	O
nicking	O
endonuclease	O
recognition	O
sites	O
makes	O
the	O
M.SssI	O
MTase	O
-protected	O
dumbbell	O
template	O
-mediated	O
RCA	O
proceed	O
in	O
a	O
multiple	O
primers	O
-like	O
exponential	O
mode	O
,	O
thus	O
providing	O
the	O
RCA	O
with	O
high	O
amplification	O
efficiency	O
.	O

The	O
introduction	O
of	O
C-rich	O
sequences	O
may	O
promote	O
the	O
folding	O
of	O
amplification	O
products	O
into	O
a	O
G-quadruplex	O
structure	O
,	O
which	O
is	O
specifically	O
recognized	O
by	O
the	O
commercially	O
available	O
fluorescent	O
probe	O
thioflavin	O
T.	O
Improved	O
RCA	O
amplification	O
efficiency	O
and	O
specific	O
fluorescent	O
recognition	O
of	O
RCA	O
products	O
provide	O
the	O
M.SssI	O
MTase	O
-	O
sensing	B-P
platform	O
with	O
high	O
sensitivity	O
.	O

When	O
a	O
dumbbell	O
template	O
containing	O
four	O
nicking	O
endonuclease	O
sites	O
is	O
used	O
,	O
highly	O
specific	O
M.SssI	O
MTase	O
activity	O
detection	O
can	O
be	O
achieved	O
in	O
the	O
range	O
of	O
0.008-50U/mL	O
with	O
a	O
detection	O
limit	O
as	O
low	O
as	O
0.0011U/mL	O
.	O

Simple	O
experimental	B-P
operation	I-P
and	O
mix-and-detection	O
fluorescent	O
sensing	O
mode	O
ensures	O
that	O
M.SssI	O
MTase	O
quantitation	O
works	O
well	O
in	O
a	O
real-time	O
RCA	O
mode	O
,	O
thus	O
further	O
simplifying	O
the	O
sensing	O
performance	O
and	O
making	O
high	O
throughput	O
detection	O
possible	O
.	O

The	O
proposed	O
MTase	O
-	O
sensing	B-P
strategy	I-P
was	O
also	O
demonstrated	O
to	O
be	O
applicable	O
for	O
screening	O
and	O
evaluating	O
the	O
inhibitory	O
activity	O
of	O
MTase	O
inhibitors	O
.	O

Narcolepsy	O
Following	O
Yellow	B-P
Fever	I-P
Vaccination	I-P
:	O
A	O
Case	O
Report	O
.	O

Narcolepsy	O
with	O
cataplexy	O
is	O
a	O
rare	O
,	O
but	O
important	O
differential	B-P
diagnosis	I-P
for	O
daytime	O
sleepiness	O
and	O
atonic	O
paroxysms	O
in	O
an	O
adolescent	O
.	O

A	O
recent	O
increase	O
in	O
incidence	O
in	O
the	O
pediatric	O
age	O
group	O
probably	O
linked	O
to	O
the	O
use	O
of	O
the	O
Pandemrix	O
influenza	O
vaccine	O
in	O
2009	O
,	O
has	O
increased	O
awareness	O
that	O
different	O
environmental	O
factors	O
can	O
``	O
trigger	O
''	O
narcolepsy	O
with	O
cataplexy	O
in	O
a	O
genetically	O
susceptible	O
population	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
13-year-old	O
boy	O
with	O
narcolepsy	O
following	O
yellow	B-P
fever	I-P
vaccination	I-P
.	O

He	O
carries	O
the	O
HLA	O
DQB1*0602	O
haplotype	O
strongly	O
associated	O
with	O
narcolepsy	O
and	O
cataplexy	O
.	O

Polysomnography	B-P
showed	O
rapid	O
sleep	O
onset	O
with	O
rapid	O
eye	O
movement	O
(	O
REM	O
)	O
latency	O
of	O
47	O
min	O
,	O
significant	O
sleep	O
fragmentation	O
and	O
a	O
mean	O
sleep	O
latency	O
of	O
1.6	O
min	O
with	O
sleep	O
onset	O
REM	O
in	O
four	O
out	O
of	O
four	O
nap	O
periods	O
.	O

Together	O
with	O
the	O
clinical	O
history	O
,	O
these	O
findings	O
are	O
diagnostic	O
of	O
narcolepsy	O
type	O
1	O
.	O

The	O
envelope	O
protein	O
E	O
of	O
the	O
yellow	O
fever	O
vaccine	O
strain	O
17D	O
has	O
significant	O
amino	O
acid	O
sequence	O
overlap	O
with	O
both	O
hypocretin	O
and	O
the	O
hypocretin	O
receptor	O
2	O
receptors	O
in	O
protein	O
regions	O
that	O
are	O
predicted	O
to	O
act	O
as	O
epitopes	O
for	O
antibody	O
production	O
.	O

These	O
findings	O
raise	O
the	O
question	O
whether	O
the	O
yellow	O
fever	O
vaccine	O
strain	O
may	O
,	O
through	O
a	O
potential	O
molecular	O
mimicry	O
mechanism	O
,	O
be	O
another	O
infectious	O
trigger	O
for	O
this	O
neuro-immunological	O
disorder	O
.	O

Lettuce	O
and	O
fruits	O
as	O
a	O
source	O
of	O
multidrug	O
resistant	O
Acinetobacter	O
spp	O
.	O

The	O
role	O
of	O
ready-to-eat	O
products	O
as	O
a	O
reservoir	O
of	O
pathogenic	O
species	O
of	O
Acinetobacter	O
remains	O
unclear	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
presence	O
of	O
Acinetobacter	O
species	O
in	O
lettuces	O
and	O
fruits	O
marketed	O
in	O
Portugal	O
,	O
and	O
their	O
susceptibility	O
to	O
antimicrobials	O
.	O

Acinetobacter	O
spp	O
.	O

were	O
isolated	O
from	O
77.9	O
%	O
of	O
the	O
samples	O
and	O
these	O
microorganisms	O
were	O
also	O
found	O
as	O
endophytes	O
(	O
i.e	O
.	O

present	O
within	O
the	O
plant	O
tissue	O
)	O
in	O
12	O
of	O
20	O
samples	O
of	O
lettuces	O
analysed	O
.	O

Among	O
253	O
isolates	O
that	O
were	O
identified	O
as	O
belonging	O
to	O
this	O
genus	O
,	O
181	O
presented	O
different	O
PFGE	B-P
profiles	O
,	O
representing	O
different	O
strains	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
the	O
partial	O
sequence	O
of	O
rpoB	O
,	O
175	O
strains	O
were	O
identified	O
as	O
members	O
of	O
eighteen	O
distinct	O
species	O
and	O
the	O
remaining	O
six	O
strains	O
may	O
represent	O
five	O
new	O
candidate	O
species	O
since	O
their	O
rpoB	O
sequence	O
similarities	O
with	O
type	O
strains	O
were	O
less	O
than	O
95	O
%	O
.	O

Acinetobacter	O
calcoaceticus	O
and	O
Acinetobacter	O
johnsonii	O
were	O
the	O
most	O
common	O
species	O
,	O
both	O
with	O
the	O
frequency	O
of	O
26.5	O
%	O
;	O
and	O
11	O
%	O
of	O
the	O
strains	O
belong	O
to	O
the	O
Acinetobacter	O
baumannii	O
group	O
(	O
i.e	O
.	O

A.	O
baumannii	O
,	O
Acinetobacter	O
pittii	O
,	O
Acinetobacter	O
seifertii	O
and	O
Acinetobacter	O
nosocomialis	O
)	O
,	O
which	O
is	O
most	O
frequently	O
associated	O
with	O
nosocomial	O
infections	O
.	O

Overall	O
,	O
the	O
strains	O
were	O
least	O
susceptible	O
to	O
piperacillin	O
(	O
80.1	O
%	O
)	O
,	O
piperacillin-tazobactam	O
(	O
64.1	O
%	O
)	O
,	O
ceftazidime	O
(	O
43.1	O
%	O
)	O
,	O
ciprofloxacin	O
(	O
16.6	O
%	O
)	O
,	O
trimethoprim-sulfamethoxazole	O
(	O
14.9	O
%	O
)	O
,	O
imipenem	O
(	O
14.4	O
%	O
)	O
and	O
colistin	O
(	O
13.3	O
%	O
)	O
.	O

The	O
most	O
active	O
antimicrobials	O
were	O
minocycline	O
and	O
tetracycline	O
,	O
with	O
0.6	O
%	O
and	O
3.9	O
%	O
of	O
strains	O
resistant	O
,	O
respectively	O
.	O

About	O
29.8	O
%	O
of	O
the	O
strains	O
were	O
classified	O
as	O
multidrug-resistant	O
(	O
MDR	O
)	O
,	O
4.4	O
%	O
as	O
extensively	O
drug-resistant	O
(	O
XDR	O
)	O
and	O
the	O
prevalence	O
of	O
MDR	O
strains	O
within	O
the	O
A.	O
baumannii	O
group	O
(	O
25	O
%	O
)	O
was	O
similar	O
to	O
other	O
species	O
(	O
30.4	O
%	O
)	O
.	O

The	O
presence	O
of	O
clinically	O
important	O
species	O
as	O
well	O
as	O
MDR	O
strains	O
in	O
lettuces	O
and	O
fruits	O
may	O
be	O
a	O
threat	O
to	O
public	O
health	O
considering	O
that	O
they	O
may	O
transmit	O
these	O
pathogens	O
to	O
environments	O
such	O
as	O
the	O
community	O
and	O
hospital	O
settings	O
.	O

Depot	O
Dependent	O
Effects	O
of	O
Dexamethasone	O
on	O
Gene	O
Expression	O
in	O
Human	O
Omental	O
and	O
Abdominal	O
Subcutaneous	O
Adipose	O
Tissues	O
from	O
Obese	O
Women	O
.	O

Glucocorticoids	O
promote	O
fat	O
accumulation	O
in	O
visceral	O
compared	O
to	O
subcutaneous	O
depots	O
,	O
but	O
the	O
molecular	O
mechanisms	O
involved	O
remain	O
poorly	O
understood	O
.	O

To	O
identify	O
long-term	O
changes	O
in	O
gene	O
expression	O
that	O
are	O
differentially	O
sensitive	O
or	O
responsive	O
to	O
glucocorticoids	O
in	O
these	O
depots	O
,	O
paired	O
samples	O
of	O
human	O
omental	O
(	O
Om	O
)	O
and	O
abdominal	O
subcutaneous	O
(	O
Abdsc	O
)	O
adipose	O
tissues	O
obtained	O
from	O
obese	O
women	O
during	O
elective	B-P
surgery	I-P
were	O
cultured	B-P
with	O
the	O
glucocorticoid	O
receptor	O
agonist	O
dexamethasone	O
(	O
Dex	O
,	O
0	O
,	O
1	O
,	O
10	O
,	O
25	O
and	O
1000	O
nM	O
)	O
for	O
7	O
days	O
.	O

Dex	O
regulated	O
32	O
%	O
of	O
the	O
19,741	O
genes	O
on	O
the	O
array	O
,	O
while	O
53	O
%	O
differed	O
by	O
Depot	O
and	O
2.5	O
%	O
exhibited	O
a	O
Depot	O
*	O
Dex	O
concentration	O
interaction	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
showed	O
Dex	O
regulation	O
of	O
the	O
expected	O
metabolic	O
and	O
inflammatory	O
pathways	O
in	O
both	O
depots	O
.	O

Cluster	O
analysis	O
of	O
the	O
460	O
transcripts	O
that	O
exhibited	O
an	O
interaction	O
of	O
Depot	O
and	O
Dex	O
concentration	O
revealed	O
sets	O
of	O
mRNAs	O
for	O
which	O
the	O
responses	O
to	O
Dex	O
differed	O
in	O
magnitude	O
,	O
sensitivity	O
or	O
direction	O
between	O
the	O
two	O
depots	O
as	O
well	O
as	O
mRNAs	O
that	O
responded	O
to	O
Dex	O
only	O
in	O
one	O
depot	O
.	O

These	O
transcripts	O
were	O
also	O
clearly	O
depot	O
different	O
in	O
fresh	O
adipose	O
tissue	O
and	O
are	O
implicated	O
in	O
processes	O
that	O
could	O
affect	O
adipose	O
tissue	O
distribution	O
or	O
functions	O
(	O
e.g	O
.	O

adipogenesis	O
,	O
triacylglycerol	O
synthesis	O
and	O
storage	O
,	O
insulin	O
action	O
)	O
.	O

Elucidation	O
of	O
the	O
mechanisms	O
underlying	O
the	O
depot	O
differences	O
in	O
the	O
effect	O
of	O
Dex	O
on	O
the	O
expression	O
of	O
specific	O
genes	O
and	O
pathways	O
that	O
regulate	O
adipose	O
function	O
may	O
offer	O
novel	O
insights	O
into	O
understanding	O
the	O
biology	O
of	O
visceral	O
adipose	O
tissues	O
and	O
their	O
links	O
to	O
metabolic	O
health	O
.	O

Beneficial	O
Effects	O
on	O
Pregnancy	O
Outcomes	O
of	O
Thyroid	B-P
Hormone	I-P
Replacement	I-P
for	O
Subclinical	O
Hypothyroidism	O
.	O

Background	O
.	O

Hypothyroidism	O
and	O
raised	O
thyroid	O
antibody	O
levels	O
have	O
been	O
associated	O
with	O
adverse	O
obstetrical	O
outcomes	O
.	O

Several	O
studies	O
have	O
investigated	O
causal	O
associations	O
,	O
but	O
results	O
have	O
been	O
inconsistent	O
and	O
few	O
studies	O
have	O
reported	O
the	O
effects	O
of	O
thyroxine	B-P
replacement	I-P
therapy	I-P
on	O
pregnancy	O
outcomes	O
in	O
hypothyroid	O
patients	O
.	O

Objective	O
.	O

The	O
primary	O
study	O
objective	O
was	O
to	O
determine	O
the	O
outcome	O
of	O
pregnancies	O
in	O
women	O
diagnosed	O
with	O
overt	O
and	O
subclinical	O
hypothyroidism	O
(	O
SCH	O
)	O
(	O
serum	B-P
TSH	I-P
>	O
2.5	O
mIU/L	O
)	O
and	O
those	O
with	O
elevated	O
circulating	O
thyroid	O
autoantibody	O
levels	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
after	O
the	O
institution	O
of	O
appropriate	O
thyroxine	B-P
replacement	I-P
therapy	I-P
to	O
maintain	O
the	O
serum	B-P
TSH	I-P
≤	O
2.5	O
mIU/L	O
.	O

Study	O
Design	O
.	O

This	O
prospective	O
observational	O
study	O
was	O
undertaken	O
between	O
2013	O
and	O
2016	O
.	O

Blood	O
samples	O
were	O
taken	O
from	O
1025	O
women	O
at	O
presentation	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
,	O
anti-thyroglobulin	O
antibodies	O
(	O
TGAb	O
)	O
,	O
and	O
thyroid	O
peroxidase	O
antibodies	O
(	O
TPOAb	O
)	O
.	O

Those	O
with	O
a	O
TSH	O
>	O
2.5	O
mIU/L	O
were	O
treated	B-P
with	I-P
thyroxine	O
and	O
managed	O
appropriately	O
to	O
ensure	O
that	O
the	O
TSH	O
was	O
maintained	O
≤2.5	O
mIU/L	O
.	O

Outcomes	O
in	O
these	O
patients	O
were	O
compared	O
to	O
those	O
in	O
euthyroid	O
patients	O
.	O

Maternal	O
antenatal	O
complications	O
and	O
perinatal	O
outcomes	O
were	O
recorded	O
.	O

Results	O
.	O

There	O
were	O
a	O
total	O
of	O
1025	O
patients	O
of	O
whom	O
382	O
(	O
37.5	O
%	O
)	O
were	O
nulliparous	O
.	O

10.1	O
%	O
had	O
a	O
TSH	O
level	O
>	O
2.5	O
mIU/L	O
and	O
18.2	O
%	O
had	O
at	O
least	O
one	O
raised	O
thyroid	O
antibody	O
level	O
.	O

No	O
differences	O
in	O
adverse	O
outcomes	O
of	O
pregnancy	O
were	O
evident	O
in	O
women	O
treated	O
for	O
SCH	O
or	O
overt	O
hypothyroidism	O
compared	O
to	O
the	O
euthyroid	O
group	O
.	O

There	O
was	O
also	O
no	O
association	O
between	O
raised	O
thyroid	O
antibodies	O
and	O
adverse	O
pregnancy	O
outcomes	O
in	O
either	O
group	O
.	O

Conclusion	O
.	O

There	O
were	O
no	O
adverse	O
outcomes	O
of	O
pregnancy	O
found	O
in	O
pregnant	O
women	O
who	O
had	O
been	O
diagnosed	O
and	O
treated	B-P
with	I-P
thyroxine	O
for	O
SCH	O
at	O
the	O
time	O
of	O
presentation	O
when	O
compared	O
to	O
euthyroid	O
patients	O
.	O

There	O
was	O
also	O
no	O
relationship	O
with	O
thyroid	O
antibodies	O
and	O
adverse	O
pregnancy	O
outcomes	O
in	O
the	O
two	O
groups	O
.	O

It	O
is	O
not	O
possible	O
to	O
unequivocally	O
advocate	O
for	O
thyroxine	O
replacement	O
in	O
pregnant	O
women	O
with	O
subclinical	O
and	O
overt	O
hypothyroidism	O
until	O
large	O
scale	O
randomized	O
controlled	O
trials	O
are	O
performed	O
.	O

Urachal	O
carcinoma	O
:	O
Report	O
of	O
two	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

Urachal	O
carcinoma	O
is	O
a	O
rare	O
tumor	O
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	O
and	O
less	O
often	O
in	O
the	O
adnexal	O
region	O
and	O
urinary	O
system	O
.	O

We	O
herein	O
present	O
two	O
cases	O
of	O
urachal	O
carcinoma	O
:	O
One	O
case	O
was	O
a	O
32-year-old	O
male	O
patient	O
who	O
presented	O
with	O
painless	O
hematuria	O
with	O
blood	O
clots	O
for	O
1	O
month	O
,	O
whereas	O
the	O
other	O
case	O
was	O
a	O
50-year-old	O
woman	O
who	O
presented	O
with	O
gross	O
hematuria	O
with	O
mild	O
dysuria	O
,	O
urgency	O
and	O
frequent	O
urination	O
for	O
1	O
year	O
.	O

Following	O
surgical	B-P
resection	I-P
,	O
the	O
two	O
patients	O
were	O
diagnosed	O
with	O
urachal	O
adenocarcinoma	O
(	O
mixed	O
type	O
)	O
and	O
urachal	O
mucinous	O
adenocarcinoma	O
,	O
respectively	O
,	O
based	O
on	O
the	O
histopathological	O
examination	O
.	O

A	O
review	O
of	O
previously	O
published	O
cases	O
and	O
relevant	O
literature	O
is	O
also	O
presented	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
help	O
understand	O
this	O
disease	O
better	O
,	O
in	O
order	O
to	O
reduce	O
the	O
rate	O
of	O
clinical	O
and	O
pathological	O
misdiagnosis	O
.	O

Long-term	O
survival	O
outcome	O
after	O
postoperative	O
recurrence	O
of	O
non-small-cell	O
lung	O
cancer	O
:	O
who	O
is	O
'	O
cured	O
'	O
from	O
postoperative	O
recurrence	O
?	O
.	O

Since	O
survival	O
after	O
postoperative	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
recurrence	O
is	O
extremely	O
poor	O
,	O
the	O
long-term	O
post	O
-	O
recurrence	O
outcomes	O
are	O
not	O
well	O
understood	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
long-term	O
post	O
-	O
recurrence	O
outcomes	O
and	O
clarify	O
who	O
are	O
possibly	O
'	O
cured	O
'	O
in	O
recent	O
clinical	O
practice	O
.	O

We	O
reviewed	O
the	O
medical	O
records	O
of	O
635	O
patients	O
who	O
developed	O
postoperative	O
recurrence	O
until	O
2012	O
after	O
R0	B-P
resection	I-P
for	O
pathological	O
Stage	O
IA-IIIA	O
NSCLC	O
between	O
1993	O
and	O
2006	O
.	O

Factors	O
associated	O
with	O
post	O
-	O
recurrence	O
surviva	O
l	O
(	O
PRS	O
)	O
and	O
the	O
characteristics	O
of	O
the	O
long-term	O
(	O
≥5	O
years	O
)	O
survivors	O
were	O
analysed	O
retrospectively	O
.	O

The	O
5-	O
year	O
PRS	O
rate	O
of	O
all	O
635	O
patients	O
was	O
13	O
%	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
female	O
[	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
0.78	O
]	O
,	O
adenocarcinoma	O
(	O
HR	O
=	O
0.77	O
)	O
,	O
locoregional	O
(	O
only	O
)	O
recurrence	O
(	O
HR	O
=	O
0.59	O
)	O
and	O
longer	O
recurrence	O
-free	O
survival	O
(	O
HR	O
=	O
0.99	O
)	O
were	O
favourably	O
associated	O
with	O
PRS	O
.	O

A	O
total	O
of	O
51	O
patients	O
achieved	O
5-	O
year	O
PRS	O
;	O
however	O
,	O
32	O
(	O
63	O
%	O
)	O
were	O
cancer	O
-bearing	O
patients	O
in	O
their	O
fifth	O
post-recurrent	O
year	O
who	O
were	O
mainly	O
treated	O
by	O
epidermal	O
growth	O
factor	O
receptor-tyrosine	O
kinase	O
inhibitor	O
(	O
EGFR-TKI	O
)	O
.	O

Subsequent	O
PRS	O
curves	O
for	O
cancer	O
-	O
controlled	O
and	O
cancer	O
-bearing	O
groups	O
were	O
different	O
(	O
8-	O
year	O
PRS	O
:	O
94	O
%	O
vs	O
31	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Among	O
19	O
cancer	O
-	O
controlled	O
patients	O
in	O
their	O
fifth	O
post-recurrent	O
year	O
,	O
17	O
(	O
89	O
%	O
)	O
patients	O
initially	O
received	O
radical	B-P
local	I-P
therapy	I-P
for	O
their	O
recurrence	O
.	O

Two-thirds	O
of	O
5-	O
year	O
survivors	O
after	O
postoperative	O
NSCLC	O
recurrence	O
had	O
a	O
cancer	O
-bearing	O
status	O
and	O
showed	O
deteriorated	O
subsequent	O
survival	O
.	O

Curability	O
of	O
postoperative	O
NSCLC	O
recurrence	O
should	O
be	O
evaluated	O
in	O
terms	O
of	O
the	O
'	O
cancer	O
-	O
controlled	O
'	O
status	O
,	O
and	O
'	O
cured	O
'	O
population	O
is	O
included	O
in	O
the	O
patients	O
who	O
are	O
'	O
cancer	O
controlled	O
'	O
at	O
the	O
fifth	O
post-recurrent	O
year	O
.	O

Does	O
training	O
of	O
fellows	O
affect	O
peri-operative	O
outcomes	O
of	O
robot-assisted	B-P
partial	I-P
nephrectomy	I-P
?	O
.	O

To	O
evaluate	O
the	O
impact	O
of	O
fellows	O
'	O
involvement	O
on	O
the	O
peri-operative	O
outcomes	O
of	O
robot-assisted	B-P
partial	I-P
nephrectomy	I-P
(	O
RAPN	B-P
)	O
.	O

We	O
analysed	O
216	O
patients	O
who	O
underwent	O
RAPN	B-P
for	O
a	O
small	O
renal	O
tumour	O
.	O

We	O
stratified	O
our	O
cohort	O
into	O
two	O
groups	O
according	O
to	O
the	O
involvement	O
of	O
a	O
fellow	O
surgeon	O
during	O
the	O
procedure	O
:	O
expert	O
surgeon	O
operating	B-P
alone	O
(	O
expert	O
group	O
)	O
and	O
fellow	O
operating	B-P
under	O
the	O
supervision	O
of	O
the	O
expert	O
surgeon	O
(	O
fellow	O
group	O
)	O
.	O

Peri-operative	O
data	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

Linear	O
and	O
logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
assess	O
the	O
impact	O
of	O
fellows	O
'	O
involvement	O
on	O
peri-operative	O
and	O
postoperative	O
outcomes	O
.	O

Trifecta	O
and	O
margins	O
ischaemia	O
complications	O
(	O
MIC	O
)	O
score	O
achievement	O
rates	O
were	O
used	O
to	O
assess	O
the	O
quality	O
of	O
surgery	B-P
in	O
both	O
the	O
expert	O
and	O
fellow	O
groups	O
.	O

Trifecta	O
was	O
defined	O
as	O
a	O
combination	O
of	O
warm	O
ischaemia	O
time	O
<	O
25	O
min	O
,	O
negative	O
surgical	O
margins	O
and	O
no	O
peri-operative	O
complications	O
.	O

MIC	O
score	O
was	O
defined	O
as	O
negative	O
surgical	O
margins	O
,	O
ischaemia	O
time	O
<	O
20	O
min	O
,	O
and	O
absence	O
of	O
complications	O
grade	O
≥3	O
.	O

Fellows	O
were	O
involved	O
in	O
a	O
total	O
of	O
89	O
procedures	O
(	O
41	O
%	O
)	O
.	O

Patients	O
'	O
characteristics	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Operating	B-P
time	O
and	O
warm	O
ischaemia	O
time	O
(	O
WIT	O
)	O
were	O
longer	O
in	O
the	O
fellow	O
group	O
(	O
180	O
vs	O
120	O
min	O
,	O
P	O
<	O
0.001	O
,	O
and	O
18	O
vs	O
14	O
min	O
,	O
P	O
=	O
0.002	O
,	O
respectively	O
)	O
.	O

Length	O
of	O
hospital	O
stay	O
(	O
LOS	O
)	O
was	O
longer	O
in	O
the	O
fellow	O
group	O
(	O
5	O
vs	O
4.3	O
days	O
;	O
P	O
=	O
0.05	O
)	O
and	O
patients	O
in	O
this	O
group	O
had	O
higher	O
estimated	O
blood	O
loss	O
(	O
EBL	O
;	O
400	O
vs	O
300	O
mL	O
;	O
P	O
=	O
0.01	O
)	O
,	O
but	O
this	O
had	O
no	O
impact	O
on	O
transfusion	B-P
rate	I-P
(	O
14	O
%	O
vs	O
11	O
%	O
;	O
P	O
=	O
0.43	O
)	O
.	O

Positive	O
surgical	O
margin	O
rates	O
were	O
similar	O
in	O
the	O
fellow	O
and	O
expert	O
groups	O
(	O
2.2	O
%	O
vs	O
3.1	O
%	O
;	O
P	O
=	O
0.70	O
)	O
.	O

Major	O
complications	O
were	O
more	O
frequent	O
in	O
the	O
fellow	O
group	O
(	O
12.3	O
%	O
vs	O
6.3	O
%	O
)	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
P	O
=	O
0.10	O
)	O
.	O

In	O
multivariable	O
analysis	O
,	O
fellow	O
involvement	O
was	O
predictive	O
of	O
longer	O
WIT	O
(	O
β	O
=	O
0.22	O
;	O
P	O
=	O
0.003	O
)	O
and	O
operating	B-P
time	O
(	O
β	O
=	O
0.49	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
was	O
not	O
associated	O
with	O
EBL	O
(	O
β	O
=	O
0.12	O
,	O
P	O
=	O
0.09	O
)	O
or	O
LOS	O
(	O
β	O
=	O
0.12	O
,	O
P	O
=	O
0.11	O
)	O
.	O

Finally	O
,	O
fellow	O
involvement	O
was	O
associated	O
with	O
a	O
lower	O
rate	O
of	O
trifecta	O
and	O
MIC	O
score	O
accomplishment	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.53	O
,	O
P	O
=	O
0.05	O
and	O
OR	O
0.46	O
,	O
P	O
=	O
0.01	O
,	O
respectively	O
)	O
.	O

Training	O
fellows	O
to	O
perform	O
RAPN	B-P
is	O
associated	O
with	O
longer	O
operating	B-P
time	O
and	O
WIT	O
but	O
does	O
not	O
appear	O
to	O
compromise	O
other	O
peri-operative	O
outcomes	O
.	O

Design	O
and	O
synthesis	O
of	O
phosphoryl-substituted	O
diphenylpyrimidines	O
(	O
Pho-DPPYs	O
)	O
as	O
potent	O
Bruton	O
's	O
tyrosine	O
kinase	O
(	O
BTK	O
)	O
inhibitors	O
:	O
Targeted	B-P
treatment	I-P
of	O
B	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
.	O

A	O
family	O
of	O
phosphoryl-substituted	O
diphenylpyrimidine	O
derivatives	O
(	O
Pho-DPPYs	O
)	O
were	O
synthesized	O
and	O
biologically	O
evaluated	O
as	O
potent	O
BTK	O
inhibitors	O
in	O
this	O
study	O
.	O

Compound	O
7b	O
was	O
found	O
to	O
markedly	O
inhibit	O
BTK	O
activity	O
at	O
concentrations	O
of	O
0.82nmol/L	O
,	O
as	O
well	O
as	O
to	O
suppress	O
the	O
proliferations	O
of	O
B-cell	O
leukemia	O
cell	O
lines	O
(	O
Ramos	O
and	O
Raji	O
)	O
expressing	O
high	O
levels	O
of	O
BTK	O
at	O
concentrations	O
of	O
3.17μM	O
and	O
6.69μM	O
.	O

Moreover	O
,	O
flow	B-P
cytometry	I-P
analysis	I-P
results	O
further	O
indicated	O
that	O
7b	O
promoted	O
cell	O
apoptosis	O
to	O
a	O
substantial	O
degree	O
.	O

In	O
a	O
word	O
,	O
compound	O
7b	O
is	O
a	O
promising	O
BTK	O
inhibitor	O
for	O
the	O
treatment	B-P
of	O
B-cell	O
lymphoblastic	O
leukemia	O
.	O

Deficient	O
cMyBP-C	O
protein	O
expression	O
during	O
cardiomyocyte	O
differentiation	O
underlies	O
human	O
hypertrophic	O
cardiomyopathy	O
cellular	B-P
phenotypes	O
in	O
disease	O
specific	O
human	O
ES	O
cell	O
derived	O
cardiomyocytes	O
.	O

Mutations	O
of	O
cardiac	O
sarcomere	O
genes	O
have	O
been	O
identified	O
to	O
cause	O
HCM	O
,	O
but	O
the	O
molecular	O
mechanisms	O
that	O
lead	O
to	O
cardiomyocyte	O
hypertrophy	O
and	O
risk	O
for	O
sudden	O
death	O
are	O
uncertain	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
HCM	O
disease	O
mechanisms	O
at	O
play	O
during	O
cardiac	O
differentiation	O
of	O
human	O
HCM	O
specific	O
pluripotent	O
stem	O
cells	O
.	O

We	O
generated	O
a	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
line	O
carrying	O
a	O
naturally	O
occurring	O
mutation	O
of	O
MYPBC3	O
(	O
c.2905	O
+1	O
G	O
>	O
A	O
)	O
to	O
study	O
HCM	O
pathogenesis	O
during	O
cardiac	O
differentiation	O
.	O

HCM	O
-	O
specific	O
hESC	O
-	O
derived	O
cardiomyocytes	O
(	O
hESC	O
-CMs	O
)	O
displayed	O
hallmark	O
aspects	O
of	O
HCM	O
including	O
sarcomere	O
disarray	O
,	O
hypertrophy	O
and	O
impaired	O
calcium	O
impulse	O
propagation	O
.	O

HCM	O
hESC	O
-CMs	O
presented	O
a	O
transient	O
haploinsufficiency	O
of	O
cMyBP-C	O
during	O
cardiomyocyte	O
differentiation	O
,	O
but	O
by	O
day	O
30	O
post	O
-	O
differentiation	O
cMyBP-C	O
levels	O
were	O
similar	O
to	O
control	O
hESC	O
-CMs	O
.	O

Gene	O
transfer	O
of	O
full-length	O
MYBPC3	O
during	O
differentiation	O
prevented	O
hypertrophy	O
,	O
sarcomere	O
disarray	O
and	O
improved	O
calcium	O
impulse	O
propagation	O
in	O
HCM	O
hESC	O
-CMs	O
.	O

These	O
findings	O
point	O
to	O
the	O
critical	O
role	O
of	O
MYBPC3	O
during	O
sarcomere	O
assembly	O
in	O
cardiac	O
myocyte	O
differentiation	O
and	O
suggest	O
developmental	O
influences	O
of	O
MYBPC3	O
truncating	O
mutations	O
on	O
the	O
mature	O
hypertrophic	O
phenotype	O
.	O

KCNQ1	O
Gene	O
Variants	O
in	O
Large	O
Asymptomatic	O
Populations	O
:	O
Considerations	O
for	O
Genomic	B-P
Screening	I-P
of	O
Military	O
Cohorts	O
.	O

The	O
advances	O
in	O
genomic	O
technology	O
of	O
large	O
populations	O
make	O
the	O
potential	O
for	O
genomic	B-P
screening	I-P
of	O
military	O
cohorts	O
and	O
recruits	O
feasible	O
,	O
affording	O
the	O
potential	O
to	O
identify	B-P
at-risk	I-P
individuals	I-P
before	O
occurrence	O
of	O
potentially	O
life-threatening	O
events	O
.	O

Exploring	O
sudden	O
cardiac	O
death	O
,	O
known	O
to	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
young	O
military	O
service	O
members	O
,	O
we	O
focused	O
on	O
the	O
most	O
common	O
gene	O
associated	O
with	O
long	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
,	O
KCNQ1	O
.	O

Using	O
the	O
publicly	O
available	O
database	O
Exome	O
Aggregation	O
Consortium	O
as	O
a	O
surrogate	O
for	O
a	O
military	O
population	O
,	O
variants	O
in	O
KCNQ1	O
were	O
filtered	O
on	O
the	O
basis	O
of	O
population	O
prevalence	O
,	O
classification	O
as	O
a	O
disease	O
mutation	O
in	O
the	O
Human	O
Gene	O
Mutation	O
database	O
,	O
and	O
classification	O
as	O
pathogenic	O
or	O
likely	O
pathogenic	O
in	O
the	O
ClinVar	O
database	O
.	O

Variant	O
prevalence	O
and	O
penetrance	O
estimates	O
were	O
derived	O
using	O
reports	O
from	O
the	O
medical	O
literature	O
.	O

We	O
showed	O
that	O
in	O
a	O
population	O
of	O
over	O
60,000	O
individuals	O
,	O
at	O
least	O
97	O
(	O
0.2	O
%	O
)	O
individuals	O
would	O
harbor	O
a	O
potentially	O
pathogenic	O
mutation	O
in	O
KCNQ1	O
,	O
which	O
is	O
more	O
prevalent	O
than	O
expected	O
on	O
the	O
basis	O
of	O
current	O
medical	O
literature	O
(	O
p	O
=	O
0.0004	O
)	O
.	O

KCNQ1	O
variant	O
penetrance	O
was	O
estimated	O
to	O
be	O
only	O
9	O
%	O
to	O
17	O
%	O
.	O

Identifying	O
the	O
importance	O
of	O
large	O
genomic	O
studies	O
,	O
our	O
study	O
demonstrates	O
that	O
46	O
%	O
of	O
pathogenic	O
mutations	O
in	O
KCNQ1	O
had	O
a	O
population	O
frequency	O
of	O
less	O
than	O
1:50,000	O
.	O

Screening	O
a	O
large	O
database	O
with	O
genomic	B-P
screening	I-P
for	O
a	O
condition	O
that	O
is	O
relevant	O
to	O
active	O
duty	O
service	O
members	O
results	O
in	O
the	O
identification	O
of	O
many	O
individuals	O
with	O
potentially	O
pathogenic	O
mutations	O
in	O
the	O
KCNQ1	O
gene	O
,	O
which	O
has	O
profound	O
implications	O
for	O
screening	O
military	O
or	O
other	O
adult	O
cohorts	O
in	O
terms	O
of	O
over	O
diagnosis	O
,	O
overtreatment	O
,	O
and	O
increased	O
medical	O
resource	O
usage	O
.	O

This	O
study	O
of	O
KCNQ1	O
provides	O
a	O
platform	O
for	O
consideration	O
of	O
other	O
genes	O
that	O
cause	O
sudden	O
cardiac	O
death	O
as	O
well	O
as	O
other	O
medically	O
actionable	O
hereditary	O
disorders	O
for	O
which	O
genomic	B-P
screening	I-P
is	O
available	O
.	O

We	O
review	O
the	O
potential	O
benefits	O
of	O
genomic	B-P
screening	I-P
and	O
also	O
present	O
the	O
complex	O
hurdles	O
that	O
will	O
be	O
encountered	O
as	O
such	O
technologies	O
unfold	O
.	O

Risk	O
factors	O
for	O
hepatitis	O
C	O
virus	O
infection	O
in	O
the	O
Colombian	O
Caribbean	O
coast	O
:	O
A	O
case-control	O
study	O
.	O

An	O
estimated	O
6.8-8.9	O
million	O
people	O
are	O
infected	O
with	O
hepatitis	O
C	O
virus	O
in	O
Latin	O
America	O
,	O
of	O
which	O
less	O
than	O
1	O
%	O
receives	O
antiviral	B-P
treatment	I-P
.	O

Studies	O
so	O
far	O
in	O
Colombia	O
have	O
attempted	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
disease	O
in	O
some	O
risk	O
groups	O
,	O
thus	O
preventing	O
the	O
identification	O
of	O
other	O
factors	O
potentially	O
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	O
.	O

To	O
identify	O
traditional	O
and	O
non-traditional	O
risk	O
factors	O
for	O
chronic	O
hepatitis	O
C	O
in	O
the	O
Colombian	O
Caribbean	O
coast	O
.	O

This	O
was	O
a	O
case-control	O
study	O
(	O
1:3	O
)	O
matched	O
by	O
health	O
care	O
provider	O
and	O
age	O
(	O
±	O
10	O
years	O
)	O
conducted	O
at	O
the	O
primary	O
care	O
level	O
of	O
gastroenterology	O
and	O
hepatology	O
outpatient	O
services	O
.	O

All	O
patients	O
with	O
a	O
positive	O
ELISA	B-P
underwent	O
a	O
confirmatory	O
viral	B-P
load	I-P
test	I-P
.	O

A	O
multivariate	O
logistic	O
regression	O
analysis	O
identified	O
the	O
independent	O
predictors	O
of	O
infection	O
.	O

Blood	B-P
transfusion	I-P
(	O
OR	O
=159.2	O
;	O
95	O
%	O
CI	O
:	O
35.4-715	O
;	O
p	O
<	O
0.001	O
)	O
and	O
history	O
of	O
hospitalization	O
before	O
1994	O
(	O
OR	O
=4.7	O
;	O
95	O
%	O
CI	O
:	O
1.3-17.1	O
;	O
p=0.018	O
)	O
were	O
identified	O
as	O
the	O
only	O
two	O
independent	O
predictors	O
of	O
infection	O
.	O

It	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility	O
of	O
these	O
results	O
and	O
to	O
conduct	O
cost-effectiveness	O
studies	O
before	O
recommending	O
their	O
use	O
in	O
the	O
design	O
of	O
new	O
screening	O
strategies	O
.	O

Visual	B-P
Analytics	I-P
for	O
Pattern	O
Discovery	O
in	O
Home	O
Care	O
.	O

Clinical	O
Relevance	O
for	O
Quality	O
Improvement	O
.	O

Visualization	O
can	O
reduce	O
the	O
cognitive	O
load	O
of	O
information	O
,	O
allowing	O
users	O
to	O
easily	O
interpret	O
and	O
assess	O
large	O
amounts	O
of	O
data	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home	O
health	O
data	O
using	O
visual	B-P
analysis	I-P
techniques	I-P
to	O
discover	O
clinically	O
salient	O
associations	O
between	O
patient	O
characteristics	O
with	O
problem-oriented	O
health	O
outcomes	O
of	O
older	O
adult	O
home	O
health	O
patients	O
during	O
the	O
home	O
health	O
service	O
period	O
.	O

Knowledge	O
,	O
Behavior	O
and	O
Status	O
ratings	O
at	O
discharge	O
as	O
well	O
as	O
change	O
from	O
admission	O
to	O
discharge	O
that	O
was	O
coded	O
using	O
the	O
Omaha	O
System	O
was	O
collected	O
from	O
a	O
dataset	O
on	O
988	O
de-identified	O
patient	O
data	O
from	O
15	O
home	O
health	O
agencies	O
.	O

SPSS	O
Visualization	O
Designer	O
v1.0	O
was	O
used	O
to	O
visually	B-P
analyze	I-P
patterns	I-P
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat	O
maps	O
and	O
histograms	O
.	O

Visualizations	O
suggesting	O
clinical	O
salience	O
were	O
tested	O
for	O
significance	O
using	O
correlation	O
analysis	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
80	O
years	O
,	O
with	O
the	O
majority	O
female	O
(	O
66	O
%	O
)	O
.	O

Of	O
the	O
150	O
visualizations	O
,	O
69	O
potentially	O
meaningful	O
patterns	O
were	O
statistically	O
evaluated	O
through	O
bivariate	O
associations	O
,	O
revealing	O
21	O
significant	O
associations	O
.	O

Further	O
,	O
14	O
associations	O
between	O
episode	O
length	O
and	O
Charlson	O
co-morbidity	O
index	O
mainly	O
with	O
urinary	O
related	O
diagnoses	O
and	O
problems	O
remained	O
significant	O
after	O
adjustment	O
analyses	O
.	O

Through	O
visual	B-P
analysis	I-P
,	O
the	O
adverse	O
association	O
of	O
the	O
longer	O
home	O
health	O
episode	O
length	O
and	O
higher	O
Charlson	O
co-morbidity	O
index	O
with	O
behavior	O
or	O
status	O
outcomes	O
for	O
patients	O
with	O
impaired	O
urinary	O
function	O
was	O
revealed	O
.	O

We	O
have	O
demonstrated	O
the	O
use	O
of	O
visual	B-P
analysis	I-P
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high-needs	O
subgroups	O
among	O
the	O
older	O
home	O
health	O
patient	O
population	O
.	O

The	O
effective	O
presentation	O
of	O
these	O
data	O
patterns	O
can	O
allow	O
clinicians	O
to	O
identify	O
areas	O
of	O
patient	O
improvement	O
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home	O
health	O
interventions	O
to	O
improve	O
patient	O
outcomes	O
.	O

Laparascopic	B-P
Splenectomy	I-P
Due	O
to	O
Splenic	O
Injury	O
after	O
Colonoscopy	B-P
.	O

Colonoscopy	B-P
,	O
which	O
is	O
routinely	O
performed	O
in	O
diagnosis	O
and	O
treatment	B-P
of	O
colorectal	O
disorders	O
,	O
is	O
a	O
reliable	O
procedure	B-P
.	O

Its	O
most	O
frequent	O
complications	O
are	O
bleeding	O
and	O
perforation	O
.	O

Splenic	O
rupture	O
is	O
a	O
very	O
rarely	O
met	O
complication	O
of	O
colonoscopy	B-P
,	O
and	O
delay	O
in	O
its	O
diagnosis	O
leads	O
to	O
increased	O
morbidity	O
and	O
mortality	O
.	O

We	O
presented	O
a	O
69	O
years	O
old	O
female	O
patient	O
,	O
who	O
was	O
diagnosed	O
by	O
computerized	B-P
abdominal	I-P
tomography	I-P
,	O
performed	O
for	O
her	O
abdominal	O
pain	O
,	O
which	O
started	O
following	O
the	O
colonoscopy	B-P
.	O

After	O
15	O
days	O
of	O
medical	B-P
treatment	I-P
and	O
follow-up	O
,	O
laparoscopic	B-P
splenectomy	I-P
was	O
performed	O
one	O
month	O
after	O
her	O
colonoscopy	B-P
.	O

The	O
patient	O
was	O
discharged	O
on	O
her	O
4	O
(	O
th	O
)	O
postoperative	O
day	O
,	O
with	O
uneventful	O
recovery	O
.	O

In	O
patients	O
who	O
have	O
complaint	O
of	O
abdominal	O
pain	O
following	O
colonoscopy	B-P
,	O
an	O
intraabdominal	O
pathological	O
condition	O
should	O
be	O
considered	O
and	O
computerized	B-P
abdominal	I-P
tomography	I-P
should	O
be	O
performed	O
.	O

If	O
there	O
is	O
no	O
detected	O
intraperitoneal	O
bleeding	O
,	O
in	O
other	O
words	O
,	O
if	O
there	O
is	O
a	O
sub-capsular	O
hematoma	O
of	O
the	O
spleen	O
,	O
medical	O
management	O
by	O
monitoring	O
the	O
vital	O
signs	O
may	O
be	O
preferred	O
.	O

Then	O
,	O
splenectomy	B-P
should	O
be	O
performed	O
at	O
an	O
appropriate	O
time	O
.	O

A	O
new	O
approach	O
to	O
nasomaxillary	O
complex	O
type	O
of	O
nasal	O
bone	O
fracture	O
:	O
Clip	O
operation	B-P
.	O

Nasal	O
bone	O
fractures	O
comprise	O
almost	O
40	O
%	O
of	O
all	O
facial	O
injuries	O
.	O

Most	O
are	O
initially	O
reduced	O
using	O
closed	B-P
reduction	I-P
.	O

This	O
study	O
introduces	O
a	O
newly	O
developed	O
method	O
,	O
the	O
clip	O
operation	B-P
via	O
endonasal	O
approach	O
.	O

The	O
operation	B-P
was	O
performed	O
in	O
these	O
patients	O
by	O
a	O
single	O
surgeon	O
extensively	O
experienced	O
in	O
facial	O
bone	O
fractures	O
.	O

An	O
absorbable	O
mesh	O
plate	O
made	O
into	O
a	O
clip	O
was	O
used	O
for	O
fixation	B-P
after	O
open	B-P
reduction	I-P
via	O
the	O
endonasal	O
approach	O
.	O

No	O
screws	O
were	O
used	O
for	O
fixation	B-P
.	O

Nasal	B-P
packing	I-P
was	O
removed	O
the	O
first	O
day	O
after	O
surgery	B-P
;	O
aluminum	O
splinting	O
was	O
removed	O
the	O
third	O
week	O
after	O
surgery	B-P
.	O

Three-dimensional	O
facial	B-P
computed	I-P
tomography	I-P
and	O
cephalolateral	B-P
radiography	I-P
were	O
performed	O
preoperatively	O
and	O
postoperatively	O
.	O

Plastic	O
surgeon	O
satisfaction	O
and	O
postoperative	O
complications	O
were	O
assessed	O
.	O

Fracture	O
relapse	O
was	O
not	O
observed	O
.	O

Reduction	B-P
status	O
was	O
well	O
maintained	O
.	O

Postoperative	O
complications	O
occurred	O
,	O
with	O
a	O
low	O
final	O
incidence	O
of	O
1.8	O
%	O
in	O
the	O
third	O
postoperative	O
month	O
.	O

Plastic	O
surgeon	O
satisfaction	O
was	O
very	O
high	O
at	O
4.58	O
.	O

This	O
operation	B-P
takes	O
5-10	O
min	O
,	O
and	O
is	O
simple	O
to	O
perform	O
.	O

It	O
entails	O
a	O
short	O
hospitalization	O
,	O
and	O
the	O
duration	O
during	O
which	O
nasal	B-P
packing	I-P
and	O
aluminum	O
splint	O
are	O
maintained	O
is	O
comparable	O
.	O

Undesirable	O
functional	O
,	O
aesthetic	O
complications	O
and	O
secondary	O
surgery	B-P
resulting	O
from	O
inaccurate	O
relapse	O
were	O
reduced	O
.	O

The	O
clip	O
operation	B-P
is	O
a	O
useful	O
technique	O
for	O
correcting	O
nasal	O
bone	O
fractures	O
,	O
especially	O
nasomaxillary	O
complex	O
type	O
.	O

pH	O
-Dependent	O
Transmembrane	O
Activity	O
of	O
Peptide	O
-Functionalized	O
Gold	O
Nanostars	O
for	O
Computed	B-P
Tomography	I-P
/	O
Photoacoustic	B-P
Imaging	I-P
and	O
Photothermal	B-P
Therapy	I-P
.	O

Progress	O
in	O
multifunctional	O
nanomaterials	O
for	O
tumor	B-P
therapy	I-P
mostly	O
depends	O
on	O
the	O
development	O
of	O
tumor	O
-	O
targeting	O
delivery	B-P
strategies	I-P
.	O

One	O
approach	O
is	O
to	O
explore	O
a	O
pH	O
-responsive	O
strategy	O
to	O
target	O
the	O
slightly	O
acidic	O
solid	O
tumor	O
microenvironment	O
.	O

A	O
novel	O
class	O
of	O
pH	O
(	O
low	O
)	O
insertion	O
peptides	O
(	O
pHLIPs	O
)	O
with	O
pH	O
-dependent	O
transmembrane	O
activity	O
can	O
fold	O
and	O
rapidly	O
insert	O
into	O
the	O
lipid	O
bilayer	O
of	O
tumor	O
cells	O
triggered	O
by	O
acidity	O
,	O
facilitating	O
the	O
cellular	O
internalization	O
of	O
nanomaterials	O
synchronously	O
.	O

Here	O
,	O
we	O
innovatively	O
decorated	O
gold	O
nanostars	O
(	O
GNSs	O
)	O
with	O
pHLIPs	O
(	O
GNS	O
-	O
pHLIP	O
)	O
to	O
improve	O
their	O
targeting	O
ability	O
and	O
photothermal	B-P
therapeutic	I-P
(	O
PTT	B-P
)	O
efficiency	O
.	O

The	O
obtained	O
GNS	O
-	O
pHLIP	O
exhibited	O
the	O
excellent	O
characteristics	O
of	O
uniform	O
size	O
and	O
good	O
biocompatibility	O
.	O

As	O
compared	O
to	O
GNS	O
-	O
mPEG	O
,	O
the	O
cellular	O
internalization	O
of	O
GNS	O
-	O
pHLIP	O
was	O
1-fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	O
in	O
media	O
at	O
pH	O
6.4	O
than	O
at	O
pH	O
7.4	O
.	O

Moreover	O
,	O
the	O
tumor	O
accumulation	O
of	O
the	O
GNS	O
-	O
pHLIP	O
was	O
3-fold	O
higher	O
than	O
that	O
of	O
GNS	O
-	O
mPEG	O
after	O
intravenous	O
injection	O
into	O
MCF-7	O
breast	O
tumor	O
animal	O
models	O
for	O
24	O
h.	O
Furthermore	O
,	O
GNS	O
-	O
pHLIP	O
exhibited	O
stronger	O
signals	O
than	O
the	O
GNS	O
-	O
mPEG	O
through	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
photoacoustic	B-P
(	I-P
PA	I-P
)	I-P
imaging	I-P
.	O

Simultaneously	O
,	O
the	O
desirable	O
targeting	O
efficiency	O
significantly	O
improved	O
the	O
PTT	B-P
efficacy	O
to	O
tumors	O
,	O
with	O
low	O
side	O
effects	O
on	O
normal	O
tissues	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	O
-	O
pHLIP	O
successfully	O
took	O
advantage	O
of	O
the	O
tumor	O
-	O
targeting	O
ability	O
of	O
pHLIPs	O
and	O
the	O
good	O
characteristics	O
of	O
GNS	O
s	O
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	O
imaging	B-P
and	O
therapy	B-P
.	O

Propensity	O
Score	O
Matched	O
Comparison	O
of	O
Partial	O
to	O
Whole	O
Gland	O
Cryotherapy	B-P
for	O
Intermediate-Risk	O
Prostate	O
Cancer	O
:	O
An	O
analysis	O
of	O
the	O
COLD	O
registry	O
data	O
.	O

To	O
compare	O
the	O
oncological	O
and	O
functional	O
outcomes	O
of	O
partial	O
versus	O
whole	O
-	O
gland	O
cryotherapy	B-P
for	O
men	O
with	O
intermediate-risk	O
prostate	O
cancer	O
.	O

Men	O
with	O
intermediate-risk	O
prostate	O
cancer	O
treated	B-P
with	I-P
primary	O
prostate	B-P
cryotherapy	I-P
from	O
1993-2013	O
were	O
selected	O
from	O
the	O
Cryo	O
On-Line	O
Data	O
Registry	O
for	O
a	O
1:1	O
matched	O
comparison	O
between	O
those	O
undergoing	O
whole	O
-	O
gland	O
and	O
partial	O
prostate	B-P
cryotherapy	I-P
(	O
targeted-ablation	B-P
,	O
unilateral/bilateral	B-P
nerve-sparing	I-P
ablations	I-P
)	O
.	O

A	O
propensity	O
score	O
was	O
developed	O
based	O
on	O
age	O
,	O
pre-biopsy	O
serum	O
PSA	O
,	O
biopsy	O
Gleason	O
score	O
,	O
clinical	O
stage	O
,	O
prostate	O
volume	O
,	O
neoadjuvant	B-P
androgen	I-P
deprivation	I-P
status	O
,	O
year	O
of	O
surgery	B-P
and	O
pre-treatment	O
potency	O
.	O

Outcomes	O
were	O
biochemical	O
progression-free	O
survival	O
(	O
BPFS	O
)	O
using	O
ASTRO	O
and	O
Phoenix	O
criteria	O
,	O
12-month	O
continence	O
(	O
strictly	O
pad-free	O
)	O
and	O
sexual	O
function	O
(	O
potency	O
sufficient	O
for	O
sexual	O
intercourse	O
)	O
.	O

After	O
propensity	O
score	O
-	O
matching	O
,	O
BPFS	O
was	O
compared	O
using	O
Kaplan-Meier	O
analysis	O
and	O
functional	O
outcomes	O
using	O
chi-square	O
tests	O
.	O

In	O
all	O
,	O
897	O
men	O
were	O
identified	O
(	O
731	O
whole	O
-	O
gland	O
and	O
166	O
partial	O
)	O
.	O

Post-matching	O
,	O
166	O
pairs	O
of	O
men	O
were	O
analysed	O
(	O
mean	O
follow-up	O
31	O
months	O
)	O
.	O

The	O
2/5	O
year	O
BPFS	O
rate	O
was	O
87.2	O
%	O
/76.4	O
%	O
for	O
whole	O
-	O
gland	O
vs.	O
80.7	O
%	O
/70.0	O
%	O
for	O
partial	O
ablation	B-P
using	O
Phoenix	O
(	O
p=0.26	O
)	O
and	O
72.3	O
%	O
/69.6	O
%	O
for	O
whole	O
gland	O
vs.	O
82.1	O
%	O
/75.0	O
%	O
for	O
partial	O
ablation	B-P
using	O
ASTRO	O
criteria	O
(	O
p=0.10	O
)	O
.	O

Of	O
164	O
pairs	O
,	O
the	O
12-month	O
continence	O
rate	O
was	O
similar	O
94.1	O
%	O
vs.	O
95.1	O
%	O
(	O
p=0.803	O
)	O
.	O

Of	O
139	O
pairs	O
,	O
the	O
12-month	O
rate	O
of	O
successful	O
intercourse	O
was	O
29.5	O
%	O
for	O
whole	O
-	O
gland	O
and	O
46.8	O
%	O
for	O
partial	O
ablation	B-P
(	O
OR	O
2.1	O
,	O
p=0.003	O
)	O
.	O

The	O
incidence	O
of	O
post-treatment	O
urinary	O
retention	O
was	O
6.0	O
%	O
and	O
6.6	O
%	O
(	O
p=0.88	O
)	O
following	O
whole	O
-	O
gland	O
and	O
partial	O
ablation	B-P
respectively	O
and	O
that	O
of	O
rectourethral	O
fistula	O
was	O
1.2	O
%	O
and	O
0	O
%	O
(	O
p=0.50	O
)	O
Conclusion	O
:	O
Partial	O
ablation	B-P
results	O
in	O
better	O
post-treatment	O
sexual	O
function	O
compared	O
to	O
whole	O
-	O
gland	O
ablation	B-P
in	O
men	O
with	O
intermediate-risk	O
prostate	O
cancer	O
.	O

We	O
did	O
not	O
observe	O
a	O
difference	O
in	O
early	O
BPFS	O
between	O
the	O
two	O
groups	O
.	O

ADHD	O
symptoms	O
in	O
non-treatment	O
seeking	O
young	O
adults	O
:	O
relationship	O
with	O
other	O
forms	O
of	O
impulsivity	O
.	O

Attention-deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
has	O
been	O
associated	O
with	O
various	O
manifestations	O
of	O
impulsivity	O
in	O
adults	O
,	O
including	O
elevated	O
rates	O
of	O
other	O
impulsive	O
disorders	O
,	O
substance	O
use	O
,	O
questionnaire	O
-based	O
impulsivity	O
scores	O
,	O
and	O
inhibitory	O
dysregulation	O
on	O
neurocognitive	B-P
tests	I-P
.	O

The	O
relationship	O
between	O
ADHD	O
and	O
all	O
these	O
other	O
forms	O
of	O
impulsivity	O
has	O
yet	O
to	O
be	O
explored	O
within	O
the	O
context	O
of	O
a	O
single	O
comprehensive	O
study	O
.	O

A	O
total	O
of	O
423	O
young	O
adults	O
,	O
who	O
gambled	O
≥5	O
times	O
in	O
the	O
preceding	O
year	O
,	O
were	O
recruited	O
using	O
media	O
advertisements	O
and	O
undertook	O
detailed	O
assessment	O
including	O
structured	O
psychiatric	B-P
interview	I-P
,	O
questionnaires	O
,	O
and	O
neurocognitive	B-P
tests	I-P
.	O

Participants	O
with	O
ADHD	O
symptoms	O
were	O
identified	O
using	O
the	O
Adult	O
ADHD	O
Self-Report	O
Scale	O
Screener	O
(	O
ASRS-V1.1	O
)	O
and	O
were	O
compared	O
to	O
controls	O
using	O
multivariate	O
analysis	O
of	O
variance	O
(	O
MANOVA	O
)	O
.	O

ADHD	O
symptoms	O
were	O
found	O
in	O
20.3	O
%	O
of	O
the	O
sample	O
,	O
but	O
only	O
7.3	O
%	O
of	O
these	O
subjects	O
had	O
ever	O
received	O
a	O
formal	O
diagnosis	O
.	O

ADHD	O
symptoms	O
were	O
associated	O
with	O
significantly	O
lower	O
quality	O
of	O
life	O
,	O
lower	O
self-esteem	O
,	O
higher	O
emotional	O
dysregulation	O
,	O
higher	O
impulsivity	O
questionnaire	O
scores	O
,	O
more	O
problematic	O
Internet	O
use	O
,	O
greater	O
occurrence	O
of	O
psychiatric	O
disorders	O
,	O
and	O
impaired	O
stop-signal	O
reaction	O
times	O
.	O

Of	O
these	O
variables	O
,	O
stop-signal	O
reaction	O
times	O
and	O
Barratt	O
attentional	O
impulsiveness	O
were	O
the	O
strongest	O
predictors	O
of	O
group	O
classification	O
.	O

ADHD	O
symptoms	O
are	O
common	O
and	O
under-diagnosed	O
in	O
young	O
adults	O
who	O
gamble	O
,	O
and	O
are	O
most	O
strongly	O
linked	O
with	O
certain	O
other	O
types	O
of	O
impulsivity	O
(	O
questionnaire	O
-	O
and	O
cognitive	O
-based	O
measures	O
)	O
and	O
with	O
emotional	O
dysregulation	O
,	O
suggesting	O
that	O
these	O
are	O
each	O
important	O
considerations	O
in	O
understanding	O
the	O
pathophysiology	O
of	O
the	O
disorder	O
,	O
but	O
also	O
potential	O
treatment	B-P
targets	O
.	O

It	O
is	O
necessary	O
to	O
question	O
whether	O
treatment	B-P
for	O
adult	O
ADHD	O
could	O
be	O
enhanced	O
by	O
considering	O
self-esteem	O
,	O
emotional	O
reactivity	O
,	O
and	O
impaired	O
inhibitory	O
control	O
as	O
specific	O
treatment	B-P
targets	O
,	O
in	O
addition	O
to	O
the	O
core	O
diagnostic	O
symptoms	O
of	O
the	O
disorder	O
.	O

Validation	O
of	O
the	O
German	O
version	O
of	O
the	O
Mediterranean	O
Diet	O
Adherence	O
Screener	O
(	O
MEDAS	O
)	O
questionnaire	O
.	O

Health	O
benefits	O
of	O
the	O
Mediterranean	B-P
Diet	I-P
(	O
MD	B-P
)	O
have	O
been	O
shown	O
in	O
different	O
at-risk	O
populations	O
.	O

A	O
German	O
translation	O
of	O
the	O
Mediterranean	O
Diet	O
Adherence	O
Screener	O
(	O
MEDAS	O
)	O
from	O
the	O
PREvención	O
con	O
DIeta	O
MEDiterránea	O
(	O
PREDIMED	O
)	O
consortium	O
was	O
used	O
in	O
the	O
LIBRE	O
study	O
,	O
investigating	O
effects	O
of	O
lifestyle	O
-	O
intervention	O
on	O
women	O
with	O
BRCA1	O
/	O
2	O
mutations	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
validate	O
the	O
MEDAS	O
German	O
version	O
.	O

LIBRE	O
is	O
a	O
multicentre	O
(	O
three	O
university	O
hospitals	O
during	O
this	O
pilot	O
phase	O
)	O
,	O
unblinded	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

Women	O
with	O
a	O
BRCA1	O
/	O
2	O
mutation	O
of	O
age	O
18	O
or	O
over	O
who	O
provided	O
written	O
consent	O
were	O
eligible	O
for	O
the	O
trial	O
.	O

As	O
part	O
of	O
the	O
assessment	O
,	O
all	O
were	O
given	O
a	O
full-length	O
Food	O
Frequency	O
Questionnaire	O
(	O
FFQ	O
)	O
and	O
MEDAS	O
at	O
baseline	O
and	O
after	O
3	O
months	O
.	O

Data	O
derived	O
from	O
FFQ	O
was	O
compared	O
to	O
MEDAS	O
in	O
order	O
to	O
evaluate	O
agreement	O
or	O
concordance	O
between	O
the	O
two	O
questionnaires	O
.	O

Additionally	O
,	O
the	O
association	O
of	O
dietary	O
intake	O
biomarkers	O
in	O
the	O
blood	O
(	O
β-carotene	O
,	O
omega-3	O
,	O
omega-6	O
and	O
omega-9	O
fatty	O
acids	O
and	O
high-sensitivity	B-P
C-reactive	I-P
protein	I-P
(	O
hsCRP	B-P
)	O
)	O
with	O
some	O
MEDAS	O
items	O
was	O
analyzed	O
using	O
t-Tests	O
and	O
a	O
multivariate	O
regression	O
.	O

The	O
participants	O
of	O
the	O
LIBRE	O
pilot	O
study	O
were	O
68	O
in	O
total	O
(	O
33	O
Intervention	O
,	O
35	O
Control	O
)	O
.	O

Only	O
participants	O
who	O
completed	O
both	O
questionnaires	O
were	O
included	O
in	O
this	O
analysis	O
(	O
baseline	O
:	O
66	O
,	O
month	O
three	O
:	O
54	O
)	O
.	O

The	O
concordance	O
between	O
these	O
two	O
questionnaires	O
varied	O
between	O
the	O
items	O
(	O
Intraclass	O
correlation	O
coefficient	O
of	O
0.91	O
for	O
pulses	O
at	O
the	O
highest	O
and	O
-0.33	O
for	O
sugar-sweetened	O
drinks	O
)	O
.	O

Mean	O
MEDAS	O
scores	O
(	O
sum	O
of	O
all	O
items	O
)	O
were	O
9	O
%	O
higher	O
than	O
their	O
FFQ	O
counter-parts	O
at	O
baseline	O
and	O
15	O
%	O
after	O
3	O
months	O
.	O

Higher	O
fish	O
consumption	O
(	O
at	O
least	O
3	O
portions	O
)	O
was	O
associated	O
with	O
lower	O
omega-6	O
fatty	O
acid	O
levels	O
(	O
p	O
=	O
0.026	O
)	O
and	O
higher	O
omega-3	O
fatty	O
acid	O
levels	O
(	O
p	O
=	O
0.037	O
)	O
,	O
both	O
results	O
being	O
statistically	O
significant	O
.	O

We	O
conclude	O
that	O
the	O
German	O
MEDAS	O
in	O
its	O
current	O
version	O
could	O
be	O
a	O
useful	O
tool	O
in	O
clinical	O
trials	O
and	O
in	O
practice	O
to	O
assess	O
adherence	O
to	O
MD	B-P
.	O

ClinicalTrials.gov	O
,	O
registered	O
on	O
March	O
12	O
,	O
2014	O
,	O
identifier	O
:	O
NCT02087592	O
.	O

World	O
Health	O
Organization	O
Trial	O
Registration	O
,	O
registered	O
on	O
3	O
August	O
2015	O
,	O
identifier	O
:	O
NCT02087592	O
.	O

CHOROIDAL	O
VASCULARITY	O
INDEX	O
:	O
A	O
Novel	O
Optical	B-P
Coherence	I-P
Tomography	I-P
Based	O
Parameter	O
in	O
Patients	O
With	O
Exudative	O
Age-Related	O
Macular	O
Degeneration	O
.	O

To	O
evaluate	O
choroidal	O
structural	O
changes	O
in	O
exudative	O
age-related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
using	O
choroidal	O
vascularity	O
index	O
computed	O
from	O
image	O
binarization	O
on	O
spectral	B-P
domain	I-P
optical	I-P
coherence	I-P
tomography	I-P
with	O
enhanced	O
depth	B-P
imaging	I-P
.	O

This	O
prospective	O
case	O
series	O
included	O
42	O
consecutive	O
patients	O
with	O
unilateral	O
exudative	O
AMD	O
.	O

Choroidal	O
images	B-P
were	O
segmented	O
into	O
luminal	O
area	O
and	O
stromal	O
area	O
.	O

Choroidal	O
vascularity	O
index	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
luminal	O
area	O
to	O
total	O
choroid	O
area	O
.	O

Mean	O
choroidal	O
vascularity	O
index	O
and	O
mean	O
choroidal	O
thickness	O
between	O
study	O
and	O
fellow	O
eyes	O
of	O
the	O
same	O
patient	O
with	O
dry	O
AMD	O
were	O
compared	O
using	O
Student	O
's	O
t-test	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
choroidal	O
vascularity	O
index	O
in	O
eyes	O
with	O
exudative	O
AMD	O
(	O
60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Luminal	O
area	O
(	O
P	O
<	O
0.01	O
)	O
was	O
decreased	O
in	O
eyes	O
with	O
exudative	O
AMD	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
total	O
choroid	O
area	O
(	O
P	O
=	O
0.05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0.93	O
)	O
between	O
study	O
and	O
fellow	O
eyes	O
.	O

Eyes	O
with	O
exudative	O
AMD	O
demonstrated	O
reduced	O
choroidal	O
vascularity	O
index	O
but	O
insignificant	O
differences	O
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	O
.	O

Choroidal	O
vascularity	O
index	O
may	O
be	O
a	O
potential	O
noninvasive	O
tool	O
for	O
studying	O
structural	O
changes	O
in	O
choroid	O
and	O
monitoring	O
choroidal	O
disease	O
in	O
exudative	O
AMD	O
.	O

The	O
adder	O
(	O
Vipera	O
berus	O
)	O
in	O
Southern	O
Altay	O
Mountains	O
:	O
population	O
characteristics	O
,	O
distribution	O
,	O
morphology	O
and	O
phylogenetic	O
position	O
.	O

As	O
the	O
most	O
widely	O
distributed	O
snake	O
in	O
Eurasia	O
,	O
the	O
adder	O
(	O
Vipera	O
berus	O
)	O
has	O
been	O
extensively	O
investigated	O
in	O
Europe	O
but	O
poorly	O
understood	O
in	O
Asia	O
.	O

The	O
Southern	O
Altay	O
Mountains	O
represent	O
the	O
adder	O
's	O
southern	O
distribution	O
limit	O
in	O
Central	O
Asia	O
,	O
whereas	O
its	O
population	O
status	O
has	O
never	O
been	O
assessed	O
.	O

We	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	O
surveys	O
for	O
the	O
adder	O
at	O
two	O
areas	O
of	O
Southern	O
Altay	O
Mountains	O
using	O
a	O
combination	O
of	O
line	O
transects	O
and	O
random	O
searches	O
.	O

We	O
also	O
described	O
the	O
morphological	O
characteristics	O
of	O
the	O
collected	B-P
specimens	I-P
and	O
conducted	O
analyses	O
of	O
external	O
morphology	O
and	O
molecular	O
phylogeny	O
.	O

The	O
results	O
showed	O
that	O
the	O
adder	O
distributed	O
in	O
both	O
survey	O
sites	O
and	O
we	O
recorded	O
a	O
total	O
of	O
34	O
sightings	O
.	O

In	O
Kanas	O
river	O
valley	O
,	O
the	O
estimated	O
encounter	O
rate	O
over	O
a	O
total	O
of	O
137	O
km	O
transects	O
was	O
0.15	O
±	O
0.05	O
sightings	O
/km	O
.	O

The	O
occurrence	O
of	O
melanism	O
was	O
only	O
17	O
%	O
.	O

The	O
small	O
size	O
was	O
typical	O
for	O
the	O
adders	O
in	O
Southern	O
Altay	O
Mountains	O
in	O
contrast	O
to	O
other	O
geographic	O
populations	O
of	O
the	O
nominate	O
subspecies	O
.	O

A	O
phylogenetic	O
tree	O
obtained	O
by	O
Bayesian	O
Inference	O
based	O
on	O
DNA	O
sequences	O
of	O
the	O
mitochondrial	O
cytochrome	O
b	O
(	O
1,023	O
bp	O
)	O
grouped	O
them	O
within	O
the	O
Northern	O
clade	O
of	O
the	O
species	O
but	O
failed	O
to	O
separate	O
them	O
from	O
the	O
subspecies	O
V.	O
b.	O
sachalinensis	O
.	O

Our	O
discovery	O
extends	O
the	O
distribution	O
range	O
of	O
V.	O
berus	O
and	O
provides	O
a	O
basis	O
for	O
further	O
researches	O
.	O

We	O
discuss	O
the	O
hypothesis	O
that	O
the	O
adder	O
expands	O
its	O
distribution	O
border	O
to	O
the	O
southwest	O
along	O
the	O
mountains	O
'	O
elevation	O
gradient	O
,	O
but	O
the	O
population	O
abundance	O
declines	O
gradually	O
due	O
to	O
a	O
drying	O
climate	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR-70	O
immunoassay	B-P
as	O
a	O
tumor	O
marker	O
for	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Lung	O
cancer	O
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	O
with	O
lung	O
cancer	O
are	O
usually	O
diagnosed	B-P
at	O
advanced	O
or	O
locally	O
advanced	O
stage	O
,	O
for	O
this	O
reason	O
early	B-P
diagnosis	I-P
of	O
lung	O
cancer	O
is	O
very	O
important	O
.	O

For	O
early	B-P
detection	I-P
of	O
lung	O
cancer	O
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose	B-P
computed	I-P
tomography	I-P
or	O
tumor	O
biomarkers	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR-70	O
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	O
in	O
detection	B-P
of	O
non-small	O
cell	O
lung	O
cancers	O
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	O
from	O
88	O
non	O
lung	O
cancer	O
patients	O
,	O
86	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disesase	O
were	O
obtained	O
.	O

Blood	O
samples	O
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR-70	O
level	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	O
,	O
22	O
female	O
)	O
.	O

Histopathologically	O
47	O
(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	B-P
with	O
squamous	O
cell	O
lung	O
cancer	O
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
mean	O
serum	O
DR-70	O
levels	O
in	O
lung	O
cancer	O
patients	O
(	O
2.43	O
±	O
1.82	O
µg/mL	O
)	O
was	O
significantly	O
higher	O
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/mL	O
)	O
(	O
p	O
<	O
0.01	O
)	O
.	O

DR-70	O
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1.98	O
µg/mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	O
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	O
level	O
is	O
1.98	O
µg/mL	O
and	O
higher	O
.	O

DR-70	O
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	O
products	O
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	O
lung	O
cancer	O
patients	O
.	O

Bioinformatic	O
analysis	O
of	O
RNA-seq	O
data	O
unveiled	O
critical	O
genes	O
in	O
rectal	O
adenocarcinoma	O
.	O

RNA-seq	O
data	O
of	O
rectal	O
adenocarcinoma	O
(	O
READ	O
)	O
were	O
analyzed	O
with	O
bioinformatics	O
tools	O
to	O
unveil	O
potential	O
biomarkers	O
in	O
the	O
disease	O
.	O

RNA-seq	O
data	O
of	O
READ	O
were	O
downloaded	O
from	O
The	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
database	O
.	O

Differential	O
analysis	O
was	O
performed	O
with	O
package	O
edgeR	O
.	O

False	O
discovery	O
rate	O
(	O
FDR	O
)	O
<	O
0.05	O
and	O
|log2	O
(	O
fold	O
change	O
)	O
|	O
>	O
1	O
were	O
set	O
as	O
cut-off	O
values	O
to	O
screen	O
out	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
.	O

Gene	O
coexpression	O
network	O
was	O
constructed	O
with	O
package	O
Ebcoexpress	O
.	O

Gene	O
Ontology	O
enrichment	O
analysis	O
was	O
performed	O
for	O
the	O
DEGs	O
in	O
the	O
gene	O
coexpression	O
network	O
with	O
DAVID	O
online	O
tool	O
.	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
pathway	O
enrichment	O
analysis	O
was	O
also	O
performed	O
for	O
the	O
genes	O
with	O
KOBASS	O
2.0	O
.	O

A	O
total	O
of	O
620	O
DEGs	O
,	O
3ated	O
genes	O
,	O
and	O
231	O
down-regulated	O
genes	O
,	O
were	O
identified	O
from	O
163	O
READ	O
samples	O
and	O
9	O
normal	O
controls	O
.	O

A	O
gene	O
coexpression	O
network	O
consisting	O
of	O
71	O
DEGs	O
and	O
253	O
edges	O
were	O
constructed	O
.	O

Genes	O
were	O
associated	O
with	O
ribosome	O
and	O
focal	O
adhesion	O
functions	O
.	O

Three	O
modules	O
were	O
identified	O
,	O
in	O
which	O
genes	O
were	O
involved	O
in	O
muscle	O
contraction	O
,	O
negative	O
regulation	O
of	O
glial	O
cell	O
proliferation	O
and	O
extracellular	O
matrix	O
organization	O
functions	O
,	O
respectively	O
.	O

Several	O
critical	O
hub	O
genes	O
were	O
disclosed	O
,	O
such	O
as	O
RPS2	O
,	O
MMP1	O
,	O
MMP11	O
and	O
FAM83H	O
.	O

Thirteen	O
relevant	O
small	O
molecule	O
drugs	O
were	O
identified	O
,	O
such	O
as	O
scriptaid	O
and	O
spaglumic	O
acid	O
.	O

A	O
total	O
of	O
8	O
TFs	O
and	O
5	O
miRNAs	O
were	O
acquired	O
,	O
such	O
as	O
MYC	O
,	O
NFY	O
,	O
STAT5A	O
,	O
miR-29	O
,	O
miR-200	O
and	O
miR-19	O
.	O

Several	O
critical	O
genes	O
and	O
relevant	O
drugs	B-P
,	O
TFs	O
and	O
miRNAs	O
were	O
revealed	O
in	O
READ	O
.	O

These	O
findings	O
could	O
advance	O
the	O
understanding	O
about	O
the	O
disease	O
and	O
benefit	O
therapy	O
development	O
.	O

How	O
do	O
different	O
delivery	O
schedules	O
of	O
tailored	O
web-based	O
physical	O
activity	O
advice	O
for	O
breast	O
cancer	O
survivors	O
influence	O
intervention	B-P
use	O
and	O
efficacy	O
?	O
.	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
investigate	O
the	O
impact	O
of	O
differing	O
delivery	O
schedules	O
of	O
computer-tailored	O
physical	O
activity	O
modules	O
on	O
engagement	O
and	O
physical	O
activity	O
behaviour	O
change	O
in	O
a	O
web-based	O
intervention	O
targeting	O
breast	O
cancer	O
survivors	O
.	O

Insufficiently	O
active	O
breast	O
cancer	O
survivors	O
(	O
n	O
=	O
492	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
one	O
of	O
the	O
following	O
intervention	B-P
schedules	O
over	O
12	O
weeks	O
:	O
a	O
three-	O
module	O
intervention	O
delivered	O
monthly	O
,	O
a	O
three-module	B-P
intervention	I-P
delivered	O
weekly	O
or	O
a	O
single	B-P
module	I-P
intervention	I-P
.	O

Engagement	O
with	O
the	O
website	O
(	O
number	O
of	O
logins	O
,	O
time	O
on	O
site	O
,	O
modules	O
viewed	O
,	O
action	O
plans	O
completed	O
)	O
was	O
measured	O
using	O
tracking	O
software	O
.	O

Other	O
outcomes	O
(	O
website	O
acceptability	O
,	O
physical	O
activity	O
behaviour	O
)	O
were	O
assessed	O
using	O
online	O
surveys	O
.	O

Physical	O
activity	O
outcomes	O
were	O
analysed	O
using	O
regression	O
models	O
for	O
both	O
study	O
completers	O
and	O
when	O
applying	O
intention-to-treat	O
(	O
using	O
multiple	O
imputation	O
)	O
.	O

Completers	O
allocated	O
to	O
the	O
monthly	O
module	O
group	O
rated	O
the	O
intervention	B-P
higher	O
(	O
b	O
=	O
2.2	O
95	O
%	O
CI	O
=	O
0.02-4.53	O
)	O
on	O
acceptability	O
and	O
had	O
higher	O
levels	O
of	O
resistance-training	B-P
(	O
IRR	O
=	O
1.88	O
,	O
95	O
%	O
CI	O
=	O
1.16-3.04	O
)	O
than	O
those	O
in	O
the	O
single	O
module	O
group	O
.	O

When	O
accounting	O
for	O
missing	O
data	O
,	O
these	O
differences	O
were	O
no	O
longer	O
significant	O
.	O

The	O
completion	O
of	O
at	O
least	O
two	O
action	O
plans	O
was	O
higher	O
among	O
those	O
allocated	O
to	O
the	O
monthly	O
module	O
group	O
compared	O
to	O
those	O
in	O
the	O
weekly	O
module	O
group	O
(	O
53	O
vs	O
40	O
%	O
,	O
p	O
=	O
0.02	O
)	O
;	O
though	O
the	O
completion	O
of	O
at	O
least	O
two	O
modules	O
was	O
higher	O
in	O
the	O
weekly	O
module	O
group	O
compared	O
to	O
the	O
monthly	O
module	O
group	O
(	O
60	O
vs	O
46	O
%	O
;	O
p	O
=	O
0.01	O
)	O
.	O

There	O
were	O
no	O
other	O
significant	O
between	O
group	O
differences	O
observed	O
.	O

This	O
study	O
provides	O
preliminary	O
evidence	O
that	O
web-based	O
computer-tailored	O
interventions	B-P
can	O
be	O
used	O
to	O
increase	O
physical	O
activity	O
among	O
breast	O
cancer	O
survivors	O
.	O

Further	O
,	O
there	O
were	O
some	O
outcome	O
differences	O
based	O
on	O
how	O
the	O
tailored	O
modules	O
were	O
delivered	O
,	O
with	O
the	O
most	O
favourable	O
outcomes	O
observed	O
in	O
the	O
monthly	O
delivery	O
group	O
.	O

This	O
study	O
will	O
be	O
useful	O
for	O
informing	O
the	O
design	O
of	O
future	O
web-based	O
interventions	O
targeting	O
breast	O
cancer	O
survivors	O
.	O

Multicenter	O
Trial	O
of	O
Rivaroxaban	O
for	O
Early	O
Discharge	O
of	O
Pulmonary	O
Embolism	O
From	O
the	O
Emergency	O
Department	O
(	O
MERCURY	O
PE	O
)	O
:	O
Rationale	O
and	O
Design	O
.	O

Traditionally	O
,	O
patients	O
with	O
pulmonary	O
embolism	O
(	O
PE	O
)	O
are	O
admitted	O
from	O
the	O
emergency	O
department	O
and	O
treated	B-P
with	I-P
low-molecular-weight	O
heparin	O
followed	O
by	O
warfarin	O
.	O

Several	O
studies	O
now	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
identify	O
low-risk	O
PE	O
patients	O
that	O
can	O
safely	O
be	O
treated	O
as	O
outpatients	O
.	O

The	O
advent	O
of	O
the	O
direct-acting	O
oral	O
anticoagulants	O
such	O
as	O
rivaroxaban	O
has	O
made	O
it	O
easier	O
than	O
ever	O
to	O
manage	O
patients	O
outside	O
of	O
the	O
hospital	O
.	O

This	O
article	O
describes	O
the	O
design	O
of	O
a	O
randomized	O
controlled	O
trial	O
aimed	O
at	O
testing	O
the	O
hypothesis	O
that	O
low-risk	O
PE	O
patients	O
can	O
be	O
safely	O
and	O
effectively	O
managed	O
at	O
home	O
using	O
rivaroxaban	O
,	O
resulting	O
in	O
fewer	O
days	O
of	O
hospitalization	O
than	O
standard-of-care	B-P
treatment	I-P
.	O

We	O
have	O
initiated	O
a	O
multicenter	O
,	O
open-label	O
,	O
randomized	O
clinical	O
trial	O
in	O
which	O
low-risk	O
adult	O
PE	O
patients	O
(	O
identified	O
by	O
the	O
Hestia	O
criteria	O
)	O
are	O
randomized	O
to	O
outpatient	O
management	O
with	O
oral	O
rivaroxaban	O
15	O
mg	O
twice	O
daily	O
for	O
21	O
days	O
followed	O
by	O
20	O
mg	O
once	O
daily	O
for	O
90	O
days	O
versus	O
standard	B-P
care	I-P
,	O
determined	O
by	O
the	O
treating	O
physician	O
and	O
based	O
on	O
local	O
practices	O
.	O

The	O
primary	O
clinical	O
endpoint	O
will	O
be	O
the	O
total	O
number	O
of	O
inpatient	O
hospital	O
days	O
(	O
including	O
the	O
index	O
admission	O
)	O
for	O
venous	O
thromboembolic	O
or	O
bleeding-related	O
events	O
during	O
the	O
first	O
30	O
days	O
after	O
randomization	O
.	O

A	O
total	O
of	O
150	O
subjects	O
per	O
group	O
will	O
provide	O
82	O
%	O
power	O
to	O
detect	O
a	O
difference	O
of	O
1	O
day	O
or	O
greater	O
in	O
the	O
primary	O
outcome	O
.	O

Patient	O
enrollment	O
is	O
ongoing	O
at	O
present	O
in	O
45	O
of	O
60	O
planned	O
sites	O
.	O

No	O
interim	O
analysis	O
is	O
planned	O
and	O
the	O
study	O
is	O
being	O
monitored	O
by	O
a	O
data	O
safety	O
management	O
board	O
.	O

The	O
MERCURY	O
PE	O
study	O
is	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
outpatient	O
management	O
of	O
low-risk	O
PE	O
patients	O
with	O
rivaroxaban	O
reduces	O
the	O
number	O
of	O
hospitalization	O
days	O
from	O
venous	O
thromboembolism	O
and	O
bleeding	O
compared	O
with	O
standard	B-P
care	I-P
.	O

This	O
article	O
describes	O
the	O
rationale	O
and	O
methodology	O
for	O
this	O
study	O
.	O

Predictive	O
position	O
computations	O
mediated	O
by	O
parietal	O
areas	O
:	O
TMS	B-P
evidence	O
.	O

When	O
objects	O
move	O
or	O
the	O
eyes	O
move	O
,	O
the	O
visual	O
system	O
can	O
predict	O
the	O
consequence	O
and	O
generate	O
a	O
percept	O
of	O
the	O
target	O
at	O
its	O
new	O
position	O
.	O

This	O
predictive	O
localization	O
may	O
depend	O
on	O
eye	O
movement	O
control	O
in	O
the	O
frontal	O
eye	O
fields	O
(	O
FEF	O
)	O
and	O
the	O
intraparietal	O
sulcus	O
(	O
IPS	O
)	O
and	O
on	O
motion	O
analysis	O
in	O
the	O
medial	O
temporal	O
area	O
(	O
MT	O
)	O
.	O

Across	O
two	O
experiments	O
we	O
examined	O
whether	O
repetitive	B-P
transcranial	I-P
magnetic	I-P
stimulation	I-P
(	O
rTMS	B-P
)	O
over	O
right	O
FEF	O
,	O
right	O
IPS	O
,	O
righ	O
t	O
MT	O
,	O
and	O
a	O
control	O
site	O
,	O
peripheral	O
V1	O
/	O
V2	O
,	O
diminished	O
participants	O
'	O
perception	O
of	O
two	O
cases	O
of	O
predictive	O
position	O
perception	O
:	O
trans-saccadic	O
fusion	O
,	O
and	O
the	O
flash	O
grab	O
illusion	O
,	O
both	O
presented	O
in	O
the	O
contralateral	O
visual	O
field	O
.	O

In	O
trans-saccadic	O
fusion	O
trials	O
,	O
participants	O
saccade	O
toward	O
a	O
stimulus	O
that	O
is	O
replaced	O
with	O
another	O
stimulus	O
during	O
the	O
saccade	O
.	O

Frequently	O
,	O
predictive	O
position	O
mechanisms	O
lead	O
to	O
a	O
fused	O
percept	O
of	O
pre	O
-	O
and	O
post	O
-	O
saccade	O
stimuli	O
(	O
Paeye	O
et	O
al.	O
,	O
2017	O
)	O
.	O

We	O
found	O
that	O
rTMS	B-P
to	O
IPS	O
significantly	O
decreased	O
the	O
frequency	O
of	O
perceiving	O
trans-saccadic	O
fusion	O
within	O
the	O
first	O
10min	O
after	O
stimulation	O
.	O

In	O
the	O
flash	O
grab	O
illusion	O
,	O
a	O
target	O
is	O
flashed	O
on	O
a	O
moving	O
background	O
leading	O
to	O
the	O
percept	O
that	O
the	O
target	O
has	O
shifted	O
in	O
the	O
direction	O
of	O
the	O
motion	O
after	O
the	O
flash	O
(	O
Cavanagh	O
and	O
Anstis	O
,	O
2013	O
)	O
.	O

In	O
the	O
first	O
experiment	O
,	O
the	O
reduction	O
in	O
the	O
flash	O
grab	O
illusion	O
after	O
rTMS	B-P
to	O
IPS	O
and	O
FEF	O
did	O
not	O
reach	O
significance	O
.	O

In	O
the	O
second	O
experiment	O
,	O
using	O
a	O
stronger	O
version	O
of	O
the	O
flash	O
grab	O
,	O
the	O
illusory	O
shift	O
did	O
decrease	O
significantly	O
after	O
rTMS	B-P
to	O
IPS	O
although	O
not	O
after	O
rTMS	B-P
to	O
FEF	O
or	O
to	O
MT	O
.	O

These	O
findings	O
suggest	O
that	O
right	O
IPS	O
contributes	O
to	O
predictive	O
position	O
perception	O
during	O
saccades	O
and	O
motion	O
processing	O
in	O
the	O
contralateral	O
visual	O
field	O
.	O

Unusual	O
axillary	O
metastasis	O
of	O
recurrent	O
nasopharyngeal	O
cancer	O
:	O
A	O
case	O
report	O
.	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
has	O
a	O
high	O
propensity	O
of	O
metastasis	O
.	O

The	O
most	O
commonly	O
described	O
sites	O
of	O
distant	O
metastasis	O
are	O
the	O
bones	O
,	O
lungs	O
,	O
and	O
liver	O
,	O
whereas	O
axillary	O
metastasis	O
is	O
seldom	O
reported	O
.	O

We	O
hereby	O
present	O
the	O
case	O
of	O
a	O
66-year-old	O
man	O
with	O
NPC	O
,	O
cT2N2M0	O
,	O
at	O
diagnosis	O
.	O

He	O
had	O
completed	O
chemoradiotherapy	B-P
and	O
been	O
disease-free	O
for	O
7	O
years	O
.	O

After	O
that	O
period	O
,	O
late	O
recurrence	O
in	O
the	O
form	O
of	O
a	O
solitary	O
axillary	O
lymph	O
node	O
metastasis	O
was	O
detected	O
and	O
confirmed	O
by	O
core-needle	B-P
biopsy	I-P
.	O

The	O
lesion	O
was	O
chemoresistant	O
but	O
responded	O
to	O
salvage	B-P
radiotherapy	I-P
at	O
a	O
dose	O
of	O
65	O
Gy	O
in	O
21	O
fractions	O
.	O

Post-radiotherapy	O
positron	B-P
emission	I-P
tomography	I-P
scan	I-P
showed	O
no	O
evidence	O
of	O
disease	O
.	O

We	O
suggested	O
that	O
long-term	O
follow-up	O
of	O
NPC	O
patients	O
is	O
important	O
because	O
a	O
late	O
relapse	O
may	O
occur	O
at	O
an	O
unusual	O
site	O
.	O

Aggressive	O
management	O
of	O
solitary	O
metastasis	O
may	O
achieve	O
good	O
outcome	O
.	O

The	O
role	O
of	O
the	O
hippocampus	O
and	O
the	O
function	O
of	O
calcitonin	O
gene-related	O
peptide	O
in	O
the	O
mechanism	O
of	O
traumatic	O
brain	O
injury	O
accelerating	O
fracture-healing	O
.	O

This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	O
plays	O
in	O
accelerated	O
fracture-healing	O
after	O
traumatic	O
brain	O
injury	O
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
during	O
this	O
process	O
.	O

Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague-Dawley	O
rats	O
that	O
were	O
split	O
into	O
four	O
groups	O
at	O
random	O
:	O
TBI	O
-	O
fracture	O
group	O
,	O
fracture	O
-	O
only	O
group	O
,	O
TBI	O
-	O
only	O
group	O
,	O
and	O
control	O
group	O
.	O

In	O
the	O
first	O
week	O
,	O
blood	O
specimen	O
would	O
be	O
drawn	O
from	O
rats	O
among	O
the	O
groups	O
except	O
those	O
of	O
the	O
control	O
group	O
at	O
three-time	O
points	O
(	O
24	O
,	O
72	O
and	O
168	O
hours	O
)	O
post	O
-	O
damage	O
.	O

These	O
rats	O
would	O
be	O
assessed	O
from	O
the	O
neurological	O
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	O
injury	O
.	O

Blood	B-P
samples	I-P
were	O
also	O
taken	O
from	O
the	O
control	O
group	O
24	O
hours	O
before	O
the	O
injury	O
,	O
and	O
whole	O
brain	O
tissues	O
in	O
the	O
injured	O
groups	O
were	O
harvested	B-P
at	O
72	O
and	O
168	O
hours	O
post	O
-	O
injury	O
.	O

We	O
compared	O
the	O
serum	O
CGRP	O
concentration	O
,	O
the	O
distribution	O
of	O
CGRP	O
,	O
the	O
CGRP	O
expression	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
brain	O
by	O
immunohistochemistry	B-P
,	O
Western	B-P
blotting	I-P
,	O
RT	O
-	O
Of	O
CGRP	O
RNA	O
expression	O
levels	O
.	O

Neurological	B-P
examinations	I-P
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	O
cortex	O
,	O
cerebellum	O
,	O
and	O
brain	O
stem	O
showed	O
significant	O
differences	O
pre	O
-	O
and	O
post	O
-	O
injury	O
(	O
p	O
<	O
0.001	O
)	O
.	O

ELISA	B-P
analysis	I-P
indicated	O
a	O
great	O
density	O
of	O
CGRP	O
in	O
TBI	O
-	O
fracture	O
group	O
at	O
different	O
time	O
points	O
.	O

Furthermore	O
,	O
in	O
the	O
TBI	O
-	O
fracture	O
group	O
,	O
CGRP	O
in	O
both	O
hippocampus	O
and	O
the	O
whole	O
brain	O
showed	O
a	O
noticeable	O
augment	O
in	O
RT-PCR	O
and	O
western	B-P
blot	I-P
analysis	I-P
at	O
72	O
and	O
168	O
h	O
post	O
-	O
injury	O
,	O
and	O
only	O
in	O
this	O
group	O
,	O
immunohistochemistry	B-P
analysis	I-P
indicated	O
that	O
CGRP	O
was	O
present	O
in	O
the	O
hippocampus	O
at	O
168	O
hours	O
post	O
-	O
injury	O
.	O

We	O
observed	O
that	O
the	O
hippocampus	O
and	O
CGRP	O
were	O
responsible	O
for	O
quick	O
bone-healing	O
mechanisms	O
.	O

We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	O
in	O
accelerated	O
fracture	O
healing	O
.	O

CGRP	O
expression	O
,	O
as	O
determined	O
by	O
IHC	B-P
,	O
can	O
not	O
be	O
observed	O
in	O
other	O
groups	O
,	O
indicating	O
that	O
the	O
hippocampus	O
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	O
that	O
responds	O
to	O
``	O
big	O
stress	O
``	O
.	O

Using	O
a	O
graphical	O
risk	O
tool	O
to	O
examine	O
willingness	O
to	O
take	O
migraine	O
prophylactic	B-P
medications	O
.	O

Many	O
migraine	O
sufferers	O
use	O
daily	O
prophylactic	B-P
therapy	I-P
to	O
reduce	O
the	O
frequency	O
of	O
their	O
headache	O
attacks	O
.	O

The	O
Food	O
and	O
Drug	O
Administration	O
has	O
approved	O
several	O
different	O
medications	O
for	O
migraine	O
prophylaxis	B-P
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	B-P
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	O
effect	O
profiles	B-P
.	O

Three	O
hundred	O
headache	O
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	O
headache	O
clinics	O
using	O
print	O
and	O
television	O
advertising	O
.	O

Participants	O
reported	O
experiencing	O
problematic	O
headache	O
attacks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
frequency	O
of	O
7.0	O
(	O
4-13	O
)	O
headache	O
days	O
per	O
month	O
.	O

These	O
sufferers	O
participated	O
in	O
a	O
cross-sectional	O
,	O
single-site	O
,	O
study	O
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O

Participants	O
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	O
effects	O
for	O
several	O
blinded	O
medication	O
profiles	B-P
:	O
divalproex	O
sodium	O
,	O
venlafaxine	O
,	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	O
effect	O
profiles	B-P
of	O
each	O
medication	O
,	O
participants	O
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	O
to	O
take	O
the	O
medication	O
for	O
a	O
given	O
headache	O
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

The	O
side	O
effect	O
profile	B-P
for	O
divalproex	O
sodium	O
was	O
associated	O
with	O
the	O
smallest	O
willingness	O
to	O
take	O
,	O
with	O
gabapentin	O
,	O
propranolol	O
,	O
and	O
topiramate	O
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

However	O
,	O
<	O
60	O
%	O
of	O
participants	O
reported	O
willingness	O
to	O
take	O
any	O
of	O
these	O
medications	O
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	O
frequency	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	O
to	O
take	O
were	O
observed	O
including	O
high	O
headache	O
-related	O
disability	O
,	O
depressive	O
symptoms	O
,	O
and	O
pain	O
medication	O
concerns	O
including	O
fear	O
of	O
tolerance	O
.	O

These	O
findings	O
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	O
effect	O
profiles	B-P
of	O
these	O
medications	O
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	B-P
.	O

Antigen	O
Masking	O
During	O
Fixation	B-P
and	O
Embedding	B-P
,	O
Dissected	O
.	O

Antigen	O
masking	O
in	O
routinely	O
processed	O
tissue	O
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	O
factors	O
.	O

We	O
sought	O
to	O
dissect	O
the	O
effect	O
on	O
antigenicity	O
of	O
each	O
step	O
of	O
processing	O
by	O
using	O
frozen	O
sections	O
as	O
proxies	O
of	O
the	O
whole	O
tissue	O
.	O

An	O
equivalent	O
extent	O
of	O
antigen	O
masking	O
occurs	O
across	O
variable	O
fixation	B-P
times	O
at	O
room	O
temperature	O
.	O

Most	O
antigens	O
benefit	O
from	O
longer	O
fixation	B-P
times	O
(	O
>	O
24	O
hr	O
)	O
for	O
optimal	O
detection	O
after	O
antigen	O
retrieval	O
(	O
AR	O
;	O
for	O
example	O
,	O
Ki-67	O
,	O
bcl-2	O
,	O
ER	O
)	O
.	O

The	O
transfer	O
to	O
a	O
graded	O
alcohol	O
series	O
results	O
in	O
an	O
enhanced	O
staining	O
effect	O
,	O
reproduced	O
by	O
treating	O
the	O
sections	O
with	O
detergents	O
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	O
immunohistochemical	B-P
detection	O
system	O
to	O
tissue	O
structures	O
.	O

A	O
second	O
round	O
of	O
masking	O
occurs	O
upon	O
entering	O
the	O
clearing	O
agent	O
,	O
mostly	O
at	O
the	O
paraffin	O
embedding	B-P
step	O
.	O

This	O
may	O
depend	O
on	O
the	O
non-freezable	O
water	O
removal	O
.	O

AR	O
fully	O
reverses	O
the	O
masking	O
due	O
both	O
to	O
the	O
fixation	B-P
time	O
and	O
the	O
paraffin	O
embedding	B-P
.	O

AR	O
itself	O
destroys	O
some	O
epitopes	O
which	O
do	O
not	O
survive	O
routine	O
processing	O
.	O

Processed	O
frozen	O
sections	O
are	O
a	O
tool	O
to	O
investigate	O
fixation	B-P
and	O
processing	O
requirements	O
for	O
antigens	O
in	O
routine	O
specimens	O
.	O

Effects	O
of	O
Obesity	O
and	O
Leptin	O
Deficiency	O
on	O
Morphine	O
Pharmacokinetics	O
in	O
a	O
Mouse	O
Model	O
.	O

Obesity	O
causes	O
multiorgan	O
dysfunction	O
,	O
specifically	O
metabolic	O
abnormalities	O
in	O
the	O
liver	O
.	O

Obese	O
patients	O
are	O
opioid	O
-	O
sensitive	O
and	O
have	O
high	O
rates	O
of	O
respiratory	O
complications	O
after	O
surgery	B-P
.	O

Obesity	O
also	O
has	O
been	O
shown	O
to	O
cause	O
resistance	O
to	O
leptin	O
,	O
an	O
adipose	O
-derived	O
hormone	O
that	O
is	O
key	O
in	O
regulating	O
hunger	O
,	O
metabolism	O
,	O
and	O
respiratory	O
stimulation	O
.	O

We	O
hypothesized	O
that	O
obesity	O
and	O
leptin	O
deficiency	O
impair	O
opioid	O
pharmacokinetics	O
(	O
PK	O
)	O
independently	O
of	O
one	O
another	O
.	O

Morphine	O
PK	O
were	O
characterized	O
in	O
C57BL/6J	O
wild-type	O
(	O
WT	O
)	O
,	O
diet-induced	O
obese	O
(	O
DIO	O
)	O
,	O
and	O
leptin-deficient	O
(	O
ob/ob	O
)	O
mice	O
,	O
and	O
in	O
ob/ob	O
mice	O
given	O
leptin-replacement	B-P
(	I-P
LR	I-P
)	I-P
therapy	I-P
.	O

WT	O
mice	O
received	O
several	O
dosing	O
regimens	O
of	O
morphine	O
.	O

Obese	O
mice	O
(	O
30	O
g	O
)	O
received	O
one	O
80	O
mg/kg	O
bolus	O
of	O
morphine	O
.	O

Blood	O
was	O
collected	O
at	O
fixed	O
times	O
after	O
morphine	O
injection	B-P
for	O
quantification	O
of	O
plasma	O
morphine	O
and	O
morphine	O
3-glucuronide	O
(	O
M3G	O
)	O
levels	O
.	O

PK	O
parameters	O
used	O
to	O
evaluate	O
morphine	O
metabolism	O
included	O
area-under	O
the	O
curve	O
(	O
AUC150	O
)	O
,	O
maximal	O
morphine	O
concentration	O
(	O
CMAX	O
)	O
,	O
and	O
M3G	O
-to-	O
morphine	O
ratio	O
,	O
and	O
drug	O
elimination	O
was	O
determined	O
by	O
clearance	O
(	O
Cl/F	O
)	O
,	O
volume	O
of	O
distribution	O
,	O
and	O
half-life	O
(	O
T1/2	O
)	O
.	O

PK	O
parameters	O
were	O
compared	O
between	O
mouse	O
groups	O
by	O
the	O
use	O
of	O
1-way	O
analysis	O
of	O
variance	O
,	O
with	O
P	O
values	O
less	O
than	O
.05	O
considered	O
significant	O
.	O

DIO	O
compared	O
with	O
WT	O
mice	O
had	O
significantly	O
decreased	O
morphine	O
metabolism	O
with	O
lower	O
M3G	O
-to-	O
morphine	O
ratio	O
(	O
mean	O
difference	O
[	O
MD	O
]	O
:	O
-4.9	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-8.8	O
to	O
-0.9	O
)	O
as	O
well	O
as	O
a	O
decreased	O
Cl/F	O
(	O
MD	O
:	O
-4.0	O
;	O
95	O
%	O
CI	O
:	O
-8.9	O
to	O
-0.03	O
)	O
Ob/ob	O
compared	O
with	O
WT	O
mice	O
had	O
a	O
large	O
increase	O
in	O
morphine	O
exposure	O
with	O
a	O
greater	O
AUC150	O
(	O
MD	O
:	O
980.4	O
;	O
95	O
%	O
CI	O
:	O
630.1-1330.6	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
6.8	O
;	O
95	O
%	O
CI	O
:	O
2.7-10.9	O
)	O
,	O
and	O
longer	O
T1/2	O
(	O
MD	O
:	O
23.1	O
;	O
95	O
%	O
CI	O
:	O
10.5-35.6	O
)	O
,	O
as	O
well	O
as	O
a	O
decreased	O
Cl/F	O
(	O
MD	O
:	O
-7.0	O
;	O
95	O
%	O
CI	O
:	O
-11.6	O
to	O
-2.7	O
)	O
.	O

Several	O
PK	O
parameters	O
were	O
significantly	O
greater	O
in	O
ob/ob	O
compared	O
with	O
DIO	O
mice	O
,	O
including	O
AUC150	O
(	O
MD	O
:	O
636.4	O
;	O
95	O
%	O
CI	O
:	O
207.4-1065.4	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
3.2-10.3	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
18.3	O
;	O
95	O
%	O
CI	O
:	O
2.8-33.7	O
)	O
.	O

When	O
leptin	O
was	O
replaced	O
in	O
ob/ob	O
mice	O
,	O
PK	O
parameters	O
began	O
to	O
approach	O
DIO	O
and	O
WT	O
levels	O
.	O

LR	B-P
compared	O
with	O
ob/ob	O
mice	O
had	O
significant	O
decreases	O
in	O
AUC150	O
(	O
MD	O
:	O
-779.9	O
;	O
95	O
%	O
CI	O
:	O
-1229.8	O
to	O
-330	O
)	O
,	O
CMAX	O
(	O
MD	O
:	O
-6.1	O
;	O
95	O
%	O
CI	O
:	O
-11.4	O
to	O
-0.9	O
)	O
,	O
and	O
T1/2	O
(	O
MD	O
:	O
-19	O
;	O
95	O
%	O
CI	O
:	O
-35.1	O
to	O
-2.8	O
)	O
.	O

Metabolism	O
increased	O
with	O
LR	B-P
,	O
with	O
LR	O
mice	O
having	O
a	O
greater	O
M3G	O
-to-	O
morphine	O
ratio	O
compared	O
with	O
DIO	O
(	O
MD	O
:	O
5.3	O
;	O
95	O
%	O
CI	O
:	O
0.3-10.4	O
)	O
.	O

Systemic	O
effects	O
associated	O
with	O
obesity	O
decrease	O
morphine	O
metabolism	O
and	O
excretion	O
.	O

A	O
previous	O
study	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
obesity	O
and	O
leptin	O
deficiency	O
decrease	O
the	O
sensitivity	O
of	O
central	O
respiratory	O
control	O
centers	O
to	O
carbon	O
dioxide	O
.	O

Obesity	O
and	O
leptin	O
deficiency	O
substantially	O
decreased	O
morphine	O
metabolism	O
and	O
clearance	O
,	O
and	O
replacing	O
leptin	O
attenuated	O
the	O
PK	O
changes	O
associated	O
with	O
leptin	O
deficiency	O
,	O
suggesting	O
leptin	O
has	O
a	O
direct	O
role	O
in	O
morphine	O
metabolism	O
.	O

A	O
New	O
Classification	O
of	O
Three-Dimensional	O
Printing	O
Technologies	O
:	O
Systematic	O
Review	O
of	O
Three-Dimensional	O
Printing	O
for	O
Patient	O
-Specific	O
Craniomaxillofacial	B-P
Surgery	I-P
.	O

Three-dimensional	O
printing	O
technology	O
has	O
been	O
advancing	O
in	O
surgical	O
applications	O
.	O

This	O
systematic	O
review	O
examines	O
its	O
patient	O
-specific	O
applications	O
in	O
craniomaxillofacial	B-P
surgery	I-P
.	O

Terms	O
related	O
to	O
``	O
three-dimensional	O
printing	O
``	O
and	O
``	O
surgery	B-P
``	O
were	O
searched	O
on	O
PubMed	O
on	O
May	O
4	O
,	O
2015	O
;	O
313	O
unique	O
articles	O
were	O
returned	O
.	O

Inclusion	O
and	O
exclusion	O
criteria	O
concentrated	O
on	O
patient	O
-specific	O
surgical	B-P
applications	O
,	O
yielding	O
141	O
full-text	O
articles	O
,	O
of	O
which	O
33	O
craniomaxillofacial	O
articles	O
were	O
analyzed	O
.	O

Thirty-three	O
articles	O
included	O
315	O
patients	O
who	O
underwent	O
three-dimensional	O
printing	O
-assisted	O
operations	B-P
.	O

The	O
most	O
common	O
modeling	O
software	O
was	O
Mimics	O
,	O
the	O
most	O
common	O
printing	O
software	O
was	O
3D	O
Systems	O
,	O
the	O
average	O
time	O
to	O
create	O
a	O
printed	O
object	O
was	O
18.9	O
hours	O
(	O
range	O
,	O
1.5	O
to	O
96	O
hours	O
)	O
,	O
and	O
the	O
average	O
cost	O
of	O
a	O
printed	O
object	O
was	O
$	O
1353.31	O
(	O
range	O
,	O
$	O
69.75	O
to	O
$	O
5500	O
)	O
.	O

Surgical	B-P
procedures	I-P
were	O
divided	O
among	O
203	O
craniofacial	O
patients	O
(	O
205	O
three-dimensional	O
printing	O
objects	O
)	O
and	O
112	O
maxillofacial	O
patients	O
(	O
137	O
objects	O
)	O
.	O

Printing	O
technologies	O
could	O
be	O
classified	O
as	O
contour	O
models	O
,	O
guides	O
,	O
splints	O
,	O
and	O
implants	O
.	O

For	O
craniofacial	O
patients	O
,	O
173	O
contour	O
models	O
(	O
84	O
percent	O
)	O
,	O
13	O
guides	O
(	O
6	O
percent	O
)	O
,	O
two	O
splints	O
(	O
1	O
percent	O
)	O
,	O
and	O
17	O
implants	O
(	O
8	O
percent	O
)	O
were	O
made	O
.	O

For	O
maxillofacial	O
patients	O
,	O
41	O
contour	O
models	O
(	O
30	O
percent	O
)	O
,	O
48	O
guides	O
(	O
35	O
percent	O
)	O
,	O
40	O
splints	O
(	O
29	O
percent	O
)	O
,	O
and	O
eight	O
implants	O
(	O
6	O
percent	O
)	O
were	O
made	O
.	O

These	O
distributions	O
were	O
significantly	O
different	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Four	O
studies	O
compared	O
three-dimensional	O
printing	O
techniques	O
to	O
conventional	O
techniques	O
;	O
two	O
of	O
them	O
found	O
that	O
three-dimensional	O
printing	O
produced	O
improved	O
outcomes	O
.	O

Three-dimensional	O
printing	O
technology	O
in	O
craniomaxillofacial	B-P
surgery	I-P
can	O
be	O
classified	O
into	O
contour	O
models	O
(	O
type	O
I	O
)	O
,	O
guides	O
(	O
type	O
II	O
)	O
,	O
splints	O
(	O
type	O
III	O
)	O
,	O
and	O
implants	O
(	O
type	O
IV	O
)	O
.	O

These	O
four	O
methods	O
vary	O
in	O
their	O
use	O
between	O
craniofacial	B-P
and	O
maxillofacial	B-P
surgery	I-P
,	O
reflecting	O
their	O
different	O
goals	O
.	O

This	O
understanding	O
may	O
help	O
advance	O
and	O
predict	O
three-dimensional	O
printing	O
applications	O
for	O
other	O
types	O
of	O
plastic	B-P
surgery	I-P
and	O
beyond	O
.	O

Subepidermal	O
Calcified	O
Nodules	O
of	O
the	O
Eyelid	O
Differ	O
in	O
Children	O
and	O
Adults	O
.	O

Subepidermal	O
calcified	O
nodule	O
of	O
the	O
eyelid	O
is	O
considered	O
as	O
one	O
of	O
the	O
types	O
of	O
calcinosis	O
cutis	O
.	O

It	O
generally	O
occurs	O
in	O
children	O
,	O
and	O
is	O
not	O
known	O
to	O
be	O
associated	O
with	O
systemic	O
disease	O
.	O

The	O
authors	O
report	O
histopathological	O
and	O
clinical	O
findings	O
in	O
14	O
cases	O
of	O
subepidermal	O
calcified	O
nodule	O
of	O
the	O
eyelid	O
,	O
including	O
3	O
older	O
patients	O
with	O
unique	O
microscopic	O
features	O
.	O

Clinical	O
records	O
and	O
pathological	O
materials	O
were	O
critically	O
reviewed	O
in	O
each	O
case	O
,	O
including	O
von	B-P
kossa	I-P
,	O
CD3	O
,	O
CD20	O
,	O
and	O
CD68	O
stains	O
.	O

The	O
14	O
cases	O
presented	O
clinically	O
as	O
nodular	O
eyelid	O
lesions	O
.	O

All	O
were	O
treated	O
with	O
surgical	B-P
excision	I-P
.	O

The	O
authors	O
found	O
2	O
distinct	O
histopathological	O
patterns	O
which	O
correlated	O
with	O
the	O
patients	O
'	O
age	O
.	O

In	O
young	O
patients	O
,	O
the	O
authors	O
observed	O
multiple	O
,	O
small	O
calcified	O
bodies	O
within	O
the	O
dermis	O
surrounded	O
by	O
chronic	O
inflammation	O
and	O
granulomatous	O
foreign	O
body	O
reaction	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
elderly	O
patients	O
,	O
lesions	O
were	O
characterized	O
by	O
a	O
single	O
,	O
large	O
,	O
well-demarcated	O
amorphous	O
calcified	O
deposit	O
surrounded	O
by	O
fibrous	O
tissue	O
,	O
without	O
chronic	O
inflammation	O
or	O
foreign	O
body	O
reaction	O
.	O

One	O
of	O
these	O
patients	O
,	O
a	O
70-	O
year-old	O
man	O
,	O
also	O
suffered	O
from	O
gout	O
.	O

The	O
presence	O
of	O
subepidermal	O
calcified	O
nodule	O
was	O
not	O
documented	O
as	O
a	O
preoperative	O
diagnostic	O
possibility	O
in	O
any	O
of	O
the	O
cases	O
.	O

Subepidermal	O
calcified	O
nodule	O
of	O
the	O
eyelid	O
is	O
a	O
rare	O
condition	O
,	O
but	O
should	O
be	O
considered	O
in	O
any	O
patient	O
presenting	O
with	O
a	O
painless	O
white	O
to	O
yellowish	O
colored	O
nodule	O
of	O
the	O
ocular	O
adnexa	O
,	O
particularly	O
during	O
the	O
teenage	O
years	O
.	O

Clinicians	O
and	O
pathologists	O
should	O
be	O
aware	O
that	O
this	O
entity	O
has	O
a	O
distinct	O
appearance	O
and	O
could	O
be	O
associated	O
with	O
systemic	O
conditions	O
in	O
elderly	O
patients	O
.	O

A	O
novel	O
assay	B-P
to	O
measure	O
tertiary	O
and	O
quaternary	O
amines	O
in	O
wastewater	O
:	O
An	O
indicator	O
for	O
NDMA	O
wastewater	O
precursors	O
.	O

This	O
study	B-P
examined	O
the	O
potential	O
of	O
using	O
a	O
novel	O
bulk	B-P
amine	I-P
assay	I-P
as	O
an	O
approximation	O
for	O
the	O
tertiary	O
and	O
quaternary	O
amine	O
load	O
in	O
wastewaters	O
and	O
surface	O
water	O
samples	O
,	O
and	O
this	O
approximation	O
was	O
compared	O
to	O
N-nitrosodimethylamine	O
(	O
NDMA	O
)	O
formation	O
potential	O
using	O
chloramines	O
.	O

An	O
existing	O
colorimetric	B-P
method	I-P
was	O
examined	O
and	O
optimized	O
for	O
the	O
detection	O
of	O
amines	O
in	O
environmental	O
water	O
samples	O
.	O

The	O
method	B-P
consists	O
of	O
liquid-liquid	B-P
extraction	I-P
followed	O
by	O
a	O
catalyzed	O
reaction	O
to	O
form	O
a	O
yet-	O
undefined	O
product	O
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	O
chromophore	O
and	O
fluorophore	O
.	O

Previous	O
work	O
verified	O
that	O
this	O
reaction	O
was	O
effectively	O
catalyzed	O
by	O
a	O
number	O
of	O
compounds	O
containing	O
tertiary	O
and	O
quaternary	O
amine	O
moieties	O
.	O

Many	O
tertiary	O
and	O
quaternary	O
compounds	O
are	O
also	O
efficient	O
producers	O
of	O
NDMA	O
under	O
chloramination	O
conditions	O
,	O
and	O
a	O
linear	O
correlation	O
was	O
consequently	O
derived	O
from	O
the	O
bulk	O
amine	O
signals	O
vs.	O
NDMA	O
formation	O
potential	O
in	O
various	O
wastewater	O
samples	O
(	O
R	O
(	O
2	O
)	O
=	O
0.74	O
;	O
n	O
=	O
24	O
;	O
p-value	O
<	O
0.05	O
)	O
.	O

The	O
results	O
provide	O
evidence	O
that	O
approximately	O
2	O
%	O
of	O
the	O
tertiary	O
and	O
quaternary	O
amines	O
measured	O
can	O
form	O
NDMA	O
and	O
an	O
estimated	O
0.01-1.3	O
%	O
of	O
nitrogen	O
in	O
dissolved	O
organic	O
nitrogen	O
originates	O
from	O
these	O
bulk	O
amines	O
.	O

The	O
normalization	O
of	O
NDMA	O
concentration	O
by	O
the	O
amine	O
measurement	O
revealed	O
that	O
ozone	O
effectively	O
destroyed	O
those	O
tertiary	O
and	O
quaternary	O
amine	O
structures	O
more	O
likely	O
to	O
form	O
NDMA	O
in	O
treated	O
wastewater	O
samples	O
.	O

This	O
bulk	B-P
amine	I-P
assay	I-P
illustrates	O
that	O
proxy	O
measurements	O
of	O
tertiary	O
and	O
quaternary	O
amines	O
can	O
be	O
linked	O
to	O
the	O
NDMA	O
formation	O
potential	O
of	O
a	O
given	O
sample	O
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	O
as	O
a	O
characterizing	O
tool	O
for	O
NDMA	O
precursors	O
in	O
wastewater	O
.	O

Efficacy	O
of	O
indefinite	B-P
chronic	I-P
oral	I-P
antimicrobial	I-P
suppression	I-P
for	O
prosthetic	O
joint	O
infection	O
in	O
the	O
elderly	O
:	O
a	O
comparative	O
study	O
.	O

During	O
prosthetic	O
joint	O
infection	O
(	O
PJI	O
)	O
,	O
surgical	O
management	O
is	O
sometimes	O
impossible	O
,	O
indefinite	B-P
chronic	I-P
oral	I-P
antimicrobial	I-P
suppression	I-P
(	O
ICOAS	B-P
)	O
may	O
sometimes	O
be	O
the	O
only	O
option	O
.	O

We	O
evaluated	O
the	O
outcome	O
of	O
elderly	O
patients	O
who	O
benefited	O
from	O
ICOAS	B-P
for	O
a	O
strictly	O
palliative	O
goal	O
METHODS	O
:	O
We	O
performed	O
a	O
national	O
retrospective	O
cohort	O
study	O
in	O
France	O
of	O
patients	O
aged	O
>	O
75years	O
old	O
with	O
PJI	O
,	O
and	O
managed	O
with	O
ICOAS	B-P
planned	O
for	O
life	O
long	O
from	O
2009	O
to	O
2014	O
,	O
and	O
compared	O
the	O
population	O
with	O
an	O
event	O
versus	O
the	O
population	O
free	O
of	O
event	O
.	O

Event	O
was	O
defined	O
as	O
a	O
composite	O
outcome	O
in	O
patients	O
under	O
ICOAS	B-P
,	O
including	O
:	O
local	O
or	O
systemic	O
progression	O
of	O
the	O
infection	O
;	O
death	O
or	O
discontinuation	O
of	O
antimicrobial	O
therapy	B-P
because	O
of	O
adverse	O
drug	O
reaction	O
.	O

Twenty-one	O
patients	O
were	O
included	O
,	O
with	O
a	O
median	O
age	O
of	O
85	O
(	O
IQR	O
:	O
81	O
;	O
88	O
)	O
years	O
old	O
.	O

There	O
were	O
8/21	O
patients	O
with	O
an	O
event	O
:	O
1	O
patient	O
with	O
adverse	O
drug	O
reaction	O
;	O
3	O
patients	O
had	O
systemic	O
progression	O
of	O
sepsis	O
;	O
and	O
2	O
had	O
local	O
progression	O
.	O

A	O
total	O
of	O
2/21	O
patients	O
died	O
.	O

No	O
deaths	O
were	O
related	O
to	O
ICOAS	B-P
or	O
infection	O
.	O

There	O
was	O
no	O
significant	O
difference	O
(	O
p	O
>	O
0.05	O
)	O
between	O
the	O
population	O
with	O
an	O
event	O
and	O
free	O
of	O
event	O
considering	O
demographic	O
,	O
clinical	O
and	O
microbiological	O
characteristics	O
.	O

In	O
our	O
cohort	O
,	O
ICOAS	B-P
seems	O
to	O
be	O
an	O
effective	O
and	O
safe	O
option	O
.	O

Minding	O
the	O
Gap	O
:	O
Factors	O
Associated	O
With	O
Primary	O
Care	O
Coordination	O
of	O
Adults	O
in	O
11	O
Countries	O
.	O

Care	O
coordination	O
has	O
been	O
identified	O
as	O
a	O
key	O
strategy	O
in	O
improving	O
the	O
effectiveness	O
,	O
safety	O
,	O
and	O
efficiency	O
of	O
the	O
US	O
health	O
care	O
system	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
whether	O
population	O
or	O
health	O
care	O
system	O
issues	O
are	O
associated	O
with	O
primary	O
care	O
coordination	O
gaps	O
in	O
the	O
United	O
States	O
and	O
other	O
high-income	O
countries	O
.	O

We	O
analyzed	O
data	O
from	O
the	O
2013	O
Commonwealth	O
Fund	O
International	O
Health	O
Policy	O
(	O
IHP	O
)	O
survey	O
with	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

Respondents	O
were	O
adult	B-P
primary	I-P
care	I-P
patients	O
from	O
11	O
countries	O
:	O
Australia	O
,	O
Canada	O
,	O
France	O
,	O
Germany	O
,	O
the	O
Netherlands	O
,	O
New	O
Zealand	O
,	O
Norway	O
,	O
Sweden	O
,	O
Switzerland	O
,	O
United	O
Kingdom	O
,	O
and	O
the	O
United	O
States	O
.	O

Poor	O
primary	O
care	O
coordination	O
was	O
defined	O
as	O
participants	O
reporting	O
at	O
least	O
3	O
gaps	O
in	O
the	O
coordination	O
of	O
care	O
out	O
of	O
a	O
maximum	O
of	O
5	O
.	O

Analyses	O
were	O
based	O
on	O
13,958	O
respondents	O
.	O

The	O
rate	O
of	O
poor	O
primary	O
care	O
coordination	O
was	O
5.2	O
%	O
(	O
724/13,958	O
respondents	O
)	O
overall	O
and	O
highest	O
in	O
the	O
United	O
States	O
,	O
at	O
9.8	O
%	O
(	O
137/1,395	O
respondents	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
among	O
all	O
respondents	O
found	O
that	O
they	O
were	O
less	O
likely	O
to	O
experience	O
poor	O
primary	O
care	O
coordination	O
if	O
their	O
primary	O
care	O
physician	O
often	O
or	O
always	O
knew	O
their	O
medical	O
history	O
,	O
spent	O
sufficient	O
time	O
,	O
involved	O
them	O
,	O
and	O
explained	O
things	O
well	O
(	O
odds	O
ratio	O
=	O
0.6	O
for	O
each	O
)	O
.	O

Poor	O
primary	O
care	O
coordination	O
was	O
more	O
likely	O
to	O
occur	O
among	O
patients	O
with	O
chronic	O
conditions	O
(	O
odds	O
ratios	O
=	O
1.4-2.1	O
depending	O
on	O
number	O
)	O
and	O
patients	O
younger	O
than	O
65	O
years	O
(	O
odds	O
ratios	O
=	O
1.6-2.3	O
depending	O
on	O
age-group	O
)	O
.	O

Among	O
US	O
respondents	O
,	O
insurance	O
status	O
,	O
health	O
status	O
,	O
household	O
income	O
,	O
and	O
sex	O
were	O
not	O
associated	O
with	O
poor	O
primary	O
care	O
coordination	O
.	O

The	O
United	O
States	O
had	O
the	O
highest	O
rate	O
of	O
poor	O
primary	O
care	O
coordination	O
among	O
the	O
11	O
high-income	O
countries	O
evaluated	O
.	O

An	O
established	O
relationship	O
with	O
a	O
primary	O
care	O
physician	O
was	O
significantly	O
associated	O
with	O
better	O
care	O
coordination	O
,	O
whereas	O
being	O
chronically	O
ill	O
or	O
younger	O
was	O
associated	O
with	O
poorer	O
care	O
coordination	O
.	O

